

CANCER in the ACT 1996-2000

Health Series Number 34

Population Health Research Centre ACT Health

November 2003

ACKNOWLEDGEMENTS

This report has been made possible by the co-operation of staff in hospitals, nursing homes and pathology laboratories throughout the ACT. The staff of the ACT Cancer Registry and Population Health Research Centre would like to acknowledge the contribution of all people concerned and our thanks are extended to them for their continued support in notifying cancer cases.

The majority of deaths data contained in this publication have been obtained from the ACT Registrar of Births, Deaths and Marriages. The Australian Bureau of Statistics supplies population and demographic data and coded death data. Our thanks are extended to the Australian Institute of Health and Welfare for assistance with matching of death data and duplicate registrations. Our special thanks to all other State and Territory Registries and to the Australasian Association of Cancer Registries for their support.

We would like to especially thank the staff of the New South Wales Central Cancer Registry for their continued support and assistance.



ISSN 1325-1090

© Australian Capital Territory, Canberra, November 2003

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without written permission from Library & Information Management, Department of Urban Services, ACT Government, GPO Box 249, Civic Square ACT 2608.

Produced for the Population Health Research Centre by ACT Health and printed on recycled paper.

Enquiries about this publication should be directed to the Population Health Research Centre, Building 5, Level 1, The Canberra Hospital, PO Box 11, Woden ACT 2606, or via email to healthinfo@act.gov.au.

Publication No: 03/0824 http://www.act.gov.au

Telephone: Canberra 13ACT1 or 132281

Suggested citation: Cancer in the ACT, 1996-2000. Population Health Research Centre, ACT Health: Health Series No 34, ACT Government, Canberra ACT.

ACT cancer publications in the Health Series can be accessed online at: http://www.health.act.gov.au/publications

CONTENTS

ACKNOWLEDGEMEN IS	2
ABBREVIATIONS	8
INTRODUCTION	9
1. A PROFILE OF THE ACT	11
1.1 DEMOGRAPHIC CHARACTERISTICS OF THE ACT POPULATION IN 2000 1.2 HEALTH STATUS OF THE ACT POPULATION IN 2000	12
2. THE INCIDENCE OF CANCER IN THE ACT, 1996-2000	
2.1 INCIDENCE OF ALL CANCERS 2.2 INCIDENCE OF LEADING CANCER SITES 2.2.1 Breast Cancer in Females 2.2.2 Prostate Cancer 2.2.3 Colorectal Cancer 2.2.4 Melanoma 2.2.5 Lung Cancer	16 17 18 18
3. MORTALITY DUE TO CANCER IN THE ACT, 1996-2000	21
3.1 MORTALITY FOR ALL CANCERS 3.2 MORTALITY FOR LEADING CANCER SITES 3.2.1 Lung Cancer 3.2.2 Colorectal Cancer 3.2.3 Breast Cancer in Females 3.2.4 Prostate Cancer 3.2.5 Melanoma	22 23 24
APPENDICES	27
APPENDIX A: 1996-2000APPENDIX B: 1995-1999	
GLOSSARY	189
REFERENCES	193

LIST OF TABLES

Table 1: Demographic Characteristics of the ACT Population	11
Table 2: Health Status of the ACT and Australia, 2000	
Table 3: Selected Causes of Death, ACT and Australia, 2000	13
Table 4: Prevalence of Modifiable Risk Factors, ACT and Australia	14
Table A1: The 10 Most Frequently Occurring Cancers and Cancer Caused Deaths by Gender in	1
the ACT, 1996-2000	
Table A2: Summary of Incidence Rates, 1996-2000	30
Table A3: Summary of Mortality Rates, 1996-2000	
Table A4-1: All Malignant Neoplasms: ICD-10 C00-97 (Excluding non melanocytic skin cancers	
(C44)	39
Table A4-2 : Malignant Neoplasm of Lip: ICD-10 C00	40
Table A4-3 : Malignant Neoplasm of Tongue: ICD-10 C01	
Table A4-4 : Malignant Neoplasm of Mouth: ICD-10 C03-06	
Table A4-5 : Malignant Neoplasm of Salivary Glands: ICD-10 C07-08	43
Table A4-6 : Malignant Neoplasm of Tonsils: ICD-10 C09	44
Table A4-7 : Malignant Neoplasm of Other Oropharynx: ICD-10 C10	
Table A4-8 : Malignant Neoplasm of Nasopharynx: ICD-10 C11	
Table A4-9 : Malignant Neoplasm of Hypopharynx: ICD-10 C12-13	
Table A4-10: Malignant Neoplasm of Unspecified Parts of Pharynx: ICD-10 C12-13	
Table A4-11: Malignant Neoplasm of Unspecified Parts of Oesophagus: ICD-10 C15	
Table A4-12 : Malignant Neoplasm of Stomach: ICD-10 C16	
Table A4-13 : Malignant Neoplasm of Small Intestine: ICD-10 C17	
Table A4-14: Malignant Neoplasm of Colon: ICD-10 C18	.52
Table A4-15: Malignant Neoplasm of Rectum: ICD-10 C19-20	
Table A4-16: Malignant Neoplasm of Anus: ICD-10 C21	
Table A4-17 : Malignant Neoplasm of Colon (Excluding anus): ICD-10 C18-20	.55
Table A4-18: Malignant Neoplasm of Colon (Including anus): ICD-10 C18-21	
Table A4-19: Malignant Neoplasm of Liver: ICD-10 C22	
Table A4-20 : Malignant Neoplasm of Gall Bladder: ICD-10 C23-24	
Table A4-21 : Malignant Neoplasm of Pancreas: ICD-10 C25	
Table A4-21: Malignant Neoplasm of Nasal Cavity: ICD-10 C30-31	
Table A4-23 : Malignant Neoplasm of Larynx: ICD-10 C32	
Table A4-25: Malignant Neoplasm of Other Thoracic Organs: ICD-10 C37-38	03
Table A4-20 . Malignant Neoplasm of Skin/Malanama, ICD 40-41	04
Table A4-27: Malignant Neoplasm of Skin/Melanoma: ICD-10 C43	00
Table A4-28 : Mesothelioma: ICD-10 C45	
Table A4-29: Kaposi's Sarcoma: ICD-10 C46	
Table A4-30: Malignant Neoplasm of Connective and Soft Tissues: ICD-10 C47-49	
Table A4-31: Malignant Neoplasm of Breast: ICD-10 C50	
Table A4-32: Malignant Neoplasm of Vulva: ICD-10 C51	
Table A4-33: Malignant Neoplasm of Vagina: ICD-10 C52	/ 1
Table A4-34: Malignant Neoplasm of Cervix Uteri: ICD-10 C53	
Table A4-35: Malignant Neoplasm of Corpus Uteri: ICD-10 C54	
Table A4-36: Malignant Neoplasm of Uterus Unspecified: ICD-10 C55	
Table A4-37: Malignant Neoplasm of Ovary: ICD-10 C56	/5
Table A4-38: Malignant Neoplasm of Other Female Genital Organs: ICD-10 C57	
Table A4-39: Malignant Neoplasm of Placenta: ICD-10 C58	
Table A4-40 : Malignant Neoplasm of Penis: ICD-10 C60	
Table A4-41: Malignant Neoplasm of Prostate: ICD-10 C61	
Table A4-42 : Malignant Neoplasm of Testis: ICD-10 C62	
Table A4-43 : Malignant Neoplasm of Other Male Genitals: ICD-10 C63	
Table A4-44: Malignant Neoplasm of Kidney: ICD-10 C64	
Table A4-45: Malignant Neoplasm of Renal Pelvis: ICD-10 C65	
Table A4-46: Malignant Neoplasm of Ureter: ICD-10 C66	84
Table A4-47: Malignant Neoplasm of Kidney, Ureter and Urethra: ICD-10 C64-66, C68	
Table A4-48: Malignant Neoplasm of Bladder: ICD-10 C67	
Table A4-49: Malignant Neoplasm of Other Urinary Organs: ICD-10 C68	87

Table A4-50 : Malignant Neoplasm of Eye: ICD-10 C69	
Table A4-51: Malignant Neoplasm of Brain: ICD-10 C71	89
Table A4-52: Malignant Neoplasm of Meninges CNC: ICD-10 C70, C72	.90
Table A4-53: Malignant Neoplasm of Brain and CNC: ICD-10 C70-72	
Table A4-54: Malignant Neoplasm of Thyroid: ICD-10 C73	
Table A4-55 : Malignant Neoplasm of Adrenal Gland: ICD-10 C74	93
Table A4-56: Malignant Neoplasm of Other Endocrine: ICD-10 C75	04
Table A4-57: Hodgkin's Disease: ICD-10 C81	.95
Table A4-58: Non-Hodgkin's Lymphoma: ICD-10 C82-85, C96	
Table A4-59 : All Lymphoma's: ICD-10 C81-85, C96	. 97
Table A4-60 : Immunoproliferative Neoplasms: ICD-10 C82-85, C96	
Table A4-61 : Multiple Myeloma: ICD-10 C90	.99
Table A4-62 : Lymphoid Leukemia: ICD-10 C911	100
Table A4-63 : Myeloid Leukemia: ICD-10 C92-941	
Table A4-64 : Lukemia Unspecified: ICD-10 C951	102
Table A4-65 : Malignant Neoplasm of Unknown Primary Site: ICD-10 C76-80, C26, C391	102
Table A4-05 : Mangriant Neophasti Or Orintowitz filliary Site. 160-10 C70-00, C20, C39	03
Table A4-66: Cancers with alcohol use as an identified risk factor: ICD-10 C01-06, C09-10, C12-	
15, C22, C32, C501	104
Table A4-67: Cancers with smoking as an identified risk factor: ICD-10 C00-06, C09-16, C21.0,	
C25, C32-34, C51.9, C 53-55, C62, C64, C65, C67	05
Table B1: The 10 Most Frequently Occurring Cancers and Cancer Caused Death by Gender in th	ıe
ACT, 1995-19991	109
Table B2: Summary of Incidence Rates, 1995-19991	
Table B3: Summary of Mortality Rates, 1995-19991	
Table B4-1 : All Malignant Neoplasms: ICD-10 C00-97 (Excluding non-melanocytic skin cancers	
(C44))	121
Table B4-2 : Malignant Neoplasm of Lip: ICD-10 C001	121
Table B4-2 : Malignant Neoplasm of Lip: ICD-10 C00	22
Table B4-3 : Malignant Neoplasm of Tongue: ICD-10 C011	
Table B4-4: Malignant Neoplasm of Mouth: ICD-10 C03-061	
Table B4-5: Malignant Neoplasm of Salivary Glands: ICD-10 C07-081	25
Table B4-6: Malignant Neoplasm of Tonsils: ICD-10 C091	126
Table B4-7: Malignant Neoplasm of Other Oropharynx: ICD-10 C101	
Table B4-8 : Malignant Neoplasm of Nasopharynx: ICD-10 C11	
Table B4-9: Malignant Neoplasm of Hypopharynx: ICD-10 C12-13	
Table B4-9: Malignant Neoplasm of Trypopharynx: ICD-10 C12-131 Table B4-10: Malignant Neoplasm of Unspecified Parts of Pharynx: ICD-10 C141	
Table 64-10 . Malignant Neoplasm of Onspecified Parts of Pharytix. ICD-10 C14	130
Table B4-11 : Malignant Neoplasm of Oesophagus: ICD-10 C151	
Table B4-12 : Malignant Neoplasm of Stomach: ICD-10 C16	
Table B4-13: Malignant Neoplasm of Small Intestine: ICD-10 C171	
Table B4-14 : Malignant Neoplasm of Colon: ICD-10 C181	134
Table B4-15: Malignant Neoplasm of Rectum: ICD-10 C19-20	135
Table B4-16: Malignant Neoplasm of Anus: ICD-10 C211	
Table B4-17 : Malignant Neoplasm of Colon (Excluding anus): ICD-10 C18-201	137
Table B4-18: Malignant Neoplasm of Colon (Including anus): ICD-10 C18-211	
Table B4-19 : Malignant Neoplasm of Liver: ICD-10 C22	139
Table B4-20 : Malignant Neoplasm of Gall Bladder: ICD-10 C23-241	
Table B4-21 : Malignant Neoplasm of Pancreas: ICD-10 C25	41
Table B4-22: Malignant Neoplasm of Nasal Cavity: ICD-10 C30-311	
Table B4-23 : Malignant Neoplasm of Larynx: ICD-10 C32	143
Table B4-24: Malignant Neoplasm of Trachea and Lung: ICD-10 C33-341	44
Table B4-25 : Malignant Neoplasm of Other Thoracic Organs: ICD-10 C37-381	45
Table B4-26: Malignant Neoplasm of Bone: ICD-10 C40-411	
Table B4-27: Malignant Neoplasm of Skin/Melanoma: ICD-10 C43	u
Table D4.20 : Mesethelisme: ICD 10 C45	140
Table B4-28 : Mesothelioma: ICD-10 C45	
Table B4-29 : Kaposi's Sarcoma: ICD-10 C461	
Table B4-30: Malignant Neoplasm of Connective and Soft Tissues: ICD-10 C47-491	
Table B4-31 : Malignant Neoplasm of Breast: ICD-10 C501	
Table B4-32: Malignant Neoplasm of Vulva: ICD-10 C511	52
Table B4-33: Malignant Neoplasm of Vagina: ICD-10 C521	
Table B4-34 : Malignant Neoplasm of Cervix Uteri: ICD-10 C531	
Table B4-35 : Malignant Neoplasm of Corpus Uteri: ICD-10 C541	155
. a.s	

Table B4-36: Malignant Neoplasm of Uterus Unspecified: ICD-10 C55	156
Table B4-37: Malignant Neoplasm of Ovary: ICD-10 C56	
Table B4-38: Malignant Neoplasm of Other Female Genital Organs: ICD-10 C57	158
Table B4-39: Malignant Neoplasm of Placenta: ICD-10 C58	
Table B4-40: Malignant Neoplasm of Penis: ICD-10 C60	
Table B4-41: Malignant Neoplasm of Prostate: ICD-10 C61	161
Table B4-42 : Malignant Neoplasm of Testis: ICD-10 C62	162
Table B4-43: Malignant Neoplasm of Other Male Genitals: ICD-10 C63	163
Table B4-44: Malignant Neoplasm of Kidney: ICD-10 C64	
Table B4-45: Malignant Neoplasm of Renal Pelvis: ICD-10 C65	165
Table B4-46: Malignant Neoplasm of Ureter: ICD-10 C66	166
Table B4-47: Malignant Neoplasm of Kidney, Ureter and Urethra: ICD-10 C64-66, C68	167
Table B4-48: Malignant Neoplasm of Bladder: ICD-10 C67	168
Table B4-49: Malignant Neoplasm of Other Urinary Organs: ICD-10 C68	169
Table B4-50 : Malignant Neoplasm of Eye: ICD-10 C69	170
Table B4-51: Malignant Neoplasm of Brain: ICD-10 C71	
Table B4-52: Malignant Neoplasm of Meninges CNS: ICD-10 C70, C72	
Table B4-53: Malignant Neoplasm of Brain and CNS: ICD-10 C70-72	
Table B4-54: Malignant Neoplasm of Thyroid: ICD-10 C73	
Table B4-55 : Malignant Neoplasm of Adrenal Gland: ICD-10 C74	
Table B4-56: Malignant Neoplasm of Other Endocrine: ICD-10 C75	
Table B4-57 : Hodgkin's Disease: ICD-10 C81	177
Table B4-58 : Non-Hodgkin's Lymphoma: ICD-10 C82-85, C96	
Table B4-59 : All Lymphoma's: ICD-10 C81-85, C96	
Table B4-60 : Immunoproliferative Neoplasms: ICD-10 C88	
Table B4-61 : Multiple Myeloma: ICD-10 C90	
Table B4-62 : Lymphoid Leukemia: ICD-10 C91	
Table B4-63 : Myeloid Leukemia: ICD-10 C92-94	
Table B4-64 : Leukemia Unspecified: ICD-10 C95	
Table B4-65 : Unknown Primary Site: ICD-10 C76-80, C26, C39	
Table B4-66: Cancers with alcohol use as an identified risk factor: ICD-10 C01-06, C09-10, C	
15, C22, C32, C50	186
Table B4-67: Cancers with smoking as an identified risk factor: ICD-10 C00-06, C09-16, C21.	
C25, C32-34, C51.9, C53-55, C62, C64, C65, C67	187

LIST OF FIGURES

Figure 1:	Age-standardised Incidence Rates (a),(b) for All Cancers (c) by Sex, ACT and Australia (d),
	1995 -2000
Figure 2:	Age-standardised Incidence Rates (a),(b) for Breast Cancer (c), ACT and Australia (d), 1995-
	2000
Figure 3:	Age-standardised Incidence Rates (a),(b) for Prostate Cancer (c), ACT and Australia (d),
	1995-2000
	Age-standardised Incidence Rates (a),(b) for Colorectal Cancer (c), by Sex, ACT and
	Australia (d), 1995-2000
Figure 5:	Age-standardised Incidence Rates (a),(b) for Melanoma (c), by Sex, ACT and Australia (d),
	1995-2000
Figure 6:	Age-standardised Incidence Rates (a),(b) for Lung Cancer (c), by Sex, ACT and Australia (d),
C: 7.	1995-2000
Figure 7:	Age-standardised Mortality Rates (a),(b) for All Cancers (c) by Sex, ACT and Australia (d), 1995 -2000
Eiguro 0:	1995 -2000
rigule 6.	1995 -2000
Figure 0.	Age-standardised Mortality Rates (a),(b) for Colorectal Cancer (c) by Sex, ACT and Australia
	(d), 1995 –2000
): Age-standardised Mortality Rates ^{(a),(b)} for Female Breast Cancer ^(c) , ACT and Australia
	^(d) , 1995 –2000
Figure 11	: Age-standardised Mortality Rates (a),(b) for Prostate Cancer (c), ACT and Australia (d), 1995
•	– 2000
Figure 12	2: Age-standardised Mortality Rates (a),(b) for Melanoma (c), ACT and Australia (d), 1995 –
	2000

ABBREVIATIONS

ABS: Australian Bureau of Statistics

ACT: Australian Capital Territory

AIHW: Australian Institute of Health and Welfare

ERP: Estimated Resident Population

ICD-10-AM: International Classification of Diseases, Version 10, Australian Modification

NMSC: Non-melanocytic skin cancer

NSW: New South Wales

PHRC: Population Health Research Centre

PSA testing: Prostate Specific Antigen testing

YLL: Years of Life Lost

INTRODUCTION

The term cancer refers to a group of neoplastic diseases in which there is a transformation of normal body cells into malignant cells. Cells have a specific function in the body and under normal conditions they grow and multiply in an orderly manner. However, they may multiply uncontrollably and form tumours or neoplasms. If the neoplasms are malignant (cancerous) they have the ability to grow and invade other parts of the body.

The prognosis for a cancer depends on the type of cancer, whether it is slow or fast growing, the stage at diagnosis and the availability of timely and appropriate treatment. Treatment may involve surgery, chemotherapy and radiotherapy depending on the type of cancer and stage of the cancer at diagnosis. Prevention usually involves avoiding the risks associated with cancer, such as certain types of diet and exposure to carcinogens such as radiation, some chemicals, tobacco and alcohol. Early detection is essential for a favourable prognosis with certain cancers.

In 1996, cancer was declared a National Health Priority Area. There are eight cancer groups – lung cancer, breast cancer, cervical cancer, colorectal cancer, melanoma, prostate cancer, non-Hodgkin's lymphoma and non-melanocytic skin cancer – identified as priorities, with potential for significant health gain.

Information on the incidence of cancer and mortality due to cancer in the ACT has been collected since 1972. The notification of cancer became mandatory in 1994, with the establishment of the ACT Cancer Registry under the Public Health Act. Since then, it has been a legal requirement that all public and private hospitals, general practitioners, pathology laboratories and nursing homes notify newly diagnosed cancers.

The ACT Cancer Registry routinely publishes information on cancer incidence and mortality in the ACT for the information of the community, health service providers and planners. In addition to publishing cancer-related information for the ACT, the Registry provides data to the National Cancer Statistics Clearing House (Australian Institute of Health and Welfare) for national reporting.

The NSW Cancer Registry undertakes data management and coding on behalf of the ACT Cancer Registry, reflecting both the considerable resources required to collect, code and process cancer registry data, and cross-border use of medical services between the ACT and NSW. The ACT Registrar of Births, Deaths and Marriages provides mortality data for the monitoring of cancer-related deaths.

This report presents a brief overview of the demographic characteristics for the ACT population, and review of a series of health status indicators and a behavioural risk factor profile for the ACT.

Incidence and mortality from all cancers for the ACT are presented as five-year averages to minimise the degree of variation in annual rates generated by small numbers, and to protect the confidentiality of individuals diagnosed with cancer.

The appended tables detail cancer incidence and mortality for the 1996 to 2000 period (Appendix A), and for the previous period, 1995 to 1999 (Appendix B). For each cancer site, the tables include the number of cases for males and females by five-year age group; crude and age standardised rates per 100,000 population; lifetime risk; years of life lost and numbers of cases as a percentage of all cancers.

The five leading cancer sites for the 1996-2000 period are presented and discussed in the main body of this report, with illustrations of recent trends using two-year averages. Note that the trends are presented for descriptive purposes only, and that no formal comparisons between the Australian and ACT rates are undertaken. The scale of each graph also varies with each cancer, so that the trends depicted for one cancer should not be directly compared to another. The comparative cancer incidence and mortality rates discussed in the text for Australia are for the year 1999 (the most recent national-level data available at the time of publication).

The ACT cancer mortality rates presented in this report will vary slightly from rates published by the Australian Institute of Health and Welfare (AIHW). This is primarily because the cancer mortality

rates published by the AIHW include deaths of individuals who are not usual residents of the ACT, but whose deaths are registered in the ACT. Mortality rates calculated in this way may be misleading, as a substantial proportion of cancer related deaths registered in the ACT (approximately 16%) are for NSW residents.

The mortality rates in this report include only usual residents of the ACT, and therefore provide the more accurate picture of mortality due to cancer in the ACT.

In addition to cancer incidence and mortality, breast cancer screening and Prostate Specific Antigen (PSA) testing are discussed briefly in the text. The age standardised participation rates that are provided for the BreastScreen program are for the period 1997 to 1998. These were the most recent participation rates available for both the ACT and Australia at the time of writing.

It is anticipated that the Cancer in the ACT Report will be published on a biennial basis. The next report, anticipated in 2004, will therefore present incidence and mortality for the period 1998-2002.

1. A PROFILE OF THE ACT

1.1 DEMOGRAPHIC CHARACTERISTICS OF THE ACT **POPULATION IN 2000**

The estimated resident population of the ACT was 315,215 persons at 30 June 2000. The ACT had a younger population than the national average, with a median age of 32.8 years compared to 35.2 years nationally.^{2,3}

The 2001 Census information suggests that the ACT population is relatively homogenous. Approximately three out of every four people in the ACT on Census night were born in Australia and one in five spoke another language at home other than English.⁴ The Aboriginal and Torres Strait Islander population accounted for 1.2 per cent of the ACT population at 30 June 2001. 5

Table 1: Demographic Characteristics of the ACT Population

<u> </u>	Units	Period	ACT	Australia
Demographic Characteristics				
Estimated resident population (ERP)	No.	2000	315,215	19,153,380
Indigenous population (ERP)	No.	2001	3,909	458,520
Rate of population growth	%	1999-2000	0.9	1.2
Median age	Years	2000	32.8	35.2
Deaths registered	No.	2000	1,300	128,300
Birth Place				
Australia	%	2001	77.4	76.9
Overseas	%	2001	22.6	23.1
Birth Trends				
Total fertility rate (per woman)	No.	2000	1.61	1.75
Mean age of women at confinement	Years	2000	30.3	29.6
Teen (15-19yrs) birth rate	No.	2000	10.9	17.4
Unemployment				
Males	%	2000-2001	5.4	6.7
Females	%	2000-2001	3.9	6.0
Persons	%	2000-2001	4.7	6.4
Education				
Post-school qualifications (of all aged 15-	%	2000	54	43.8
64) Did not complete highest level of secondary school (of all aged 15-64)	%	2000	16.5	32
Females - with post-school educational qualifications	%	2000	48.4	45.8

Sources

ABS. Australian Social Trends-2001, 2002. Catalog No. 4102.0 ABS. Australian Demographic Statistics, December Quarter 2002. Catalog No. 3101.0 ABS. Births Australia – 2000. Catalog. No. 3301.0.

The total fertility rate (TFR), which represents the average number of babies a woman could expect to bear during her lifetime based on current age-specific fertility rates, was 1.61 for the ACT in 2000. This was slightly lower than the national TFR (1.75), and was the lowest TFR of all States and Territories in Australia in 2000.

The ACT teenage birth rate (births to mothers aged 15-19 years) was lower than the rate for Australia in 2000. There were 120 births to teenage mothers in the ACT in 2000, equivalent to a rate of 10.9 births per 1,000 females aged 15-19 years. This compares to a national rate of 17.4 teenage births in 2000.

Fertility trends over time suggest that women in the ACT are continuing to delay childbirth. There has been a gradual increase in age-specific fertility rates in age groups less than 30 years and a gradual increase in fertility rates in age groups over 30 years. Since 1997, the 30-34 year age group has had the highest fertility rate in the ACT, similar to the national population. The mean age of women at confinement in the ACT has increased from 29.1 years in 1991 to 30.3 years in 2000.

In 2000, there were 4,065 births registered in the ACT where the mother was a usual resident of the Territory. This represented a four per cent decrease in registered births (about four per cent) from 1999, and a decrease of about nine per cent from 1990. 6,7,8

During the 2000 to 2001 period, the unemployment rate for the ACT was 4.7 per cent, which was lower than the rate for Australia (6.4%). The unemployment rate for ACT women was 3.9 per cent, notably lower than the rate for women nationally (6.0%). For males, the ACT and national unemployment rates were 5.4 per cent and 6.7 per cent, respectively.⁹

Education levels in the ACT were higher than the levels for the Australian population in 2000. Fifty-four per cent of the ACT population aged 15-64 years had post school qualifications, compared to 43.8 per cent nationally. Further, 16.5 per cent of the ACT population aged 15-64 years had not completed the highest level of secondary school education, compared to 32.0 per cent nationally and 48.4 per cent of ACT females had post-school educational qualifications compared to 45.8 per cent nationally. ³

1.2 HEALTH STATUS OF THE ACT POPULATION IN 2000

In general, summary health measures suggest the ACT population enjoys a high level of health status. Life expectancy is a key indicator of population health. In 2000, life expectancy at birth for ACT males was 78.3 years compared to 76.6 years for Australia. Life expectancy at birth for ACT females was 82.3 years, similar to life expectancy for females nationally (82.0 years).

The ACT had lower standardised death and infant mortality rates than Australia in 2000. The ACT infant mortality rate was 4.2 deaths per 1,000 live births compared to 5.2 deaths per 1,000 live births nationally. The standardised death rate for the ACT was 5.1 deaths per 1,000 population compared to 5.7 deaths per 1,000 national population. The median age at death for males in the ACT was 73.5 years, compared to 79.9 years for females and the median age at death for males nationally was 75.3 years, compared to 81.7 years for females. ⁵

Table 2: Health Status of the ACT and Australia, 2000

Health Status	ACT	Australia
Life expectancy (years)		
Male life expectancy at birth	78.3	76.6
Female life expectancy at birth	82.3	82.0
Mortality		
Crude death rate (per 1,000 population)	4.2	6.7
Standardised death rate (per 1,000 population)	5.1	5.7
Infant mortality rate (per 1,000 live births)	4.2	5.2

Source: ABS. Australian Social Trends 2002. Catalog No. 4102.0.

The leading causes of mortality for ACT residents in 2000 were cardiovascular disease and cancer. Together, they accounted for approximately 70 per cent of all deaths among ACT residents. They also account for the majority of deaths in Australia each year (Table 3).

Cardiovascular disease was the leading cause of death, accounting for 39.2 per cent of all ACT resident's deaths in 2000, compared to 38.7 per cent nationally.

Malignant neoplasms (cancers) were the second leading cause of death in 2000, accounting for 30 per cent and 27.8 per cent of all deaths in the ACT and Australia, respectively. In the ACT,

31.9 per cent of all male deaths and 28.3 per cent of all female deaths were due to cancer, compared to 30.2 per cent and 25.2 per cent nationally. 7,10

Table 3: Selected Causes of Death, ACT and Australia, 2000

Cause of Death	ACT (%)	Australia (%)
Diseases of the circulatory system	39.2	38.7
Malignant neoplasms	30.0	27.8
Diseases of the respiratory system	6.8	8.5
Diseases of the digestive system	2.3	3.2
Endocrine, nutritional and metabolic diseases	2.2	3.2
Mental and behavioural disorders	2.2	2.4
Other causes of death	17.3	16.2

Sources: ABS. Demography, Australian Capital Territory 2000 . Catalog. No. 3311.8
ABS. Causes of Death. Australia 2000 . Catalog. No. 3303.0

1.3 RISK FACTOR PROFILE FOR THE ACT

Chronic diseases such as cancer, cardiovascular disease, diabetes and depression account for a large proportion of the burden of disease in Australia. Avoidable, or modifiable risk factors associated with chronic disease, such as smoking, harmful levels of alcohol consumption, physical inactivity and poor nutrition, present an opportunity for significant health gain.

In general, the prevalence of modifiable risk factors in the ACT compare favourably with the prevalence of modifiable risk factors nationally. Estimates derived from the 2001 National Health Survey suggest that about one in ten (11.7%; 95% CI 10.0-13.4) adults (18 years or more) in the ACT consumed alcohol at 'risky' or 'high risk' levels in 2001. This was similar to the national rate (10.8%; 95% CI 10.3-11.3) in 2001. The survey results indicate smoking rates among adults in the ACT (20.0%; 95% CI 17.9-22.1) were lower, and rates of moderate to high intensity physical activity were higher in the ACT (38.3%; 95% CI 35.7-40.9) compared to Australia (smokers: 24.3%, 95% CI 23.7-24.9; moderate-high physical activity: 30.7%, 95% CI 30.0-31.4) in 2001. ¹¹

The results of the 2000 National Physical Activity Survey indicate 42.2 per cent (95% CI 37.2-47.1) of the adult (18-75 years) ACT population were above a healthy weight (30.7% overweight and 11.5% obese) in 2000. In comparison, 45.2 per cent (95% CI 43.1-47.1) of Australians were overweight (33.2%) or obese (12.0%). Fifty-four per cent of people in the ACT were within the healthy weight range, and four per cent of the population were underweight.¹²

A healthy diet is essential for good health and wellbeing. Whilst good nutrition may have a protective effect against diseases such as osteoporosis, poor nutrition is an important risk factor for certain cancers and other diseases such as obesity, coronary heart disease, stroke and diabetes mellitus.

The results of the 2001 National Health Survey suggest there was a high prevalence of sub-optimal, eating behaviours among ACT residents aged 12 years or more in 2001. However, the results for the ACT were either similar, or more favourable than the results for Australia. For instance, approximately 20.9 per cent (95% CI 19.6 - 22.2) of ACT respondents indicated that they did not consume the recommended daily serves of vegetables to maintain a healthy diet. The comparable estimate for Australia was 22.5 per cent (95% CI 22.1 - 22.9). Approximately 46.8 per cent (95% CI 45.3 - 48.3) of ACT respondents indicated that they did not consume the recommended daily serves of fruit to maintain a healthy diet. The comparable estimate for Australia was similar at 47.3 per cent (95% CI 46.8 - 47.8).

A large proportion of ACT respondents (46.5%; 95% CI 45.0-48.0) also reported a preference for whole milk, which has a high fat content compared to the low fat varieties recommended for adults, however, a greater proportion of respondents reported a preference for whole milk at the national level (48.7%; 95% CI 48.2-49.2). In addition, a considerable proportion of ACT respondents were

inclined to add salt to food after cooking (36.1%; 95% CI 34.7 - 37.5). Once again, the comparable result for Australia was higher (45.0%; 95% CI 44.5 - 45.5).

Table 4: Prevalence of Modifiable Risk Factors, ACT and Australia

RISK FACTOR	ACT (%)	Australia (%)
Percentage of Persons Aged 18 Years or More		
Smoking Status Smoker Ex-smoker Never smoked	20.0 29.3 50.7	24.3 26.3 49.4
Drinking Status Did not consume/low risk Risky/high risk	88.3 11.7	89.2 10.8
Exercise Level Sedentary Low Moderate High	24.1 37.6 30.2 8.1	31.5 37.8 24.3 6.4
Body Mass Index (BMI) % of Persons Aged 18 – 75 Years		
Body Mass Index (BMI) Underweight (BMI <18.5) Normal range (BMI 18.5 – 24.99) Overweight (BMI 25 – 29.99) Obese (BMI 30+)	3.7 54.2 30.7 11.5	3.4 51.4 33.2 12.0
Daily Food Consumption - % of Persons Aged 12 Years or More		
Usual daily serves of vegetables Doesn't eat vegetables/1 serve or less (a) 2-3 serves 4 serves or more	20.9 51.3 27.9	22.5 47.8 29.7
Usual daily serves of fruit Doesn't eat fruit/1 serve or less (b) 2-3 serves 4 serves or more	46.8 42.6 10.5	47.3 42.4 10.3
Usual type of milk Whole ^(c) Low/reduced fat Skim Others	46.5 34.2 10.0 9.3	48.7 29.9 12.4 9.0
Salt added after cooking Never/rarely Sometimes Usually	63.9 16.9 19.2	54.9 19.5 25.5

Sources:

ABS. 2001 National Health Survey: Summary of Results. Catalog. No. 4364.0. ACT Health, PHRC. Physical Activity Patterns of Adults in the ACT, 2000. Health Series No. 29.

⁽a) This is below NHMRC minimum daily requirements.
(b) This is below NHMRC minimum daily requirements.
(c) The NHMRC recommend low/reduced fat milk for adults.

2. THE INCIDENCE OF CANCER IN THE ACT, 1996-2000

In this section, cancer incidence for the ACT is defined as the number of new primary cancers diagnosed in people resident in the ACT for a specific period. Incidence data has been grouped into multiple years and presented as averages to minimise the degree of variation in annual rates generated by small numbers, and to protect the confidentiality of ACT residents diagnosed with cancer

Age-standardised incidence rates for individual cancer sites are provided according to the International Classification of Diseases, 10th Revision, Topo10 (ICD-10 Topography) code. Non-melanocytic skin cancer (NMSC), ICD-10 code C44, is excluded from the analysis, and colorectal cancer (ICD-10 code C18-C21) includes cancer of the anus (C21). The data are standardised to the 1991 Australian population.

Incidence rates discussed in the text for the ACT are based on five-year averages for 1996 to 2000 and compared to Australian rates for the year 1999. Incidence data for 2000 were not available for Australia.

Trends in cancer incidence over time are presented in this section to assist the reader in visualising the relative positions of the ACT and Australian populations. Recent trends for the top five leading cancer incidence sites are provided, and detailed information on incidence for individual cancer sites is provided in the Appendices. The trend figures presented in graphs in this section are based upon two-year moving averages, for both the ACT and Australia. No formal comparisons of the ACT and Australian incidence trends over time have been undertaken, the trends are presented for descriptive purposes only.

2.1 INCIDENCE OF ALL CANCERS

There were 5,246 new cases of cancer registered for ACT residents between 1996 and 2000. Fifty-four per cent of these new cases were reported in males and 46 per cent were reported in females. The age-standardised incidence rates for all cancers combined for males and females in the ACT were 494.0 (95% CI 474.9-513.1) and 336.3 (95% CI 322.6-350.0) per 100,000, respectively. During this period, males had a greater risk of being diagnosed with cancer than females. The estimated lifetime risk of cancer in the ACT was one in three for men and one in four for women during the period 1996 to 2000. This was the same as the lifetime risk of cancer observed nationally in 1999. If


The risk of cancer is low in childhood, but increases with age. The average age at which ACT residents were diagnosed with cancer was 63 years for males and 60 years for females between 1996 and 2000. Approximately one per cent of all cancer registrations were for residents less than 15 years of age. In this age group, the most common cancers registered were leukemias (39%), cancers of the brain and central nervous system (22%), and lymphomas (12%).

Forty-one per cent of all cancers registered were for residents in the 15-59 year age group, with the most frequently diagnosed cancers being breast (23%), melanoma (16%) and colorectal (11%) cancers.

Fifty-eight per cent of the cancer diagnoses that were registered between 1996 and 2000 were for persons aged 60 years and over. In this age group, the most common cancers diagnosed were prostate (21%), colorectal (15%), breast (10%), and trachea, bronchus and lung (9%) cancers.

Between 1996 and 2000, the Australian and ACT female age-standardised incidence rates for all cancers were relatively stable, with a slight increase in the ACT rates observed for the 1999 to 2000 period. There was a decrease in ACT and Australian male cancer incidence during the 1996 to 2000 period, although incidence rates for ACT males rose slightly in 1999-2000 (Figure 1).

Figure 1: Age-standardised Incidence Rates (a),(b) for All Cancers (c) by Sex, ACT and Australia (d), 1995 -2000



Sources

ACT Cancer Registry, 1995-2000.

AIHW. Cancer in Australia, 1999. Catalog. No. CAN 15

- IVV. Cancer in Australia, 1995. Catalog. 190. CAN 13.

 The rates presented are two-year averages.

 The rates have been standardised to the 1991 Australian population.
- Data excludes non-melanocytic skin cancers.

 At the time of preparation, 2000 data for Australia were not available.

2.2 INCIDENCE OF LEADING CANCER SITES

The five leading cancer incidence sites accounted for 61 per cent of all new cancers registered in the ACT between 1996 and 2000. The five most common cancers registered were prostate (15.2%), breast (15.2%), colorectal - including anus (13.2%), melanoma (10.2%) and trachea, bronchus and lung (7.2%) cancers. For males, the five most common cancers registered were prostate (28.3%), colorectal - including anus (13.6%), melanoma (11.1%), trachea, bronchus and lung (7.8%) cancers and non-Hodgkin's lymphomas (4.5%). For females, the five most common cancers registered were breast (32.6%), colorectal (12.7%), melanoma (9.2%), trachea, bronchus and lung (6.5%) and non-Hodgkin's lymphomas (4.2%).

2.2.1 **Breast Cancer in Females**


Breast cancer is the most common cancer (apart from non-melanocytic skin cancer) in Australian women. Some of the risk factors for the disease include having a family history of the disease, nulliparity, early onset of menstruation, later menopause, mutations in the BRCA1 and BRCA2 genes, use of oral contraceptives, hormone replacement therapy, obesity and consumption of alcohol. The risk of disease increases with age in women. 15 Males can also develop the disease. although it is uncommon.

Breast cancer was the second most common registered cancer (excluding non-melanocytic skin cancer) among all residents of the ACT and the most common cancer registered for female residents during the 1996 to 2000 period. Breast cancer accounted for 43 per cent of all cancers reported in females between the ages of 45 and 64 years.

ACT and Australian breast cancer incidence rates increased between 1995 and 2000 (Figure 2). While there was a notable increase in breast cancer incidence for the ACT over this period, which will be closely monitored over time, the five-year age-standardised ACT breast cancer incidence rate for 1996 to 2000 was 104.9 per 100,000 population (95% CI 97.4-112.4). 13 This was within the range for the Australian rate in 1999, 97.7 per 100,000, population (95% CI 95.9-99.6). 1

The Population Health Research Centre has published a discussion paper on breast cancer in the ACT, available from the ACT Health website: http://www.health.act.gov.au/publications

Figure 2: Age-standardised Incidence Rates (a),(b) for Breast Cancer (c), ACT and Australia (d), 1995-2000



Sources

ACT Cancer Registry, 1995-2000.

AIHW. Cancer in Australia, 1999. Catalog. No. CAN 15

- The rates presented are two-year averages.

 The rates have been standardised to the 1991 Australian population.
- Data excludes non-melanocytic skin cancers
- At the time of preparation, 2000 data for Australia were not available.

Prostate Cancer

The growth of cancer cells in the prostate, like that of normal prostate cells, is stimulated by male hormones especially testosterone. Compared with other types of cancer, prostate cancer is relatively slow growing and men with prostate cancer may live for many years without ever having the cancer diagnosed.

As is the case with other cancers, the cause of prostate cancer is unknown. Studies have found that age, family history, ethnicity, environmental pollutants and diet are potential risk factors for prostate cancer. Being over 60, having a father, uncle/s or brother/s with prostate cancer, having African-American, Afro-Caribbean or Latino ancestry, long term consumption of inorganic arsenic (through drinking water) and a diet high in animal fat appears to increase the risk of developing the disease. Diets high in fruit and vegetables may decrease the risk. 15

Prostate cancer in men rose from being the fourth leading cancer reported prior to 1987 to the most common cancer in men between 1996 and 2000. A total of 796 new cases of prostate cancer were diagnosed in ACT males during this period.


The five-year age-standardised ACT prostate cancer incidence rate was 151.7 per 100,000 population (95% CI 140.8-162.6). ¹³ This was higher than the Australian rate in 1999, 109.5 per 100,000, population (95% CI 107.3-111.6). ¹⁴

The rise in prostate cancer diagnoses in the ACT was largely due to an increase in public awareness of the disease, together with the use of Prostate Specific Antigen (PSA) testing. The test increased the detection rate of prostate cancer in the first half of the 1990s. PSA tests are specifically designed to identify prostate cancers before the onset of clinical symptoms, and many of these cancers may not otherwise have been detected. ACT prostate cancer incidence trends over time show a substantial time lag behind Australia, which reflects a delayed uptake of PSA testing in the ACT, compared to Australia.

The Cancer Council of Australia has stated that there is insufficient evidence to determine whether or not routine PSA testing prevents death from prostate cancer at this point in time. Because most prostate cancers are slow growing and occur in older men, many men who have prostate cancer

but are not treated for it will never suffer from the effects of their cancer. However, some men that are treated do suffer serious side effects from treatment, such as impotence and incontinence. The Cancer Council Australia does not advocate routine screening for prostate cancer.

Figure 3: Age-standardised Incidence Rates (a),(b) for Prostate Cancer (c), ACT and Australia (d), 1995-2000



Sources:

ACT Cancer Registry, 1995-2000.

AIHW. Cancer in Australia, 1999. Catalog. No. CAN 15.

- The rates presented are two-year averages.

 The rates have been standardised to the 1991 Australian population.
- Data excludes non-melanocytic skin cancers.

 At the time of preparation, 2000 data for Australia were not available.

2.2.3 **Colorectal Cancer**


Colorectal cancer develops from polyps, or growths, on the internal lining of the bowel. The predisposing risk factors for the disease include polyps, diabetes, family history of colorectal cancer, having had inflammatory bowel disease and increasing age. The modifiable risk factors for colorectal cancer include poor diet, physical inactivity, alcohol consumption, smoking and excessive weight. 15

The prognosis for people diagnosed with the disease is largely dependent on the extent of the cancer at diagnosis. In its early stages, colorectal cancer is largely manageable and treatable.

The age standardised colorectal cancer incidence rate for ACT males between 1996 and 2000 was 66.8 per 100,000 population (95% CI 59.8-73.8), which was similar to the national rate in 1999 (65.1 per 100,000 population; 95% CI 63.5-66.7). The incidence rate for colorectal cancer in ACT females was 45.3 per 100,000 population (95% CI 40.2-50.5), which was also similar to the national rate in 1999 (47.0 per 100,000 population; 95% CI 45.7-48.3).

Colorectal cancer was the third most common cancer registered for both males and females during the 1996 to 2000 period. ACT colorectal cancer rates fluctuate annually, reflecting the small number of cases registered (Figure 4).

Figure 4: Age-standardised Incidence Rates ^{(a),(b)} for Colorectal Cancer ^(c), by Sex, ACT and Australia ^(d), 1995-2000



Sources:

ACT Cancer Registry, 1995-2000.

AIHW. Cancer in Australia, 1999. Catalog. No. CAN 15.

- The rates presented are two-year averages
- The rates have been standardised to the 1991 Australian population.
- Data excludes non-melanocytic skin cancers.
- At the time of preparation, 2000 data for Australia were not available.


2.2.4 Melanoma

Melanoma usually presents as a pre-existing mole that has changed colour or shape, or a newly developed, irregular mole. Major risk factors include having a fair complexion, having multiple dark moles, older age and a personal or family history of melanoma. 17,18

Australia has one of the highest prevalence rates for melanoma in the world. During the 1996 to 2000 period, for both males and females, melanoma was the fourth most commonly diagnosed cancer, accounting for 11.1 per cent of all male and 9.2 per cent of all female cancers in the ACT.

The incidence rate for melanoma among ACT females was slightly lower (29.1 per 100,000 population; 95% CI 25.2-33.0) for the period 1996 to 2000, than observed nationally in 1999 (34.2 per 100,000 population; 95% CI 33.0-35.3). Although the incidence rate of melanoma in ACT males fluctuated over the 1996 to 2000 period, it was similar to that observed nationally (Figure 5). 13, 14

Figure 5: Age-standardised Incidence Rates (a),(b) for Melanoma (c), by Sex, ACT and Australia (d), 1995-2000



Sources

ACT Cancer Registry, 1995-2000. AIHW. Cancer in Australia,1999. Catalog. No. CAN 15.

- The rates presented are two-year averages.

 The rates have been standardised to the 1991 Australian population.
- Data excludes non-melanocytic skin cancers.
 At the time of preparation, 2000 data for Australia were not available.


2.2.5 **Lung Cancer**

Cancer that starts in the lung is known as primary lung cancer. Tobacco smoking is the major risk factor for lung cancer and estimates suggest that approximately 92 per cent of all lung cancers in Australia are attributable to smoking. 19 Exposure to asbestos, uranium, chromium, nickel and radon are also risk factors for lung cancer. As with other cancers, the risk for developing lung cancer increases with age. 15 Males have a higher risk of developing the disease than females, which is largely a reflection of the historically higher smoking rates among men.²⁰

During the 1996 to 2000 period, the risk of developing lung cancer by the age of 75 was one in 29 for males, compared to one in 46 for females. There were 219 new cases of lung cancer diagnosed in ACT men and 159 new cases in ACT women between 1996 and 2000. During this period, lung cancer was the fifth most commonly diagnosed cancer for ACT males and females, with 1.4 times more males than females diagnosed with the disease.

The incidence of male lung cancer in the ACT was 40.5 per 100,000 population (95% CI 35.0-46.1), which was notably lower the national rate for males at 56.0 per 100,000 population (95% CI 54.5-57.5). The overall rate of lung cancer in ACT females, while varying from year to year, was similar to that observed nationally (Figure 6). 13, 14

Figure 6: Age-standardised Incidence Rates (a),(b) for Lung Cancer (c), by Sex, ACT and Australia (d), 1995-2000



Sources:

ACT Cancer Registry, 1995-2000.

AIHW. Cancer in Australia,1999. Catalog. No. CAN 15.

- The rates presented are two-year averages.
 The rates have been standardised to the 1991 Australian population.
- Data excludes non-melanocytic skin cancers.
- At the time of preparation, 2000 data for Australia were not available.

3. MORTALITY DUE TO CANCER IN THE ACT, 1996-2000

In this section, cancer mortality is defined as the number of people resident in the ACT when diagnosed with cancer, who died from cancer between 1 January 1996 and 31 December 2000. Mortality data has been grouped into multiple years and presented as averages to minimise the degree of variation in annual rates generated by small numbers, and to protect the confidentiality of ACT residents that have died from cancer.

Age-standardised mortality rates for all cancers and individual cancer sites are provided according to the International Classification of Diseases, 10th Revision, Topo10 (ICD-10 Topography) code. Non-melanocytic skin cancer (NMSC), ICD-10 code C44, is excluded from the analysis, and colorectal cancer (ICD-10 code C18-C21) includes cancer of the anus (C21). The data are standardised to the 1991 Australian population.

Mortality rates discussed in the text for the ACT are based on five-year averages for the 1996 to 2000 period and compared to Australian rates for the year 1999.

The ACT cancer mortality rates presented in this report will vary slightly from rates for the ACT presented in cancer reports produced by the Australian Institute of Health and Welfare (AIHW). This is primarily because the cancer mortality rates presented by the AIHW include deaths of individuals who are not usual residents of the ACT, but who die while in the ACT. Mortality rates calculated in this way may be misleading, as a substantial proportion of cancer related deaths registered in the ACT (approximately 16%) are for NSW residents.

The mortality rates in this report include only usual residents of the ACT, and therefore provide the more accurate picture of mortality due to cancer in the ACT.

Trends in cancer mortality over time are presented in this section to assist the reader in visualising the relative positions of the ACT and Australian populations. Recent trends for the top five leading cancer mortality sites are provided - detailed information on mortality for individual cancer sites is provided in the Appendices. The trend figures presented in graphs in this section are based upon two-year moving averages, for both the ACT and Australia. No formal comparisons of the ACT and Australian mortality trends over time have been undertaken, the trends are presented for descriptive purposes only.

Caution should be exercised when interpreting recent trends in mortality as much of the observed variation will reflect fluctuation due to very small numbers.

3.1 MORTALITY FOR ALL CANCERS


Cancer was the second leading cause of death in the ACT after cardiovascular disease, accounting for 30 per cent of all ACT resident's deaths in 2000. The most common cancers causing death in ACT males were cancer of the trachea, bronchus and lung (16.5%), colorectal cancer (including anus) (12.9%) and prostate cancer (11.0%), accounting for 40 per cent of all cancer deaths in males. The most common cancers causing death in ACT females were breast cancer (20.5%), cancer of the trachea, bronchus and lung (13.5%) and colorectal cancer (13.0%), accounting for 47 per cent of all female cancer deaths.

There were 2,163 cancer deaths during the 1996 to 2000 period. Males are generally at greater risk of death than females for the vast majority of cancers. Fifty-three per cent (1,151 deaths) of cancer deaths occurred in ACT males and 47 per cent (1,012 deaths) occurred in ACT females. The age-standardised cancer death rate for males was 228.0 per 100,000 population (95% CI 214.3-241.8) while the rate for females was 147.8 per 100,000 population (95% CI 138.5-157.1). If the mortality rates for the 1996 to 2000 period were to continue, one in seven ACT males and one in nine ACT females would die from cancer by the age of 75.

The age-standardised all cancer mortality rate for both males and females in the ACT, for the five-

year period 1996 to 2000, was 180.2 deaths per 100,000 population (95% CI 172.4-187.9), which was higher than the rate observed nationally in 1999 (162.6 deaths per 100,000 population; 95% CI 160.9-164.3). The overall difference primarily reflects a higher death rate among ACT females for the period 1996 to 2000 (147.8 per 100,000 population; 95% CI 138.5-157.1), compared to females nationally in 1999 (127.4 per 100,000 population; 95% CI 125.3-129.5). The male mortality rates were generally similar to the national rates for the period 1996 to 2000 (Figure 7). 13,14

Figure 7: Age-standardised Mortality Rates (a),(b) for All Cancers (c) by Sex, ACT and Australia, 1995 -2000



Sources:

ACT Cancer Registry, 1995-2000. AIHW. Cancer in Australia,1999. Catalog. No. CAN 15.

- The rates presented are two-year averages. The rates have been standardised to the 1991 Australian population.
- Data excludes non-melanocytic skin cancers.

3.2 MORTALITY FOR LEADING CANCER SITES

For males and females combined, the five leading causes of cancer mortality were cancer of the trachea, bronchus and lung (15.1%), colorectal cancer (13.0%), breast cancer (9.7%), cancer with an unknown primary site (8.9%) and prostate cancer (5.9%). Together they accounted for more than half (52.6%) of all ACT resident's cancer deaths between 1996 and 2000.

This section provides an overview of statistics and trends for the five leading cancer mortality sites in the ACT. The five leading mortality sites are similar to the five leading incidence sites, however, statistics and trends in cancer mortality where the primary site was 'unknown' has not been reviewed in this section. Mortality statistics and trends for melanoma (one of the five leading incidence sites) have been reviewed instead.


3.2.1 **Lung Cancer**

Lung cancer was the most common cause of cancer death during the 1996 to 2000 period. accounting for 15.1 per cent (327 deaths) of all cancer deaths among ACT residents. Lung cancer has been the most common cause of cancer death for males in the ACT since 1983. It was the second most common cause of cancer death for females between 1996 and 2000. Lung cancer places a high burden of disease on the population, accounting for an estimated 2,485 years of life lost in the ACT between 1996 and 2000.

Lung cancer mortality rates declined considerably for both ACT and Australian males during the five-year period to 2000 (Figure 8). The mortality rate for ACT males (36.5 deaths per 100,000 population; 31.2-41.9) for the period 1996 to 2000 was significantly lower than the national rate in 1999 (49.5 deaths per 100.000 population: 95% CI 48.0-50.9). ACT female lung cancer mortality

rates were lower than ACT male rates, but increased over the five-year period to 2000. The mortality rate for ACT females (20.6 deaths per 100,000 population; 17.1-24.1) for the period 1996 to 2000 was similar to the national mortality rate for females in 1999 (18.6 deaths per 100,000 population; 95% CI 17.8-19.4). 13,14

Figure 8: Age-standardised Mortality Rates (a),(b) for Lung Cancer (c) by Sex, ACT and Australia, 1995 -2000



Sources:

ACT Cancer Registry, 1995-2000.

- AltHW. Cancer in Australia, 1999. Catalog. No. CAN 15.

 (a) The rates presented are two-year averages.


 (b) The rates have been standardised to the 1991 Australian population.
- Data excludes non-melanocytic skin cancers.

3.2.2 **Colorectal Cancer**

Colorectal cancer was the second most common cause of cancer death in men and the third most common cause of cancer death in women for the 1996 to 2000 period, accounting for 13.0 per cent of all ACT resident's cancer deaths and 2,198 years of life lost.

Colorectal mortality rates for both ACT males and females declined during the five-year period to 2000 (Figure 9). The colorectal cancer mortality rate for ACT males (28.8 deaths per 100,000 population; 24.0-33.6), for the period 1996 to 2000, was similar to the national rate for males in 1999 (26.5 deaths per 100,000 population; 95% CI 25.5-27.6). The colorectal cancer mortality rate for ACT females (19.3 deaths per 100,000 population; 15.9-22.6), for the period 1996 to 2000, was similar to the national rate for females in 1999 (17.1 deaths per 100,000 population; 95% CI 16.4-17.9). ^{13,14}

Figure 9: Age-standardised Mortality Rates (a),(b) for Colorectal Cancer (c) by Sex, ACT and Australia, 1995 -2000



Sources:

ACT Cancer Registry, 1995-2000.

AIHW. Cancer in Australia,1999. Catalog. No. CAN 15.

- The rates presented are two-year averages.
 The rates have been standardised to the 1991 Australian population.
- Data excludes non-melanocytic skin cancers.


3.2.3 **Breast Cancer in Females**

Between 1996 and 2000, breast cancer was the leading cause of cancer death in ACT females, accounting for 20.5 per cent of all cancer deaths in ACT females. The burden of disease from breast cancer is significant, with 2,458 years of life lost in the ACT between 1996 and 2000.

Although the ACT female breast cancer mortality rate (29.2 deaths per 100,000 population; 95% CI 25.1-33.3) for the 1996 to 2000 period was significantly higher than the Australian rate in 1999 (22.0 deaths per 100,000 population; 95% CI 21.1-22.9), it has declined in recent years (Figure 10). Breast cancer in the ACT is discussed in further detail in a recent publication, which is available from the Population Health Research Centre, ACT Health.

Early detection of breast cancer, through participation in screening programs, may improve survival. BreastScreen Australia recommends a mammogram every two years and aims to recruit 70 per cent of women aged 50 to 69 years. The age-standardised ACT participation rate for women aged 50 to 69 years was 58.9 per cent compared to 54.3 per cent nationally, for the period 1997 to 1998. In 1997, 33 per cent of all breast cancers in the ACT were diagnosed by the BreastScreen program.²¹

Figure 10: Age-standardised Mortality Rates (a),(b) for Female Breast Cancer (c), ACT and Australia, 1995 -2000



Sources:

ACT Cancer Registry, 1995-2000.

AIHW. Cancer in Australia, 1999. Catalog. No. CAN 15


- The rates presented are two-year averages.
 The rates have been standardised to the 1991 Australian population.
- Data excludes non-melanocytic skin cancers.

3.2.4 **Prostate Cancer**

Prostate cancer was the third leading cause of cancer death in ACT males, and has been since 1983. The disease accounted for 11.0 per cent of all ACT male cancer deaths between 1996 and 2000 and 330 years of life lost.

Prostate cancer has a relatively low mortality rate in comparison to the incidence rate. Prostate cancer mortality rates for the 1996 to 2000 period, like most ACT cancer mortality rates, fluctuated annually due to the relatively small number of deaths each year. However, there was a general decline in mortality rates during the five-year period to 2000, for both the ACT and Australia (Figure 11). The Australian prostate cancer mortality rate (28.1 deaths per 100,000 population; 95% CI 27.0-29.2) in 1999 was similar to the rate for the ACT (29.9 deaths per 100,000 population; 95% CI 24.6-35.3) for the period 1996 to 2000. 13,14

Figure 11: Age-standardised Mortality Rates (a),(b) for Prostate Cancer (c), ACT and Australia, 1995 –2000



Sources

ACT Cancer Registry, 1995-2000.

- AIHW. Cancer in Australia,1999. Catalog. No. CAN 15.


 (a) The rates presented are two-year averages.

 (b) The rates have been standardised to the 1991 Australian population.
- Data excludes non-melanocytic skin cancers.

3.2.5 Melanoma

There were 33 ACT male melanoma related deaths and 17 ACT female deaths during the 1996 to 2000 period. Male mortality rates for melanoma are higher than mortality rates for females (Figure 12). The age standardised mortality rates for melanoma in the ACT for the period 1996 to 2000 were 5.9 deaths per 100,000 population (95% CI 3.8-8.0) and 2.4 deaths per 100,000 population (95% CI 1.3-3.6) for males and females, respectively. The comparative rates for Australia in 1999 were very similar (males: 6.7 deaths per 100,000 population, 95% CI 6.2-7.3; females: 3.2 deaths per 100,000 population, 95% CI 2.9-3.5). There were 678 years of life lost due to melanoma in the ACT during the 1996 to 2000 period. ^{13,14}

Figure 12: Age-standardised Mortality Rates (a),(b) for Melanoma (c), ACT and Australia, 1995 –2000



Sources:

ACT Cancer Registry, 1995-2000. AIHW. Cancer in Australia,1999. Catalog. No. CAN 15.

The rates presented are two-year averages.

The rates have been standardised to the 1991 Australian population.

Data excludes non-melanocytic skin cancers.

APPENDICES

APPENDIX A: 1996-2000

Table A1: The 10 Most Frequently Occurring Cancers and Cancer Caused Deaths by Gender in the ACT, 1996-2000

		New Ca	ases			Deaths					
		Per cent of all			Lifetime			Per cent of all			
	Number	new cancers	ASR (A)	ASR (W)	Risk		Number	cancer deaths	ASR (A)	ASR (W)	PYLL*
Males						Males					
Prostate	796	28.3	151.7	103.2	1 in 8	Trachea, bronchus &	190	16.5	36.5	24.0	1367.5
Colorectal (including	383	13.6	66.8	48.3	1 in 17	Colorectal (including	149	12.9	28.8	19.6	1222.5
Skin-melanoma	312	11.1	45.1	36.5	1 in 24	Prostate	127	11.0	29.9	16.8	330
Trachea, bronchus &	219	7.8	40.5	27.8	1 in 29	Unknown primary sit	105	9.1	20.5	13.2	955
Non-Hodgkin lympho	126	4.5	21.8	15.2	1 in 63	All lymphomas	63	5.5	12.1	7.8	677.5
Unknown primary sit	115	4.1	22.0	14.4	1 in 67	Stomach	62	5.4	11.6	8.1	635
Bladder	97	3.5	19.7	11.8	1 in 79	Bladder	62	5.4	14.1	7.7	197.5
Leukaemias	82	2.9	14.6	11.2	1 in 113	Leukaemias	50	4.3	10.9	6.2	435
Kidney, ureter & uret	81	2.9	13.3	9.8	1 in 88	Brain & CNS	44	3.8	7.5	5.3	707.5
Head & neck	78	2.8	12.3	9.4	1 in 99	Kidney, ureter & uret	43	3.7	8.4	5.5	355
Females						Females					
Breast	794	32.6	104.9	86.7	1 in 10	Breast	207	20.5	29.2	21.6	2457.5
Colorectal (including	309	12.7	45.3	32.5	1 in 28	Trachea, bronchus &	137	13.5	20.6	14.3	1117.5
Skin-melanoma	223	9.2	29.1	24.1	1 in 41	Colorectal (including	132	13.0	19.3	12.9	975
Trachea, bronchus &	159	6.5	23.8	17.4	1 in 46	Unknown primary sit	88	8.7	12.5	7.7	552.5
Unknown primary sit	103	4.2	14.6	9.3	1 in 121	All lymphomas	63	6.2	9.3	5.8	425
Non-Hodgkin lympho	102	4.2	14.4	10.4	1 in 85	Ovary	50	4.9	7.0	5.2	642.5
Corpus uteri	95	3.9	13.9	11.1	1 in 68	Pancreas	48	4.7	7.4	4.6	210
Ovary	71	2.9	9.4	7.6	1 in 115	Stomach	37	3.7	5.4	3.6	292.5
Kidney, ureter & uret	61	2.5	8.7	5.9	1 in 153	Leukaemias	36	3.6	5.2	3.9	520
Leukaemias	60	2.5	8.3	7.2	1 in 140	Brain & CNS	32	3.2	4.3	3.4	572.5
Persons						Persons					
Breast	800	15.2	55.3	45.1	1 in 20	Trachea, bronchus &	327	15.1	27.5	18.7	2485
Prostate	796	15.2	67.9	47.6	1 in 16	Colorectal (including	281	13.0	23.8	16.2	2197.5
Colorectal (including	692	13.2	55.4	40.0	1 in 22	Breast	210	9.7	16.3	11.7	2470
Skin-melanoma	535	10.2	36.7	30.1	1 in 31	Unknown primary sit	193	8.9	16.2	10.3	1507.5
Trachea, bronchus &	378	7.2	31.2	22.1	1 in 36	Prostate	127	5.9	11.7	6.8	330
Non-Hodgkin lympho	228	4.3	17.6	12.6	1 in 73	All lymphomas	126	5.8	10.6	6.8	1102.5
Unknown primary sit	218	4.2	18.0	11.7	1 in 88	Stomach	99	4.6	8.2	5.7	927.5
Kidney, ureter & uret	142	2.7	10.9	7.9	1 in 112	Pancreas	90	4.2	7.7	5.0	617.5
Leukaemias	142	2.7	10.8	8.9	1 in 125	Leukaemias	86	4.0	7.2	4.6	955
Bladder	121	2.3	10.4	6.7	1 in 122	Bladder	77	3.6	7.0	4.1	317.5

Note 1: Rates are expressed per 100,000 population and age-standardised to the Australian 1991 Population (ASR (A)) and to the World Population (ASR (W)).

Note 2: Non-melanocytic skin cancer, known to be the most common cancer type, is excluded from this list as it is not registered by cancer registries.

^{*} These measures are calculated for ages 0–74 years.

Table A2: Summary of Incidence Rates, 1996-2000

			ı	Males			Females				
			AS Rate	AS Rate	Lifetime	Sex ratio		AS Rate	AS Rate	Lifetime	
ICDO-2	Cancer site/type	Number	(Aust 1991)	(World)	risk	M:F	Number	(Aust 1991)	(World)	risk	
C00	Lip	18	2.6	2.0	1 in 426	1.3	14	2.0	1.5	1 in 561	
C01	Tongue	4	0.8	0.4	1 in 2382	4.0	1	0.1	0.1	1 in 12379	
C02	Other tongue	13	2.1	1.6	1 in 454	1.3	10	1.3	1.0	1 in 1096	
C03	Gum	0	0.0	0.0	NA	NA	0	0.0	0.0	NA	
C04	Floor of mouth	8	1.1	1.0	1 in 1031	NA	0	0.0	0.0	NA	
C05	Palate	5	0.8	0.6	1 in 1438	1.0	5	0.6	0.5	1 in 1599	
C06	Other & unspecified parts of mouth	5	0.7	0.6	1 in 1827	1.0	5	0.7	0.6	1 in 1290	
C07	Parotid gland	16	2.8	1.8	1 in 667	8.0	2	0.2	0.2	1 in 5609	
C08	Salivary glands	3	0.3	0.3	1 in 3917	1.0	3	0.4	0.3	1 in 3291	
C09	Tonsil	7	0.9	0.8	1 in 1105	3.5	2	0.2	0.2	1 in 5027	
C10	Oropharynx	2	0.3	0.3	1 in 3307	2.0	1	0.2	0.1	1 in 3684	
C11	Nasopharynx	5	0.9	0.8	1 in 2186	1.7	3	0.3	0.3	1 in 3855	
C12	Pyriform sinus	5	0.7	0.6	1 in 1099	5.0	1	0.1	0.1	1 in 12379	
C13	Hypopharynx	3	0.4	0.4	1 in 1625	NA	0	0.0	0.0	NA	
C14	Pharynx unspecified	2	0.4	0.2	1 in 3107	2.0	1	0.2	0.2	1 in 4893	
C15	Oesophagus	38	7.3	4.7	1 in 186	2.1	18	2.8	2.0	1 in 393	
C16	Stomach	66	12.1	8.4	1 in 99	1.4	47	7.1	5.2	1 in 156	
C17	Small intestine	6	0.8	0.7	1 in 1064	0.9	7	1.0	0.9	1 in 1081	
C18	Colon	247	44.2	31.1	1 in 27	1.1	215	31.7	23.2	1 in 37	
C19	Rectosigmoid junction	41	6.5	4.9	1 in 147	1.7	24	3.4	2.4	1 in 419	
C20	Rectum	89	14.9	11.4	1 in 72	1.5	60	8.9	5.9	1 in 173	
C21	Anus & anal canal	6	1.3	0.9	1 in 763	0.6	10	1.3	1.0	1 in 1465	
C22	Liver	32	5.8	4.1	1 in 183	2.3	14	2.0	1.6	1 in 508	
C23	Gallbladder	2	0.3	0.3	1 in 2462	0.3	6	0.8	0.7	1 in 1328	
C24	Other biliary tract	9	2.0	1.1	1 in 1231	1.3	7	0.9	0.6	1 in 2318	
C25	Pancreas	49	9.2	6.3	1 in 136	0.9	52	7.8	5.2	1 in 168	
C30	Nasal cavities & middle ear	5	0.7	0.6	1 in 1536	5.0	1	0.2	0.1	NA	
C31	Accessory sinuses	3	0.5	0.4	1 in 1657	3.0	1	0.1	0.1	1 in 12379	
C32	Larynx	29	5.2	3.3	1 in 291	7.3	4	0.6	0.3	1 in 2696	
C33	Trachea	1	0.1	0.1	1 in 6812	NA	0	0.0	0.0	NA	
C34	Bronchus & lung	218	40.4	27.7	1 in 29	1.4	159	23.8	17.4	1 in 46	
C37	Thymus	1	0.1	0.1	1 in 10198	NA	0	0.0	0.0	NA	

			ı	Males			Females				
	Cancer site/type		AS Rate	AS Rate	Lifetime	Sex ratio		AS Rate	AS Rate	Lifetime	
ICDO-2		Number	(Aust 1991)	(World)	risk	M:F	Number	(Aust 1991)	(World)	risk	
C38	Heart, mediastinum & pleura	2	0.2	0.2	1 in 5615	2.0	1	0.1	0.1	1 in 12686	
C40	Bone & articular cartilage	4	0.5	0.5	1 in 1922	1.0	4	0.5	0.6	1 in 2933	
C41	Other bone & articular cartilage	4	0.5	0.5	1 in 2176	0.7	6	0.8	0.7	1 in 2137	
C43	Skin-melanoma	312	45.1	36.5	1 in 24	1.4	223	29.1	24.1	1 in 41	
C44	Skin-non-melanocytic (NMSC)	0	0.0	0.0	NA	NA	0	0.0	0.0	NA	
C45	Mesothelioma	19	3.3	2.4	1 in 294	6.3	3	0.5	0.3	1 in 1916	
C46	Kaposi's sarcoma	5	0.6	0.6	1 in 1868	2.5	2	0.2	0.2	1 in 4011	
C47	Peripheral nerves & ANS	2	0.4	0.3	1 in 4893	NA	0	0.0	0.0	NA	
C48	Retroperitoneum & peritoneum	2	0.2	0.3	1 in 5285	0.4	5	0.7	0.5	1 in 1951	
C49	Other connective & soft tissue	10	1.4	1.2	1 in 886	1.3	8	1.2	0.8	1 in 875	
C50	Breast	6	1.0	0.8	1 in 1194	0.0	794	104.9	86.7	1 in 10	
C51	Vulva	0	0.0	0.0	NA	0.0	11	1.5	1.1	1 in 711	
C52	Vagina	0	0.0	0.0	NA	0.0	3	0.4	0.2	1 in 3684	
C53	Cervix	0	0.0	0.0	NA	0.0	53	6.8	5.6	1 in 181	
C54	Corpus uteri	0	0.0	0.0	NA	0.0	95	13.9	11.1	1 in 68	
C55	Uterus unspecified	0	0.0	0.0	NA	0.0	5	0.7	0.5	1 in 2823	
C56	Ovary	0	0.0	0.0	NA	0.0	71	9.4	7.6	1 in 115	
C57	Other & unspecified female genital orga	0	0.0	0.0	NA	0.0	6	0.9	0.6	1 in 859	
C58	Placenta	0	0.0	0.0	NA	0.0	2	0.2	0.2	1 in 6509	
C60	Penis	5	1.0	0.6	1 in 2051	NA	0	0.0	0.0	NA	
C61	Prostate	796	151.7	103.2	1 in 8	NA	0	0.0	0.0	NA	
C62	Testis	66	8.0	7.0	1 in 179	NA	0	0.0	0.0	NA	
C63	Other male genital organs	3	0.5	0.4	1 in 1373	NA	0	0.0	0.0	NA	
C64	Kidney	74	11.9	9.0	1 in 97	1.5	49	7.0	4.8	1 in 198	
C65	Renal pelvis	2	0.3	0.3	1 in 2462	0.3	8	1.2	0.8	1 in 912	
C66	Urether	2	0.4	0.3	1 in 3855	0.7	3	0.4	0.2	1 in 10054	
C67	Bladder	97	19.7	11.8	1 in 79	4.0	24	3.6	2.7	1 in 244	
C68	Other urinary organs	3	0.6	0.3	1 in 3107	3.0	1	0.2	0.1	1 in 3684	
C69	Eye	12	1.9	1.6	1 in 552	1.5	8	1.0	0.9	1 in 1277	
C70	Meninges	1	0.1	0.1	1 in 12492	0.3	3	0.4	0.3	1 in 6083	
C71	Brain	54	8.5	6.6	1 in 163	1.5	36	4.7	4.3	1 in 239	
C72	Other CNS	0	0.0	0.0	NA	0.0	1	0.1	0.2	1 in 11102	

ICDO-2 Cancer site/type Number (Aust 1991) (World) risk M:F Number (Aust 1991) World C73 Thyroid gland 14 1.8 1.6 1 in 651 0.3 42 5.2 4.5 1 in 25 C74 Adrenal gland 1 0.2 0.2 1 in 651 NA 0 0.0 0.0 1.0 1.0 0.0 1.0 1.0 0.0 0.0 0 NA 0.0 0 1.0 0.0 1.0 1.0 0 0 1.0 0 0 1.0 0 0 1.0 0 0 0 0 0 0 0 0 1.0 1.0 0 0 1.0				ı	Males			Females					
C73 Thyroid gland 14 1.8 1.6 1 in 661 0.3 42 5.2 4.5 1 in 26 C74 Adrenal gland 1 0.2 0.2 1 in 3855 NA 0 0.0.0 0.0 N NA 0.0 1 0.1 0.2 1 in 198 C76-80, 26 Unknown primary site 115 22.0 14.4 1 in 67 1.1 103 14.6 9.3 1 in 12 C81 Hodgkin's lisease 12 1.5 1.4 1 in 1034 0.8 15 1.9 1.8 1 in 57 C82 Follicular/nodular non-Hodgkin's lymphoma 55 9.6 6.6 1 in 151 1.1 51 7.4 5.1 1 in 16 C83 Diffuse non-Hodgkin's lymphoma 55 9.6 6.6 1 in 151 1.1 51 7.4 5.1 1 in 16 C84 Peripheral & cutaneous T-cell lymphon 9 1.7 1.2 1 in 735 3.0 3 0.4 0.3 1 in 52 C85 Other & unspecified non-Hodgkin's lym 34 5.9 4.0 1 in 249 1.3 27 3.8 2.6 1 in 4.2 C88 Immunoproliferative neoplasms 4 0.8 0.5 1 in 2156 NA 0 0.0 0.0 0.0 N N C90 Multiple myeloma 37 7.1 4.7 1 in 196 2.5 15 2.4 1.7 1 in 38 C91 Lymphoid leukaemia 39 8.0 5.5 1 in 200 1.4 30 4.1 3.7 1 in 32 C92 Myeloid leukaemia 39 8.0 5.2 1 in 280 1.4 27 3.8 3.3 1 in 22 C93 Monocytic leukaemia 0 0 0.0 0.0 NA NA 0 0 0.0 0.0 N N NA NA 0 0 0.0 0 N N NA NA 0 0 0.0 0.0 N N N NA 0 0 0.0 0 N N N N N N N N N N N N N N N		-		AS Rate	AS Rate	Lifetime	Sex ratio		AS Rate	AS Rate	Lifetime		
C74 Adrenal gland 1 0.2 0.2 1 in 3855 NA 0 0 0.0 0.0 NA C75 Other endocrine glands 0 0 0.0 0.0 NA 0.0 1 0.1 0.2 1 in 1196 C76-80, 26 Unknown primary site 115 22.0 14.4 1 in 67 1.1 103 14.6 9.3 1 in 12 C81 Hodgkin's disease 12 1.5 1.4 1 in 1034 0.8 15 1.9 1.8 1 in 57 C82 Follicular/nodular non-Hodgkin's lymph 28 4.5 3.4 1 in 253 1.3 21 2.8 2.4 1 in 36 C83 Diffuse non-Hodgkin's lymphoma 55 9.6 6.6 1 in 151 1.1 51 7.4 51 1 in 16 C84 Peripheral & cutaneous T-cell lymphom 9 1.7 1.2 1 in 735 3.0 3 3 0.4 0.3 1 in 257 C85 Other & unspecified non-Hodgkin's lym 4 5.9 4.0 1 in 249 1.3 27 3.8 2.6 1 in 42 C88 Immunoproliferative neoplasms 4 0.8 0.5 1 in 2156 NA 0 0 0.0 0.0 0.0 C8 C91 Lymphoid leukaemia 39 8.0 5.2 1 in 250 1.4 27 3.8 3.3 1 in 32 C91 2.4 1.0 1 in 36 C92 Molicular neoplasms 4 0 0.0 0.0 0.0 NA NA 0.0 0.0 0.0 0.0 NA NA 0.0 0.0 0.0 0.0 NA NA NA 0.0 0.0 0.0 0.0 NA NA NA 0.0 0.0 0.0 0.0 NA NA NA 0.0 0.0 NA NA NA 0.0 0.0 0.0	ICDO-2	Cancer site/type	Number	(Aust 1991)	(World)	risk	M:F	Number	(Aust 1991)	(World)	risk		
C75 Other endocrine glands 0 0.0 0.0 NA 0.0 1 0.1 0.2 1 in 1986 C76-80, 26 Unknown primary site 115 22.0 14.4 1 in 67 1.1 103 14.6 9.3 1 in 1986 C81 Hodgkin's disease 12 1.5 1.4 1 in 167 1.1 103 14.6 9.3 1 in 178 C82 Follicular non-Hodgkin's lymphoma 28 4.5 3.4 1 in 253 1.3 21 2.8 2.4 1 in 36 C83 Diffuse non-Hodgkin's lymphoma 55 9.6 6.6 1 in 151 1.1 51 7.4 5.1 1 in 186 C84 Peripheral & cutaneous T-cell lymphon 9 1.7 1.2 1 in 735 3.0 3 0.4 0.3 1 in 52 C85 Other & unspecified non-Hodgkin's lym 34 5.9 4.0 1 in 258 3.3 3 0.0 0.0 0.0 0.0 1 in 252 1.1 1.1	C73	Thyroid gland	14	1.8	1.6	1 in 651	0.3	42	5.2	4.5	1 in 298		
C76-80, 26 Unknown primary site 115 22.0 14.4 1 in 67 1.1 103 14.6 9.3 1 in 12 C81 Hodgkin's disease 12 1.5 1.4 1 in 1034 0.8 15 1.9 1.8 1 in 52 C82 Follicular/nodular non-Hodgkin's lymph 28 4.5 3.4 1 in 253 1.3 21 2.8 2.4 1 in 36 C83 Diffuse non-Hodgkin's lymphoma 55 9.6 6.6 1 in 151 1.1 51 7.4 5.1 1 in 16 C84 Peripheral & cutaneous T-cell lymphom 9 1.7 1.2 1 in 735 3.0 3 0.4 0.3 1 in 527 C85 Other & unspecified non-Hodgkin's lym 34 5.9 4.0 1 in 249 1.3 27 3.8 2.6 1 in 42 C88 Immunoproliferative neoplasms 4 0.8 0.5 1 in 2156 NA 0 0.0 0.0 0.0 NA 0.0 0.0 NA 0.0 0.0 0.0 0.0 NA 0.0 0.0 0	C74	Adrenal gland	1	0.2	0.2	1 in 3855	NA	0	0.0	0.0	NA		
C81 Hodgkin's disease 12 1.5 1.4 1 in 1034 0.8 15 1.9 1.8 1 in 15 in 15 in 15 in 15 in 15 in 103 C82 Follicular/nodular non-Hodgkin's lymphoma 55 9.6 6.6 1 in 151 1.7 4 5.1 1 in 15 i	C75	Other endocrine glands	0	0.0	0.0	NA	0.0	1	0.1	0.2	1 in 11958		
C82 Follicular/nodular non-Hodgkin's lymph 28 4.5 3.4 1 in 253 1.3 21 2.8 2.4 1 in 36 C83 Diffuse non-Hodgkin's lymphorna 55 9.6 6.6 1 in 151 1.1 51 7.4 5.1 1 in 15 C84 Peripheral & cutaneous T-cell lymphon 9 1.7 1.2 1 in 735 3.0 3 0.4 5.1 1 in 16 C85 Other & unspecified non-Hodgkin's lym 34 5.9 4.0 1 in 249 1.3 27 3.8 2.6 1 in 426 C88 Immunoproliferative neoplasms 4 0.8 0.5 1 in 2156 NA 0 0.0 0.0 NA C90 Multiple myeloma 37 7.1 4.7 1 in 196 2.5 15 2.4 1.7 1 in 36 C91 Lymphoid leukaemia 39 8.0 5.2 1 in 280 1.4 27 3.8 3.3 1 in 26 C93 Myeloid leukaemia	C76-80, 26 Unknown primary site		115	22.0	14.4	1 in 67	1.1	103	14.6	9.3	1 in 121		
C83 Diffuse non-Hodgkin's lymphoma 55 9.6 6.6 1 in 151 1.1 51 7.4 5.1 1 in 15 can C84 Peripheral & cutaneous T-cell lymphon 9 1.7 1.2 1 in 735 3.0 3 0.4 0.3 1 in 527 C85 Other & unspecified non-Hodgkin's lym 34 5.9 4.0 1 in 245 1.3 27 3.8 2.6 1 in 627 C88 Immunoproliferative neoplasms 4 0.8 0.5 1 in 2456 NA 0 0.0 0.0 NA C90 Multiple myeloma 37 7.1 4.7 1 in 196 2.5 15 2.4 1.7 1 in 32 C91 Lymphoid leukaemia 42 6.4 5.9 1 in 200 1.4 30 4.1 3.7 1 in 33 C92 Myeloid leukaemia 39 8.0 5.2 1 in 280 1.4 27 3.8 3.3 1 in 32 C93 Monocytic leukaemia 39 <td>C81</td> <td>Hodgkin's disease</td> <td>12</td> <td>1.5</td> <td>1.4</td> <td>1 in 1034</td> <td>0.8</td> <td>15</td> <td>1.9</td> <td>1.8</td> <td>1 in 579</td>	C81	Hodgkin's disease	12	1.5	1.4	1 in 1034	0.8	15	1.9	1.8	1 in 579		
C84 Peripheral & culaneous T-cell lymphon 9 1.7 1.2 1 in 735 3.0 3 0.4 0.3 1 in 527 C85 Other & unspecified non-Hodgkin's lym 34 5.9 4.0 1 in 249 1.3 27 3.8 2.6 1 in 42 C88 Immunoproliferative neoplasms 4 0.8 0.5 1 in 2496 NA 0 0.0 0.0 0.0 C90 Multiple myeloma 37 7.1 4.7 1 in 196 2.5 15 2.4 1.7 1 in 36 C91 Lymphoid leukaemia 42 6.4 5.9 1 in 200 1.4 30 4.1 3.7 1 in 36 C92 Myeloid leukaemia 39 8.0 5.2 1 in 280 1.4 27 3.8 3.3 1 in 26 C93 Monocytic leukaemia 0 0.0 0.0 NA NA 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0<	C82	Follicular/nodular non-Hodgkin's lymph	28	4.5	3.4	1 in 253	1.3	21	2.8	2.4	1 in 362		
C85 Other & unspecified non-Hodgkin's lym 34 5.9 4.0 1 in 249 1.3 27 3.8 2.6 1 in 42 C88 Immunoproliferative neoplasms 4 0.8 0.5 1 in 2156 NA 0 0.0 0.0 0.0 NC 0.0 Multiple myeloma 37 7.1 4.7 1 in 196 2.5 15 2.4 1.7 1 in 39 2.5 Myeloid leukaemia 42 6.4 5.9 1 in 200 1.4 30 4.1 3.7 1 in 39 2.2 Myeloid leukaemia 39 8.0 5.2 1 in 280 1.4 27 3.8 3.3 1 in 25 2.3 Myeloid leukaemia 39 8.0 5.2 1 in 280 1.4 27 3.8 3.3 1 in 25 2.3 Myeloid leukaemia 0 0.0 0.0 NA 0.0 1 0.1 0.1 0.1 1 in 1005 0.4 Other leukaemias of specified cell type 0 0.0 0.0 NA NA 0.0 1 0.1 0.1 0.1 1 in 1005 0.5 0.5 Leukaemia of unspecified cell type 1 0.0 0.0 NA NA NA 0 0.0 0.0 NA NA 0.0 0.0 NA NA NA 0 0.0 0.0 NA NA NA 0 0.0 0.0 NA NA NA 0 0.0 NA NA 0.	C83	Diffuse non-Hodgkin's lymphoma	55	9.6	6.6	1 in 151	1.1	51	7.4	5.1	1 in 153		
C88 Immunoproliferative neoplasms 4 0.8 0.5 1 in 2156 NA 0 0.0 0.0 NN C90 Multiple myeloma 37 7.1 4.7 1 in 196 2.5 15 2.4 1.7 1 in 38 C91 Lymphoid leukaemia 42 6.4 5.9 1 in 200 1.4 30 4.1 3.7 1 in 38 C92 Myeloid leukaemia 39 8.0 5.2 1 in 280 1.4 27 3.8 3.3 1 in 26 C93 Monocytic leukaemia 0 0.0 0.0 NA 0.0 1 0.1 0.1 1 in 1 in 100 C94 Other leukaemias of specified cell type 0 0.0 0.0 NA NA 0 0.0 0.0 NA C95 Leukaemia of unspecified pyrboid, haemati 0 0.0 0.0 NA NA 0 0.0 0.0 NA C97 Malignant neoplasms of independent (j 0 0.0	C84	Peripheral & cutaneous T-cell lymphon	9	1.7	1.2	1 in 735	3.0	3	0.4	0.3	1 in 5276		
C90 Multiple myeloma 37 7.1 4.7 1 in 196 2.5 15 2.4 1.7 1 in 38 C91 Lymphoid leukaemia 42 6.4 5.9 1 in 200 1.4 30 4.1 3.7 1 in 32 C92 Myeloid leukaemia 39 8.0 5.2 1 in 280 1.4 27 3.8 3.3 1 in 26 C93 Monocytic leukaemias of specified cell type 0 0.0 0.0 NA 0.0 1 0.1 0.1 1 in 100 0.0 NA NA 0 0.0 0.0 NA	C85	Other & unspecified non-Hodgkin's lym	34	5.9	4.0	1 in 249	1.3	27	3.8	2.6	1 in 421		
C91 Lymphoid leukaemia 42 6.4 5.9 1 in 200 1.4 30 4.1 3.7 1 in 32 C92 Myeloid leukaemia 39 8.0 5.2 1 in 280 1.4 27 3.8 3.3 1 in 25 C93 Monocytic leukaemia 0 0.0 0.0 NA 0.0 1 0.1 0.1 1 in 1005 C94 Other leukaemias of specified cell type 0 0.0 0.0 NA NA 0 0.0 0.0 N C95 Leukaemia of unspecified cell type 1 0.2 0.2 1 in 3855 0.5 2 0.3 0.1 N C96 Other & unspecified lymphoid, haemat 0 0.0 0.0 NA NA 0 0.0 0.0 N C97 Malignant neoplasms of independent (i 0 0.0 0.0 NA NA 0 0.0 0.0 N C01-02 Tongue 17 2.9 2.0	C88	Immunoproliferative neoplasms	4	0.8	0.5	1 in 2156	NA	0	0.0	0.0	NA		
C92 Myeloid leukaemia 39 8.0 5.2 1 in 280 1.4 27 3.8 3.3 1 in 262 C93 Monocytic leukaemia 0 0.0 0.0 NA 0.0 1 0.1 0.1 1 in 1005 C94 Other leukaemias of specified cell type 0 0.0 0.0 NA NA 0 0.0 0.0 N C95 Leukaemia of unspecified cell type 1 0.2 0.2 1 in 3855 0.5 2 0.3 0.1 N C96 Other & unspecified lymphoid, haemati 0 0.0 0.0 NA NA 0 0.0 0.0 NA C97 Malignant neoplasms of independent (r 0 0.0 0.0 NA NA 0 0.0 0.0 NA C10-02 Tongue 17 2.9 2.0 1 in 381 1.5 11 1.4 1.1 1 in 100 C01-02 Tongue 17 2.9 2.0 <	C90	Multiple myeloma	37	7.1	4.7	1 in 196	2.5	15	2.4	1.7	1 in 397		
C93 Monocytic leukaemia 0 0.0 0.0 NA 0.0 1 0.1 0.1 1 in 1005 C94 Other leukaemias of specified cell type 0 0.0 0.0 NA NA 0 0.0 0.0 N C95 Leukaemia of unspecified cell type 1 0.2 0.2 1 in 3855 0.5 2 0.3 0.1 N C96 Other & unspecified lymphoid, haemati 0 0.0 0.0 NA NA 0 0.0 0.0 N C97 Malignant neoplasms of independent (f 0 0.0 0.0 NA NA 0 0.0 0.0 N C01-02 Tongue 17 2.9 2.0 1 in 381 1.5 11 1.4 1.1 1 in 10 1.	C91	Lymphoid leukaemia	42	6.4	5.9	1 in 200	1.4	30	4.1	3.7	1 in 320		
C94 Other leukaemias of specified cell type 0 0.0 0.0 NA NA NA 0 0.0 0.0 NA NA 0 0.0 NA	C92	Myeloid leukaemia	39	8.0	5.2	1 in 280	1.4	27	3.8	3.3	1 in 253		
C95 Leukaemia of unspecified cell type 1 0.2 0.2 1 in 3855 0.5 2 0.3 0.1 N C96 Other & unspecified lymphoid, haemati 0 0.0 0.0 NA NA NA 0 0.0 0.0 N NA NA 0 0.0 0.0 N N NA NA 0 0.0 0.0 N N NA NA 0 0.0 0.0 N N NA NA 0 0.0 N N N N N N N N N N N N N N N N N	C93	Monocytic leukaemia	0	0.0	0.0	NA	0.0	1	0.1	0.1	1 in 10054		
C96 Other & unspecified lymphoid, haemati	C94	Other leukaemias of specified cell type	0	0.0	0.0	NA	NA	0	0.0	0.0	NA		
C97 Malignant neoplasms of independent (f 0 0.0 0.0 NA NA 0 0.0 0.0 N C01-02 Tongue 17 2.9 2.0 1 in 381 1.5 11 1.4 1.1 1 in 100 C01-14 Head & neck 78 12.3 9.4 1 in 99 2.3 34 4.3 3.6 1 in 25 C03-06 Mouth 18 2.7 2.2 1 in 452 1.8 10 1.3 1.1 1 in 71 C05-06 Other & unspecified parts of mouth 10 1.5 1.2 1 in 805 1.0 10 1.3 1.1 1 in 71 C07-08 Salivary gland 19 3.2 2.1 1 in 570 3.8 5 0.7 0.5 1 in 207 C09-10 Tonsil & oropharynx 9 1.1 1.1 1 in 828 3.0 3 0.4 0.3 1 in 207 C18-20 Colorectal (excluding Anus) 377 65.6 47.4	C95	Leukaemia of unspecifed cell type	1	0.2	0.2	1 in 3855	0.5	2	0.3	0.1	NA		
C01-02 Tongue 17 2.9 2.0 1 in 381 1.5 11 1.4 1.1 1 in 10 10 C01-14 Head & neck 78 12.3 9.4 1 in 99 2.3 34 4.3 3.6 1 in 25 C03-06 Mouth 18 2.7 2.2 1 in 452 1.8 10 1.3 1.1 1 in 71 C05-06 Other & unspecified parts of mouth 10 1.5 1.2 1 in 805 1.0 10 1.3 1.1 1 in 71 C07-08 Salivary gland 19 3.2 2.1 1 in 570 3.8 5 0.7 0.5 1 in 207 C09-10 Tonsil & oropharynx 9 1.1 1.1 1 in 828 3.0 3 0.4 0.3 1 in 212 C12-13 Hypopharynx 8 1.2 1.0 1 in 656 8.0 1 0.1 0.1 1.1 in 123 C18-20 Colorectal (excluding Anus) 377 65.6 47.4 1 in 48 1.5 84 12.2 8.3 1 in 2 <tr< td=""><td>C96</td><td>Other & unspecified lymphoid, haemate</td><td>0</td><td>0.0</td><td>0.0</td><td>NA</td><td>NA</td><td>0</td><td>0.0</td><td>0.0</td><td>NA</td></tr<>	C96	Other & unspecified lymphoid, haemate	0	0.0	0.0	NA	NA	0	0.0	0.0	NA		
C01-14 Head & neck 78 12.3 9.4 1 in 99 2.3 34 4.3 3.6 1 in 25 C03-06 Mouth 18 2.7 2.2 1 in 452 1.8 10 1.3 1.1 1 in 71 C05-06 Other & unspecified parts of mouth 10 1.5 1.2 1 in 805 1.0 10 1.3 1.1 1 in 71 C07-08 Salivary gland 19 3.2 2.1 1 in 570 3.8 5 0.7 0.5 1 in 27 C09-10 Tonsil & oropharynx 9 1.1 1.1 1 in 828 3.0 3 0.4 0.3 1 in 27 C12-13 Hypopharynx 8 1.2 1.0 1 in 656 8.0 1 0.1 0.1 1 in 1237 C18-20 Colorectal (excluding Anus) 377 65.6 47.4 1 in 18 1.3 299 44.0 31.5 1 in 2 C19-20 Rectum 130 21.4 16.2	C97	Malignant neoplasms of independent (0	0.0	0.0	NA	NA	0	0.0	0.0	NA		
C03-06 Mouth 18 2.7 2.2 1 in 452 1.8 10 1.3 1.1 1 in 71 C05-06 Other & unspecified parts of mouth 10 1.5 1.2 1 in 805 1.0 10 1.3 1.1 1 in 71 C07-08 Salivary gland 19 3.2 2.1 1 in 570 3.8 5 0.7 0.5 1 in 207 C09-10 Tonsil & oropharynx 9 1.1 1.1 1 in 828 3.0 3 0.4 0.3 1 in 207 C12-13 Hypopharynx 8 1.2 1.0 1 in 656 8.0 1 0.1 0.1 0.1 1 in 1237 C18-20 Colorectal (excluding Anus) 377 65.6 47.4 1 in 18 1.3 299 44.0 31.5 1 in 2 C19-20 Rectum 130 21.4 16.2 1 in 48 1.5 84 12.2 8.3 1 in 2 C18-21 Colorectal (including Anus) 383	C01-02	Tongue	17	2.9	2.0	1 in 381	1.5	11	1.4	1.1	1 in 1007		
C05-06 Other & unspecified parts of mouth 10 1.5 1.2 1 in 805 1.0 10 1.3 1.1 1 in 71 C07-08 Salivary gland 19 3.2 2.1 1 in 570 3.8 5 0.7 0.5 1 in 207 C09-10 Tonsil & oropharynx 9 1.1 1.1 1 in 828 3.0 3 0.4 0.3 1 in 207 C12-13 Hypopharynx 8 1.2 1.0 1 in 656 8.0 1 0.1 0.1 0.1 1 in 1237 C18-20 Colorectal (excluding Anus) 377 65.6 47.4 1 in 18 1.3 299 44.0 31.5 1 in 207 C19-20 Rectum 130 21.4 16.2 1 in 48 1.5 84 12.2 8.3 1 in 12 C18-21 Colorectal (including Anus) 383 66.8 48.3 1 in 17 1.2 309 45.3 32.5 1 in 20 C23-24 Gallbladder <td< td=""><td>C01-14</td><td>Head & neck</td><td>78</td><td>12.3</td><td>9.4</td><td>1 in 99</td><td>2.3</td><td>34</td><td>4.3</td><td>3.6</td><td>1 in 257</td></td<>	C01-14	Head & neck	78	12.3	9.4	1 in 99	2.3	34	4.3	3.6	1 in 257		
C07-08 Salivary gland 19 3.2 2.1 1 in 570 3.8 5 0.7 0.5 1 in 207 C09-10 Tonsil & oropharynx 9 1.1 1.1 1 in 828 3.0 3 0.4 0.3 1 in 212 C12-13 Hypopharynx 8 1.2 1.0 1 in 656 8.0 1 0.1 0.1 0.1 1 in 1237 C18-20 Colorectal (excluding Anus) 377 65.6 47.4 1 in 18 1.3 299 44.0 31.5 1 in 22 C19-20 Rectum 130 21.4 16.2 1 in 48 1.5 84 12.2 8.3 1 in 12 C18-21 Colorectal (including Anus) 383 66.8 48.3 1 in 17 1.2 309 45.3 32.5 1 in 22 C23-24 Gallbladder 11 2.3 1.3 1 in 821 0.8 13 1.8 1.2 1 in 84 C30-31 Nasal cavity 8 1.2 1.0 1 in 798 4.0 2 0.3 0.2 1 in 1237 C33-34 Trachea, bronchus & lung 219 40.5 27.8 1 in 29 1.4 159 23.8 17.4 1 in 4 C37-38 Other thoracic organs 3 0.3 0.3 1 in 3621 3.0 1 0.1 0.1 0.1 1 in 1268	C03-06	Mouth	18	2.7	2.2	1 in 452	1.8	10	1.3	1.1	1 in 714		
C09-10 Tonsil & oropharynx 9 1.1 1.1 1 in 828 3.0 3 0.4 0.3 1 in 212 C12-13 Hypopharynx 8 1.2 1.0 1 in 656 8.0 1 0.1 0.1 0.1 1 in 1237 C18-20 Colorectal (excluding Anus) 377 65.6 47.4 1 in 18 1.3 299 44.0 31.5 1 in 2 C19-20 Rectum 130 21.4 16.2 1 in 48 1.5 84 12.2 8.3 1 in 12 C18-21 Colorectal (including Anus) 383 66.8 48.3 1 in 17 1.2 309 45.3 32.5 1 in 2 C23-24 Gallbladder 11 2.3 1.3 1 in 821 0.8 13 1.8 1.2 1 in 84 C30-31 Nasal cavity 8 1.2 1.0 1 in 798 4.0 2 0.3 0.2 1 in 1237 C33-34 Trachea, bronchus & lung 219	C05-06	Other & unspecified parts of mouth	10	1.5	1.2	1 in 805	1.0	10	1.3	1.1	1 in 714		
C12-13 Hypopharynx 8 1.2 1.0 1 in 656 8.0 1 0.1 0.1 1 in 1237 C18-20 Colorectal (excluding Anus) 377 65.6 47.4 1 in 18 1.3 299 44.0 31.5 1 in 2 C19-20 Rectum 130 21.4 16.2 1 in 48 1.5 84 12.2 8.3 1 in 12 C18-21 Colorectal (including Anus) 383 66.8 48.3 1 in 17 1.2 309 45.3 32.5 1 in 2 C23-24 Gallbladder 11 2.3 1.3 1 in 821 0.8 13 1.8 1.2 1 in 84 C30-31 Nasal cavity 8 1.2 1.0 1 in 798 4.0 2 0.3 0.2 1 in 1237 C33-34 Trachea, bronchus & lung 219 40.5 27.8 1 in 29 1.4 159 23.8 17.4 1 in 48 C37-38 Other thoracic organs 3 0.3 0.3 1 in 3621 3.0 1 0.1 0.1 1 in 1268 <td>C07-08</td> <td>Salivary gland</td> <td>19</td> <td>3.2</td> <td>2.1</td> <td>1 in 570</td> <td>3.8</td> <td>5</td> <td>0.7</td> <td>0.5</td> <td>1 in 2074</td>	C07-08	Salivary gland	19	3.2	2.1	1 in 570	3.8	5	0.7	0.5	1 in 2074		
C18-20 Colorectal (excluding Anus) 377 65.6 47.4 1 in 18 1.3 299 44.0 31.5 1 in 2 C19-20 Rectum 130 21.4 16.2 1 in 48 1.5 84 12.2 8.3 1 in 12 C18-21 Colorectal (including Anus) 383 66.8 48.3 1 in 17 1.2 309 45.3 32.5 1 in 2 C23-24 Gallbladder 11 2.3 1.3 1 in 821 0.8 13 1.8 1.2 1 in 84 C30-31 Nasal cavity 8 1.2 1.0 1 in 798 4.0 2 0.3 0.2 1 in 1237 C33-34 Trachea, bronchus & lung 219 40.5 27.8 1 in 29 1.4 159 23.8 17.4 1 in 48 C37-38 Other thoracic organs 3 0.3 0.3 1 in 3621 3.0 1 0.1 0.1 1 in 1268	C09-10	Tonsil & oropharynx	9	1.1	1.1	1 in 828	3.0	3	0.4	0.3	1 in 2126		
C19-20 Rectum 130 21.4 16.2 1 in 48 1.5 84 12.2 8.3 1 in 12 C18-21 Colorectal (including Anus) 383 66.8 48.3 1 in 17 1.2 309 45.3 32.5 1 in 2 C23-24 Gallbladder 11 2.3 1.3 1 in 821 0.8 13 1.8 1.2 1 in 84 C30-31 Nasal cavity 8 1.2 1.0 1 in 798 4.0 2 0.3 0.2 1 in 1237 C33-34 Trachea, bronchus & lung 219 40.5 27.8 1 in 29 1.4 159 23.8 17.4 1 in 48 C37-38 Other thoracic organs 3 0.3 0.3 1 in 3621 3.0 1 0.1 0.1 1 in 1268	C12-13	Hypopharynx	8	1.2	1.0	1 in 656	8.0	1	0.1	0.1	1 in 12379		
C18-21 Colorectal (including Anus) 383 66.8 48.3 1 in 17 1.2 309 45.3 32.5 1 in 2 C23-24 Gallbladder 11 2.3 1.3 1 in 821 0.8 13 1.8 1.2 1 in 84 C30-31 Nasal cavity 8 1.2 1.0 1 in 798 4.0 2 0.3 0.2 1 in 1237 C33-34 Trachea, bronchus & lung 219 40.5 27.8 1 in 29 1.4 159 23.8 17.4 1 in 4 C37-38 Other thoracic organs 3 0.3 0.3 1 in 3621 3.0 1 0.1 0.1 1 in 1268	C18-20	Colorectal (excluding Anus)	377	65.6	47.4	1 in 18	1.3	299	44.0	31.5	1 in 28		
C23-24 Gallbladder 11 2.3 1.3 1 in 821 0.8 13 1.8 1.2 1 in 84 C30-31 Nasal cavity 8 1.2 1.0 1 in 798 4.0 2 0.3 0.2 1 in 1237 C33-34 Trachea, bronchus & lung 219 40.5 27.8 1 in 29 1.4 159 23.8 17.4 1 in 4 C37-38 Other thoracic organs 3 0.3 0.3 1 in 3621 3.0 1 0.1 0.1 1 in 1268	C19-20	Rectum	130	21.4	16.2	1 in 48	1.5	84	12.2	8.3	1 in 123		
C30-31 Nasal cavity 8 1.2 1.0 1 in 798 4.0 2 0.3 0.2 1 in 1237 C33-34 Trachea, bronchus & lung 219 40.5 27.8 1 in 29 1.4 159 23.8 17.4 1 in 4 C37-38 Other thoracic organs 3 0.3 0.3 1 in 3621 3.0 1 0.1 0.1 0.1 1 in 1268	C18-21	Colorectal (including Anus)	383	66.8	48.3	1 in 17	1.2	309	45.3	32.5	1 in 28		
C33-34 Trachea, bronchus & lung 219 40.5 27.8 1 in 29 1.4 159 23.8 17.4 1 in 4 C37-38 Other thoracic organs 3 0.3 0.3 1 in 3621 3.0 1 0.1 0.1 1 in 1268	C23-24	Gallbladder	11	2.3	1.3	1 in 821	0.8	13	1.8	1.2	1 in 845		
C37-38 Other thoracic organs 3 0.3 0.3 1 in 3621 3.0 1 0.1 0.1 1 in 1268	C30-31	Nasal cavity	8	1.2	1.0	1 in 798	4.0	2	0.3	0.2	1 in 12379		
· · · · · · · · · · · · · · · · · · ·	C33-34	Trachea, bronchus & lung	219	40.5	27.8	1 in 29	1.4	159	23.8	17.4	1 in 46		
C40-41 Bone 8 1.0 1.0 1 in 1021 0.8 10 1.3 1.3 1 in 123	C37-38	Other thoracic organs	3	0.3	0.3	1 in 3621	3.0	1	0.1	0.1	1 in 12686		
	C40-41	Bone	8	1.0	1.0	1 in 1021	0.8	10	1.3	1.3	1 in 1237		

			ı	Males			Females				
	_		AS Rate	AS Rate	Lifetime	Sex ratio		AS Rate	AS Rate	Lifetime	
ICDO-2	Cancer site/type	Number	(Aust 1991)	(World)	risk	M:F	Number	(Aust 1991)	(World)	risk	
C47-49	Connective & soft tissue	14	2.0	1.7	1 in 657	1.1	13	1.9	1.3	1 in 604	
C54-55	Uterus	0	0.0	0.0	NA	0.0	100	14.6	11.6	1 in 67	
C60+63	Penis & other & unspecified male genit	8	1.5	0.9	1 in 823	NA	0	0.0	0.0	NA	
C64-66, 68 Kidney, ureter & urethra		81	13.3	9.8	1 in 88	1.3	61	8.7	5.9	1 in 153	
C70+72	Meninges & other CNS	1	0.1	0.1	1 in 12492	0.3	4	0.5	0.5	1 in 3930	
C70-72	Brain & CNS	55	8.6	6.7	1 in 161	1.4	40	5.2	4.8	1 in 226	
C74-75	adrenal and other endocrine glands & ı	1	0.2	0.2	1 in 3855	1.0	1	0.1	0.2	1 in 11958	
C82-85, 9	6 Non-Hodgkin lymphoma	126	21.8	15.2	1 in 63	1.2	102	14.4	10.4	1 in 85	
C81-85, 9	6 All lymphomas	138	23.3	16.6	1 in 59	1.2	117	16.3	12.2	1 in 74	
C92-94	Myeloid , monocytic & other leukaemia	39	8.0	5.2	1 in 280	1.4	28	3.9	3.4	1 in 247	
C91-95	Leukaemias	82	14.6	11.2	1 in 113	1.4	60	8.3	7.2	1 in 140	
C00-97 ex	xx All cancers (excluding NMSC)	2810	494.0	351.0	1 in 3	1.2	2,436	336.3	261.9	1 in 4	

Note: Rates are expressed per 100,000 population and age-standardised (AS rate) to both the Australian 1991 Standard Population and the World Standard Population.

NA indicates "Not Applicable".

^{*} Non-melanocytic skin cancer incidence data is not routinely collected by State and Territory cancer registries.

Table A3: Summary of Mortality Rates, 1996-2000

				Males			Females			
		L.	AS Rate	AS Rate	PYLL	Sex ratio		AS Rate	AS Rate	PYLL
ICD-10	Cancer site	Number	(Aust 1991)	(World)	(<75 yrs)	M:F	Number	(Aust 1991)	(World)	(<75 yrs)
C00	Lip	2	0.2	0.2	55	NA	0	0.0	0.0	0
C01	Tongue	4	0.7	0.5	23	NA	0	0.0	0.0	0
C02	Other tongue	2	0.3	0.2	20	2.0	1	0.1	0.1	28
C03	Gum	0	0.0	0.0	0	NA	0	0.0	0.0	0
C04	Floor of mouth	4	0.6	0.5	65	4.0	1	0.2	0.2	8
C05	Palate	1	0.2	0.2	13	1.0	1	0.2	0.1	0
C06	Other & unspecified parts of mouth	1	0.2	0.2	13	0.5	2	0.3	0.2	8
C07	Parotid gland	3	0.6	0.3	3	NA	0	0.0	0.0	0
C08	Salivary glands	1	0.1	0.1	48	0.3	3	0.5	0.2	3
C09	Tonsil	1	0.1	0.1	28	NA	0	0.0	0.0	0
C10	Oropharynx	1	0.1	0.1	18	NA	0	0.0	0.0	0
C11	Nasopharynx	1	0.2	0.2	8	NA	0	0.0	0.0	0
C12	Pyriform sinus	5	0.8	0.7	58	5.0	1	0.1	0.1	23
C13	Hypopharynx	1	0.1	0.1	18	NA	0	0.0	0.0	0
C14	Pharynx unspecified	1	0.3	0.2	0	1.0	1	0.2	0.2	8
C15	Oesophagus	27	5.6	3.5	190	2.3	12	2.0	1.2	33
C16	Stomach	62	11.6	8.1	635	1.7	37	5.4	3.6	293
C17	Small intestine	5	0.9	0.6	43	1.7	3	0.5	0.3	8
C18	Colon	97	19.2	13.0	698	1.1	92	13.7	9.4	680
C19	Rectosigmoid junction	16	2.8	1.8	133	1.5	11	1.5	0.9	130
C20	Rectum	33	6.2	4.4	365	1.2	28	3.9	2.5	165
C21	Anus & anal canal	3	0.6	0.5	28	3.0	1	0.1	0.1	0
C22	Liver	25	4.6	3.1	250	1.9	13	2.0	1.5	140
C23	Gallbladder	1	0.1	0.1	18	0.2	5	0.7	0.6	65
C24	Other biliary tract	10	2.0	1.2	90	2.5	4	0.6	0.4	8
C25	Pancreas	42	7.9	5.5	408	0.9	48	7.4	4.6	210
C30	Nasal cavities & middle ear	0	0.0	0.0	0	0.0	1	0.2	0.2	13
C31	Accessory sinuses	1	0.2	0.2	8	1.0	1	0.1	0.1	28
C32	Larynx	12	2.4	1.6	80	12.0	1	0.1	0.1	0
C33	Trachea	0	0.0	0.0	0	NA	0	0.0	0.0	0
C34	Bronchus & lung	190	36.5	24.0	1,368	1.4	137	20.6	14.3	1,118
C37	Thymus	0	0.0	0.0	0	0.0	1	0.2	0.2	8

				Males			Females			
			AS Rate	AS Rate	PYLL	Sex ratio		AS Rate	AS Rate	PYLL
ICD-10	Cancer site	Number	(Aust 1991)	(World)	(<75 yrs)	M:F	Number	(Aust 1991)	(World)	(<75 yrs)
C38	Heart, mediastinum & pleura	0	0.0	0.0	0	0.0	1	0.1	0.1	43
C40	Bone & articular cartilage	2	0.2	0.2	70	NA	0	0.0	0.0	0
C41	Other bone & articular cartilage	2	0.3	0.3	60	1.0	2	0.2	0.2	80
C43	Skin-melanoma	33	5.9	4.1	385	1.9	17	2.4	1.9	293
C44	Skin-non-melanocytic (NMSC)	0	0.0	0.0	0	NA	0	0.0	0.0	0
C45	Mesothelioma	14	2.8	1.8	100	4.7	3	0.5	0.3	10
C46	Kaposi's sarcoma	1	0.1	0.1	43	NA	0	0.0	0.0	0
C47	Peripheral nerves & ANS	0	0.0	0.0	0	NA	0	0.0	0.0	0
C48	Retroperitoneum & peritoneum	1	0.1	0.1	23	0.3	3	0.4	0.3	28
C49	Other connective & soft tissue	6	0.9	0.7	178	1.2	5	0.8	0.5	48
C50	Breast	3	0.6	0.4	13	0.0	207	29.2	21.6	2,458
C51	Vulva	0	0.0	0.0	0	0.0	2	0.3	0.1	0
C52	Vagina	0	0.0	0.0	0	0.0	1	0.2	0.1	3
C53	Cervix	0	0.0	0.0	0	0.0	18	2.5	2.0	385
C54	Corpus uteri	0	0.0	0.0	0	0.0	19	3.0	2.1	115
C55	Uterus unspecified	0	0.0	0.0	0	NA	0	0.0	0.0	0
C56	Ovary	0	0.0	0.0	0	0.0	50	7.0	5.2	643
C57	Other & unspecified female genital organs	0	0.0	0.0	0	0.0	2	0.3	0.2	8
C58	Placenta	0	0.0	0.0	0	NA	0	0.0	0.0	0
C60	Penis	0	0.0	0.0	0	NA	0	0.0	0.0	0
C61	Prostate	127	29.9	16.8	330	NA	0	0.0	0.0	0
C62	Testis	2	0.2	0.2	75	NA	0	0.0	0.0	0
C63	Other male genital organs	0	0.0	0.0	0	NA	0	0.0	0.0	0
C64	Kidney	38	7.3	4.9	338	2.5	15	2.3	1.2	18
C65	Renal pelvis	1	0.2	0.1	0	0.1	7	0.9	0.6	50
C66	Urether	3	0.6	0.4	15	1.5	2	0.3	0.1	0
C67	Bladder	62	14.1	7.7	198	4.1	15	2.5	1.8	120
C68	Other urinary organs	1	0.2	0.1	3	1.0	1	0.2	0.1	3
C69	Eye	4	0.5	0.4	85	1.3	3	0.4	0.3	28
C70	Meninges	0	0.0	0.0	0	0.0	2	0.3	0.2	3
C71	Brain	44	7.5	5.3	708	1.5	30	3.9	3.2	570
C72	Other CNS	0	0.0	0.0	0	NA	0	0.0	0.0	0

				Males			Females			
	_		AS Rate	AS Rate	PYLL	Sex ratio		AS Rate	AS Rate	PYLL
ICD-10	Cancer site	Number	Number (Aust 1991) (World)	(<75 yrs)	M:F	Number	(Aust 1991)	(World)	(<75 yrs)	
C73	Thyroid gland	1	0.1	0.1	33	0.5	2	0.3	0.1	0
C74	Adrenal gland	3	0.4	0.5	163	NA	0	0.0	0.0	0
C75	Other endocrine glands	0	0.0	0.0	0	NA	0	0.0	0.0	0
C76-80, 26, 39	Unknown primary site	105	20.5	13.2	955	1.2	88	12.5	7.7	553
C81	Hodgkin's disease	4	0.5	0.4	155	1.3	3	0.4	0.3	55
C82	Follicular/nodular non-Hodgkin's lymphon	5	0.9	0.6	48	1.3	4	0.7	0.5	50
C83	Diffuse non-Hodgkin's lymphoma	37	7.0	4.4	395	0.9	39	5.8	3.5	175
C84	Peripheral & cutaneous T-cell lymphomas	2	0.4	0.3	20	NA	0	0.0	0.0	0
C85	Other & unspecified non-Hodgkin's lymph	15	3.4	2.0	60	0.9	17	2.4	1.5	145
C88	Immunoproliferative neoplasms	1	0.2	0.2	13	1.0	1	0.1	0.1	0
C90	Multiple myeloma	32	6.9	4.1	168	2.9	11	1.8	1.0	25
C91	Lymphoid leukaemia	10	2.1	1.4	153	0.8	13	1.8	1.3	168
C92	Myeloid leukaemia	40	8.8	4.8	283	1.9	21	3.1	2.5	353
C93	Monocytic leukaemia	0	0.0	0.0	0	NA	0	0.0	0.0	0
C94	Other leukaemias of specified cell type	0	0.0	0.0	0	NA	0	0.0	0.0	0
C95	Leukaemia of unspecifed cell type	0	0.0	0.0	0	0.0	2	0.3	0.1	0
C96	Other & unspecified lymphoid, haematopo	0	0.0	0.0	0	NA	0	0.0	0.0	0
C97	Malignant neoplasms of independent (prin	0	0.0	0.0	0	0.0	1	0.2	0.1	3
C01-02	Tongue	6	1.0	0.7	43	6.0	1	0.1	0.1	28
C01-14	Head & neck	26	4.4	3.4	310	2.6	10	1.5	1.0	75
C03-06	Mouth	6	0.9	0.9	90	1.5	4	0.7	0.4	15
C05-06	Other & unspecified parts of mouth	2	0.3	0.3	25	0.7	3	0.5	0.3	8
C07-08	Salivary gland	4	0.7	0.4	50	1.3	3	0.5	0.2	3
C09-10	Tonsil & oropharynx	2	0.2	0.2	45	NA	0	0.0	0.0	0
C12-13	Hypopharynx	6	0.9	0.8	75	6.0	1	0.1	0.1	23
C18-20	Colorectal (excluding Anus)	146	28.2	19.2	1,195	1.1	131	19.1	12.8	975
C19-20	Rectum	49	9.0	6.2	498	1.3	39	5.4	3.4	295
C18-21	Colorectal (including Anus)	149	28.8	19.6	1,223	1.1	132	19.3	12.9	975
C23-24	Gallbladder	11	2.1	1.3	108	1.2	9	1.3	0.9	73
C30-31	Nasal cavity	1	0.2	0.2	8	0.5	2	0.3	0.3	40
C33-34	Trachea, bronchus & lung	190	36.5	24.0	1,368	1.4	137	20.6	14.3	1,118
C37-38	Other thoracic organs	0	0.0	0.0	0	0.0	2	0.3	0.2	50
C40-41	Bone	4	0.5	0.5	130	2.0	2	0.2	0.2	80

				Males				Fe	emales	
ICD-10	Cancer site	Number	AS Rate (Aust 1991)	AS Rate (World)	PYLL (<75 yrs)	Sex ratio M:F	Number	AS Rate (Aust 1991)	AS Rate (World)	PYLL (<75 yrs)
C47-49	Connective & soft tissue	7	1.0	0.8	200	0.9	8	1.2	0.8	75
C54-55	Uterus	0	0.0	0.0	0	0.0	19	3.0	2.1	115
C60+63	Penis & other & unspecified male genital (0	0.0	0.0	0	NA	0	0.0	0.0	0
C64-66, 68	Kidney, ureter & urethra	43	8.4	5.5	355	1.7	25	3.8	2.0	70
C70+72	Meninges & other CNS	0	0.0	0.0	0	0.0	2	0.3	0.2	3
C70-72	Brain & CNS	44	7.5	5.3	708	1.4	32	4.3	3.4	573
C74-75	adrenal and other endocrine glands & relat	3	0.4	0.5	163	NA	0	0.0	0.0	0
C82-85, 96	Non-Hodgkin lymphoma	59	11.7	7.4	523	1.0	60	8.9	5.5	370
C81-85, 96	All lymphomas	63	12.1	7.8	678	1.0	63	9.3	5.8	425
C92-94	Myeloid, monocytic & other leukaemia	40	8.8	4.8	283	1.9	21	3.1	2.5	353
C91-95	Leukaemias	50	10.9	6.2	435	1.4	36	5.2	3.9	520
C00-97 excl C44	All cancers (excluding NMSC)	1,151	228.0	146.8	9,738	1.1	1,012	147.8	101.8	9,395

Note: Rates are expressed per 100,000 population and age-standardised (AS rate) to both the Australian 1991 Standard Population and the World Standard Population.

NA indicates "Not Applicable".

Table A4: Age And Sex Specific Cancer Incidence And Mortality Rates By Cancer Site, 1996-2000

Table A4-1: All Malignant Neoplasms: ICD-10 C00-97 (Excluding non melanocytic skin cancers (C44)

			Incide	nce					Morta	lity		
	Male	es	Femal	les	Perso	ns	Male	es	Fema	les	Pers	ons
	Number	Rate										
Age group												
0-4	12	21.9	12	22.7	24	22.3	2	3.6	1	1.9	3	2.8
5–9	5	8.7	3	5.4	8	7.1	2	3.5	1	1.8	3	2.7
10-14	10	17.4	9	16.2	19	16.8	1	1.7	2	3.6	3	2.7
15–19	14	22.2	14	23.4	28	22.8	1	1.6	1	1.7	2	1.6
20-24	25	36.3	17	25.5	42	30.9	6	8.7	1	1.5	7	5.2
25–29	34	51.6	43	64.1	77	57.9	8	12.1	8	11.9	16	12.0
30-34	47	76.6	50	78.8	97	77.7	7	11.4	4	6.3	11	8.8
35–39	55	88.1	93	142.7	148	116.0	15	24.0	18	27.6	33	25.9
40-44	105	178.0	147	232.7	252	206.3	29	49.2	23	36.4	52	42.6
45-49	156	264.3	221	357.1	377	311.8	36	61.0	69	111.5	105	86.8
50-54	237	464.8	325	646.6	562	555.0	55	107.9	73	145.2	128	126.4
55–59	283	831.0	268	803.5	551	817.4	82	240.8	75	224.8	157	232.9
60-64	343	1,402.3	218	891.2	561	1,146.7	114	466.1	71	290.3	185	378.2
65-69	380	1,971.6	247	1,237.1	627	1,597.9	166	861.3	125	626.1	291	741.6
70–74	432	2,781.4	252	1,368.4	684	2,014.8	203	1,307.0	148	803.6	351	1,033.9
75–79	364	3,464.0	204	1,432.8	568	2,295.3	176	1,674.9	130	913.0	306	1,236.6
80-84	206	4,012.5	158	1,768.7	364	2,587.6	143	2,785.4	126	1,410.5	269	1,912.3
85 and over	102	3,681.0	155	2,295.6	257	2,698.7	105	3,789.2	136	2,014.2	241	2,530.7
Total	2,810		2,436		5,246		1,151		1,012		2,163	
Crude rate		363.9		309.4		336.4		149.1		128.5		138.7
95% CI	3.	50.4 - 377.3	2	97.1 – 321.7	3:	27.3 – 345.5	14	40.4 - 157.7	1:	20.6 – 136.5		132.9 – 144.5
AS rate (Aust 1991)		494.0		336.3		403.3		228.0		147.8		180.2
95% CI	4′	74.9 – 513.1	3:	22.6 - 350.0	3	92.1 – 414.5	21	14.3 - 241.8	1:	38.5 – 157.1		172.4 – 187.9
AS rate (World)		351.0		261.9		300.7		146.8		101.8		120.5
95% CI	33	37.7 – 364.3	2.	51.1 - 272.8	29	92.3 – 309.1	13	38.0 – 155.5		95.2 – 108.5		115.2 - 125.7
Lifetime risk (0-74)		1 in 3		1 in 4		1 in 3		1 in 7		1 in 9		1 in 8
PYLL (0–74) Per cent of all								9,737.5		9,395.0		19,132.5
cancers		100.0		100.0		100.0		100.0		100.0		100.0

Table A4-2: Malignant Neoplasm of Lip: ICD-10 C00

			Incide	nce					Mortali	ty		
_	Male	s	Femal	les	Person	ıs	Males	1	Female	s	Person	S
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	2	3.0	0	0.0	2	1.5	0	0.0	0	0.0	0	0.0
30-34	2	3.3	1	1.6	3	2.4	0	0.0	0	0.0	0	0.0
35-39	1	1.6	0	0.0	1	0.8	1	1.6	0	0.0	1	0.8
40-44	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
45-49	3	5.1	1	1.6	4	3.3	0	0.0	0	0.0	0	0.0
50-54	1	2.0	3	6.0	4	4.0	0	0.0	0	0.0	0	0.0
55-59	3	8.8	0	0.0	3	4.5	1	2.9	0	0.0	1	1.5
60-64	0	0.0	1	4.1	1	2.0	0	0.0	0	0.0	0	0.0
65-69	2	10.4	2	10.0	4	10.2	0	0.0	0	0.0	0	0.0
70-74	2	12.9	2	10.9	4	11.8	0	0.0	0	0.0	0	0.0
75–79	2	19.0	2	14.0	4	16.2	0	0.0	0	0.0	0	0.0
80-84	0	0.0	1	11.2	1	7.1	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	18		14		32		2		0		2	
Crude rate		2.3		1.8		2.1		0.3		0.0		0.1
95% CI		1.3 - 3.4		0.8 - 2.7		1.3 - 2.8		0.0 - 0.6		0.0 - 0.0		0.0 - 0.3
AS rate (Aust 1991)	1	2.6		2.0		2.3		0.2		0.0		0.1
95% CI		1.4 - 3.9		0.9 - 3.1		1.5 - 3.1		0.0 - 0.6		0.0 - 0.0		0.0 - 0.3
AS rate (World)		2.0		1.5		1.8		0.2		0.0		0.1
95% CI		1.1 - 3.0		0.7 - 2.3		1.1 - 2.4		0.0 - 0.5		0.0 - 0.0		0.0 - 0.3
Lifetime risk (0-74)	ı	1 in 426		1 in 561		1 in 485		1 in 4,408		#DIV/0!		1 in 8,823
PYLL (0–74) Per cent of all								55.0		0.0		55.0
cancers		0.6		0.6		0.6		0.2		0.0		0.1

Table A4-3: Malignant Neoplasm of Tongue: ICD-10 C01

			Inciden	ce					Mortalit	y		
_	Males	5	Female	s	Person	ıs	Males		Females	1	Person	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	1	1.5	1	0.8	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	2	3.2	2	1.7	0	0.0	1	1.6	1	0.8
50-54	3	5.9	2	4.0	5	4.9	0	0.0	0	0.0	0	0.0
55-59	4	11.7	1	3.0	5	7.4	2	5.9	0	0.0	2	3.0
60-64	0	0.0	2	8.2	2	4.1	0	0.0	0	0.0	0	0.0
65-69	3	15.6	0	0.0	3	7.6	0	0.0	0	0.0	0	0.0
70–74	3	19.3	0	0.0	3	8.8	3	19.3	0	0.0	3	8.8
75–79	2	19.0	0	0.0	2	8.1	1	9.5	0	0.0	1	4.0
80-84	2	39.0	2	22.4	4	28.4	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	0	0.0	0	0.0
Total	17		11		28		6		1		7	
Crude rate		2.2		1.4		1.8		0.8		0.1		0.4
95% CI		1.2 - 3.2		0.6 - 2.2		1.1 - 2.5		0.2 - 1.4		0.0 - 0.4		0.1 - 0.8
AS rate (Aust 1991)		2.9		1.4		2.1		1.0		0.1		0.5
95% CI		1.5 - 4.3		0.6 - 2.3		1.3 - 2.9		0.2 - 1.9		0.0 - 0.3		0.1 - 0.9
AS rate (World)		2.0		1.1		1.5		0.7		0.1		0.4
95% CI		1.0 - 3.0		0.4 - 1.9		1.0 - 2.1		0.1 - 1.3		0.0 - 0.3		0.1 - 0.7
Lifetime risk (0-74)		1 in 381		1 in 1,007		1 in 567		1 in 795		1 in 12,379		1 in 1,584
PYLL (0–74) Per cent of all								42.5		27.5		70.0
cancers		0.6		0.5		0.5		0.5		0.1		0.3

Table A4-4: Malignant Neoplasm of Mouth: ICD-10 C03-06

			Incide	nce					Mortal	ity		
_	Male	es	Femal	les	Person	ns	Males	3	Femal	es	Perso	ns
_	Number	Rate	Number	Rate								
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	1	1.5	1	0.8	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	2	3.4	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
45-49	1	1.7	1	1.6	2	1.7	1	1.7	0	0.0	1	0.8
50-54	3	5.9	2	4.0	5	4.9	0	0.0	0	0.0	0	0.0
55-59	4	11.7	2	6.0	6	8.9	1	2.9	0	0.0	1	1.5
60-64	4	16.4	1	4.1	5	10.2	3	12.3	0	0.0	3	6.1
65-69	1	5.2	0	0.0	1	2.5	1	5.2	2	10.0	3	7.6
70–74	0	0.0	2	10.9	2	5.9	0	0.0	0	0.0	0	0.0
75–79	3	28.5	0	0.0	3	12.1	0	0.0	1	7.0	1	4.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	1	14.8	1	10.5
Total	18		10		28		6		4		10	
Crude rate		2.3		1.3		1.8		0.8		0.5		0.6
95% CI		1.3 - 3.4		0.5 - 2.1		1.1 - 2.5		0.2 - 1.4		0.0 - 1.0		0.2 - 1.0
AS rate (Aust 1991)		2.7		1.3		2.0		0.9		0.7		0.9
95% CI		1.4 - 4.0		0.5 - 2.1		1.2 - 2.7		0.2 - 1.7		0.0 - 1.3		0.3 - 1.4
AS rate (World)		2.2		1.1		1.6		0.9		0.4		0.7
95% CI		1.1 - 3.2		0.4 - 1.8		1.0 - 2.3		0.2 - 1.6		0.0 - 0.9		0.2 - 1.1
Lifetime risk (0-74)		1 in 452		1 in 714		1 in 548		1 in 906		1 in 1,997		1 in 1,244
PYLL (0–74) Per cent of all								90.0		15.0		105.0
cancers		0.6		0.4		0.5		0.5		0.4		0.5

Table A4-5: Malignant Neoplasm of Salivary Glands: ICD-10 C07-08

			Inciden	ice					Mortali	ity		
_	Male	S	Female	es	Person	ıs	Males	5	Female	es	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	1	1.5	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	1	1.5	0	0.0	1	0.8
30-34	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
35–39	2	3.2	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
40-44	2	3.4	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
45-49	2	3.4	0	0.0	2	1.7	0	0.0	0	0.0	0	0.0
50-54	2	3.9	2	4.0	4	4.0	0	0.0	0	0.0	0	0.0
55-59	1	2.9	0	0.0	1	1.5	0	0.0	0	0.0	0	0.0
60-64	0	0.0	1	4.1	1	2.0	0	0.0	0	0.0	0	0.0
65-69	2	10.4	0	0.0	2	5.1	0	0.0	0	0.0	0	0.0
70–74	1	6.4	0	0.0	1	2.9	1	6.4	1	5.4	2	5.9
75–79	4	38.1	1	7.0	5	20.2	2	19.0	0	0.0	2	8.1
80-84	1	19.5	0	0.0	1	7.1	0	0.0	2	22.4	2	14.2
85 and over	1	36.1	0	0.0	1	10.5	0	0.0	0	0.0	0	0.0
Total	19		5		24		4		3		7	
Crude rate		2.5		0.6		1.5		0.5		0.4		0.4
95% CI		1.4 - 3.6		0.1 - 1.2		0.9 - 2.2		0.0 - 1.0		0.0 - 0.8		0.1 - 0.8
AS rate (Aust 1991)		3.2		0.7		1.7		0.7		0.5		0.6
95% CI		1.6 - 4.7		0.1 - 1.2		1.0 - 2.4		0.0 - 1.5		0.0 - 1.0		0.2 - 1.1
AS rate (World)		2.1		0.5		1.2		0.4		0.2		0.3
95% CI		1.1 - 3.1		0.0 - 1.0		0.7 - 1.7		0.0 - 0.9		0.0 - 0.5		0.1 - 0.6
Lifetime risk (0-74)		1 in 570		1 in 2,074		1 in 913		1 in 2,514		1 in 3,684		1 in 3,011
PYLL (0–74) Per cent of all								50.0		2.5		52.5
cancers		0.7		0.2		0.5		0.3		0.3		0.3

Table A4-6: Malignant Neoplasm of Tonsils: ICD-10 C09

_			Inciden	ce					Mortalit	y		
_	Males	5	Female	es	Person	ıs	Males		Female	S	Person	S
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
45-49	2	3.4	0	0.0	2	1.7	1	1.7	0	0.0	1	0.8
50-54	1	2.0	2	4.0	3	3.0	0	0.0	0	0.0	0	0.0
55–59	2	5.9	0	0.0	2	3.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	1	5.2	0	0.0	1	2.5	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	7		2		9		1		0		1	
Crude rate		0.9		0.3		0.6		0.1		0.0		0.1
95% CI		0.2 - 1.6		0.0 - 0.6		0.2 - 1.0		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (Aust 1991)		0.9		0.2		0.5		0.1		0.0		0.0
95% CI		0.2 - 1.5		0.0 - 0.5		0.2 - 0.9		0.0 - 0.3		0.0 - 0.0		0.0 - 0.1
AS rate (World)		0.8		0.2		0.5		0.1		0.0		0.0
95% CI		0.2 - 1.4		0.0 - 0.5		0.2 - 0.8		0.0 - 0.3		0.0 - 0.0		0.0 - 0.1
Lifetime risk (0-74)		1 in 1,105		1 in 5,027		1 in 1,827		1 in 11,804		NA		1 in 24,182
PYLL (0–74) Per cent of all								27.5		0.0		27.5
cancers		0.2		0.1		0.2		0.1		0.0		0.0

Table A4-7: Malignant Neoplasm of Other Oropharynx: ICD-10 C10

Age group -4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0				Inciden	ice					Mortali	ty		
Age group	_	Males	S	Female	es	Person	ns	Males		Female	es	Person	ıs
0-4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 <th< th=""><th></th><th>Number</th><th>Rate</th><th>Number</th><th>Rate</th><th>Number</th><th>Rate</th><th>Number</th><th>Rate</th><th>Number</th><th>Rate</th><th>Number</th><th>Rate</th></th<>		Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
5-9 0 0.0	Age group												
10-14	0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0	10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0.0 0 <td>15–19</td> <td>0</td> <td>0.0</td> <td>0</td> <td>0.0</td> <td>0</td> <td>0.0</td> <td>0</td> <td>0.0</td> <td>0</td> <td>0.0</td> <td>0</td> <td>0.0</td>	15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44 0 0.0 0 0 0.0 0	30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0	35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54 1 2.0 0 0.0 1 1.0 0 0.0 0.0 0.0 0.0 55-59 0 0.0 0 0.0 0 0.0 1 2.9 0 0.0 1 1.5 60-64 1 4.1 0 0.0 1 2.0 0 0.0	40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59 0 0.0 0 0.0 0 0.0 1 2.9 0 0.0 1 1.5 5.5 60-64 1 4.1 0 0.0 1 2.9 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0 0.0 0	45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64 1 4.1 0 0.0 1 2.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0	50-54	1	2.0	0	0.0	1	1.0	0	0.0	0	0.0	0	0.0
65-69 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0.0 0 0 0.0 0 <td>55–59</td> <td>0</td> <td>0.0</td> <td>0</td> <td>0.0</td> <td>0</td> <td>0.0</td> <td>1</td> <td>2.9</td> <td>0</td> <td>0.0</td> <td>1</td> <td>1.5</td>	55–59	0	0.0	0	0.0	0	0.0	1	2.9	0	0.0	1	1.5
70–74 0 0.0 1 5.4 1 2.9 0 0.0 0 0.0 0 0.0 75–79 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0 0.0 0	60-64	1	4.1	0	0.0	1	2.0	0	0.0	0	0.0	0	0.0
75-79 0 0.0 0 <t< th=""><td>65-69</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td><td>0</td><td>0.0</td></t<>	65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80–84 0 0.0 0 0 0.0 0 0.0 <	70–74	0	0.0	1	5.4	1	2.9	0	0.0	0	0.0	0	0.0
85 and over 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0	75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total 2 1 3 1 0 1 Crude rate 0.3 0.1 0.2 0.1 0.0 0.1 95% CI 0.0 - 0.6 0.0 - 0.4 0.0 - 0.4 0.0 - 0.4 0.0 - 0.4 0.0 - 0.0 0.0 - 0.2 AS rate (Aust 1991) 0.3 0.2 0.2 0.1 0.0 0.0 0.1 95% CI 0.0 - 0.7 0.0 - 0.5 0.0 - 0.5 0.0 - 0.4 0.0 - 0.0 0.0 - 0.2 AS rate (World) 0.3 0.1 0.2 0.1 0.0 0.0 0.1 95% CI 0.0 - 0.6 0.0 - 0.3 0.0 - 0.4 0.0 - 0.3 0.0 - 0.0 0.0 - 0.2 Lifetime risk (0-74) 1 in 3,307 1 in 3,684 1 in 3,346 1 in 6,812 NA 1 in 13,483	80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Crude rate 0.3 0.1 0.2 0.1 0.0 0.1 95% CI 0.0 - 0.6 0.0 - 0.4 0.0 - 0.4 0.0 - 0.4 0.0 - 0.4 0.0 - 0.0 0.0 - 0.2 AS rate (Aust 1991) 0.3 0.2 0.2 0.1 0.0 0.1 95% CI 0.0 - 0.7 0.0 - 0.5 0.0 - 0.5 0.0 - 0.4 0.0 - 0.0 0.0 - 0.2 AS rate (World) 0.3 0.1 0.2 0.1 0.0 0.1 95% CI 0.0 - 0.6 0.0 - 0.3 0.0 - 0.4 0.0 - 0.3 0.0 - 0.0 0.0 - 0.2 Lifetime risk (0-74) 1 in 3,307 1 in 3,684 1 in 3,346 1 in 6,812 NA 1 in 13,483	85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
95% CI 0.0 - 0.6 0.0 - 0.4 0.0 - 0.4 0.0 - 0.4 0.0 - 0.4 0.0 - 0.0 0.0 - 0.2 AS rate (Aust 1991) 0.3 0.2 0.2 0.1 0.0 0.1 95% CI 0.0 - 0.7 0.0 - 0.5 0.0 - 0.5 0.0 - 0.4 0.0 - 0.0 0.0 - 0.2 AS rate (World) 0.3 0.1 0.2 0.1 0.0 0.1 95% CI 0.0 - 0.6 0.0 - 0.3 0.0 - 0.4 0.0 - 0.3 0.0 - 0.2 Lifetime risk (0-74) 1 in 3,307 1 in 3,684 1 in 3,346 1 in 6,812 NA 1 in 13,483	Total	2		1		3		1		0		1	
AS rate (Aust 1991) 0.3 0.2 0.2 0.1 0.0 0.1 95% CI 0.0 - 0.7 0.0 - 0.5 0.0 - 0.5 0.0 - 0.4 0.0 - 0.0 0.0 - 0.2 AS rate (World) 0.3 0.1 0.2 0.1 0.0 0.1 95% CI 0.0 - 0.6 0.0 - 0.3 0.0 - 0.4 0.0 - 0.3 0.0 - 0.0 0.0 - 0.2 Lifetime risk (0-74) 1 in 3,307 1 in 3,684 1 in 3,346 1 in 6,812 NA 1 in 13,483	Crude rate		0.3		0.1		0.2		0.1		0.0		0.1
95% CI 0.0 – 0.7 0.0 – 0.5 0.0 – 0.5 0.0 – 0.4 0.0 – 0.0 0.0 – 0.2 AS rate (World) 0.3 0.1 0.2 0.1 0.0 0.1 95% CI 0.0 – 0.6 0.0 – 0.3 0.0 – 0.4 0.0 – 0.3 0.0 – 0.0 0.0 – 0.2 Lifetime risk (0–74) 1 in 3,307 1 in 3,684 1 in 3,346 1 in 6,812 NA 1 in 13,483	95% CI		0.0 - 0.6		0.0 - 0.4		0.0 - 0.4		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (World) 0.3 0.1 0.2 0.1 0.0 0.1 95% CI 0.0 - 0.6 0.0 - 0.3 0.0 - 0.4 0.0 - 0.3 0.0 - 0.0 0.0 - 0.2 Lifetime risk (0-74) 1 in 3,307 1 in 3,684 1 in 3,346 1 in 6,812 NA 1 in 13,483	AS rate (Aust 1991)		0.3		0.2		0.2		0.1		0.0		0.1
95% CI 0.0 - 0.6 0.0 - 0.3 0.0 - 0.4 0.0 - 0.3 0.0 - 0.0 0.0 - 0.2 Lifetime risk (0-74) 1 in 3,307 1 in 3,684 1 in 3,346 1 in 6,812 NA 1 in 13,483	95% CI		0.0 - 0.7		0.0 - 0.5		0.0 - 0.5		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
Lifetime risk (0–74) 1 in 3,307 1 in 3,684 1 in 3,346 1 in 6,812 NA 1 in 13,483	AS rate (World)		0.3		0.1		0.2		0.1		0.0		0.1
	95% CI		0.0 - 0.6		0.0 - 0.3		0.0 - 0.4		0.0 - 0.3		0.0 - 0.0		0.0 - 0.2
	Lifetime risk (0-74)		1 in 3,307		1 in 3,684		1 in 3,346		1 in 6,812		NA		1 in 13,483
PYLL (0-74) Per cent of all	PYLL (0-74)								17.5		0.0		17.5
			0.1		0.0		0.1		0.1		0.0		0.0

Table A4-8: Malignant Neoplasm of Nasopharynx: ICD-10 C11

			Inciden	ice					Mortalit	ty		
	Male	es	Female	es	Person	ıs	Males	5	Female	s	Person	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	2	3.5	0	0.0	2	1.8	0	0.0	0	0.0	0	0.0
15-19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
45-49	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.0	1	1.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	1	4.1	0	0.0	1	2.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	1	5.2	0	0.0	1	2.5
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	1	36.1	0	0.0	1	10.5	0	0.0	0	0.0	0	0.0
Total	5		3		8		1		0		1	
Crude rate		0.6		0.4		0.5		0.1		0.0		0.1
95% CI		0.1 - 1.2		0.0 - 0.8		0.2 - 0.9		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (Aust 1991)		0.9		0.3		0.5		0.2		0.0		0.1
95% CI		0.0 - 1.7		0.0 - 0.7		0.2 - 0.9		0.0 - 0.6		0.0 - 0.0		0.0 - 0.3
AS rate (World)		0.8		0.3		0.5		0.2		0.0		0.1
95% CI		0.1 - 1.5		0.0 - 0.6		0.1 - 0.9		0.0 - 0.5		0.0 - 0.0		0.0 - 0.2
Lifetime risk (0-74)		1 in 2,186		1 in 3,855		1 in 2,755		1 in 3,855		NA		1 in 7,849
PYLL (0–74) Per cent of all								7.5		0.0		7.5
cancers		0.2		0.1		0.2		0.1		0.0		0.0

Table A4-9: Malignant Neoplasm of Hypopharynx: ICD-10 C12-13

			Incidend	ee					Mortalit	y		
_	Males	S	Female	s	Person	ıs	Males	5	Females	S	Person	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
50-54	1	2.0	0	0.0	1	1.0	0	0.0	1	2.0	1	1.0
55-59	4	11.7	0	0.0	4	5.9	3	8.8	0	0.0	3	4.5
60-64	0	0.0	0	0.0	0	0.0	1	4.1	0	0.0	1	2.0
65-69	2	10.4	0	0.0	2	5.1	1	5.2	0	0.0	1	2.5
70–74	1	6.4	0	0.0	1	2.9	1	6.4	0	0.0	1	2.9
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	8		1		9		6		1		7	
Crude rate		1.0		0.1		0.6		0.8		0.1		0.4
95% CI		0.3 - 1.8		0.0 - 0.4		0.2 - 1.0		0.2 - 1.4		0.0 - 0.4		0.1 - 0.8
AS rate (Aust 1991)		1.2		0.1		0.6		0.9		0.1		0.5
95% CI		0.3 - 2.0		0.0 - 0.3		0.2 - 1.1		0.2 - 1.7		0.0 - 0.3		0.1 - 0.9
AS rate (World)		1.0		0.1		0.5		0.8		0.1		0.4
95% CI		0.3 - 1.7		0.0 - 0.3		0.2 - 0.9		0.2 - 1.4		0.0 - 0.3		0.1 - 0.8
Lifetime risk (0–74)		1 in 656		1 in 12,379		1 in 1,267		1 in 816		1 in 10,054		1 in 1,542
PYLL (0–74) Per cent of all								75.0		22.5		97.5
cancers		0.3		0.0		0.2		0.5		0.1		0.3

Table A4-10: Malignant Neoplasm of Unspecified Parts of Pharynx: ICD-10 C12-13

			Inciden	ce					Mortali	ty		
_	Males		Female	es	Person	s	Males		Female	s	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	1	4.1	1	2.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	1	5.0	1	2.5
70–74	1	6.4	0	0.0	1	2.9	0	0.0	0	0.0	0	0.0
75–79	1	9.5	0	0.0	1	4.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	1	36.1	0	0.0	1	10.5
Total	2		1		3		1		1		2	
Crude rate		0.3		0.1		0.2		0.1		0.1		0.1
95% CI		0.0 - 0.6		0.0 - 0.4		0.0 - 0.4		0.0 - 0.4		0.0 - 0.4		0.0 - 0.3
AS rate (Aust 1991)		0.4		0.2		0.3		0.3		0.2		0.2
95% CI		0.0 - 1.0		0.0 - 0.5		0.0 - 0.6		0.0 - 1.0		0.0 - 0.6		0.0 - 0.5
AS rate (World)		0.2		0.2		0.2		0.2		0.2		0.1
95% CI		0.0 - 0.5		0.0 - 0.5		0.0 - 0.4		0.0 - 0.5		0.0 - 0.4		0.0 - 0.3
Lifetime risk (0-74)		1 in 3,107		1 in 4,893		1 in 4,009		NA		1 in 3,994		1 in 7,849
PYLL (0–74) Per cent of all								0.0		7.5		7.5
cancers		0.1		0.0		0.1		0.1		0.1		0.1

Table A4-11: Malignant Neoplasm of Unspecified Parts of Oesophagus: ICD-10 C15

			Incider	nce					Mortali	ity		
	Male	S	Femal	es	Person	ıs	Males	3	Female	es	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
40-44	1	1.7	0	0.0	1	0.8	1	1.7	0	0.0	1	0.8
45-49	3	5.1	0	0.0	3	2.5	3	5.1	0	0.0	3	2.5
50-54	2	3.9	0	0.0	2	2.0	1	2.0	0	0.0	1	1.0
55–59	3	8.8	2	6.0	5	7.4	0	0.0	0	0.0	0	0.0
60-64	2	8.2	2	8.2	4	8.2	0	0.0	0	0.0	0	0.0
65-69	4	20.8	3	15.0	7	17.8	5	25.9	3	15.0	8	20.4
70–74	9	57.9	4	21.7	13	38.3	6	38.6	4	21.7	10	29.5
75–79	5	47.6	4	28.1	9	36.4	4	38.1	3	21.1	7	28.3
80-84	5	97.4	0	0.0	5	35.5	3	58.4	0	0.0	3	21.3
85 and over	3	108.3	3	44.4	6	63.0	4	144.4	2	29.6	6	63.0
Total	38		18		56		27		12		39	
Crude rate		4.9		2.3		3.6		3.5		1.5		2.5
95% CI		3.4 - 6.5		1.2 - 3.3		2.7 - 4.5		2.2 - 4.8		0.7 - 2.4		1.7 - 3.3
AS rate (Aust 1991)		7.3		2.8		4.7		5.6		2.0		3.4
95% CI		4.9 - 9.7		1.5 - 4.2		3.4 - 5.9		3.4 - 7.8		0.8 - 3.1		2.3 - 4.5
AS rate (World)		4.7		2.0		3.1		3.5		1.2		2.2
95% CI		3.1 - 6.2		1.0 - 2.9		2.3 - 4.0		2.1 - 4.8		0.5 - 2.0		1.5 - 2.8
Lifetime risk (0–74)		1 in 186		1 in 393		1 in 258		1 in 273		1 in 545		1 in 370
PYLL (0–74) Per cent of all								190.0		32.5		222.5
cancers		1.4		0.7		1.1		2.3		1.2		1.8

Table A4-12: Malignant Neoplasm of Stomach: ICD-10 C16

			Incider	nce					Mortali	ity		
_	Male	es	Femal	es	Person	ns	Males	}	Female	es	Person	as
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	1	1.5	1	0.8	0	0.0	1	1.5	1	0.8
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	2	3.2	0	0.0	2	1.6	2	3.2	1	1.5	3	2.4
40-44	1	1.7	1	1.6	2	1.6	1	1.7	0	0.0	1	0.8
45-49	4	6.8	1	1.6	5	4.1	5	8.5	2	3.2	7	5.8
50-54	5	9.8	4	8.0	9	8.9	4	7.8	1	2.0	5	4.9
55-59	5	14.7	3	9.0	8	11.9	6	17.6	3	9.0	9	13.4
60-64	11	45.0	7	28.6	18	36.8	7	28.6	3	12.3	10	20.4
65-69	10	51.9	7	35.1	17	43.3	11	57.1	4	20.0	15	38.2
70–74	11	70.8	8	43.4	19	56.0	10	64.4	4	21.7	14	41.2
75–79	9	85.6	5	35.1	14	56.6	6	57.1	4	28.1	10	40.4
80-84	5	97.4	4	44.8	9	64.0	4	77.9	6	67.2	10	71.1
85 and over	3	108.3	6	88.9	9	94.5	6	216.5	8	118.5	14	147.0
Total	66		47		113		62		37		99	
Crude rate		8.5		6.0		7.2		8.0		4.7		6.3
95% CI		6.5 - 10.6		4.3 - 7.7		5.9 - 8.6		6.0 - 10.0		3.2 - 6.2		5.1 - 7.6
AS rate (Aust 1991)		12.1		7.1		9.3		11.6		5.4		8.2
95% CI		9.0 - 15.1		5.1 - 9.2		7.6 - 11.1		8.5 - 14.6		3.6 - 7.2		6.5 - 9.8
AS rate (World)		8.4		5.2		6.7		8.1		3.6		5.7
95% CI		6.3 - 10.5		3.6 - 6.7		5.4 - 7.9		6.0 - 10.2		2.4 - 4.8		4.5 - 6.8
Lifetime risk (0-74)		1 in 99		1 in 156		1 in 122		1 in 106		1 in 281		1 in 157
PYLL (0–74) Per cent of all								635.0		292.5		927.5
cancers		2.3		1.9		2.2		5.4		3.7		4.6

Table A4-13: Malignant Neoplasm of Small Intestine: ICD-10 C17

			Inciden	ce					Mortali	ity		
	Male	s	Femal	es	Person	ns	Males	S	Female	es	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	1	1.7	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	2	3.4	2	3.2	4	3.3	0	0.0	0	0.0	0	0.0
50-54	1	2.0	0	0.0	1	1.0	1	2.0	0	0.0	1	1.0
55-59	1	2.9	0	0.0	1	1.5	0	0.0	0	0.0	0	0.0
60-64	1	4.1	2	8.2	3	6.1	1	4.1	0	0.0	1	2.0
65-69	0	0.0	0	0.0	0	0.0	1	5.2	1	5.0	2	5.1
70–74	1	6.4	1	5.4	2	5.9	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	2	19.0	1	7.0	3	12.1
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	1	14.8	1	10.5
Total	6		7		13		5		3		8	
Crude rate		0.8		0.9		0.8		0.6		0.4		0.5
95% CI		0.2 - 1.4		0.2 - 1.5		0.4 - 1.3		0.1 - 1.2		0.0 - 0.8		0.2 - 0.9
AS rate (Aust 1991)		0.8		1.0		0.9		0.9		0.5		0.7
95% CI		0.1 - 1.4		0.2 - 1.7		0.4 - 1.4		0.1 - 1.7		0.0 - 1.0		0.2 - 1.2
AS rate (World)		0.7		0.9		0.8		0.6		0.3		0.5
95% CI		0.1 - 1.3		0.2 - 1.5		0.4 - 1.2		0.1 - 1.2		0.0 - 0.7		0.1 - 0.8
Lifetime risk (0-74)		1 in 1,064		1 in 1,081		1 in 1,075		1 in 1,780		1 in 3,994		1 in 2,461
PYLL (0-74)								42.5		7.5		50.0
Per cent of all												
cancers		0.2		0.3		0.2		0.4		0.3		0.4

Table A4-14: Malignant Neoplasm of Colon: ICD-10 C18

_			Inciden	ce					Mortali	ity		
_	Males		Female	es	Person	s	Males	5	Female	es	Perso	ons
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	1	1.5	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
30-34	2	3.3	2	3.2	4	3.2	1	1.6	0	0.0	1	0.8
35–39	2	3.2	4	6.1	6	4.7	0	0.0	1	1.5	1	0.8
40-44	7	11.9	4	6.3	11	9.0	2	3.4	1	1.6	3	2.5
45-49	7	11.9	12	19.4	19	15.7	1	1.7	4	6.5	5	4.1
50-54	26	51.0	18	35.8	44	43.5	3	5.9	6	11.9	9	8.9
55–59	33	96.9	27	80.9	60	89.0	4	11.7	7	21.0	11	16.3
60-64	33	134.9	27	110.4	60	122.6	18	73.6	10	40.9	28	57.2
65-69	33	171.2	30	150.3	63	160.6	20	103.8	11	55.1	31	79.0
70–74	41	264.0	26	141.2	67	197.4	20	128.8	14	76.0	34	100.2
75–79	30	285.5	24	168.6	54	218.2	14	133.2	13	91.3	27	109.1
80-84	20	389.6	21	235.1	41	291.5	8	155.8	9	100.8	17	120.9
85 and over	11	397.0	20	296.2	31	325.5	6	216.5	16	237.0	22	231.0
Total	247		215		462		97		92		189	
Crude rate		32.0		27.3		29.6		12.6		11.7		12.1
95% CI	2	28.0 - 36.0		23.7 – 31.0		26.9 – 32.3	1	10.1 – 15.1		9.3 – 14.1		10.4 – 13.8
AS rate (Aust 1991)		44.2		31.7		37.2		19.2		13.7		16.2
95% CI	3	38.4 - 50.0		27.4 – 36.1		33.7 – 40.6	1	15.3 – 23.1		10.9 – 16.5		13.9 – 18.6
AS rate (World)		31.1		23.2		26.8		13.0		9.4		11.1
95% CI	2	27.1 – 35.1	:	20.0 - 26.5		24.2 - 29.3	1	10.3 – 15.6		7.4 - 11.5		9.5 – 12.7
Lifetime risk (0–74)		1 in 27		1 in 37		1 in 31		1 in 61		1 in 94		1 in 75
PYLL (0–74) Per cent of all								697.5		680.0		1,377.5
cancers		8.8		8.8		8.8		8.4		9.1		8.7

Table A4-15: Malignant Neoplasm of Rectum: ICD-10 C19-20

			Incide	nce					Mortal	ity		
_	Male	es	Fema	les	Perso	ns	Males	s	Femal	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	2	2.9	0	0.0	2	1.5	1	1.5	0	0.0	1	0.7
25–29	1	1.5	1	1.5	2	1.5	0	0.0	0	0.0	0	0.0
30-34	0	0.0	1	1.6	1	0.8	0	0.0	1	1.6	1	0.8
35–39	1	1.6	1	1.5	2	1.6	0	0.0	1	1.5	1	0.8
40-44	5	8.5	3	4.7	8	6.5	2	3.4	0	0.0	2	1.6
45-49	14	23.7	5	8.1	19	15.7	1	1.7	4	6.5	5	4.1
50-54	14	27.5	6	11.9	20	19.8	4	7.8	2	4.0	6	5.9
55–59	16	47.0	7	21.0	23	34.1	7	20.6	2	6.0	9	13.4
60-64	15	61.3	5	20.4	20	40.9	6	24.5	0	0.0	6	12.3
65-69	22	114.1	12	60.1	34	86.6	6	31.1	0	0.0	6	15.3
70–74	20	128.8	6	32.6	26	76.6	8	51.5	10	54.3	18	53.0
75–79	15	142.7	13	91.3	28	113.1	6	57.1	8	56.2	14	56.6
80-84	2	39.0	11	123.1	13	92.4	5	97.4	3	33.6	8	56.9
85 and over	3	108.3	13	192.5	16	168.0	3	108.3	8	118.5	11	115.5
Total	130		84		214		49		39		88	
Crude rate		16.8		10.7		13.7		6.3		5.0		5.6
95% CI		13.9 - 19.7		8.4 - 13.0		11.9 – 15.6		4.6 - 8.1		3.4 - 6.5		4.5 - 6.8
AS rate (Aust 1991)		21.4		12.2		16.9		9.0		5.4		7.1
95% CI		17.5 - 25.2		9.6 - 14.9		14.5 - 19.2		6.4 - 11.7		3.7 - 7.2		5.6 - 8.7
AS rate (World)		16.2		8.3		12.3		6.2		3.4		4.8
95% CI		13.4 - 19.1		6.4 - 10.1		10.6 - 14.0		4.4 - 8.0		2.3 - 4.5		3.7 - 5.8
Lifetime risk (0-74)		1 in 48		1 in 123		1 in 71		1 in 141		1 in 271		1 in 186
PYLL (0–74) Per cent of all								497.5		295.0		792.5
cancers		4.6		3.4		4.1		4.3		3.9		4.1

Table A4-16: Malignant Neoplasm of Anus: ICD-10 C21

_			Inciden	ce					Mortali	ty		
_	Male	s	Female	s	Person	ıs	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.0	1	1.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	2	6.0	2	3.0	0	0.0	0	0.0	0	0.0
60-64	2	8.2	1	4.1	3	6.1	1	4.1	0	0.0	1	2.0
65-69	1	5.2	0	0.0	1	2.5	2	10.4	0	0.0	2	5.1
70–74	2	12.9	0	0.0	2	5.9	0	0.0	0	0.0	0	0.0
75–79	0	0.0	1	7.0	1	4.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	1	36.1	4	59.2	5	52.5	0	0.0	1	14.8	1	10.5
Total	6		10		16		3		1		4	
Crude rate		0.8		1.3		1.0		0.4		0.1		0.3
95% CI		0.2 - 1.4		0.5 - 2.1		0.5 - 1.5		0.0 - 0.8		0.0 - 0.4		0.0 - 0.5
AS rate (Aust 1991)		1.3		1.3		1.3		0.6		0.1		0.4
95% CI		0.2 - 2.3		0.5 - 2.2		0.7 - 2.0		0.0 - 1.2		0.0 - 0.4		0.0 - 0.8
AS rate (World)		0.9		1.0		1.0		0.5		0.1		0.3
95% CI		0.2 - 1.7		0.3 - 1.6		0.5 - 1.4		0.0 - 1.0		0.0 - 0.2		0.0 - 0.6
Lifetime risk (0-74)		1 in 763		1 in 1,465		1 in 1,034		1 in 1,383		NA		1 in 2,801
PYLL (0–74) Per cent of all								27.5		0.0		27.5
cancers		0.2		0.4		0.3		0.3		0.1		0.2

Table A4-17: Malignant Neoplasm of Colon (Excluding anus): ICD-10 C18-20

J	•		Inciden	•					Mortali	ty		
_	Males	}	Female	es	Person	ıs	Males	3	Female	es	Perso	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	2	2.9	0	0.0	2	1.5	1	1.5	0	0.0	1	0.7
25-29	2	3.0	1	1.5	3	2.3	0	0.0	0	0.0	0	0.0
30-34	2	3.3	3	4.7	5	4.0	1	1.6	1	1.6	2	1.6
35–39	3	4.8	5	7.7	8	6.3	0	0.0	2	3.1	2	1.6
40-44	12	20.3	7	11.1	19	15.6	4	6.8	1	1.6	5	4.1
45-49	21	35.6	17	27.5	38	31.4	2	3.4	8	12.9	10	8.3
50-54	40	78.4	24	47.7	64	63.2	7	13.7	8	15.9	15	14.8
55-59	49	143.9	34	101.9	83	123.1	11	32.3	9	27.0	20	29.7
60-64	48	196.2	32	130.8	80	163.5	24	98.1	10	40.9	34	69.5
65-69	55	285.4	42	210.4	97	247.2	26	134.9	11	55.1	37	94.3
70–74	61	392.7	32	173.8	93	273.9	28	180.3	24	130.3	52	153.2
75–79	45	428.2	37	259.9	82	331.4	20	190.3	21	147.5	41	165.7
80-84	22	428.5	32	358.2	54	383.9	13	253.2	12	134.3	25	177.7
85 and over	14	505.2	33	488.7	47	493.5	9	324.8	24	355.5	33	346.5
Total	377		299		676		146		131		277	
Crude rate		48.8		38.0		43.3		18.9		16.6		17.8
95% CI	4	43.9 – 53.7		33.7 – 42.3		40.1 - 46.6	1	15.8 - 22.0		13.8 – 19.5		15.7 – 19.9
AS rate (Aust 1991)		65.6		44.0		54.0		28.2		19.1		23.4
95% CI		58.6 – 72.5		38.9 – 49.1		49.9 – 58.2	2	23.5 - 33.0		15.8 - 22.5		20.6 - 26.2
AS rate (World)		47.4		31.5		39.0		19.2		12.8		15.9
95% CI	4	42.5 – 52.2		27.7 – 35.3		36.0 - 42.1	1	16.0 - 22.4		10.5 - 15.2		13.9 - 17.8
Lifetime risk (0-74)		1 in 18		1 in 28		1 in 22		1 in 43		1 in 70		1 in 53
PYLL (0–74) Per cent of all								1,195.0		975.0		2,170.0
cancers		13.4		12.3		12.9		12.7		12.9		12.8

Table A4-18: Malignant Neoplasm of Colon (Including anus): ICD-10 C18-21

			Inciden	ce					Mortali	ty		
	Males	5	Female	es	Person	ıs	Males		Female	s	Perso	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												_
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	2	2.9	0	0.0	2	1.5	1	1.5	0	0.0	1	0.7
25–29	2	3.0	1	1.5	3	2.3	0	0.0	0	0.0	0	0.0
30-34	2	3.3	3	4.7	5	4.0	1	1.6	1	1.6	2	1.6
35–39	3	4.8	5	7.7	8	6.3	0	0.0	2	3.1	2	1.6
40-44	12	20.3	8	12.7	20	16.4	4	6.8	1	1.6	5	4.1
45-49	21	35.6	17	27.5	38	31.4	2	3.4	8	12.9	10	8.3
50-54	40	78.4	25	49.7	65	64.2	7	13.7	8	15.9	15	14.8
55-59	49	143.9	36	107.9	85	126.1	11	32.3	9	27.0	20	29.7
60-64	50	204.4	33	134.9	83	169.7	25	102.2	10	40.9	35	71.5
65-69	56	290.5	42	210.4	98	249.7	28	145.3	11	55.1	39	99.4
70–74	63	405.6	32	173.8	95	279.8	28	180.3	24	130.3	52	153.2
75–79	45	428.2	38	266.9	83	335.4	20	190.3	21	147.5	41	165.7
80-84	22	428.5	32	358.2	54	383.9	13	253.2	12	134.3	25	177.7
85 and over	15	541.3	37	548.0	52	546.0	9	324.8	25	370.3	34	357.0
Total	383		309		692		149		132		281	
Crude rate		49.6		39.3		44.4		19.3		16.8		18.0
95% CI		44.6 – 54.6	:	34.9 – 43.6		41.1 - 47.7	1	6.2 - 22.4	1	3.9 – 19.6		15.9 - 20.1
AS rate (Aust 1991)		66.8		45.3		55.4		28.8		19.3		23.8
95% CI	:	59.8 – 73.8		40.2 - 50.5		51.1 – 59.6	2	24.0 - 33.6	1	15.9 - 22.6		20.9 - 26.6
AS rate (World)		48.3		32.5		40.0		19.6		12.9		16.2
95% CI		43.3 – 53.2		28.6 – 36.3		36.9 – 43.1	1	6.4 - 22.9	1	0.6 - 15.2		14.2 - 18.1
Lifetime risk (0-74)		1 in 17		1 in 28		1 in 22		1 in 42		1 in 70		1 in 52
PYLL (0-74)								1,222.5		975.0		2,197.5
Per cent of all												
cancers		13.6		12.7		13.2		12.9		13.0		13.0

Table A4-19: Malignant Neoplasm of Liver: ICD-10 C22

			Inciden	ice					Mortali	ty		
	Males	}	Female	es	Person	ıs	Males		Female	es	Person	18
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	1	1.9	1	0.9	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	1	1.6	1	1.5	2	1.6	1	1.6	1	1.5	2	1.6
40-44	0	0.0	0	0.0	0	0.0	1	1.7	0	0.0	1	0.8
45-49	3	5.1	1	1.6	4	3.3	3	5.1	2	3.2	5	4.1
50-54	0	0.0	2	4.0	2	2.0	0	0.0	0	0.0	0	0.0
55-59	3	8.8	0	0.0	3	4.5	0	0.0	0	0.0	0	0.0
60-64	6	24.5	1	4.1	7	14.3	4	16.4	1	4.1	5	10.2
65-69	6	31.1	2	10.0	8	20.4	5	25.9	4	20.0	9	22.9
70–74	6	38.6	3	16.3	9	26.5	4	25.8	2	10.9	6	17.7
75–79	5	47.6	2	14.0	7	28.3	5	47.6	2	14.0	7	28.3
80-84	2	39.0	0	0.0	2	14.2	2	39.0	0	0.0	2	14.2
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	1	14.8	1	10.5
Total	32		14		46		25		13		38	
Crude rate		4.1		1.8		2.9		3.2		1.7		2.4
95% CI		2.7 - 5.6		0.8 - 2.7		2.1 - 3.8		2.0 - 4.5		0.8 - 2.5		1.7 - 3.2
AS rate (Aust 1991)		5.8		2.0		3.8		4.6		2.0		3.2
95% CI		3.7 - 7.8		0.9 - 3.1		2.7 - 4.9		2.7 - 6.4		0.9 - 3.2		2.2 - 4.2
AS rate (World)		4.1		1.6		2.8		3.1		1.5		2.2
95% CI		2.7 - 5.6		0.7 - 2.5		2.0 - 3.6		1.9 - 4.4		0.6 - 2.3		1.5 - 3.0
Lifetime risk (0–74)		1 in 183		1 in 508		1 in 273		1 in 262		1 in 504		1 in 349
PYLL (0–74) Per cent of all								250.0		140.0		390.0
cancers		1.1		0.6		0.9		2.2		1.3		1.8

Table A4-20: Malignant Neoplasm of Gall Bladder: ICD-10 C23-24

			Inciden	ce					Mortali	ty		
_	Males	3	Female	es	Person	ıs	Males		Female	es	Person	1S
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	1	1.7	1	1.6	2	1.6	1	1.7	0	0.0	1	0.8
45-49	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
50-54	0	0.0	3	6.0	3	3.0	1	2.0	2	4.0	3	3.0
55-59	2	5.9	0	0.0	2	3.0	2	5.9	0	0.0	2	3.0
60-64	0	0.0	1	4.1	1	2.0	1	4.1	1	4.1	2	4.1
65-69	2	10.4	1	5.0	3	7.6	0	0.0	2	10.0	2	5.1
70–74	1	6.4	1	5.4	2	5.9	2	12.9	0	0.0	2	5.9
75–79	1	9.5	1	7.0	2	8.1	1	9.5	1	7.0	2	8.1
80-84	3	58.4	2	22.4	5	35.5	2	39.0	1	11.2	3	21.3
85 and over	1	36.1	2	29.6	3	31.5	1	36.1	2	29.6	3	31.5
Total	11		13		24		11		9		20	
Crude rate		1.4		1.7		1.5		1.4		1.1		1.3
95% CI		0.6 - 2.3		0.8 - 2.5		0.9 - 2.2		0.6 - 2.3		0.4 - 1.9		0.7 - 1.8
AS rate (Aust 1991)		2.3		1.8		1.9		2.1		1.3		1.6
95% CI		0.9 - 3.7		0.8 - 2.7		1.1 - 2.7		0.8 - 3.4		0.4 - 2.2		0.9 - 2.3
AS rate (World)		1.3		1.2		1.3		1.3		0.9		1.1
95% CI		0.5 - 2.2		0.5 - 2.0		0.7 - 1.8		0.5 - 2.1		0.3 - 1.6		0.6 - 1.6
Lifetime risk (0–74)		1 in 821		1 in 845		1 in 835		1 in 755		1 in 1,106		1 in 917
PYLL (0–74) Per cent of all								107.5		72.5		180.0
cancers		0.4		0.5		0.5		1.0		0.9		0.9

Table A4-21: Malignant Neoplasm of Pancreas: ICD-10 C25

			Incide	nce					Mortal	ity		
_	Males	5	Femal	les	Person	ns	Males	3	Femal	es	Perso	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	1	1.6	0	0.0	1	0.8	1	1.6	0	0.0	1	0.8
35–39	1	1.6	0	0.0	1	0.8	1	1.6	0	0.0	1	0.8
40-44	1	1.7	2	3.2	3	2.5	1	1.7	0	0.0	1	0.8
45-49	3	5.1	2	3.2	5	4.1	2	3.4	1	1.6	3	2.5
50-54	5	9.8	3	6.0	8	7.9	2	3.9	2	4.0	4	4.0
55–59	3	8.8	4	12.0	7	10.4	4	11.7	2	6.0	6	8.9
60-64	6	24.5	4	16.4	10	20.4	5	20.4	1	4.1	6	12.3
65-69	7	36.3	6	30.1	13	33.1	4	20.8	9	45.1	13	33.1
70–74	9	57.9	9	48.9	18	53.0	13	83.7	9	48.9	22	64.8
75–79	3	28.5	9	63.2	12	48.5	2	19.0	7	49.2	9	36.4
80-84	6	116.9	7	78.4	13	92.4	3	58.4	9	100.8	12	85.3
85 and over	4	144.4	6	88.9	10	105.0	4	144.4	8	118.5	12	126.0
Total	49		52		101		42		48		90	
Crude rate		6.3		6.6		6.5		5.4		6.1		5.8
95% CI		4.6 - 8.1		4.8 - 8.4		5.2 - 7.7		3.8 - 7.1		4.4 - 7.8		4.6 - 7.0
AS rate (Aust 1991)		9.2		7.8		8.3		7.9		7.4		7.7
95% CI		6.5 - 11.9		5.6 - 9.9		6.7 - 10.0		5.4 - 10.4		5.3 - 9.5		6.1 - 9.3
AS rate (World)		6.3		5.2		5.6		5.5		4.6		5.0
95% CI		4.5 - 8.1		3.7 - 6.6		4.5 - 6.8		3.8 - 7.2		3.2 - 6.0		4.0 - 6.1
Lifetime risk (0-74)		1 in 136		1 in 168		1 in 151		1 in 135		1 in 183		1 in 157
PYLL (0–74) Per cent of all								407.5		210.0		617.5
cancers		1.7		2.1		1.9		3.6		4.7		4.2

Table A4-22: Malignant Neoplasm of Nasal Cavity: ICD-10 C30-31

			Incidend	ce					Mortalit	ty		
_	Males		Female	s	Person	s	Males		Female	s	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	2	3.2	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
40-44	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
45-49	1	1.7	1	1.6	2	1.7	0	0.0	1	1.6	1	0.8
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	1	2.9	0	0.0	1	1.5	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	1	4.1	1	2.0
65-69	3	15.6	0	0.0	3	7.6	1	5.2	0	0.0	1	2.5
70-74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	1	7.0	1	4.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	8		2		10		1		2		3	
Crude rate		1.0		0.3		0.6		0.1		0.3		0.2
95% CI		0.3 - 1.8		0.0 - 0.6		0.2 - 1.0		0.0 - 0.4		0.0 - 0.6		0.0 - 0.4
AS rate (Aust 1991)		1.2		0.3		0.7		0.2		0.3		0.2
95% CI		0.3 - 2.1		0.0 - 0.6		0.3 - 1.2		0.0 - 0.6		0.0 - 0.7		0.0 - 0.5
AS rate (World)		1.0		0.2		0.6		0.2		0.3		0.2
95% CI		0.3 - 1.7		0.0 - 0.4		0.2 - 0.9		0.0 - 0.5		0.0 - 0.6		0.0 - 0.4
Lifetime risk (0–74)		1 in 798		1 in 12,379		1 in 1,519		1 in 3,855		1 in 3,507		1 in 3,691
PYLL (0-74) Per cent of all								7.5		40.0		47.5
cancers		0.3		0.1		0.2		0.1		0.2		0.1

Table A4-23: Malignant Neoplasm of Larynx: ICD-10 C32

			Incider	ice					Mortali	ty		
_	Male	s	Femal	es	Person	ıs	Males		Female	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	1	1.7	0	0.0	1	0.8
50-54	6	11.8	1	2.0	7	6.9	1	2.0	0	0.0	1	1.0
55-59	3	8.8	0	0.0	3	4.5	0	0.0	0	0.0	0	0.0
60-64	2	8.2	0	0.0	2	4.1	1	4.1	0	0.0	1	2.0
65-69	4	20.8	0	0.0	4	10.2	1	5.2	0	0.0	1	2.5
70–74	3	19.3	1	5.4	4	11.8	4	25.8	0	0.0	4	11.8
75–79	7	66.6	1	7.0	8	32.3	1	9.5	0	0.0	1	4.0
80-84	4	77.9	1	11.2	5	35.5	1	19.5	1	11.2	2	14.2
85 and over	0	0.0	0	0.0	0	0.0	2	72.2	0	0.0	2	21.0
Total	29		4		33		12		1		13	
Crude rate		3.8		0.5		2.1		1.6		0.1		0.8
95% CI		2.4 - 5.1		0.0 - 1.0		1.4 - 2.8		0.7 - 2.4		0.0 - 0.4		0.4 - 1.3
AS rate (Aust 1991)		5.2		0.6		2.6		2.4		0.1		1.1
95% CI		3.2 - 7.2		0.0 - 1.1		1.7 - 3.6		1.0 - 3.9		0.0 - 0.4		0.5 - 1.7
AS rate (World)		3.3		0.3		1.7		1.6		0.1		0.7
95% CI		2.1 - 4.6		0.0 - 0.7		1.1 - 2.3		0.7 - 2.5		0.0 - 0.2		0.3 - 1.1
Lifetime risk (0–74)		1 in 291		1 in 2,696		1 in 535		1 in 517		NA		1 in 1,100
PYLL (0–74) Per cent of all								80.0		0.0		80.0
cancers		1.0		0.2		0.6		1.0		0.1		0.6

Table A4-24: Malignant Neoplasm of Trachea and Lung: ICD-10 C33-34

_	•		Inciden	ice			Mortality						
	Males		Femal	es	Person	s	Males	3	Female	es	Perso	ons	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20–24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
30-34	1	1.6	1	1.6	2	1.6	0	0.0	0	0.0	0	0.0	
35–39	2	3.2	1	1.5	3	2.4	1	1.6	1	1.5	2	1.6	
40-44	3	5.1	3	4.7	6	4.9	2	3.4	3	4.7	5	4.1	
45-49	8	13.6	8	12.9	16	13.2	6	10.2	5	8.1	11	9.1	
50-54	11	21.6	14	27.9	25	24.7	7	13.7	12	23.9	19	18.8	
55-59	23	67.5	17	51.0	40	59.3	19	55.8	11	33.0	30	44.5	
60-64	31	126.7	20	81.8	51	104.2	23	94.0	14	57.2	37	75.6	
65-69	35	181.6	22	110.2	57	145.3	30	155.7	20	100.2	50	127.4	
70–74	44	283.3	28	152.0	72	212.1	39	251.1	23	124.9	62	182.6	
75–79	42	399.7	20	140.5	62	250.5	37	352.1	18	126.4	55	222.3	
80-84	12	233.7	11	123.1	23	163.5	18	350.6	17	190.3	35	248.8	
85 and over	7	252.6	14	207.3	21	220.5	8	288.7	13	192.5	21	220.5	
Total	219		159		378		190		137		327		
Crude rate		28.4		20.2		24.2		24.6		17.4		21.0	
95% CI	2	24.6 – 32.1		17.1 – 23.3		21.8 - 26.7	2	21.1 – 28.1		14.5 - 20.3		18.7 - 23.2	
AS rate (Aust 1991)		40.5		23.8		31.2		36.5		20.6		27.5	
95% CI	3	35.0 – 46.1		20.0 - 27.5		28.0 - 34.4	3	31.2 – 41.9		17.1 – 24.1		24.5 – 30.6	
AS rate (World)		27.8		17.4		22.1		24.0		14.3		18.7	
95% CI	2	24.0 – 31.6		14.5 - 20.2		19.8 - 24.4	2	20.5 - 27.5		11.8 – 16.9		16.6 - 20.8	
Lifetime risk (0–74)		1 in 29		1 in 46		1 in 36		1 in 35		1 in 57		1 in 44	
PYLL (0–74) Per cent of all								1,367.5		1,117.5		2,485.0	
cancers		7.8		6.5		7.2		16.5		13.5		15.1	

Table A4-25: Malignant Neoplasm of Other Thoracic Organs: ICD-10 C37-38

	Incidence						Mortality					
	Males		Females	S	Person	s	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	1	1.6	1	0.8	0	0.0	1	1.6	1	0.8
35–39	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	2	3.9	0	0.0	2	2.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	1	5.0	1	2.5
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	3		1		4		0		2		2	
Crude rate		0.4		0.1		0.3		0.0		0.3		0.1
95% CI		0.0 - 0.8		0.0 - 0.4		0.0 - 0.5		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
AS rate (Aust 1991)		0.3		0.1		0.2		0.0		0.3		0.2
95% CI		0.0 - 0.7		0.0 - 0.4		0.0 - 0.4		0.0 - 0.0		0.0 - 0.8		0.0 - 0.4
AS rate (World)		0.3		0.1		0.2		0.0		0.2		0.1
95% CI		0.0 - 0.6		0.0 - 0.3		0.0 - 0.4		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
Lifetime risk (0–74)		1 in 3,621		1 in 12,686		1 in 5,618		NA		1 in 3,038		1 in 5,971
PYLL (0-74) Per cent of all								0.0		50.0		50.0
cancers		0.1		0.0		0.1		0.0		0.2		0.1

Table A4-26: Malignant Neoplasm of Bone: ICD-10 C40-41

	Incidence						Mortality					
_	Males	S	Female	es	Person	ıs	Males		Female	es	Person	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	1	1.7	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
10–14	0	0.0	1	1.8	1	0.9	0	0.0	0	0.0	0	0.0
15–19	0	0.0	4	6.7	4	3.3	0	0.0	0	0.0	0	0.0
20–24	1	1.5	1	1.5	2	1.5	1	1.5	1	1.5	2	1.5
25–29	1	1.5	0	0.0	1	0.8	1	1.5	0	0.0	1	0.8
30-34	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	1	1.7	1	1.6	2	1.7	0	0.0	1	1.6	1	0.8
50-54	2	3.9	0	0.0	2	2.0	1	2.0	0	0.0	1	1.0
55–59	0	0.0	1	3.0	1	1.5	0	0.0	0	0.0	0	0.0
60-64	1	4.1	0	0.0	1	2.0	0	0.0	0	0.0	0	0.0
65-69	1	5.2	0	0.0	1	2.5	1	5.2	0	0.0	1	2.5
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	1	7.0	1	4.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	8		10		18		4		2		6	
Crude rate		1.0		1.3		1.2		0.5		0.3		0.4
95% CI		0.3 - 1.8		0.5 - 2.1		0.6 - 1.7		0.0 - 1.0		0.0 - 0.6		0.1 - 0.7
AS rate (Aust 1991)		1.0		1.3		1.2		0.5		0.2		0.4
95% CI		0.3 - 1.8		0.5 - 2.1		0.6 - 1.7		0.0 - 1.1		0.0 - 0.5		0.1 - 0.7
AS rate (World)		1.0		1.3		1.1		0.5		0.2		0.4
95% CI		0.3 - 1.8		0.5 - 2.1		0.6 - 1.7		0.0 - 1.0		0.0 - 0.5		0.1 - 0.6
Lifetime risk (0-74)		1 in 1,021		1 in 1,237		1 in 1,126		1 in 1,977		1 in 6,426		1 in 3,036
PYLL (0-74)								130.0		80.0		210.0
Per cent of all												
cancers		0.3		0.4		0.3		0.3		0.2		0.3

Table A4-27: Malignant Neoplasm of Skin/Melanoma: ICD-10 C43

			Incide	nce			Mortality					
	Males	S	Femal	les	Person	s	Males	3	Femal	es	Perso	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	1	1.9	1	0.9	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	1	1.7	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
15–19	1	1.6	2	3.3	3	2.4	0	0.0	0	0.0	0	0.0
20-24	4	5.8	7	10.5	11	8.1	0	0.0	0	0.0	0	0.0
25–29	10	15.2	13	19.4	23	17.3	1	1.5	0	0.0	1	0.8
30-34	12	19.6	12	18.9	24	19.2	1	1.6	1	1.6	2	1.6
35–39	13	20.8	15	23.0	28	21.9	0	0.0	2	3.1	2	1.6
40-44	34	57.6	23	36.4	57	46.7	1	1.7	1	1.6	2	1.6
45-49	44	74.6	24	38.8	68	56.2	2	3.4	3	4.8	5	4.1
50-54	49	96.1	31	61.7	80	79.0	4	7.8	0	0.0	4	4.0
55-59	33	96.9	23	69.0	56	83.1	3	8.8	1	3.0	4	5.9
60-64	25	102.2	15	61.3	40	81.8	2	8.2	1	4.1	3	6.1
65-69	32	166.0	20	100.2	52	132.5	3	15.6	3	15.0	6	15.3
70-74	28	180.3	10	54.3	38	111.9	7	45.1	3	16.3	10	29.5
75–79	15	142.7	6	42.1	21	84.9	5	47.6	1	7.0	6	24.2
80-84	7	136.3	11	123.1	18	128.0	1	19.5	1	11.2	2	14.2
85 and over	4	144.4	10	148.1	14	147.0	3	108.3	0	0.0	3	31.5
Total	312		223		535		33		17		50	
Crude rate		40.4		28.3		34.3		4.3		2.2		3.2
95% CI		35.9 – 44.9		24.6 - 32.0		31.4 - 37.2		2.8 - 5.7		1.1 - 3.2		2.3 - 4.1
AS rate (Aust 1991)		45.1		29.1		36.7		5.9		2.4		3.9
95% CI		39.8 – 50.4		25.2 - 33.0		33.5 – 39.9		3.8 - 8.0		1.3 - 3.6		2.8 - 5.0
AS rate (World)		36.5		24.1		30.1		4.1		1.9		2.8
95% CI		32.4 - 40.7		20.8 - 27.4		27.5 – 32.7		2.7 - 5.5		0.9 - 2.8		2.0 - 3.6
Lifetime risk (0–74)		1 in 24		1 in 41		1 in 31		1 in 214		1 in 405		1 in 284
PYLL (0-74)								385.0		292.5		677.5
Per cent of all												
cancers		11.1		9.2		10.2		2.9		1.7		2.3

Table A4-28: Mesothelioma: ICD-10 C45

			Inciden	ce			Mortality					
_	Males	3	Female	es	Person	ıs	Males	5	Female	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	1	1.6	0	0.0	1	0.8	1	1.6	0	0.0	1	0.8
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
50-54	4	7.8	0	0.0	4	4.0	1	2.0	0	0.0	1	1.0
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	1	4.1	0	0.0	1	2.0	0	0.0	0	0.0	0	0.0
65-69	4	20.8	1	5.0	5	12.7	4	20.8	1	5.0	5	12.7
70–74	5	32.2	1	5.4	6	17.7	4	25.8	1	5.4	5	14.7
75–79	1	9.5	0	0.0	1	4.0	2	19.0	0	0.0	2	8.1
80-84	1	19.5	0	0.0	1	7.1	1	19.5	0	0.0	1	7.1
85 and over	1	36.1	1	14.8	2	21.0	1	36.1	1	14.8	2	21.0
Total	19		3		22		14		3		17	
Crude rate		2.5		0.4		1.4		1.8		0.4		1.1
95% CI		1.4 - 3.6		0.0 - 0.8		0.8 - 2.0		0.9 - 2.8		0.0 - 0.8		0.6 - 1.6
AS rate (Aust 1991)		3.3		0.5		1.8		2.8		0.5		1.5
95% CI		1.8 - 4.9		0.0 - 1.0		1.0 - 2.5		1.3 - 4.3		0.0 - 1.0		0.8 - 2.2
AS rate (World)		2.4		0.3		1.3		1.8		0.3		1.0
95% CI		1.3 - 3.5		0.0 - 0.7		0.7 - 1.8		0.8 - 2.8		0.0 - 0.7		0.5 - 1.5
Lifetime risk (0–74)		1 in 294		1 in 1,916		1 in 527		1 in 400		1 in 1,916		1 in 684
PYLL (0–74) Per cent of all								100.0		10.0		110.0
cancers		0.7		0.1		0.4		1.2		0.3		0.8

Table A4-29: Kaposi's Sarcoma: ICD-10 C46

			Inciden	ce					Mortali	ty		
_	Males	3	Female	es	Person	ıs	Males		Female	es	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	1	1.6	0	0.0	1	0.8	1	1.6	0	0.0	1	0.8
35–39	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	2	3.4	0	0.0	2	1.7	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.0	1	1.0	0	0.0	0	0.0	0	0.0
55–59	0	0.0	1	3.0	1	1.5	0	0.0	0	0.0	0	0.0
60-64	1	4.1	0	0.0	1	2.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	5		2		7		1		0		1	
Crude rate		0.6		0.3		0.4		0.1		0.0		0.1
95% CI		0.1 - 1.2		0.0 - 0.6		0.1 - 0.8		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (Aust 1991)		0.6		0.2		0.4		0.1		0.0		0.1
95% CI		0.1 - 1.2		0.0 - 0.5		0.1 - 0.7		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (World)		0.6		0.2		0.4		0.1		0.0		0.0
95% CI		0.1 - 1.1		0.0 - 0.5		0.1 - 0.7		0.0 - 0.3		0.0 - 0.0		0.0 - 0.1
Lifetime risk (0-74)		1 in 1,868		1 in 4,011		1 in 2,580		1 in 12,276		NA		1 in 24,962
PYLL (0–74) Per cent of all								42.5		0.0		42.5
cancers		0.2		0.1		0.1		0.1		0.0		0.0

Table A4-30: Malignant Neoplasm of Connective and Soft Tissues: ICD-10 C47-49

			Inciden	ce					Mortali	ty		
_	Males	S	Female	es	Persor	ıs	Males		Female	s	Person	18
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	1	1.8	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	1	1.6	1	1.7	2	1.6	0	0.0	0	0.0	0	0.0
20-24	1	1.5	0	0.0	1	0.7	3	4.4	0	0.0	3	2.2
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
35–39	0	0.0	1	1.5	1	0.8	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	1	1.6	1	0.8
45-49	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
50-54	3	5.9	1	2.0	4	4.0	1	2.0	1	2.0	2	2.0
55-59	3	8.8	0	0.0	3	4.5	1	2.9	0	0.0	1	1.5
60-64	1	4.1	0	0.0	1	2.0	0	0.0	0	0.0	0	0.0
65-69	1	5.2	2	10.0	3	7.6	0	0.0	2	10.0	2	5.1
70–74	0	0.0	3	16.3	3	8.8	1	6.4	2	10.9	3	8.8
75–79	1	9.5	2	14.0	3	12.1	0	0.0	0	0.0	0	0.0
80-84	1	19.5	1	11.2	2	14.2	1	19.5	2	22.4	3	21.3
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	0	0.0	0	0.0
Total	14		13		27		7		8		15	
Crude rate		1.8		1.7		1.7		0.9		1.0		1.0
95% CI		0.9 - 2.8		0.8 - 2.5		1.1 - 2.4		0.2 - 1.6		0.3 - 1.7		0.5 - 1.4
AS rate (Aust 1991)		2.0		1.9		2.0		1.0		1.2		1.1
95% CI		0.9 - 3.1		0.8 - 3.0		1.2 - 2.8		0.2 - 1.8		0.4 - 2.1		0.5 - 1.7
AS rate (World)		1.7		1.3		1.6		0.8		0.8		0.8
95% CI		0.8 - 2.7		0.6 - 2.1		1.0 - 2.2		0.2 - 1.4		0.2 - 1.4		0.4 - 1.2
Lifetime risk (0-74)		1 in 657		1 in 604		1 in 613		1 in 1,275		1 in 819		1 in 980
PYLL (0–74) Per cent of all								200.0		75.0		275.0
cancers		0.5		0.5		0.5		0.6		0.8		0.7

Table A4-31: Malignant Neoplasm of Breast: ICD-10 C50

			Incide	ence			Mortality					
_	Male	es	Fema	ales	Perso	ns	Male	s	Femal	es	Pers	ons
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	4	6.0	4	3.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	18	28.4	18	14.4	0	0.0	1	1.6	1	0.8
35–39	0	0.0	36	55.3	36	28.2	0	0.0	5	7.7	5	3.9
40-44	0	0.0	71	112.4	71	58.1	0	0.0	6	9.5	6	4.9
45-49	2	3.4	107	172.9	109	90.2	0	0.0	23	37.2	23	19.0
50-54	0	0.0	149	296.4	149	147.2	0	0.0	22	43.8	22	21.7
55-59	0	0.0	105	314.8	105	155.8	0	0.0	23	69.0	23	34.1
60-64	2	8.2	79	323.0	81	165.6	1	4.1	24	98.1	25	51.1
65-69	1	5.2	76	380.6	77	196.2	0	0.0	21	105.2	21	53.5
70–74	0	0.0	58	314.9	58	170.8	0	0.0	18	97.7	18	53.0
75–79	1	9.5	43	302.0	44	177.8	2	19.0	21	147.5	23	92.9
80-84	0	0.0	27	302.3	27	191.9	0	0.0	24	268.7	24	170.6
85 and over	0	0.0	21	311.0	21	220.5	0	0.0	19	281.4	19	199.5
Total	6		794		800		3		207		210	
Crude rate		0.8		100.9		51.3		0.4		26.3		13.5
95% CI		0.2 - 1.4		93.8 – 107.9		47.7 – 54.9		0.0 - 0.8		22.7 – 29.9		11.6 – 15.3
AS rate (Aust 1991)		1.0		104.9		55.3		0.6		29.2		16.3
95% CI		0.2 - 1.8		97.4 – 112.4		51.3 – 59.2		0.0 - 1.3		25.1 – 33.3		14.0 – 18.6
AS rate (World)		0.8		86.7		45.1		0.4		21.6		11.7
95% CI		0.1 - 1.4		80.5 - 93.0		41.9 – 48.3		0.0 - 0.8		18.5 – 24.6		10.0 - 13.3
Lifetime risk (0-74)		1 in 1,194		1 in 10		1 in 20		1 in 4,893		1 in 43		1 in 83
PYLL (0–74) Per cent of all								12.5		2,457.5		2,470.0
cancers		0.2		32.6		15.2		0.3		20.5		9.7

Table A4-32: Malignant Neoplasm of Vulva: ICD-10 C51

			Inciden	ce			Mortality					
_	Males	}	Female	es	Person	ns	Males	}	Femal	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	3	4.8	3	2.5	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.0	1	1.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	1	5.0	1	2.5	0	0.0	0	0.0	0	0.0
70–74	0	0.0	3	16.3	3	8.8	0	0.0	0	0.0	0	0.0
75–79	0	0.0	1	7.0	1	4.0	0	0.0	1	7.0	1	4.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	2	29.6	2	21.0	0	0.0	1	14.8	1	10.5
Total	0		11		11		0		2		2	
Crude rate		0.0		1.4		0.7		0.0		0.3		0.1
95% CI		0.0 - 0.0		0.6 - 2.2		0.3 - 1.1		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
AS rate (Aust 1991)		0.0		1.5		0.8		0.0		0.3		0.2
95% CI		0.0 - 0.0		0.6 - 2.4		0.3 - 1.3		0.0 - 0.0		0.0 - 0.7		0.0 - 0.4
AS rate (World)		0.0		1.1		0.6		0.0		0.1		0.1
95% CI		0.0 - 0.0		0.4 - 1.7		0.2 - 1.0		0.0 - 0.0		0.0 - 0.3		0.0 - 0.2
Lifetime risk (0–74)		NA		1 in 711		1 in 1,347		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.0		0.5		0.2		0.0		0.2		0.1

Table A4-33: Malignant Neoplasm of Vagina: ICD-10 C52

	Incidence						Mortality					
_	Males	}	Female	es	Person	ns	Males	3	Female	s	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	1	5.4	1	2.9	0	0.0	1	5.4	1	2.9
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	1	11.2	1	7.1	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	0	0.0	0	0.0
Total	0		3		3		0		1		1	
Crude rate		0.0		0.4		0.2		0.0		0.1		0.1
95% CI		0.0 - 0.0		0.0 - 0.8		0.0 - 0.4		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2
AS rate (Aust 1991)		0.0		0.4		0.3		0.0		0.2		0.1
95% CI		0.0 - 0.0		0.0 - 0.9		0.0 - 0.6		0.0 - 0.0		0.0 - 0.5		0.0 - 0.3
AS rate (World)		0.0		0.2		0.1		0.0		0.1		0.1
95% CI		0.0 - 0.0		0.0 - 0.5		0.0 - 0.3		0.0 - 0.0		0.0 - 0.3		0.0 - 0.2
Lifetime risk (0–74)		NA		1 in 3,684		1 in 6,790		NA		1 in 3,684		1 in 6,790
PYLL (0–74) Per cent of all								0.0		2.5		2.5
cancers		0.0		0.1		0.1		0.0		0.1		0.0

Table A4-34: Malignant Neoplasm of Cervix Uteri: ICD-10 C53

			Inciden	ice			Mortality					
_	Male	s	Female	es	Person	ns	Males		Female	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	7	10.4	7	5.3	0	0.0	2	3.0	2	1.5
30-34	0	0.0	2	3.2	2	1.6	0	0.0	0	0.0	0	0.0
35–39	0	0.0	10	15.3	10	7.8	0	0.0	0	0.0	0	0.0
40-44	0	0.0	6	9.5	6	4.9	0	0.0	5	7.9	5	4.1
45-49	0	0.0	6	9.7	6	5.0	0	0.0	1	1.6	1	0.8
50-54	0	0.0	4	8.0	4	4.0	0	0.0	2	4.0	2	2.0
55-59	0	0.0	5	15.0	5	7.4	0	0.0	1	3.0	1	1.5
60-64	0	0.0	1	4.1	1	2.0	0	0.0	1	4.1	1	2.0
65-69	0	0.0	5	25.0	5	12.7	0	0.0	3	15.0	3	7.6
70–74	0	0.0	2	10.9	2	5.9	0	0.0	1	5.4	1	2.9
75–79	0	0.0	2	14.0	2	8.1	0	0.0	1	7.0	1	4.0
80-84	0	0.0	2	22.4	2	14.2	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	1	14.8	1	10.5
Total	0		53		53		0		18		18	
Crude rate		0.0		6.7		3.4		0.0		2.3		1.2
95% CI		0.0 - 0.0		4.9 - 8.5		2.5 - 4.3		0.0 - 0.0		1.2 - 3.3		0.6 - 1.7
AS rate (Aust 1991)		0.0		6.8		3.5		0.0		2.5		1.3
95% CI		0.0 - 0.0		4.9 - 8.7		2.6 - 4.5		0.0 - 0.0		1.3 - 3.6		0.7 - 1.9
AS rate (World)		0.0		5.6		2.9		0.0		2.0		1.0
95% CI		0.0 - 0.0		4.0 - 7.1		2.1 - 3.6		0.0 - 0.0		1.0 - 2.9		0.5 - 1.5
Lifetime risk (0-74)		NA		1 in 181		1 in 354		NA		1 in 455		1 in 889
PYLL (0–74) Per cent of all								0.0		385.0		385.0
cancers		0.0		2.2		1.0		0.0		1.8		0.8

Table A4-35: Malignant Neoplasm of Corpus Uteri: ICD-10 C54

			Inciden	ce					Mortali	ty		
_	Males	S	Female	es	Person	ıs	Males		Female	s	Person	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	2	3.2	2	1.6	0	0.0	0	0.0	0	0.0
35-39	0	0.0	2	3.1	2	1.6	0	0.0	0	0.0	0	0.0
40-44	0	0.0	4	6.3	4	3.3	0	0.0	0	0.0	0	0.0
45-49	0	0.0	4	6.5	4	3.3	0	0.0	0	0.0	0	0.0
50-54	0	0.0	15	29.8	15	14.8	0	0.0	1	2.0	1	1.0
55-59	0	0.0	12	36.0	12	17.8	0	0.0	1	3.0	1	1.5
60-64	0	0.0	17	69.5	17	34.7	0	0.0	4	16.4	4	8.2
65-69	0	0.0	12	60.1	12	30.6	0	0.0	1	5.0	1	2.5
70–74	0	0.0	15	81.5	15	44.2	0	0.0	7	38.0	7	20.6
75–79	0	0.0	11	77.3	11	44.5	0	0.0	4	28.1	4	16.2
80-84	0	0.0	1	11.2	1	7.1	0	0.0	1	11.2	1	7.1
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	0		95		95		0		19		19	
Crude rate		0.0		12.1		6.1		0.0		2.4		1.2
95% CI		0.0 - 0.0		9.6 - 14.5		4.9 - 7.3		0.0 - 0.0		1.3 - 3.5		0.7 - 1.8
AS rate (Aust 1991)		0.0		13.9		7.2		0.0		3.0		1.6
95% CI		0.0 - 0.0		11.0 - 16.8		5.7 - 8.7		0.0 - 0.0		1.6 - 4.4		0.9 - 2.4
AS rate (World)		0.0		11.1		5.7		0.0		2.1		1.1
95% CI		0.0 - 0.0		8.8 - 13.4		4.5 - 6.9		0.0 - 0.0		1.1 - 3.1		0.6 - 1.6
Lifetime risk (0-74)		NA		1 in 68		1 in 132		NA		1 in 311		1 in 592
PYLL (0–74) Per cent of all								0.0		115.0		115.0
cancers		0.0		3.9		1.8		0.0		1.9		0.9

Table A4-36: Malignant Neoplasm of Uterus Unspecified: ICD-10 C55

			Inciden	ice					Mortali	ity		
_	Male	s	Femal	es	Person	ıs	Males	3	Female	es	Person	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	1	3.0	1	1.5	0	0.0	0	0.0	0	0.0
60-64	0	0.0	1	4.1	1	2.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	1	11.2	1	7.1	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	2	29.6	2	21.0	0	0.0	0	0.0	0	0.0
Total	0		5		5		0		0		0	
Crude rate		0.0		0.6		0.3		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.1 - 1.2		0.0 - 0.6		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (Aust 1991)		0.0		0.7		0.4		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.1 - 1.3		0.0 - 0.8		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (World)		0.0		0.5		0.3		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.9		0.0 - 0.5		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
Lifetime risk (0-74)		NA		1 in 2,823		1 in 5,670		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.0		0.2		0.1		0.0		0.0		0.0

Table A4-37: Malignant Neoplasm of Ovary: ICD-10 C56

			Inciden	ce					Mortal	ity		
_	Male	s	Female	es	Person	ıs	Males	1	Female	es	Perso	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	2	3.0	2	1.5	0	0.0	1	1.5	1	0.8
30-34	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
35–39	0	0.0	2	3.1	2	1.6	0	0.0	1	1.5	1	0.8
40-44	0	0.0	5	7.9	5	4.1	0	0.0	1	1.6	1	0.8
45-49	0	0.0	11	17.8	11	9.1	0	0.0	6	9.7	6	5.0
50-54	0	0.0	9	17.9	9	8.9	0	0.0	7	13.9	7	6.9
55-59	0	0.0	12	36.0	12	17.8	0	0.0	6	18.0	6	8.9
60-64	0	0.0	6	24.5	6	12.3	0	0.0	3	12.3	3	6.1
65-69	0	0.0	5	25.0	5	12.7	0	0.0	6	30.1	6	15.3
70–74	0	0.0	7	38.0	7	20.6	0	0.0	6	32.6	6	17.7
75–79	0	0.0	5	35.1	5	20.2	0	0.0	7	49.2	7	28.3
80-84	0	0.0	4	44.8	4	28.4	0	0.0	5	56.0	5	35.5
85 and over	0	0.0	2	29.6	2	21.0	0	0.0	1	14.8	1	10.5
Total	0		71		71		0		50		50	
Crude rate		0.0		9.0		4.6		0.0		6.4		3.2
95% CI		0.0 - 0.0		6.9 – 11.1		3.5 - 5.6		0.0 - 0.0		4.6 - 8.1		2.3 - 4.1
AS rate (Aust 1991)		0.0		9.4		5.0		0.0		7.0		3.8
95% CI		0.0 - 0.0		7.2 - 11.7		3.8 - 6.2		0.0 - 0.0		5.0 - 9.0		2.7 - 4.8
AS rate (World)		0.0		7.6		3.9		0.0		5.2		2.7
95% CI		0.0 - 0.0		5.8 - 9.4		3.0 - 4.9		0.0 - 0.0		3.7 - 6.7		1.9 - 3.5
Lifetime risk (0-74)		NA		1 in 115		1 in 224		NA		1 in 166		1 in 322
PYLL (0-74)								0.0		642.5		642.5
Per cent of all												
cancers		0.0		2.9		1.4		0.0		4.9		2.3

Table A4-38: Malignant Neoplasm of Other Female Genital Organs: ICD-10 C57

			Incide	nce					Mortali	ty		
_	Male	es	Femal	les	Person	s	Males		Female	s	Person	1S
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.0	1	1.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	1	5.0	1	2.5	0	0.0	1	5.0	1	2.5
70–74	0	0.0	3	16.3	3	8.8	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	1	14.8	1	10.5
Total	0		6		6		0		2		2	
Crude rate		0.0		0.8		0.4		0.0		0.3		0.1
95% CI		0.0 - 0.0		0.2 - 1.4		0.1 - 0.7		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
AS rate (Aust 1991)		0.0		0.9		0.5		0.0		0.3		0.2
95% CI		0.0 - 0.0		0.2 - 1.6		0.1 - 0.9		0.0 - 0.0		0.0 - 0.8		0.0 - 0.5
AS rate (World)		0.0		0.6		0.4		0.0		0.2		0.1
95% CI		0.0 - 0.0		0.1 - 1.2		0.1 - 0.6		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
Lifetime risk (0–74)		NA		1 in 859		1 in 1,617		NA		1 in 3,994		1 in 7,849
PYLL (0–74) Per cent of all								0.0		7.5		7.5
cancers		0.0		0.2		0.1		0.0		0.2		0.1

Table A4-39: Malignant Neoplasm of Placenta: ICD-10 C58

			Inciden	ce					Mortali	ty		
_	Males	8	Female	S	Person	ıs	Males	3	Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	1	1.5	1	0.8	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	0		2		2		0		0		0	
Crude rate		0.0		0.3		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (Aust 1991)		0.0		0.2		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (World)		0.0		0.2		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.5		0.0 - 0.3		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
Lifetime risk (0-74)		NA		1 in 6,509		1 in 12,735		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.0		0.1		0.0		0.0		0.0		0.0

Table A4-40: Malignant Neoplasm of Penis: ICD-10 C60

			Inciden	ce					Mortali	ty		
_	Male	S	Female	es	Person	ns	Males	}	Female	S	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	1	2.9	0	0.0	1	1.5	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	1	5.2	0	0.0	1	2.5	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	2	39.0	0	0.0	2	14.2	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	5		0		5		0		0		0	
Crude rate		0.6		0.0		0.3		0.0		0.0		0.0
95% CI		0.1 - 1.2		0.0 - 0.0		0.0 - 0.6		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (Aust 1991)		1.0		0.0		0.4		0.0		0.0		0.0
95% CI		0.1 - 1.9		0.0 - 0.0		0.0 - 0.8		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (World)		0.6		0.0		0.3		0.0		0.0		0.0
95% CI		0.1 - 1.1		0.0 - 0.0		0.0 - 0.5		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
Lifetime risk (0-74)		1 in 2,051		NA		1 in 4,139		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.2		0.0		0.1		0.0		0.0		0.0

Table A4-41: Malignant Neoplasm of Prostate: ICD-10 C61

			Incide	nce					Mortal	ity		
_	Mal	es	Femal	les	Perso	ns	Males	3	Femal	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	2	3.4	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
45-49	12	20.3	0	0.0	12	9.9	0	0.0	0	0.0	0	0.0
50-54	39	76.5	0	0.0	39	38.5	0	0.0	0	0.0	0	0.0
55-59	87	255.5	0	0.0	87	129.1	2	5.9	0	0.0	2	3.0
60-64	128	523.3	0	0.0	128	261.6	7	28.6	0	0.0	7	14.3
65-69	140	726.4	0	0.0	140	356.8	20	103.8	0	0.0	20	51.0
70–74	159	1,023.7	0	0.0	159	468.4	23	148.1	0	0.0	23	67.8
75–79	133	1,265.7	0	0.0	133	537.5	20	190.3	0	0.0	20	80.8
80-84	65	1,266.1	0	0.0	65	462.1	30	584.3	0	0.0	30	213.3
85 and over	31	1,118.7	0	0.0	31	325.5	25	902.2	0	0.0	25	262.5
Total	796		0		796		127		0		127	
Crude rate		103.1		0.0		51.0		16.4		0.0		8.1
95% CI		95.9 - 110.2		0.0 - 0.0		47.5 - 54.6		13.6 – 19.3		0.0 - 0.0		6.7 - 9.6
AS rate (Aust 1991)		151.7		0.0		67.9		29.9		0.0		11.7
95% CI	1	40.8 - 162.6		0.0 - 0.0		63.1 - 72.7		24.6 – 35.3		0.0 - 0.0		9.7 - 13.7
AS rate (World)		103.2		0.0		47.6		16.8		0.0		6.8
95% CI		95.9 – 110.6		0.0 - 0.0		44.2 - 51.1		13.8 – 19.8		0.0 - 0.0		5.5 - 8.0
Lifetime risk (0-74)		1 in 8		NA		1 in 16		1 in 70		NA		1 in 148
PYLL (0-74)								330.0		0.0		330.0
Per cent of all												
cancers		28.3		0.0		15.2		11.0		0.0		5.9

Table A4-42: Malignant Neoplasm of Testis: ICD-10 C62

_			Incidenc	ee					Mortalit	ty		
	Males		Female	s	Person	ıs	Males		Female	s	Perso	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	1	1.8	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	7	10.2	0	0.0	7	5.2	0	0.0	0	0.0	0	0.0
25–29	8	12.1	0	0.0	8	6.0	1	1.5	0	0.0	1	0.8
30-34	15	24.4	0	0.0	15	12.0	0	0.0	0	0.0	0	0.0
35-39	9	14.4	0	0.0	9	7.1	0	0.0	0	0.0	0	0.0
40-44	10	17.0	0	0.0	10	8.2	0	0.0	0	0.0	0	0.0
45-49	7	11.9	0	0.0	7	5.8	1	1.7	0	0.0	1	0.8
50-54	5	9.8	0	0.0	5	4.9	0	0.0	0	0.0	0	0.0
55–59	3	8.8	0	0.0	3	4.5	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	66		0		66		2		0		2	
Crude rate		8.5		0.0		4.2		0.3		0.0		0.1
95% CI		6.5 - 10.6		0.0 - 0.0		3.2 - 5.3		0.0 - 0.6		0.0 - 0.0		0.0 - 0.3
AS rate (Aust 1991)		8.0		0.0		4.0		0.2		0.0		0.1
95% CI		6.1 - 10.0		0.0 - 0.0		3.0 - 4.9		0.0 - 0.5		0.0 - 0.0		0.0 - 0.3
AS rate (World)		7.0		0.0		3.5		0.2		0.0		0.1
95% CI		5.3 - 8.8		0.0 - 0.0		2.6 - 4.3		0.0 - 0.5		0.0 - 0.0		0.0 - 0.3
Lifetime risk (0-74)		1 in 179		NA		1 in 362		1 in 6,226		NA		1 in 12,668
PYLL (0–74) Per cent of all								75.0		0.0		75.0
cancers		2.3		0.0		1.3		0.2		0.0		0.1
		2.3		0.0		1.0		0.2		0.0		0.1

Table A4-43: Malignant Neoplasm of Other Male Genitals: ICD-10 C63

			Inciden	ice					Mortali	ty		
_	Male	es	Femal	es	Person	ıs	Males	}	Female	es	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	2	12.9	0	0.0	2	5.9	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	3		0		3		0		0		0	
Crude rate		0.4		0.0		0.2		0.0		0.0		0.0
95% CI		0.0 - 0.8		0.0 - 0.0		0.0 - 0.4		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (Aust 1991)		0.5		0.0		0.2		0.0		0.0		0.0
95% CI		0.0 - 1.1		0.0 - 0.0		0.0 - 0.5		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (World)		0.4		0.0		0.2		0.0		0.0		0.0
95% CI		0.0 - 0.8		0.0 - 0.0		0.0 - 0.4		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
Lifetime risk (0-74)		1 in 1,373		NA		1 in 2,981		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.1		0.0		0.1		0.0		0.0		0.0

Table A4-44: Malignant Neoplasm of Kidney: ICD-10 C64

			Incider	ıce					Mortali	ty		
	Males	}	Femal	es	Person	s	Males	3	Female	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	1	1.9	1	0.9	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	1	1.7	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
15–19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
35-39	0	0.0	2	3.1	2	1.6	0	0.0	0	0.0	0	0.0
40-44	4	6.8	4	6.3	8	6.5	4	6.8	0	0.0	4	3.3
45-49	4	6.8	3	4.8	7	5.8	1	1.7	0	0.0	1	0.8
50-54	15	29.4	5	9.9	20	19.8	3	5.9	0	0.0	3	3.0
55-59	9	26.4	1	3.0	10	14.8	1	2.9	0	0.0	1	1.5
60-64	12	49.1	3	12.3	15	30.7	4	16.4	0	0.0	4	8.2
65-69	3	15.6	3	15.0	6	15.3	3	15.6	2	10.0	5	12.7
70-74	11	70.8	8	43.4	19	56.0	9	57.9	1	5.4	10	29.5
75–79	7	66.6	9	63.2	16	64.7	8	76.1	6	42.1	14	56.6
80-84	5	97.4	6	67.2	11	78.2	0	0.0	4	44.8	4	28.4
85 and over	2	72.2	3	44.4	5	52.5	5	180.4	2	29.6	7	73.5
Total	74		49		123		38		15		53	
Crude rate		9.6		6.2		7.9		4.9		1.9		3.4
95% CI		7.4 - 11.8		4.5 - 8.0		6.5 - 9.3		3.4 - 6.5		0.9 - 2.9		2.5 - 4.3
AS rate (Aust 1991)		11.9		7.0		9.3		7.3		2.3		4.5
95% CI		9.0 - 14.8		5.0 - 9.0		7.6 - 11.0		4.9 - 9.8		1.2 - 3.5		3.3 - 5.7
AS rate (World)		9.0		4.8		6.8		4.9		1.2		2.8
95% CI		6.9 - 11.1		3.4 - 6.2		5.6 - 8.1		3.3 - 6.5		0.6 - 1.9		2.0 - 3.6
Lifetime risk (0-74)		1 in 97		1 in 198		1 in 131		1 in 187		1 in 1,295		1 in 340
PYLL (0–74) Per cent of all								337.5		17.5		355.0
cancers		2.6		2.0		2.3		3.3		1.5		2.5

Table A4-45: Malignant Neoplasm of Renal Pelvis: ICD-10 C65

			Incide	nce					Mortali	ty		
_	Male	es	Femal	les	Person	ns	Males		Female	es	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.0	1	1.0	0	0.0	2	4.0	2	2.0
55–59	1	2.9	0	0.0	1	1.5	0	0.0	0	0.0	0	0.0
60-64	0	0.0	1	4.1	1	2.0	0	0.0	0	0.0	0	0.0
65-69	1	5.2	1	5.0	2	5.1	0	0.0	0	0.0	0	0.0
70–74	0	0.0	2	10.9	2	5.9	0	0.0	2	10.9	2	5.9
75–79	0	0.0	0	0.0	0	0.0	1	9.5	0	0.0	1	4.0
80-84	0	0.0	2	22.4	2	14.2	0	0.0	2	22.4	2	14.2
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	1	14.8	1	10.5
Total	2		8		10		1		7		8	
Crude rate		0.3		1.0		0.6		0.1		0.9		0.5
95% CI		0.0 - 0.6		0.3 - 1.7		0.2 - 1.0		0.0 - 0.4		0.2 - 1.5		0.2 - 0.9
AS rate (Aust 1991)		0.3		1.2		0.9		0.2		0.9		0.6
95% CI		0.0 - 0.8		0.4 - 2.1		0.3 - 1.4		0.0 - 0.6		0.2 - 1.7		0.2 - 1.1
AS rate (World)		0.3		0.8		0.6		0.1		0.6		0.4
95% CI		0.0 - 0.7		0.2 - 1.4		0.2 - 1.0		0.0 - 0.3		0.1 - 1.1		0.1 - 0.6
Lifetime risk (0-74)		1 in 2,462		1 in 912		1 in 1,291		NA		1 in 1,348		1 in 2,543
PYLL (0–74) Per cent of all								0.0		50.0		50.0
cancers		0.1		0.3		0.2		0.1		0.7		0.4

Table A4-46: Malignant Neoplasm of Ureter: ICD-10 C66

			Inciden	ce					Mortali	ty		
_	Male	s	Female	es	Person	s	Males		Female	s	Person	s
-	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.0	1	1.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	1	5.2	0	0.0	1	2.5	2	10.4	0	0.0	2	5.1
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	1	9.5	1	7.0	2	8.1	1	9.5	1	7.0	2	8.1
80-84	0	0.0	1	11.2	1	7.1	0	0.0	1	11.2	1	7.1
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	2		3		5		3		2		5	
Crude rate		0.3		0.4		0.3		0.4		0.3		0.3
95% CI		0.0 - 0.6		0.0 - 0.8		0.0 - 0.6		0.0 - 0.8		0.0 - 0.6		0.0 - 0.6
AS rate (Aust 1991)		0.4		0.4		0.4		0.6		0.3		0.5
95% CI		0.0 - 1.0		0.0 - 0.9		0.0 - 0.8		0.0 - 1.3		0.0 - 0.7		0.1 - 0.9
AS rate (World)		0.3		0.2		0.2		0.4		0.1		0.3
95% CI		0.0 - 0.6		0.0 - 0.5		0.0 - 0.5		0.0 - 0.9		0.0 - 0.3		0.0 - 0.5
Lifetime risk (0–74)		1 in 3,855		1 in 10,054		1 in 5,657		1 in 1,928		NA		1 in 3,925
PYLL (0–74) Per cent of all								15.0		0.0		15.0
cancers		0.1		0.1		0.1		0.3		0.2		0.2

Table A4-47: Malignant Neoplasm of Kidney, Ureter and Urethra: ICD-10 C64-66, C68

			Incider	ıce					Mortal	ity		
_	Males		Femal	es	Person	ns	Males	1	Femal	es	Perso	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	1	1.9	1	0.9	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	1	1.7	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
15–19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
35–39	0	0.0	2	3.1	2	1.6	0	0.0	0	0.0	0	0.0
40-44	4	6.8	4	6.3	8	6.5	4	6.8	0	0.0	4	3.3
45-49	4	6.8	3	4.8	7	5.8	1	1.7	0	0.0	1	0.8
50-54	15	29.4	7	13.9	22	21.7	3	5.9	2	4.0	5	4.9
55–59	10	29.4	1	3.0	11	16.3	1	2.9	0	0.0	1	1.5
60-64	12	49.1	4	16.4	16	32.7	4	16.4	0	0.0	4	8.2
65-69	5	25.9	4	20.0	9	22.9	5	25.9	2	10.0	7	17.8
70–74	12	77.3	11	59.7	23	67.8	10	64.4	4	21.7	14	41.2
75–79	10	95.2	10	70.2	20	80.8	10	95.2	7	49.2	17	68.7
80-84	5	97.4	9	100.8	14	99.5	0	0.0	7	78.4	7	49.8
85 and over	2	72.2	4	59.2	6	63.0	5	180.4	3	44.4	8	84.0
Total	81		61		142		43		25		68	
Crude rate		10.5		7.7		9.1		5.6		3.2		4.4
95% CI		8.2 - 12.8		5.8 - 9.7		7.6 - 10.6		3.9 - 7.2		1.9 - 4.4		3.3 - 5.4
AS rate (Aust 1991)		13.3		8.7		10.9		8.4		3.8		5.8
95% CI		10.2 - 16.3		6.5 - 11.0		9.1 - 12.8		5.7 - 11.0		2.3 - 5.2		4.4 - 7.2
AS rate (World)		9.8		5.9		7.9		5.5		2.0		3.6
95% CI		7.6 - 12.0		4.4 - 7.5		6.5 - 9.2		3.8 - 7.2		1.2 - 2.9		2.7 - 4.5
Lifetime risk (0–74)		1 in 88		1 in 153		1 in 112		1 in 162		1 in 560		1 in 258
PYLL (0–74) Per cent of all								355.0		70.0		425.0
cancers		2.9		2.5		2.7		3.7		2.5		3.1

Table A4-48: Malignant Neoplasm of Bladder: ICD-10 C67

			Incider	nce					Mortali	ty		
	Male	es	Femal	les	Person	ıs	Males	S	Female	es	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	1	1.5	1	0.8	0	0.0	1	1.5	1	0.8
40-44	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
45-49	1	1.7	0	0.0	1	0.8	1	1.7	0	0.0	1	0.8
50-54	5	9.8	1	2.0	6	5.9	2	3.9	0	0.0	2	2.0
55-59	5	14.7	6	18.0	11	16.3	1	2.9	1	3.0	2	3.0
60-64	8	32.7	2	8.2	10	20.4	0	0.0	1	4.1	1	2.0
65-69	14	72.6	4	20.0	18	45.9	11	57.1	6	30.1	17	43.3
70–74	19	122.3	6	32.6	25	73.6	10	64.4	3	16.3	13	38.3
75–79	23	218.9	1	7.0	24	97.0	12	114.2	0	0.0	12	48.5
80-84	17	331.1	2	22.4	19	135.1	16	311.6	3	33.6	19	135.1
85 and over	4	144.4	1	14.8	5	52.5	9	324.8	0	0.0	9	94.5
Total	97		24		121		62		15		77	
Crude rate		12.6		3.0		7.8		8.0		1.9		4.9
95% CI		10.1 - 15.1		1.8 - 4.3		6.4 - 9.1		6.0 - 10.0		0.9 - 2.9		3.8 - 6.0
AS rate (Aust 1991)	19.7		3.6		10.4		14.1		2.5		7.0
95% CI		15.7 - 23.7		2.2 - 5.1		8.5 - 12.3		10.5 - 17.7		1.2 - 3.8		5.4 - 8.5
AS rate (World)		11.8		2.7		6.7		7.7		1.8		4.1
95% CI		9.4 - 14.2		1.6 - 3.9		5.4 - 7.9		5.8 - 9.7		0.8 - 2.7		3.1 - 5.0
Lifetime risk (0-74	.)	1 in 79		1 in 244		1 in 122		1 in 154		1 in 364		1 in 222
PYLL (0–74) Per cent of all								197.5		120.0		317.5
cancers		3.5		1.0		2.3		5.4		1.5		3.6

Table A4-49: Malignant Neoplasm of Other Urinary Organs: ICD-10 C68

			Inciden	ce					Mortali	ty		
_	Males	s	Female	es	Person	s	Males		Female	s	Person	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	1	6.4	1	5.4	2	5.9	1	6.4	1	5.4	2	5.9
75–79	2	19.0	0	0.0	2	8.1	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	3		1		4		1		1		2	
Crude rate		0.4		0.1		0.3		0.1		0.1		0.1
95% CI		0.0 - 0.8		0.0 - 0.4		0.0 - 0.5		0.0 - 0.4		0.0 - 0.4		0.0 - 0.3
AS rate (Aust 1991)		0.6		0.2		0.4		0.2		0.2		0.2
95% CI		0.0 - 1.3		0.0 - 0.5		0.0 - 0.7		0.0 - 0.6		0.0 - 0.5		0.0 - 0.4
AS rate (World)		0.3		0.1		0.2		0.1		0.1		0.1
95% CI		0.0 - 0.7		0.0 - 0.3		0.0 - 0.4		0.0 - 0.4		0.0 - 0.3		0.0 - 0.3
Lifetime risk (0-74)		1 in 3,107		1 in 3,684		1 in 3,395		1 in 3,107		1 in 3,684		1 in 3,395
PYLL (0–74) Per cent of all								2.5		2.5		5.0
cancers		0.1		0.0		0.1		0.1		0.1		0.1

Table A4-50: Malignant Neoplasm of Eye: ICD-10 C69

			Incide	nce					Mortali	ty		
_	Male	es	Femal	les	Person	ıs	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	1	1.8	1	1.9	2	1.9	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	2	3.0	0	0.0	2	1.5	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	1	1.5	1	0.8	0	0.0	0	0.0	0	0.0
40-44	2	3.4	2	3.2	4	3.3	1	1.7	0	0.0	1	0.8
45-49	0	0.0	0	0.0	0	0.0	1	1.7	0	0.0	1	0.8
50-54	0	0.0	1	2.0	1	1.0	1	2.0	1	2.0	2	2.0
55-59	2	5.9	1	3.0	3	4.5	0	0.0	0	0.0	0	0.0
60-64	1	4.1	1	4.1	2	4.1	0	0.0	0	0.0	0	0.0
65-69	1	5.2	0	0.0	1	2.5	0	0.0	0	0.0	0	0.0
70–74	2	12.9	0	0.0	2	5.9	1	6.4	2	10.9	3	8.8
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	1	19.5	1	11.2	2	14.2	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	12		8		20		4		3		7	
Crude rate		1.6		1.0		1.3		0.5		0.4		0.4
95% CI		0.7 - 2.4		0.3 - 1.7		0.7 - 1.8		0.0 - 1.0		0.0 - 0.8		0.1 - 0.8
AS rate (Aust 1991)		1.9		1.0		1.4		0.5		0.4		0.5
95% CI		0.8 - 3.0		0.3 - 1.8		0.8 - 2.1		0.0 - 1.0		0.0 - 0.9		0.1 - 0.8
AS rate (World)		1.6		0.9		1.2		0.4		0.3		0.4
95% CI		0.7 - 2.5		0.2 - 1.7		0.7 - 1.8		0.0 - 0.9		0.0 - 0.7		0.1 - 0.7
Lifetime risk (0-74)		1 in 552		1 in 1,277		1 in 788		1 in 1,697		1 in 1,557		1 in 1,606
PYLL (0–74) Per cent of all								85.0		27.5		112.5
cancers		0.4		0.3		0.4		0.3		0.3		0.3

Table A4-51: Malignant Neoplasm of Brain: ICD-10 C71

			Inciden	ice					Mortal	ity		
_	Male	s	Female	es	Person	ıs	Males	3	Female	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	3	5.5	2	3.8	5	4.6	0	0.0	0	0.0	0	0.0
5-9	1	1.7	2	3.6	3	2.7	1	1.7	1	1.8	2	1.8
10-14	1	1.7	1	1.8	2	1.8	0	0.0	0	0.0	0	0.0
15–19	1	1.6	1	1.7	2	1.6	0	0.0	0	0.0	0	0.0
20-24	1	1.5	1	1.5	2	1.5	0	0.0	0	0.0	0	0.0
25–29	2	3.0	1	1.5	3	2.3	2	3.0	0	0.0	2	1.5
30-34	2	3.3	0	0.0	2	1.6	1	1.6	0	0.0	1	0.8
35–39	5	8.0	1	1.5	6	4.7	2	3.2	3	4.6	5	3.9
40-44	4	6.8	2	3.2	6	4.9	2	3.4	2	3.2	4	3.3
45-49	5	8.5	3	4.8	8	6.6	2	3.4	3	4.8	5	4.1
50-54	3	5.9	6	11.9	9	8.9	4	7.8	4	8.0	8	7.9
55–59	4	11.7	6	18.0	10	14.8	6	17.6	7	21.0	13	19.3
60-64	3	12.3	1	4.1	4	8.2	5	20.4	0	0.0	5	10.2
65-69	5	25.9	2	10.0	7	17.8	6	31.1	3	15.0	9	22.9
70–74	4	25.8	3	16.3	7	20.6	2	12.9	3	16.3	5	14.7
75–79	5	47.6	2	14.0	7	28.3	4	38.1	2	14.0	6	24.2
80-84	5	97.4	1	11.2	6	42.7	7	136.3	1	11.2	8	56.9
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	1	14.8	1	10.5
Total	54		36		90		44		30		74	
Crude rate		7.0		4.6		5.8		5.7		3.8		4.7
95% CI		5.1 - 8.9		3.1 - 6.1		4.6 - 7.0		4.0 - 7.4		2.4 - 5.2		3.7 - 5.8
AS rate (Aust 1991)		8.5		4.7		6.3		7.5		3.9		5.5
95% CI		6.1 - 10.8		3.1 - 6.2		5.0 - 7.7		5.1 - 9.8		2.5 - 5.4		4.2 - 6.7
AS rate (World)		6.6		4.3		5.4		5.3		3.2		4.2
95% CI		4.8 - 8.4		2.8 - 5.8		4.2 - 6.5		3.7 - 6.9		2.0 - 4.4		3.2 - 5.1
Lifetime risk (0-74)		1 in 163		1 in 239		1 in 195		1 in 189		1 in 268		1 in 222
PYLL (0–74) Per cent of all								707.5		570.0		1,277.5
cancers		1.9		1.5		1.7		3.8		3.0		3.4

Table A4-52: Malignant Neoplasm of Meninges CNC: ICD-10 C70, C72

			Inciden	ce					Mortali	ty		
_	Males		Female	es	Person	s	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	1	1.8	1	0.9	0	0.0	0	0.0	0	0.0
15-19	0	0.0	1	1.7	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	1	5.4	1	2.9
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	1	11.2	1	7.1	0	0.0	1	11.2	1	7.1
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	1		4		5		0		2		2	
Crude rate		0.1		0.5		0.3		0.0		0.3		0.1
95% CI		0.0 - 0.4		0.0 - 1.0		0.0 - 0.6		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
AS rate (Aust 1991)		0.1		0.5		0.3		0.0		0.3		0.2
95% CI		0.0 - 0.4		0.0 - 1.0		0.0 - 0.6		0.0 - 0.0		0.0 - 0.7		0.0 - 0.4
AS rate (World)		0.1		0.5		0.3		0.0		0.2		0.1
95% CI		0.0 - 0.3		0.0 - 1.0		0.0 - 0.5		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2
Lifetime risk (0-74)		1 in 12,492		1 in 3,930		1 in 6,044		NA		1 in 3,684		1 in 6,790
PYLL (0–74) Per cent of all								0.0		2.5		2.5
cancers		0.0		0.2		0.1		0.0		0.2		0.1

Table A4-53: Malignant Neoplasm of Brain and CNC: ICD-10 C70-72

			Inciden	ice					Mortali	ity		
_	Males	5	Femal	es	Person	ıs	Males	1	Female	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	3	5.5	2	3.8	5	4.6	0	0.0	0	0.0	0	0.0
5–9	1	1.7	2	3.6	3	2.7	1	1.7	1	1.8	2	1.8
10-14	1	1.7	2	3.6	3	2.7	0	0.0	0	0.0	0	0.0
15–19	1	1.6	2	3.3	3	2.4	0	0.0	0	0.0	0	0.0
20-24	1	1.5	1	1.5	2	1.5	0	0.0	0	0.0	0	0.0
25-29	2	3.0	1	1.5	3	2.3	2	3.0	0	0.0	2	1.5
30-34	2	3.3	0	0.0	2	1.6	1	1.6	0	0.0	1	0.8
35-39	6	9.6	1	1.5	7	5.5	2	3.2	3	4.6	5	3.9
40-44	4	6.8	2	3.2	6	4.9	2	3.4	2	3.2	4	3.3
45-49	5	8.5	4	6.5	9	7.4	2	3.4	3	4.8	5	4.1
50-54	3	5.9	6	11.9	9	8.9	4	7.8	4	8.0	8	7.9
55–59	4	11.7	6	18.0	10	14.8	6	17.6	7	21.0	13	19.3
60-64	3	12.3	1	4.1	4	8.2	5	20.4	0	0.0	5	10.2
65-69	5	25.9	2	10.0	7	17.8	6	31.1	3	15.0	9	22.9
70–74	4	25.8	3	16.3	7	20.6	2	12.9	4	21.7	6	17.7
75–79	5	47.6	2	14.0	7	28.3	4	38.1	2	14.0	6	24.2
80-84	5	97.4	2	22.4	7	49.8	7	136.3	2	22.4	9	64.0
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	1	14.8	1	10.5
Total	55		40		95		44		32		76	
Crude rate		7.1		5.1		6.1		5.7		4.1		4.9
95% CI		5.2 - 9.0		3.5 - 6.7		4.9 - 7.3		4.0 - 7.4		2.7 - 5.5		3.8 - 6.0
AS rate (Aust 1991)		8.6		5.2		6.7		7.5		4.3		5.6
95% CI		6.2 - 11.0		3.5 - 6.8		5.3 - 8.1		5.1 - 9.8		2.7 - 5.8		4.3 - 6.9
AS rate (World)		6.7		4.8		5.6		5.3		3.4		4.3
95% CI		4.9 - 8.5		3.2 - 6.3		4.5 - 6.8		3.7 - 6.9		2.2 - 4.6		3.3 - 5.2
Lifetime risk (0-74)		1 in 161		1 in 226		1 in 189		1 in 189		1 in 250		1 in 215
PYLL (0–74) Per cent of all								707.5		572.5		1,280.0
cancers		2.0		1.6		1.8		3.8		3.2		3.5

Table A4-54: Malignant Neoplasm of Thyroid: ICD-10 C73

			Inciden	ce					Mortali	ty		
_	Males	1	Female	es	Person	ıs	Males	3	Female	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	1	1.8	1	0.9	0	0.0	0	0.0	0	0.0
15–19	0	0.0	1	1.7	1	0.8	0	0.0	0	0.0	0	0.0
20-24	4	5.8	4	6.0	8	5.9	0	0.0	0	0.0	0	0.0
25-29	1	1.5	7	10.4	8	6.0	0	0.0	0	0.0	0	0.0
30-34	1	1.6	2	3.2	3	2.4	0	0.0	0	0.0	0	0.0
35–39	0	0.0	8	12.3	8	6.3	0	0.0	0	0.0	0	0.0
40-44	3	5.1	4	6.3	7	5.7	1	1.7	0	0.0	1	0.8
45-49	2	3.4	4	6.5	6	5.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	3	6.0	3	3.0	0	0.0	0	0.0	0	0.0
55–59	1	2.9	0	0.0	1	1.5	0	0.0	0	0.0	0	0.0
60-64	0	0.0	2	8.2	2	4.1	0	0.0	0	0.0	0	0.0
65-69	2	10.4	1	5.0	3	7.6	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	4	28.1	4	16.2	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	2	29.6	2	21.0
Total	14		42		56		1		2		3	
Crude rate		1.8		5.3		3.6		0.1		0.3		0.2
95% CI		0.9 - 2.8		3.7 - 6.9		2.7 - 4.5		0.0 - 0.4		0.0 - 0.6		0.0 - 0.4
AS rate (Aust 1991)		1.8		5.2		3.6		0.1		0.3		0.2
95% CI		0.8 - 2.8		3.6 - 6.9		2.7 - 4.6		0.0 - 0.4		0.0 - 0.6		0.0 - 0.5
AS rate (World)		1.6		4.5		3.1		0.1		0.1		0.2
95% CI		0.8 - 2.5		3.1 - 5.8		2.3 - 3.9		0.0 - 0.3		0.0 - 0.4		0.0 - 0.3
Lifetime risk (0-74)		1 in 651		1 in 298		1 in 407		1 in 11,798		NA		1 in 24,430
PYLL (0-74)								32.5		0.0		32.5
Per cent of all												
cancers		0.5		1.7		1.1		0.1		0.2		0.1

Table A4-55: Malignant Neoplasm of Adrenal Gland: ICD-10 C74

			Incidenc	ee					Mortali	ty		
_	Males		Female	s	Person	s	Males		Female	s	Persor	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	1	1.8	0	0.0	1	0.9
5–9	0	0.0	0	0.0	0	0.0	1	1.7	0	0.0	1	0.9
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	1	2.0	0	0.0	1	1.0
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	1	5.2	0	0.0	1	2.5	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	1		0		1		3		0		3	
Crude rate		0.1		0.0		0.1		0.4		0.0		0.2
95% CI		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2		0.0 - 0.8		0.0 - 0.0		0.0 - 0.4
AS rate (Aust 1991)		0.2		0.0		0.1		0.4		0.0		0.2
95% CI		0.0 - 0.6		0.0 - 0.0		0.0 - 0.3		0.0 - 0.8		0.0 - 0.0		0.0 - 0.4
AS rate (World)		0.2		0.0		0.1		0.5		0.0		0.2
95% CI		0.0 - 0.5		0.0 - 0.0		0.0 - 0.2		0.0 - 1.1		0.0 - 0.0		0.0 - 0.5
Lifetime risk (0-74)		1 in 3,855		NA		1 in 7,849		1 in 3,620		NA		1 in 7,132
PYLL (0–74) Per cent of all								162.5		0.0		162.5
cancers		0.0		0.0		0.0		0.3		0.0		0.1

Table A4-56: Malignant Neoplasm of Other Endocrine: ICD-10 C75

			Incidenc	e					Mortalit	ty		
_	Males	i	Females		Persons	s	Males		Female	s	Person	IS
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	1	1.7	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	0		1		1		0		0		0	
Crude rate		0.0		0.1		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (Aust 1991)		0.0		0.1		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (World)		0.0		0.2		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
Lifetime risk (0–74)		#DIV/0!		1 in 11,958		1 in 24,567		NA		NA		NA
PYLL (0–74) Per cent of all				, -		,		0.0		0.0		0.0
cancers		0.0		0.0		0.0		0.0		0.0		0.0

Table A4-57: Hodgkin's Disease: ICD-10 C81

			Incider	ice					Mortali	ty		
_	Males	3	Femal	es	Person	ns	Males		Female	es	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	2	3.5	0	0.0	2	1.8	0	0.0	0	0.0	0	0.0
15–19	0	0.0	2	3.3	2	1.6	0	0.0	0	0.0	0	0.0
20-24	2	2.9	2	3.0	4	2.9	1	1.5	0	0.0	1	0.7
25-29	1	1.5	3	4.5	4	3.0	0	0.0	1	1.5	1	0.8
30-34	2	3.3	0	0.0	2	1.6	1	1.6	0	0.0	1	0.8
35-39	3	4.8	2	3.1	5	3.9	1	1.6	0	0.0	1	0.8
40-44	2	3.4	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
45-49	0	0.0	2	3.2	2	1.7	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.0	1	1.0	1	2.0	0	0.0	1	1.0
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	2	10.0	2	5.1	0	0.0	1	5.0	1	2.5
70–74	0	0.0	1	5.4	1	2.9	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	1	14.8	1	10.5
Total	12		15		27		4		3		7	
Crude rate		1.6		1.9		1.7		0.5		0.4		0.4
95% CI		0.7 - 2.4		0.9 - 2.9		1.1 - 2.4		0.0 - 1.0		0.0 - 0.8		0.1 - 0.8
AS rate (Aust 1991)		1.5		1.9		1.7		0.5		0.4		0.5
95% CI		0.7 - 2.3		0.9 - 3.0		1.1 - 2.4		0.0 - 0.9		0.0 - 1.0		0.1 - 0.9
AS rate (World)		1.4		1.8		1.6		0.4		0.3		0.4
95% CI		0.6 - 2.1		0.9 - 2.7		1.0 - 2.2		0.0 - 0.8		0.0 - 0.7		0.1 - 0.7
Lifetime risk (0-74)		1 in 1,034		1 in 579		1 in 736		1 in 3,012		1 in 3,078		1 in 3,026
PYLL (0–74) Per cent of all								155.0		55.0		210.0
cancers		0.4		0.6		0.5		0.3		0.3		0.3

Table A4-58: Non-Hodgkin's Lymphoma: ICD-10 C82-85, C96

	J	• •	Incide	nce					Mortal	ity		
_	Male	s	Femal	les	Person	ıs	Male	S	Femal	es	Perso	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	3	5.2	1	1.8	4	3.5	1	1.7	0	0.0	1	0.9
15–19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	1	1.5	1	1.5	2	1.5	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	1	1.5	1	0.8
30-34	4	6.5	3	4.7	7	5.6	0	0.0	0	0.0	0	0.0
35–39	4	6.4	3	4.6	7	5.5	3	4.8	0	0.0	3	2.4
40-44	6	10.2	1	1.6	7	5.7	1	1.7	1	1.6	2	1.6
45-49	13	22.0	5	8.1	18	14.9	0	0.0	5	8.1	5	4.1
50-54	11	21.6	13	25.9	24	23.7	5	9.8	1	2.0	6	5.9
55–59	7	20.6	15	45.0	22	32.6	1	2.9	2	6.0	3	4.5
60-64	18	73.6	7	28.6	25	51.1	9	36.8	2	8.2	11	22.5
65-69	8	41.5	9	45.1	17	43.3	7	36.3	6	30.1	13	33.1
70–74	17	109.5	13	70.6	30	88.4	8	51.5	10	54.3	18	53.0
75–79	14	133.2	10	70.2	24	97.0	11	104.7	11	77.3	22	88.9
80-84	15	292.2	13	145.5	28	199.0	9	175.3	10	111.9	19	135.1
85 and over	4	144.4	8	118.5	12	126.0	4	144.4	11	162.9	15	157.5
Total	126		102		228		59		60		119	
Crude rate		16.3		13.0		14.6		7.6		7.6		7.6
95% CI		13.5 - 19.2		10.4 - 15.5		12.7 - 16.5		5.7 - 9.6		5.7 - 9.5		6.3 - 9.0
AS rate (Aust 1991)		21.8		14.4		17.6		11.7		8.9		10.1
95% CI		17.8 - 25.8		11.5 - 17.2		15.2 - 19.9		8.6 - 14.8		6.6 - 11.1		8.3 - 12.0
AS rate (World)		15.2		10.4		12.6		7.4		5.5		6.4
95% CI		12.5 - 18.0		8.3 - 12.6		10.9 - 14.3		5.4 - 9.3		4.0 - 7.0		5.2 - 7.6
Lifetime risk (0-74)		1 in 63		1 in 85		1 in 73		1 in 138		1 in 180		1 in 156
PYLL (0-74)								522.5		370.0		892.5
Per cent of all												
cancers		4.5		4.2		4.3		5.1		5.9		5.5

Table A4-59: All Lymphoma's: ICD-10 C81-85, C96

			Incide	nce			Mortality					
_	Male	es	Femal	les	Person	ns	Males	S	Femal	es	Persons	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	5	8.7	1	1.8	6	5.3	1	1.7	0	0.0	1	0.9
15–19	1	1.6	2	3.3	3	2.4	0	0.0	0	0.0	0	0.0
20-24	3	4.4	3	4.5	6	4.4	1	1.5	0	0.0	1	0.7
25-29	1	1.5	3	4.5	4	3.0	0	0.0	2	3.0	2	1.5
30-34	6	9.8	3	4.7	9	7.2	1	1.6	0	0.0	1	0.8
35-39	7	11.2	5	7.7	12	9.4	4	6.4	0	0.0	4	3.1
40-44	8	13.6	1	1.6	9	7.4	1	1.7	1	1.6	2	1.6
45-49	13	22.0	7	11.3	20	16.5	0	0.0	5	8.1	5	4.1
50-54	11	21.6	14	27.9	25	24.7	6	11.8	1	2.0	7	6.9
55-59	7	20.6	15	45.0	22	32.6	1	2.9	2	6.0	3	4.5
60-64	18	73.6	7	28.6	25	51.1	9	36.8	2	8.2	11	22.5
65-69	8	41.5	11	55.1	19	48.4	7	36.3	7	35.1	14	35.7
70–74	17	109.5	14	76.0	31	91.3	8	51.5	10	54.3	18	53.0
75–79	14	133.2	10	70.2	24	97.0	11	104.7	11	77.3	22	88.9
80-84	15	292.2	13	145.5	28	199.0	9	175.3	10	111.9	19	135.1
85 and over	4	144.4	8	118.5	12	126.0	4	144.4	12	177.7	16	168.0
Total	138		117		255		63		63		126	
Crude rate		17.9		14.9		16.4		8.2		8.0		8.1
95% CI		14.9 - 20.9		12.2 - 17.6		14.3 - 18.4		6.1 - 10.2		6.0 - 10.0		6.7 - 9.5
AS rate (Aust 1991)		23.3		16.3		19.3		12.1		9.3		10.6
95% CI		19.2 - 27.4		13.3 - 19.3		16.9 - 21.7		9.0 - 15.3		7.0 - 11.6		8.7 - 12.5
AS rate (World)		16.6		12.2		14.2		7.8		5.8		6.8
95% CI		13.7 – 19.4		9.9 - 14.5		12.4 - 16.0		5.8 - 9.8		4.3 - 7.4		5.6 - 8.0
Lifetime risk (0-74)		1 in 59		1 in 74		1 in 66		1 in 132		1 in 170		1 in 148
PYLL (0-74)								677.5		425.0		1,102.5
Per cent of all												
cancers		4.9		4.8		4.9		5.5		6.2		5.8

Table A4-60: Immunoproliferative Neoplasms: ICD-10 C82-85, C96

	Incidence						Mortality					
_	Male	S	Female	es	Person	ıs	Males		Female	S	Persons	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	1	4.1	0	0.0	1	2.0	1	4.1	0	0.0	1	2.0
65-69	1	5.2	0	0.0	1	2.5	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	1	9.5	0	0.0	1	4.0	0	0.0	0	0.0	0	0.0
80-84	1	19.5	0	0.0	1	7.1	0	0.0	1	11.2	1	7.1
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	4		0		4		1		1		2	
Crude rate		0.5		0.0		0.3		0.1		0.1		0.1
95% CI		0.0 - 1.0		0.0 - 0.0		0.0 - 0.5		0.0 - 0.4		0.0 - 0.4		0.0 - 0.3
AS rate (Aust 1991)		0.8		0.0		0.4		0.2		0.1		0.2
95% CI		0.0 - 1.7		0.0 - 0.0		0.0 - 0.7		0.0 - 0.5		0.0 - 0.4		0.0 - 0.4
AS rate (World)		0.5		0.0		0.2		0.2		0.1		0.1
95% CI		0.0 - 1.0		0.0 - 0.0		0.0 - 0.5		0.0 - 0.5		0.0 - 0.2		0.0 - 0.3
Lifetime risk (0-74)		1 in 2,156		NA		1 in 4,355		1 in 4,893		NA		1 in 9,785
PYLL (0–74) Per cent of all								12.5		0.0		12.5
cancers		0.1		0.0		0.1		0.1		0.1		0.1

Table A4-61: Multiple Myeloma: ICD-10 C90

			Inciden		Mortality							
_	Males		Female	s	Person	s	Males	}	Female	S	Persons	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	2	3.4	1	1.6	3	2.5	1	1.7	0	0.0	1	0.8
50-54	3	5.9	0	0.0	3	3.0	0	0.0	0	0.0	0	0.0
55–59	3	8.8	1	3.0	4	5.9	3	8.8	0	0.0	3	4.5
60-64	6	24.5	1	4.1	7	14.3	4	16.4	0	0.0	4	8.2
65-69	5	25.9	4	20.0	9	22.9	3	15.6	3	15.0	6	15.3
70–74	5	32.2	4	21.7	9	26.5	6	38.6	1	5.4	7	20.6
75–79	3	28.5	4	28.1	7	28.3	3	28.5	2	14.0	5	20.2
80-84	7	136.3	0	0.0	7	49.8	8	155.8	2	22.4	10	71.1
85 and over	2	72.2	0	0.0	2	21.0	4	144.4	3	44.4	7	73.5
Total	37		15		52		32		11		43	
Crude rate		4.8		1.9		3.3		4.1		1.4		2.8
95% CI		3.2 - 6.3		0.9 - 2.9		2.4 - 4.2		2.7 - 5.6		0.6 - 2.2		1.9 - 3.6
AS rate (Aust 1991)		7.1		2.4		4.4		6.9		1.8		3.8
95% CI		4.7 - 9.5		1.2 - 3.7		3.2 - 5.6		4.4 - 9.4		0.7 - 2.8		2.7 - 5.0
AS rate (World)		4.7		1.7		3.0		4.1		1.0		2.4
95% CI		3.1 - 6.2		0.8 - 2.6		2.2 - 3.9		2.7 - 5.6		0.4 - 1.7		1.6 - 3.1
Lifetime risk (0-74)		1 in 196		1 in 397		1 in 264		1 in 247		1 in 978		1 in 406
PYLL (0–74) Per cent of all								167.5		25.0		192.5
cancers		1.3		0.6		1.0		2.8		1.1		2.0

Table A4-62: Lymphoid Leukemia: ICD-10 C91

			Incide	nce		Mortality						
_	Male	s	Femal	les	Person	ns	Males		Female	es	Persons	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	5	9.1	4	7.6	9	8.3	1	1.8	0	0.0	1	0.9
5–9	3	5.2	1	1.8	4	3.6	0	0.0	0	0.0	0	0.0
10-14	0	0.0	2	3.6	2	1.8	0	0.0	0	0.0	0	0.0
15–19	4	6.3	0	0.0	4	3.3	1	1.6	1	1.7	2	1.6
20-24	1	1.5	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0
25-29	3	4.6	0	0.0	3	2.3	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	1	1.5	1	0.8	0	0.0	1	1.5	1	0.8
40-44	2	3.4	2	3.2	4	3.3	0	0.0	0	0.0	0	0.0
45-49	2	3.4	0	0.0	2	1.7	0	0.0	0	0.0	0	0.0
50-54	2	3.9	4	8.0	6	5.9	0	0.0	1	2.0	1	1.0
55-59	3	8.8	4	12.0	7	10.4	0	0.0	2	6.0	2	3.0
60-64	5	20.4	1	4.1	6	12.3	1	4.1	1	4.1	2	4.1
65-69	4	20.8	2	10.0	6	15.3	1	5.2	0	0.0	1	2.5
70–74	2	12.9	2	10.9	4	11.8	1	6.4	1	5.4	2	5.9
75–79	5	47.6	3	21.1	8	32.3	2	19.0	2	14.0	4	16.2
80-84	1	19.5	3	33.6	4	28.4	2	39.0	1	11.2	3	21.3
85 and over	0	0.0	1	14.8	1	10.5	1	36.1	3	44.4	4	42.0
Total	42		30		72		10		13		23	
Crude rate		5.4		3.8		4.6		1.3		1.7		1.5
95% CI		3.8 - 7.1		2.4 - 5.2		3.6 - 5.7		0.5 - 2.1		0.8 - 2.5		0.9 - 2.1
AS rate (Aust 1991)		6.4		4.1		5.3		2.1		1.8		1.9
95% CI		4.4 - 8.4		2.6 - 5.6		4.0 - 6.5		0.7 - 3.4		0.8 - 2.8		1.1 - 2.7
AS rate (World)		5.9		3.7		4.8		1.4		1.3		1.3
95% CI		4.0 - 7.7		2.3 - 5.1		3.6 - 6.0		0.5 - 2.3		0.5 - 2.0		0.7 - 1.9
Lifetime risk (0-74)		1 in 200		1 in 320		1 in 247		1 in 1,046		1 in 966		1 in 1,009
PYLL (0–74) Per cent of all								152.5		167.5		320.0
cancers		1.5		1.2		1.4		0.9		1.3		1.1

Table A4-63: Myeloid Leukemia: ICD-10 C92-94

			Incider	ıce		Mortality						
_	Male	es	Femal	es	Person	ns	Males	3	Female	es	Persons	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	1	1.8	2	3.8	3	2.8	0	0.0	1	1.9	1	0.9
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	2	3.6	2	1.8	0	0.0	2	3.6	2	1.8
15–19	2	3.2	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
20-24	0	0.0	1	1.5	1	0.7	0	0.0	0	0.0	0	0.0
25-29	1	1.5	0	0.0	1	0.8	1	1.5	0	0.0	1	0.8
30-34	1	1.6	1	1.6	2	1.6	0	0.0	0	0.0	0	0.0
35–39	1	1.6	1	1.5	2	1.6	2	3.2	0	0.0	2	1.6
40-44	3	5.1	1	1.6	4	3.3	2	3.4	0	0.0	2	1.6
45-49	1	1.7	1	1.6	2	1.7	1	1.7	2	3.2	3	2.5
50-54	2	3.9	4	8.0	6	5.9	1	2.0	2	4.0	3	3.0
55-59	1	2.9	2	6.0	3	4.5	0	0.0	0	0.0	0	0.0
60-64	2	8.2	1	4.1	3	6.1	2	8.2	2	8.2	4	8.2
65-69	4	20.8	2	10.0	6	15.3	1	5.2	2	10.0	3	7.6
70–74	3	19.3	7	38.0	10	29.5	5	32.2	6	32.6	11	32.4
75–79	4	38.1	1	7.0	5	20.2	9	85.6	2	14.0	11	44.5
80-84	5	97.4	0	0.0	5	35.5	9	175.3	1	11.2	10	71.1
85 and over	8	288.7	2	29.6	10	105.0	7	252.6	1	14.8	8	84.0
Total	39		28		67		40		21		61	
Crude rate		5.1		3.6		4.3		5.2		2.7		3.9
95% CI		3.5 - 6.6		2.2 - 4.9		3.3 - 5.3		3.6 - 6.8		1.5 - 3.8		2.9 - 4.9
AS rate (Aust 1991)		8.0		3.9		5.2		8.8		3.1		5.1
95% CI		5.3 - 10.7		2.4 - 5.3		4.0 - 6.5		6.0 - 11.7		1.7 - 4.4		3.8 - 6.4
AS rate (World)		5.2		3.4		3.9		4.8		2.5		3.2
95% CI		3.5 - 6.9		2.0 - 4.7		2.9 - 4.9		3.3 - 6.4		1.4 - 3.6		2.4 - 4.1
Lifetime risk (0-74)		1 in 280		1 in 247		1 in 260		1 in 349		1 in 316		1 in 332
PYLL (0–74) Per cent of all								282.5		352.5		635.0
cancers		1.4		1.1		1.3		3.5		2.1		2.8

Table A4-64: Lukemia Unspecified: ICD-10 C95

	·		Incider		Mortality							
_	Male	es	Femal	es	Person	ıs	Males		Female	es	Persons	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	1	5.2	0	0.0	1	2.5	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	1	7.0	1	4.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	1	11.2	1	7.1
85 and over	0	0.0	1	14.8	1	10.5	0	0.0	1	14.8	1	10.5
Total	1		2		3		0		2		2	
Crude rate		0.1		0.3		0.2		0.0		0.3		0.1
95% CI		0.0 - 0.4		0.0 - 0.6		0.0 - 0.4		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
AS rate (Aust 1991)		0.2		0.3		0.3		0.0		0.3		0.2
95% CI		0.0 - 0.6		0.0 - 0.7		0.0 - 0.6		0.0 - 0.0		0.0 - 0.7		0.0 - 0.4
AS rate (World)		0.2		0.1		0.2		0.0		0.1		0.1
95% CI		0.0 - 0.5		0.0 - 0.3		0.0 - 0.4		0.0 - 0.0		0.0 - 0.3		0.0 - 0.2
Lifetime risk (0-74)		1 in 3,855		NA		1 in 7,849		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.0		0.1		0.1		0.0		0.2		0.1

Table A4-65: Malignant Neoplasm of Unknown Primary Site: ICD-10 C76-80, C26, C39

		Incider	ice		Mortality							
_	Males		Femal	es	Person	ıs	Males	}	Female	es	Persons	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	1	1.5	1	1.5	2	1.5	1	1.5	2	3.0	3	2.3
30-34	1	1.6	0	0.0	1	0.8	1	1.6	0	0.0	1	0.8
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	6	10.2	4	6.3	10	8.2	6	10.2	2	3.2	8	6.5
45-49	4	6.8	5	8.1	9	7.4	2	3.4	5	8.1	7	5.8
50-54	10	19.6	9	17.9	19	18.8	6	11.8	3	6.0	9	8.9
55-59	9	26.4	7	21.0	16	23.7	14	41.1	6	18.0	20	29.7
60-64	13	53.1	3	12.3	16	32.7	7	28.6	1	4.1	8	16.4
65-69	11	57.1	9	45.1	20	51.0	15	77.8	6	30.1	21	53.5
70–74	19	122.3	10	54.3	29	85.4	14	90.1	10	54.3	24	70.7
75–79	19	180.8	13	91.3	32	129.3	15	142.7	11	77.3	26	105.1
80-84	11	214.3	20	223.9	31	220.4	13	253.2	17	190.3	30	213.3
85 and over	11	397.0	22	325.8	33	346.5	11	397.0	25	370.3	36	378.0
Total	115		103		218		105		88		193	
Crude rate		14.9		13.1		14.0		13.6		11.2		12.4
95% CI	-	12.2 - 17.6		10.6 - 15.6		12.1 - 15.8	1	11.0 - 16.2		8.8 - 13.5		10.6 - 14.1
AS rate (Aust 1991)		22.0		14.6		18.0		20.5		12.5		16.2
95% CI		17.8 - 26.2		11.8 - 17.5		15.5 - 20.4	1	16.4 - 24.6		9.9 - 15.2		13.9 – 18.5
AS rate (World)		14.4		9.3		11.7		13.2		7.7		10.3
95% CI		11.7 – 17.1		7.4 - 11.2		10.1 - 13.3	1	10.6 - 15.8		6.0 - 9.3		8.8 - 11.8
Lifetime risk (0–74)		1 in 67		1 in 121		1 in 88		1 in 76		1 in 158		1 in 103
PYLL (0–74) Per cent of all								955.0		552.5		1,507.5
cancers		4.1		4.2		4.2		9.1		8.7		8.9

Table A4-66: Cancers with alcohol use as an identified risk factor: ICD-10 C01-06, C09-10, C12-15, C22, C32, C50

_		Incidence						Mortality					
_	Males	S	Female	es	Perso	ns	Males	5	Female	es	Persons		
	Number	Rate	Number	Rate									
Age group													
0-4	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25–29	0	0.0	6	0.4	6	0.2	0	0.0	0	0.0	0	0.0	
30-34	0	0.0	18	0.6	18	0.3	0	0.0	1	0.0	1	0.0	
35–39	2	0.6	37	1.3	39	0.9	1	0.3	6	0.3	7	0.3	
40-44	4	1.4	71	3.4	75	2.4	2	0.6	6	0.3	8	0.4	
45-49	9	2.8	112	6.1	121	4.5	9	2.8	26	1.7	35	2.3	
50-54	17	7.6	158	10.7	175	9.1	2	0.9	23	1.5	25	1.2	
55–59	23	12.7	110	10.5	133	11.6	7	3.9	23	2.1	30	3.0	
60-64	15	11.6	86	11.8	101	11.7	9	7.0	25	3.4	34	5.2	
65-69	21	16.2	81	13.5	102	14.8	13	10.1	31	7.5	44	8.8	
70–74	23	16.8	69	14.7	92	15.6	18	13.3	24	5.4	42	9.0	
75–79	23	13.8	50	4.9	73	8.7	11	6.4	27	2.9	38	4.4	
80-84	13	8.8	30	4.0	43	5.8	6	3.7	25	3.2	31	3.4	
85 and over	3	3.2	27	5.2	30	4.6	7	8.7	23	4.3	30	5.6	
Total	153		856		1,009		85		240		325		
Crude rate		2.8		3.3		3.0		1.4		0.9		1.2	
95% CI		1.6 - 4.0		2.0 - 4.6		2.2 - 3.9		0.6 - 2.2		0.2 - 1.6		0.6 - 1.7	
AS rate (Aust 1991)		3.3		3.4		3.3		1.8		1.1		1.4	
95% CI		1.8 - 4.7		2.1 - 4.8		2.4 - 4.3		0.7 - 2.9		0.3 - 1.8		0.7 - 2.1	
AS rate (World)		2.7		2.9		2.8		1.4		0.8		1.1	
95% CI		1.5 - 3.8		1.8 - 4.1		2.0 - 3.6		0.5 - 2.2		0.2 - 1.5		0.6 - 1.6	
Lifetime risk (0-74)		1 in 288		1 in 275		1 in 281		1 in 515		1 in 899		1 in 663	
PYLL (0-74)								139.0		96.7		235.7	
Per cent of all													
cancers		0.8		1.1		0.9		0.9		0.7		0.8	

Table A4-67: Cancers with smoking as an identified risk factor: ICD-10 C00-06, C09-16, C21.0, C25, C32-34, C51.9, C 53-55, C62, C64, C65, C67

			Incide	nce	Mortality							
_	Male	5	Fema	les	Perso	ns	Males	S	Femal	es	Persons	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	1	0.0	1	0.0	2	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	3	0.0	0	0.0	3	0.0	0	0.0	0	0.0	0	0.0
15–19	3	1.4	0	0.0	3	0.7	0	0.0	0	0.0	0	0.0
20-24	7	2.7	0	0.0	7	1.4	0	0.0	0	0.0	0	0.0
25-29	10	5.4	10	4.3	20	4.8	1	0.4	3	0.9	4	0.7
30-34	19	11.1	7	3.2	26	7.1	1	0.4	0	0.0	1	0.2
35-39	16	10.0	16	5.5	32	7.7	5	3.2	3	1.9	8	2.6
40-44	24	16.4	23	10.9	47	13.6	9	6.3	8	5.1	17	5.7
45-49	36	29.0	32	19.3	68	24.1	22	18.6	10	8.0	32	13.2
50-54	64	59.6	59	34.7	123	47.2	20	19.6	19	20.2	39	19.9
55-59	72	121.7	55	52.3	127	87.3	39	69.1	19	27.3	58	48.4
60-64	80	177.2	64	77.9	144	127.6	45	108.0	24	43.0	69	75.5
65-69	87	257.8	66	106.5	153	180.8	68	198.6	49	99.4	117	148.1
70–74	114	391.3	91	152.2	205	261.6	95	324.2	51	103.6	146	204.5
75–79	104	537.6	66	124.5	170	299.9	72	392.4	39	96.9	111	222.3
80-84	56	465.9	40	88.3	96	226.1	45	445.7	37	103.0	82	228.1
85 and over	25	382.5	44	148.3	69	216.4	39	561.2	35	111.1	74	242.0
Total	721		574		1,295		461		297		758	
Crude rate		47.0		21.1		33.9		31.8		13.9		22.7
95% CI		42.2 - 51.8		17.9 - 24.3		31.0 - 36.8	2	27.8 - 35.8		11.3 – 16.5		20.4 - 25.1
AS rate (Aust 1991)		64.1		24.1		42.0		47.3		16.5		29.6
95% CI		57.3 – 71.0		20.4 - 27.9		38.3 - 45.6	2	41.2 – 53.5		13.3 – 19.6		26.5 - 32.8
AS rate (World)		44.9		18.3		30.5		31.2		11.9		20.4
95% CI		40.2 - 49.6		15.4 - 21.2		27.9 - 33.2	2	27.2 - 35.2		9.6 - 14.2		18.2 - 22.6
Lifetime risk (0-74)		1 in 19		1 in 43		1 in 27		1 in 27		1 in 65		1 in 39
PYLL (0–74) Per cent of all								1,902.5		1,032.8		2,935.3
cancers		12.9		6.8		10.1		21.3		10.8		16.4

APPENDIX B: 1995-1999

Table B1: The 10 Most Frequently Occurring Cancers and Cancer Caused Death by Gender in the ACT, 1995-1999

		New Ca	ises					Death	ıs		
		Per cent of all			Lifetime			Per cent of all			
	Number	new cancers	ASR (A)	ASR (W)	Risk		Number	cancer deaths	ASR (A)	ASR (W)	PYLL*
Males						Males					
Prostate	814	30.0	163.0	111.0	1 in 7	Trachea, bronchus &	182	16.3	37.6	23.6	1255
Colorectal (including	365	13.5	65.8	47.8	1 in 18	Colorectal (including	155	13.9	30.7	21.4	1373
Skin-melanoma	308	11.4	46.5	37.5	1 in 23	Prostate	123	11.0	29.6	16.5	375
Trachea, bronchus &	204	7.5	40.2	27.0	1 in 31	Unknown primary sit	100	9.0	20.0	13.5	955
Non-Hodgkin lympho	111	4.1	19.9	14.1	1 in 62	Leukaemias	64	5.7	13.5	8.3	810
Unknown primary sit	110	4.1	21.9	14.7	1 in 61	All lymphomas	63	5.7	12.8	8.0	670
Bladder	87	3.2	18.5	11.4	1 in 75	Stomach	56	5.0	11.2	7.7	590
Kidney, ureter & uret	78	2.9	13.4	9.8	1 in 87	Bladder	52	4.7	12.3	7.1	215
Leukaemias	71	2.6	12.6	9.8	1 in 117	Brain & CNS	44	3.9	7.7	5.8	825
Stomach	70	2.6	13.1	9.3	1 in 88	Pancreas	43	3.9	9.0	6.0	343
Females						Females					
Breast	742	32.1	101.5	83.8	1 in 11	Breast	203	20.3	29.6	22.0	2658
Colorectal (including	262	11.4	39.5	28.6	1 in 31	Colorectal (including	137	13.7	20.9	13.8	1093
Skin-melanoma	236	10.2	32.2	26.6	1 in 36	Trachea, bronchus &	115	11.5	18.1	12.4	880
Trachea, bronchus &	147	6.4	22.9	16.5	1 in 49	Unknown primary sit	73	7.3	10.6	6.6	568
Non-Hodgkin lympho	103	4.5	15.2	11.1	1 in 78	All lymphomas	65	6.5	10.1	6.4	473
Unknown primary sit	93	4.0	13.9	9.1	1 in 114	Ovary	52	5.2	7.3	5.8	758
Corpus uteri	91	3.9	13.9	10.9	1 in 70	Pancreas	48	4.8	7.8	5.0	248
Ovary	63	2.7	8.7	7.2	1 in 113	Leukaemias	38	3.8	5.6	4.3	555
Cervix	60	2.6	7.9	6.4	1 in 152	Stomach	35	3.5	5.4	3.5	258
Leukaemias	57	2.5	8.3	7.0	1 in 136	Brain & CNS	33	3.3	4.6	3.6	593
Persons						Persons					
Prostate	814	16.2	72.9	51.1	1 in 15	Trachea, bronchus &	297	14.0	26.3	17.3	2135
Breast	749	14.9	53.6	43.6	1 in 20	Colorectal (including	292	13.8	25.5	17.4	2465
Colorectal (including	627	12.5	51.6	37.6	1 in 23	Breast	206	9.7	16.5	11.9	2670
Skin-melanoma	544	10.8	38.9	31.8	1 in 28	Unknown primary sit	173	9.0	15.0	9.9	1523
Trachea, bronchus &	351	7.0	30.4	21.2	1 in 38	All lymphomas	128	8.2	11.3	7.1	1143
Non-Hodgkin lympho	214	4.3	17.3	12.5	1 in 70	Prostate	123	6.1	11.7	6.7	375
Unknown primary sit	203	4.0	17.5	11.7	1 in 81	Leukaemias	102	5.8	8.7	5.9	1365
Kidney, ureter & uret	134	2.7	10.9	7.7	1 in 115	Stomach	91	4.8	7.9	5.3	848
Leukaemias	128	2.6	10.1	8.2	1 in 126	Pancreas	91	4.5	8.2	5.4	590
Stomach	113	2.3	9.6	6.8	1 in 121	Brain & CNS	77	4.3	6.0	4.6	1418

Note 1: Rates are expressed per 100,000 population and age-standardised to the Australian 1991 Population (ASR (A)) and to the World Population (ASR (W)).

Note 2: Non-melanocytic skin cancer, known to be the most common cancer type, is excluded from this list as it is not registered by cancer registries.

^{*} These measures are calculated for ages 0–74 years.

 Table B2: Summary of Incidence Rates, 1995-1999

			M	Iales				Fe	emales	
			AS Rate	AS Rate	Lifetime	Sex ratio		AS Rate	AS Rate	Lifetime
ICDO-2	Cancer site/type	Number	(Aust 1991)	(World)	risk	M:F	Number	(Aust 1991)	(World)	risk
C00	Lip	18	2.7	2.3	1 in 330	1.5	12	1.8	1.3	1 in 599
C01	Tongue	3	0.5	0.3	1 in 2293	1.5	2	0.3	0.2	1 in 2799
C02	Other tongue	11	1.9	1.4	1 in 559	2.2	5	0.6	0.5	1 in 3793
C03	Gum	0	0.0	0.0	NA	NA	0	0.0	0.0	NA
C04	Floor of mouth	8	1.2	1.1	1 in 787	4.0	2	0.3	0.2	1 in 3028
C05	Palate	5	0.9	0.7	1 in 1395	1.3	4	0.5	0.4	1 in 1412
C06	Other & unspecified parts of mouth	3	0.5	0.4	1 in 3159	0.8	4	0.6	0.4	1 in 1684
C07	Parotid gland	16	3.0	1.9	1 in 651	4.0	4	0.5	0.4	1 in 3795
C08	Salivary glands	3	0.3	0.3	1 in 3856	1.5	2	0.3	0.2	1 in 9378
C09	Tonsil	4	0.5	0.4	1 in 2339	1.3	3	0.5	0.4	1 in 1677
C10	Oropharynx	1	0.1	0.1	1 in 9571	NA	0	0.0	0.0	NA
C11	Nasopharynx	4	0.8	0.7	1 in 2595	1.3	3	0.3	0.3	1 in 3737
C12	Pyriform sinus	5	0.8	0.6	1 in 990	5.0	1	0.1	0.1	1 in 12250
C13	Hypopharynx	2	0.3	0.3	1 in 2059	NA	0	0.0	0.0	NA
C14	Pharynx unspecified	2	0.5	0.3	1 in 3015	2.0	1	0.2	0.2	1 in 4671
C15	Oesophagus	32	6.3	4.0	1 in 209	1.6	20	3.3	2.2	1 in 360
C16	Stomach	70	13.1	9.3	1 in 88	1.6	43	6.7	4.7	1 in 186
C17	Small intestine	7	0.9	0.8	1 in 948	0.9	8	1.1	1.0	1 in 1053
C18	Colon	238	44.0	31.2	1 in 28	1.3	178	27.0	19.8	1 in 43
C19	Rectosigmoid junction	44	7.1	5.4	1 in 144	1.8	24	3.6	2.6	1 in 363
C20	Rectum	77	13.4	10.2	1 in 81	1.4	54	8.1	5.6	1 in 177
C21	Anus & anal canal	6	1.3	1.0	1 in 739	1.0	6	0.9	0.6	1 in 2085
C22	Liver	26	4.7	3.4	1 in 226	2.6	10	1.5	1.2	1 in 877
C23	Gallbladder	4	0.8	0.5	1 in 1330	0.6	7	1.0	0.8	1 in 1270
C24	Other biliary tract	9	1.9	1.1	1 in 856	0.9	10	1.5	0.9	1 in 1537
C25	Pancreas	42	8.5	5.8	1 in 161	0.8	53	8.2	5.5	1 in 153
C30	Nasal cavities & middle ear	3	0.3	0.3	1 in 4090	3.0	1	0.2	0.1	NA
C31	Accessory sinuses	2	0.3	0.3	1 in 2851	2.0	1	0.1	0.1	1 in 12250
C32	Larynx	30	5.6	3.8	1 in 233	15.0	2	0.3	0.1	NA
C33	Trachea	0	0.0	0.0	NA	NA	0	0.0	0.0	NA
C34	Bronchus & lung	204	40.2	27.0	1 in 31	1.4	147	22.9	16.5	1 in 49
C37	Thymus	1	0.3	0.1	NA	NA	0	0.0	0.0	NA

			M	ales				Fe	emales	
			AS Rate	AS Rate	Lifetime	Sex ratio		AS Rate	AS Rate	Lifetime
ICDO-2	Cancer site/type	Number	(Aust 1991)	(World)	risk	M:F	Number	(Aust 1991)	(World)	risk
C38	Heart, mediastinum & pleura	0	0.0	0.0	NA	0.0	1	0.1	0.1	1 in 12746
C40	Bone & articular cartilage	4	0.6	0.6	1 in 1873	1.3	3	0.4	0.5	1 in 3904
C41	Other bone & articular cartilage	3	0.4	0.4	1 in 2583	0.8	4	0.6	0.5	1 in 3174
C43	Skin-melanoma	308	46.5	37.5	1 in 23	1.3	236	32.2	26.6	1 in 36
C44	Skin-non-melanocytic (NMSC)	0	0.0	0.0	NA	NA	0	0.0	0.0	NA
C45	Mesothelioma	16	3.1	2.2	1 in 334	5.3	3	0.5	0.3	1 in 1890
C46	Kaposi's sarcoma	5	0.6	0.5	1 in 2438	2.5	2	0.2	0.2	1 in 3764
C47	Peripheral nerves & ANS	2	0.5	0.3	1 in 4715	NA	0	0.0	0.0	NA
C48	Retroperitoneum & peritoneum	2	0.2	0.3	1 in 5143	0.3	6	0.8	0.6	1 in 1687
C49	Other connective & soft tissue	11	1.6	1.5	1 in 780	1.0	11	1.7	1.1	1 in 741
C50	Breast	7	1.2	0.9	1 in 1165	0.0	742	101.5	83.8	1 in 11
C51	Vulva	0	0.0	0.0	NA	0.0	11	1.5	1.1	1 in 962
C52	Vagina	0	0.0	0.0	NA	0.0	2	0.3	0.2	1 in 3627
C53	Cervix	0	0.0	0.0	NA	0.0	60	7.9	6.4	1 in 152
C54	Corpus uteri	0	0.0	0.0	NA	0.0	91	13.9	10.9	1 in 70
C55	Uterus unspecified	0	0.0	0.0	NA	0.0	2	0.3	0.2	1 in 6287
C56	Ovary	0	0.0	0.0	NA	0.0	63	8.7	7.2	1 in 113
C57	Other & unspecified female genital organs	0	0.0	0.0	NA	0.0	6	0.9	0.7	1 in 843
C58	Placenta	0	0.0	0.0	NA	0.0	2	0.2	0.2	1 in 6464
C60	Penis	4	0.8	0.4	1 in 4268	NA	0	0.0	0.0	NA
C61	Prostate	814	163.0	111.0	1 in 7	NA	0	0.0	0.0	NA
C62	Testis	63	7.7	6.8	1 in 188	NA	0	0.0	0.0	NA
C63	Other male genital organs	1	0.1	0.1	1 in 11796	NA	0	0.0	0.0	NA
C64	Kidney	70	11.8	8.8	1 in 99	1.6	45	6.7	4.6	1 in 204
C65	Renal pelvis	4	0.7	0.5	1 in 1201	0.7	6	0.9	0.5	1 in 2778
C66	Urether	2	0.4	0.3	1 in 3759	0.5	4	0.6	0.4	1 in 2616
C67	Bladder	87	18.5	11.4	1 in 75	4.8	18	2.9	2.2	1 in 349
C68	Other urinary organs	2	0.4	0.2	1 in 3015	2.0	1	0.2	0.1	1 in 3627
C69	Eye	8	1.4	1.0	1 in 752	1.1	7	1.0	0.7	1 in 1567
C70	Meninges	1	0.1	0.1	1 in 12474	0.3	3	0.4	0.3	1 in 6067
C71	Brain	56	9.1	6.9	1 in 146	1.6	35	4.8	4.4	1 in 237
C72	Other CNS	0	0.0	0.0	NA	0.0	1	0.1	0.2	1 in 11141

			M	ales				Fe	emales	
	-		AS Rate	AS Rate	Lifetime	Sex ratio		AS Rate	AS Rate	Lifetime
ICDO-2	Cancer site/type	Number	(Aust 1991)	(World)	risk	M:F	Number	(Aust 1991)	(World)	risk
C73	Thyroid gland	13	1.8	1.5	1 in 611	0.3	43	5.3	4.4	1 in 307
C74	Adrenal gland	2	0.3	0.4	1 in 5558	2.0	1	0.1	0.1	1 in 13267
C75	Other endocrine glands	0	0.0	0.0	NA	0.0	1	0.1	0.1	1 in 12021
C76-80, 26, 39	Unknown primary site	110	21.9	14.7	1 in 61	1.2	93	13.9	9.1	1 in 114
C81	Hodgkin's disease	11	1.4	1.3	1 in 1126	0.6	17	2.2	2.1	1 in 527
C82	Follicular/nodular non-Hodgkin's lymphoma	24	3.9	3.1	1 in 245	1.3	19	2.5	2.2	1 in 426
C83	Diffuse non-Hodgkin's lymphoma	49	8.7	6.0	1 in 162	0.9	53	8.0	5.7	1 in 137
C84	Peripheral & cutaneous T-cell lymphomas	9	1.9	1.3	1 in 548	4.5	2	0.4	0.2	1 in 3946
C85	Other & unspecified non-Hodgkin's lymphoma	29	5.3	3.7	1 in 246	1.0	29	4.3	3.0	1 in 336
C88	Immunoproliferative neoplasms	5	1.1	0.6	1 in 1839	5.0	1	0.2	0.1	NA
C90	Multiple myeloma	36	7.2	4.9	1 in 183	1.8	20	3.2	2.2	1 in 357
C91	Lymphoid leukaemia	36	5.6	5.2	1 in 196	1.2	30	4.3	3.7	1 in 302
C92	Myeloid leukaemia	34	6.8	4.4	1 in 313	1.4	24	3.6	3.0	1 in 254
C93	Monocytic leukaemia	0	0.0	0.0	NA	0.0	1	0.1	0.1	1 in 9378
C94	Other leukaemias of specified cell type	0	0.0	0.0	NA	NA	0	0.0	0.0	NA
C95	Leukaemia of unspecifed cell type	1	0.2	0.2	1 in 3759	0.5	2	0.3	0.2	NA
C96	Other & unspecified lymphoid, haematopoietic & related tiss	0	0.0	0.0	NA	NA	0	0.0	0.0	NA
C97	Malignant neoplasms of independent (primary) multiple sites	0	0.0	0.0	NA	NA	0	0.0	0.0	NA
C01-02	Tongue	14	2.4	1.7	1 in 450	2.0	7	0.9	0.7	1 in 1611
C01-14	Head & neck	67	11.3	8.5	1 in 111	2.2	31	4.2	3.3	1 in 265
C03-06	Mouth	16	2.5	2.1	1 in 434	1.6	10	1.4	1.1	1 in 613
C05-06	Other & unspecified parts of mouth	8	1.4	1.0	1 in 968	1.0	8	1.1	0.9	1 in 768
C07-08	Salivary gland	19	3.3	2.2	1 in 557	3.2	6	0.8	0.6	1 in 2702
C09-10	Tonsil & oropharynx	5	0.6	0.5	1 in 1880	1.7	3	0.5	0.4	1 in 1677
C12-13	Hypopharynx	7	1.1	0.9	1 in 669	7.0	1	0.1	0.1	1 in 12250
C18-20	Colorectal (excluding Anus)	359	64.5	46.8	1 in 18	1.4	256	38.7	27.9	1 in 32
C19-20	Rectum	121	20.5	15.6	1 in 52	1.6	78	11.7	8.1	1 in 119
C18-21	Colorectal (including Anus)	365	65.8	47.8	1 in 18	1.4	262	39.5	28.6	1 in 31
C23-24	Gallbladder	13	2.7	1.6	1 in 521	0.8	17	2.5	1.7	1 in 696
C30-31	Nasal cavity	5	0.7	0.6	1 in 1680	2.5	2	0.3	0.2	1 in 12250
C33-34	Trachea, bronchus & lung	204	40.2	27.0	1 in 31	1.4	147	22.9	16.5	1 in 49
C37-38	Other thoracic organs	1	0.3	0.1	NA	1.0	1	0.1	0.1	1 in 12746
C40-41	Bone	7	1.0	0.9	1 in 1086	1.0	7	0.9	0.9	1 in 1751

			M	ales				Fe	emales	
			AS Rate	AS Rate	Lifetime	Sex ratio		AS Rate	AS Rate	Lifetime
ICDO-2	Cancer site/type	Number	(Aust 1991)	(World)	risk	M:F	Number	(Aust 1991)	(World)	risk
C47-49	Connective & soft tissue	15	2.3	2.1	1 in 593	0.9	17	2.5	1.8	1 in 515
C54-55	Uterus	0	0.0	0.0	NA	0.0	93	14.2	11.1	1 in 69
C60+63	Penis & other & unspecified male genital organs	5	0.9	0.5	1 in 3134	NA	0	0.0	0.0	NA
C64-66, 68	Kidney, ureter & urethra	78	13.4	9.8	1 in 87	1.4	56	8.4	5.6	1 in 169
C70+72	Meninges & other CNS	1	0.1	0.1	1 in 12474	0.3	4	0.5	0.5	1 in 3928
C70-72	Brain & CNS	57	9.3	7.0	1 in 144	1.5	39	5.3	4.8	1 in 223
C74-75	adrenal and other endocrine glands & related structures	2	0.3	0.4	1 in 5558	1.0	2	0.3	0.3	1 in 6307
C82-85, 96	Non-Hodgkin lymphoma	111	19.9	14.1	1 in 62	1.1	103	15.2	11.1	1 in 78
C81-85, 96	All lymphomas	122	21.3	15.3	1 in 59	1.0	120	17.4	13.2	1 in 68
C92-94	Myeloid, monocytic & other leukaemia	34	6.8	4.4	1 in 313	1.4	25	3.7	3.1	1 in 247
C91-95	Leukaemias	71	12.6	9.8	1 in 117	1.2	57	8.3	7.0	1 in 136
C00-97 excl C44	All cancers (excluding NMSC)	2709	497.8	353.9	1 in 3	1.2	2,308	330.0	256.3	1 in 4

Note: Rates are expressed per 100,000 population and age-standardised (AS rate) to both the Australian 1991 Standard Population and the World Standard Population.

^{*} Non-melanocytic skin cancer incidence data is not routinely collected by State and Territory cancer registries.

Table B3: Summary of Mortality Rates, 1995-1999

			M	ales			Females				
			AS Rate	AS Rate	PYLL	Sex ratio		AS Rate	AS Rate	PYLL	
ICD-10	Cancer site	Number	(Aust 1991)	(World)	(<75 yrs)	M:F	Number	(Aust 1991)	(World)	(<75 yrs)	
C00	Lip	2	0.3	0.2	55	NA	0	0.0	0.0	C	
C01	Tongue	4	0.8	0.5	23	NA	0	0.0	0.0	0	
C02	Other tongue	2	0.3	0.3	20	2.0	1	0.1	0.1	28	
C03	Gum	0	0.0	0.0	0	NA	0	0.0	0.0	0	
C04	Floor of mouth	3	0.4	0.4	58	3.0	1	0.2	0.2	8	
C05	Palate	0	0.0	0.0	0	0.0	4	0.7	0.4	8	
C06	Other & unspecified parts of mouth	1	0.2	0.2	13	0.5	2	0.3	0.2	8	
C07	Parotid gland	3	0.7	0.3	3	NA	0	0.0	0.0	0	
C08	Salivary glands	1	0.1	0.1	48	1.0	1	0.2	0.1	3	
C09	Tonsil	1	0.1	0.1	33	0.5	2	0.4	0.3	10	
C10	Oropharynx	1	0.1	0.1	18	NA	0	0.0	0.0	0	
C11	Nasopharynx	1	0.1	0.2	68	NA	0	0.0	0.0	0	
C12	Pyriform sinus	6	1.0	0.9	65	NA	0	0.0	0.0	0	
C13	Hypopharynx	1	0.1	0.1	18	NA	0	0.0	0.0	0	
C14	Pharynx unspecified	1	0.3	0.2	0	1.0	1	0.2	0.2	8	
C15	Oesophagus	19	4.0	2.5	153	1.4	14	2.4	1.4	35	
C16	Stomach	56	11.2	7.7	590	1.6	35	5.4	3.5	258	
C17	Small intestine	6	1.1	0.7	65	1.2	5	0.8	0.6	20	
C18	Colon	99	19.7	13.9	825	1.1	92	14.2	9.6	715	
C19	Rectosigmoid junction	18	3.5	2.2	115	1.5	12	1.8	1.0	128	
C20	Rectum	35	6.7	4.8	418	1.1	31	4.6	3.0	233	
C21	Anus & anal canal	3	0.8	0.5	15	1.5	2	0.3	0.2	18	
C22	Liver	22	4.3	2.9	215	2.0	11	1.7	1.2	125	
C23	Gallbladder	2	0.4	0.2	18	0.4	5	0.8	0.6	43	
C24	Other biliary tract	10	1.9	1.1	95	1.7	6	1.0	0.5	10	
C25	Pancreas	43	9.0	6.0	343	0.9	48	7.8	5.0	248	
C30	Nasal cavities & middle ear	1	0.1	0.1	18	1.0	1	0.1	0.1	0	
C31	Accessory sinuses	0	0.0	0.0	0	0.0	1	0.1	0.1	28	
C32	Larynx	14	2.9	1.9	113	14.0	1	0.2	0.1	0	
C33	Trachea	0	0.0	0.0	0	NA	0	0.0	0.0	0	
C34	Bronchus & lung	182	37.6	23.6	1,255	1.6	115	18.1	12.4	880	
C37	Thymus	0	0.0	0.0	0	0.0	1	0.2	0.2	8	

			M	ales				Fe	emales	
			AS Rate	AS Rate	PYLL	Sex ratio		AS Rate	AS Rate	PYLL
ICD-10	Cancer site	Number	(Aust 1991)	(World)	(<75 yrs)	M:F	Number	(Aust 1991)	(World)	(<75 yrs)
C38	Heart, mediastinum & pleura	0	0.0	0.0	0	0.0	1	0.1	0.1	43
C40	Bone & articular cartilage	2	0.2	0.2	70	NA	0	0.0	0.0	0
C41	Other bone & articular cartilage	2	0.3	0.3	60	2.0	1	0.1	0.1	28
C43	Skin-melanoma	31	5.9	4.2	403	1.4	22	3.2	2.4	383
C44	Skin-non-melanocytic (NMSC)	0	0.0	0.0	0	NA	0	0.0	0.0	0
C45	Mesothelioma	11	2.3	1.5	95	3.7	3	0.5	0.3	10
C46	Kaposi's sarcoma	1	0.1	0.1	43	NA	0	0.0	0.0	0
C47	Peripheral nerves & ANS	0	0.0	0.0	0	NA	0	0.0	0.0	0
C48	Retroperitoneum & peritoneum	1	0.1	0.1	23	0.3	4	0.6	0.5	60
C49	Other connective & soft tissue	5	0.8	0.6	160	1.0	5	0.8	0.6	70
C50	Breast	3	0.6	0.4	13	0.0	203	29.6	22.0	2,658
C51	Vulva	0	0.0	0.0	0	0.0	2	0.3	0.2	0
C52	Vagina	0	0.0	0.0	0	0.0	1	0.2	0.1	3
C53	Cervix	0	0.0	0.0	0	0.0	26	3.7	2.8	430
C54	Corpus uteri	0	0.0	0.0	0	0.0	17	2.8	1.9	115
C55	Uterus unspecified	0	0.0	0.0	0	NA	0	0.0	0.0	0
C56	Ovary	0	0.0	0.0	0	0.0	52	7.3	5.8	758
C57	Other & unspecified female genital organs	0	0.0	0.0	0	0.0	1	0.2	0.2	8
C58	Placenta	0	0.0	0.0	0	NA	0	0.0	0.0	0
C60	Penis	1	0.3	0.2	0	NA	0	0.0	0.0	0
C61	Prostate	123	29.6	16.5	375	NA	0	0.0	0.0	0
C62	Testis	2	0.2	0.2	75	NA	0	0.0	0.0	0
C63	Other male genital organs	0	0.0	0.0	0	NA	0	0.0	0.0	0
C64	Kidney	34	7.2	4.5	263	2.4	14	2.3	1.2	25
C65	Renal pelvis	1	0.2	0.1	0	0.1	8	1.2	0.8	63
C66	Urether	5	1.2	0.6	15	2.5	2	0.3	0.1	0
C67	Bladder	52	12.3	7.1	215	4.7	11	2.0	1.4	55
C68	Other urinary organs	1	0.2	0.1	3	1.0	1	0.2	0.1	3
C69	Eye	2	0.3	0.2	30	0.7	3	0.4	0.3	28
C70	Meninges	0	0.0	0.0	0	0.0	2	0.3	0.2	3
C71	Brain	44	7.7	5.8	825	1.4	31	4.3	3.4	590
C72	Other CNS	0	0.0	0.0	0	NA	0	0.0	0.0	0

		Males						Females			
			AS Rate	AS Rate	PYLL	Sex ratio		AS Rate	AS Rate	PYLL	
ICD-10	Cancer site	Number	(Aust 1991)	(World)	(<75 yrs)	M:F	Number	(Aust 1991)	(World)	(<75 yrs)	
C73	Thyroid gland	1	0.1	0.1	33	0.5	2	0.3	0.2	0	
C74	Adrenal gland	3	0.4	0.5	163	1.0	3	0.4	0.4	148	
C75	Other endocrine glands	0	0.0	0.0	0	NA	0	0.0	0.0	0	
C76-80, 26, 39	Unknown primary site	100	20.0	13.5	955	1.4	73	10.6	6.6	568	
C81	Hodgkin's disease	3	0.3	0.3	113	1.0	3	0.4	0.3	95	
C82	Follicular/nodular non-Hodgkin's lymphoma	7	1.5	0.9	48	1.2	6	1.0	0.8	80	
C83	Diffuse non-Hodgkin's lymphoma	35	7.1	4.4	345	0.8	42	6.6	4.0	170	
C84	Peripheral & cutaneous T-cell lymphomas	2	0.4	0.3	20	NA	0	0.0	0.0	0	
C85	Other & unspecified non-Hodgkin's lymphoma	16	3.4	2.1	145	1.1	14	2.2	1.3	128	
C88	Immunoproliferative neoplasms	1	0.2	0.2	13	0.5	2	0.3	0.1	0	
C90	Multiple myeloma	25	5.5	3.2	145	1.9	13	2.1	1.2	45	
C91	Lymphoid leukaemia	14	3.1	1.9	185	1.0	14	2.0	1.6	260	
C92	Myeloid leukaemia	50	10.4	6.4	625	2.3	22	3.4	2.6	295	
C93	Monocytic leukaemia	0	0.0	0.0	0	NA	0	0.0	0.0	0	
C94	Other leukaemias of specified cell type	0	0.0	0.0	0	NA	0	0.0	0.0	0	
C95	Leukaemia of unspecifed cell type	0	0.0	0.0	0	0.0	2	0.3	0.1	0	
C96	Other & unspecified lymphoid, haematopoietic &	0	0.0	0.0	0	NA	0	0.0	0.0	0	
C97	Malignant neoplasms of independent (primary) n	0	0.0	0.0	0	0.0	1	0.2	0.1	3	
C01-02	Tongue	6	1.1	0.7	43	6.0	1	0.1	0.1	28	
C01-14	Head & neck	25	4.4	3.4	363	2.1	12	2.0	1.4	70	
C03-06	Mouth	4	0.6	0.6	70	0.6	7	1.2	0.8	23	
C05-06	Other & unspecified parts of mouth	1	0.2	0.2	13	0.2	6	1.0	0.6	15	
C07-08	Salivary gland	4	0.8	0.5	50	4.0	1	0.2	0.1	3	
C09-10	Tonsil & oropharynx	2	0.3	0.2	50	1.0	2	0.4	0.3	10	
C12-13	Hypopharynx	7	1.2	1.0	83	NA	0	0.0	0.0	0	
C18-20	Colorectal (excluding Anus)	152	29.9	20.9	1,358	1.1	135	20.6	13.6	1,075	
C19-20	Rectum	53	10.2	7.0	533	1.2	43	6.4	4.0	360	
C18-21	Colorectal (including Anus)	155	30.7	21.4	1,373	1.1	137	20.9	13.8	1,093	
C23-24	Gallbladder	12	2.4	1.4	113	1.1	11	1.8	1.1	53	
C30-31	Nasal cavity	1	0.1	0.1	18	0.5	2	0.2	0.2	28	
C33-34	Trachea, bronchus & lung	182	37.6	23.6	1,255	1.6	115	18.1	12.4	880	
C37-38	Other thoracic organs	0	0.0	0.0	0	0.0	2	0.3	0.2	50	

			M	ales			Females			
ICD-10	Cancer site	Number	AS Rate (Aust 1991)	AS Rate (World)	PYLL (<75 yrs)	Sex ratio M:F	Number	AS Rate (Aust 1991)	AS Rate (World)	PYLL (<75 yrs)
C40-41	Bone	4	0.5	0.5	130	4.0	1	0.1	0.1	28
C47-49	Connective & soft tissue	6	0.9	0.7	183	0.7	9	1.4	1.1	130
C54-55	Uterus	0	0.0	0.0	0	0.0	17	2.8	1.9	115
C60+63	Penis & other & unspecified male genital organs	1	0.3	0.2	0	NA	0	0.0	0.0	0
C64-66, 68	Kidney, ureter & urethra	41	8.8	5.3	280	1.6	25	4.0	2.3	90
C70+72	Meninges & other CNS	0	0.0	0.0	0	0.0	2	0.3	0.2	3
C70-72	Brain & CNS	44	7.7	5.8	825	1.3	33	4.6	3.6	593
C74-75	adrenal and other endocrine glands & related stru	3	0.4	0.5	163	1.0	3	0.4	0.4	148
C82-85, 96	Non-Hodgkin lymphoma	60	12.4	7.6	558	1.0	62	9.7	6.1	378
C81-85, 96	All lymphomas	63	12.8	8.0	670	1.0	65	10.1	6.4	473
C92-94	Myeloid, monocytic & other leukaemia	50	10.4	6.4	625	2.3	22	3.4	2.6	295
C91-95	Leukaemias	64	13.5	8.3	810	1.7	38	5.6	4.3	555
C00-97 excl C44	All cancers (excluding NMSC)	1,115	229.8	148.1	10,105	1.1	999	151.5	104.9	9,933

Note: Rates are expressed per 100,000 population and age-standardised (AS rate) to both the Australian 1991 Standard Population and the World Standard Population.

NA indicates "Not Applicable".

Table B4: Age And Sex Specific Cancer Incidence And Mortality Rates By Cancer Site, 1995-1999

Table B4-1: All Malignant Neoplasms: ICD-10 C00-97 (Excluding non-melanocytic skin cancers (C44))

			Incide	nce					Morta	lity		
_	Male	es	Fema	es	Perso	ns	Male	es	Fema	les	Perso	ns
	Number	Rate										
Age group												
0–4	11	19.8	10	18.7	21	19.2	3	5.4	3	5.6	6	5.5
5–9	7	12.1	4	7.3	11	9.8	3	5.2	1	1.8	4	3.5
10–14	9	15.6	7	12.6	16	14.1	2	3.5	1	1.8	3	2.6
15–19	10	15.9	13	21.6	23	18.7	3	4.8	1	1.7	4	3.2
20–24	28	39.6	18	26.2	46	33.0	8	11.3	0	0.0	8	5.7
25-29	33	50.6	44	66.3	77	58.5	9	13.8	10	15.1	19	14.4
30-34	43	69.6	45	70.6	88	70.1	6	9.7	8	12.6	14	11.2
35–39	56	89.8	99	152.1	155	121.6	14	22.4	18	27.7	32	25.1
40–44	106	179.7	158	250.7	264	216.4	34	57.7	28	44.4	62	50.8
45–49	150	252.6	219	357.6	369	305.9	41	69.1	72	117.6	113	93.7
50-54	216	451.4	286	610.0	502	529.9	44	91.9	73	155.7	117	123.5
55–59	265	817.0	258	820.8	523	818.9	88	271.3	80	254.5	168	263.0
60-64	324	1,374.5	187	8.008	511	1,089.0	106	449.7	66	282.6	172	366.5
65–69	408	2,171.1	238	1,206.3	646	1,677.0	154	819.5	120	608.2	274	711.3
70–74	439	2,912.5	249	1,373.3	688	2,072.0	207	1,373.3	152	838.3	359	1,081.2
75–79	321	3,335.4	193	1,455.5	514	2,246.1	163	1,693.7	125	942.7	288	1,258.5
80–84	192	4,019.3	144	1,698.5	336	2,534.9	139	2,909.8	127	1,498.0	266	2,006.8
85 and over	91	3,539.5	136	2,185.8	227	2,581.6	91	3,539.5	114	1,832.2	205	2,331.4
Total	2,709		2,308		5,017		1,115		999		2,114	
Crude rate		353.1		295.9		324.2		145.3		128.1		136.6
95% CI		9.8 – 366.4	28	3.8 – 307.9	31	5.3 – 333.2	13	6.8 – 153.9	12	0.1 – 136.0	13	30.8 – 142.5
AS rate (Aust 1991)		497.8		330.0		401.4		229.8		151.5		182.8
95% CI	47	8.1 – 517.5	31	6.2 – 343.8	39	0.0 – 412.9	21:	5.7 – 244.0	14	2.0 – 161.1	17	4.8 – 190.7
AS rate (World)		353.9		256.3		299.0		148.1		104.9		122.6
95% CI	34	0.3 – 367.5	24	5.4 – 267.2	29	0.5 - 307.5	13	9.2 – 157.0	9	8.0 – 111.7	11	7.2 – 128.0
Lifetime risk (0-74)		1 in 3		1 in 4		1 in 3		1 in 7		1 in 9		1 in 8
PYLL (0-74)								10,105.0		9,932.5		20,037.5
Per cent of		100.0		400.0		100.0		100.0		100.0		400.5
all cancers		100.0		100.0		100.0		100.0		100.0		100.0

Table B4-2: Malignant Neoplasm of Lip: ICD-10 C00

			Inciden	ce					Mortali	ty		
_	Males	S	Female	s	Person	ıs	Male	s	Female	es	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	2	3.1	0	0.0	2	1.5	0	0.0	0	0.0	0	0.0
30-34	2	3.2	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	1	1.6	0	0.0	1	0.8
40-44	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
45-49	2	3.4	0	0.0	2	1.7	0	0.0	0	0.0	0	0.0
50-54	1	2.1	3	6.4	4	4.2	0	0.0	0	0.0	0	0.0
55–59	5	15.4	0	0.0	5	7.8	1	3.1	0	0.0	1	1.6
60-64	1	4.2	1	4.3	2	4.3	0	0.0	0	0.0	0	0.0
65-69	3	16.0	2	10.1	5	13.0	0	0.0	0	0.0	0	0.0
70–74	2	13.3	2	11.0	4	12.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	2	15.1	2	8.7	0	0.0	0	0.0	0	0.0
80-84	0	0.0	1	11.8	1	7.5	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	18		12		30		2		0		2	
Crude rate		2.3		1.5		1.9		0.3		0.0		0.1
95% CI		1.3 - 3.4		0.7 - 2.4		1.2 - 2.6		0.0 - 0.6		0.0 - 0.0		0.0 - 0.3
AS rate (Aust 1991)		2.7		1.8		2.3		0.3		0.0		0.1
95% CI		1.4 - 3.9		0.8 - 2.9		1.4 - 3.1		0.0 - 0.6		0.0 - 0.0		0.0 - 0.3
AS rate (World)		2.3		1.3		1.8		0.2		0.0		0.1
95% CI		1.2 - 3.3		0.5 - 2.1		1.2 - 2.5		0.0 - 0.5		0.0 - 0.0		0.0 - 0.3
Lifetime risk (0–74)		1 in 330		1 in 599		1 in 427		1 in 4,268				1 in 8,510
PYLL (0–74) Per cent of all								55.0		0.0		55.0
cancers		0.7		0.5		0.6		0.2		0.0		0.1

Table B4-3: Malignant Neoplasm of Tongue: ICD-10 C01

			Inciden	ice					Mortalit	y		
	Males		Female	es	Person	ns	Males	3	Females		Person	S
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	1	1.5	1	1.5	2	1.5	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	2	3.3	2	1.7	0	0.0	1	1.6	1	0.8
50-54	3	6.3	1	2.1	4	4.2	0	0.0	0	0.0	0	0.0
55–59	2	6.2	0	0.0	2	3.1	2	6.2	0	0.0	2	3.1
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	2	10.6	0	0.0	2	5.2	0	0.0	0	0.0	0	0.0
70–74	3	19.9	1	5.5	4	12.0	3	19.9	0	0.0	3	9.0
75–79	2	20.8	0	0.0	2	8.7	1	10.4	0	0.0	1	4.4
80-84	1	20.9	1	11.8	2	15.1	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	0	0.0	0	0.0
Total	14		7		21		6		1		7	
Crude rate		1.8		0.9		1.4		0.8		0.1		0.5
95% CI		0.9 - 2.8		0.2 - 1.6		0.8 - 1.9		0.2 - 1.4		0.0 - 0.4		0.1 - 0.8
AS rate (Aust 1991)		2.4		0.9		1.6		1.1		0.1		0.5
95% CI		1.1 - 3.8		0.2 - 1.6		0.9 - 2.3		0.2 - 2.0		0.0 - 0.3		0.1 - 1.0
AS rate (World)		1.7		0.7		1.2		0.7		0.1		0.4
95% CI		0.8 - 2.6		0.2 - 1.2		0.7 - 1.7		0.1 - 1.3		0.0 - 0.3		0.1 - 0.7
Lifetime risk (0–74)		1 in 450		1 in 1,611		1 in 721		1 in 768		1 in 12,250		1 in 1,540
PYLL (0–74) Per cent of all								42.5		27.5		70.0
cancers		0.5		0.3		0.4		0.5		0.1		0.3

Table B4-4: Malignant Neoplasm of Mouth: ICD-10 C03-06

			Inciden	ice					Mortal	ity		
_	Males	5	Femal	es	Person	s	Males	S	Femal	es	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	1	1.5	1	0.8	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	1	1.5	1	0.8	0	0.0	0	0.0	0	0.0
40-44	2	3.4	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
45-49	1	1.7	1	1.6	2	1.7	1	1.7	0	0.0	1	0.8
50-54	2	4.2	0	0.0	2	2.1	0	0.0	0	0.0	0	0.0
55–59	3	9.2	2	6.4	5	7.8	1	3.1	0	0.0	1	1.6
60-64	4	17.0	0	0.0	4	8.5	2	8.5	0	0.0	2	4.3
65-69	2	10.6	1	5.1	3	7.8	0	0.0	2	10.1	2	5.2
70–74	0	0.0	3	16.5	3	9.0	0	0.0	3	16.5	3	9.0
75–79	2	20.8	0	0.0	2	8.7	0	0.0	1	7.5	1	4.4
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	1	16.1	1	11.4
Total	16		10		26		4		7		11	
Crude rate		2.1		1.3		1.7		0.5		0.9		0.7
95% CI		1.1 - 3.1		0.5 - 2.1		1.0 - 2.3		0.0 - 1.0		0.2 - 1.6		0.3 - 1.1
AS rate (Aust 1991)		2.5		1.4		2.0		0.6		1.2		1.0
95% CI		1.3 - 3.8		0.5 - 2.3		1.2 - 2.8		0.0 - 1.2		0.3 - 2.1		0.4 - 1.5
AS rate (World)		2.1		1.1		1.6		0.6		0.8		0.7
95% CI		1.0 - 3.1		0.4 - 1.8		1.0 - 2.3		0.0 - 1.1		0.2 - 1.4		0.3 - 1.2
Lifetime risk (0-74)		1 in 434		1 in 613		1 in 499		1 in 1,510		1 in 750		1 in 958
PYLL (0–74) Per cent of all								70.0		22.5		92.5
cancers		0.6		0.4		0.5		0.4		0.7		0.5

Table B4-5: Malignant Neoplasm of Salivary Glands: ICD-10 C07-08

			Incider	ice					Mortali	ty		
_	Males	S	Femal	es	Person	ıs	Males		Female	S	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20–24	1	1.4	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	1	1.5	0	0.0	1	0.8
30–34	0	0.0	2	3.1	2	1.6	0	0.0	0	0.0	0	0.0
35–39	2	3.2	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
40–44	2	3.4	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
45–49	2	3.4	0	0.0	2	1.7	0	0.0	0	0.0	0	0.0
50-54	2	4.2	2	4.3	4	4.2	0	0.0	0	0.0	0	0.0
55–59	1	3.1	0	0.0	1	1.6	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	2	10.6	0	0.0	2	5.2	0	0.0	0	0.0	0	0.0
70–74	1	6.6	0	0.0	1	3.0	1	6.6	1	5.5	2	6.0
75–79	4	41.6	2	15.1	6	26.2	2	20.8	0	0.0	2	8.7
80-84	1	20.9	0	0.0	1	7.5	0	0.0	0	0.0	0	0.0
85 and over	1	38.9	0	0.0	1	11.4	0	0.0	0	0.0	0	0.0
Total	19		6		25		4		1		5	
Crude rate		2.5		0.8		1.6		0.5		0.1		0.3
95% CI		1.4 - 3.6		0.2 - 1.4		1.0 - 2.2		0.0 - 1.0		0.0 - 0.4		0.0 - 0.6
AS rate (Aust 1991)		3.3		0.8		1.9		0.8		0.2		0.4
95% CI		1.7 - 4.9		0.1 - 1.5		1.1 - 2.6		0.0 - 1.6		0.0 - 0.5		0.0 - 0.8
AS rate (World)		2.2		0.6		1.3		0.5		0.1		0.3
95% CI		1.2 - 3.2		0.1 - 1.0		0.8 - 1.8		0.0 - 0.9		0.0 - 0.3		0.0 - 0.5
Lifetime risk (0-74)		1 in 557		1 in 2,702		1 in 945		1 in 2,449		1 in 3,627		1 in 2,949
PYLL (0–74) Per cent of all								50.0		2.5		52.5
cancers		0.7		0.3		0.5		0.4		0.1		0.2

Table B4-6: Malignant Neoplasm of Tonsils: ICD-10 C09

			Inciden	ce					Mortali	ty		
_	Males	3	Female	S	Person	s	Males		Female	S	Person	s
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	1	1.7	0	0.0	1	0.8	1	1.7	0	0.0	1	0.8
45-49	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
50-54	1	2.1	1	2.1	2	2.1	0	0.0	0	0.0	0	0.0
55-59	1	3.1	0	0.0	1	1.6	0	0.0	0	0.0	0	0.0
60-64	0	0.0	1	4.3	1	2.1	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	1	5.1	1	2.6
70–74	0	0.0	1	5.5	1	3.0	0	0.0	1	5.5	1	3.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	4		3		7		1		2		3	
Crude rate		0.5		0.4		0.5		0.1		0.3		0.2
95% CI		0.0 - 1.0		0.0 - 0.8		0.1 - 0.8		0.0 - 0.4		0.0 - 0.6		0.0 - 0.4
AS rate (Aust 1991)		0.5		0.5		0.5		0.1		0.4		0.3
95% CI		0.0 - 0.9		0.0 - 1.0		0.1 - 0.8		0.0 - 0.4		0.0 - 0.9		0.0 - 0.5
AS rate (World)		0.4		0.4		0.4		0.1		0.3		0.2
95% CI		0.0 - 0.9		0.0 - 0.8		0.1 - 0.7		0.0 - 0.3		0.0 - 0.6		0.0 - 0.4
Lifetime risk (0–74)		1 in 2,339		1 in 1,677		1 in 1,911		1 in 11,796		1 in 1,890		1 in 3,112
PYLL (0-74)								32.5		10.0		42.5
Per cent of all												
cancers		0.1		0.1		0.1		0.1		0.2		0.1

Table B4-7: Malignant Neoplasm of Other Oropharynx: ICD-10 C10

			Inciden	ce					Mortali	ty		
_	Males		Female	es	Person	ıs	Males		Female	es	Person	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	1	2.1	0	0.0	1	1.1	0	0.0	0	0.0	0	0.0
55–59	0	0.0	0	0.0	0	0.0	1	3.1	0	0.0	1	1.6
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	1		0		1		1		0		1	
Crude rate		0.1		0.0		0.1		0.1		0.0		0.1
95% CI		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (Aust 1991)		0.1		0.0		0.1		0.1		0.0		0.1
95% CI		0.0 - 0.3		0.0 - 0.0		0.0 - 0.2		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (World)		0.1		0.0		0.1		0.1		0.0		0.1
95% CI		0.0 - 0.3		0.0 - 0.0		0.0 - 0.2		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
Lifetime risk (0–74)		1 in 9,571		#DIV/0!		1 in 18,949		1 in 6,488		NA		1 in 12,774
PYLL (0-74) Per cent of all								17.5		0.0		17.5
cancers		0.0		0.0		0.0		0.1		0.0		0.0

Table B4-8: Malignant Neoplasm of Nasopharynx: ICD-10 C11

			Incider	ıce					Mortalit	ty		
	Male	es	Femal	es	Person	ns	Males		Female	s	Person	s
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	1	1.7	0	0.0	1	0.9	1	1.7	0	0.0	1	0.9
10-14	1	1.7	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
45-49	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.1	1	1.1	0	0.0	0	0.0	0	0.0
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	1	4.2	0	0.0	1	2.1	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	1	38.9	0	0.0	1	11.4	0	0.0	0	0.0	0	0.0
Total	4		3		7		1		0		1	
Crude rate		0.5		0.4		0.5		0.1		0.0		0.1
95% CI		0.0 - 1.0		0.0 - 0.8		0.1 - 0.8		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (Aust 1991)		0.8		0.3		0.5		0.1		0.0		0.1
95% CI		0.0 - 1.6		0.0 - 0.7		0.1 - 0.9		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (World)		0.7		0.3		0.5		0.2		0.0		0.1
95% CI		0.0 - 1.4		0.0 - 0.6		0.1 - 0.8		0.0 - 0.5		0.0 - 0.0		0.0 - 0.3
Lifetime risk (0-74)		1 in 2,595		1 in 3,737		1 in 3,029		1 in 11,524		NA		1 in 22,557
PYLL (0–74) Per cent of all								67.5		0.0		67.5
cancers		0.1		0.1		0.1		0.1		0.0		0.0

Table B4-9: Malignant Neoplasm of Hypopharynx: ICD-10 C12-13

			Incidenc	ee					Mortalit	y		
_	Males	8	Females	S	Persons	s	Males	S	Females	i	Persons	s
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
50-54	1	2.1	0	0.0	1	1.1	0	0.0	0	0.0	0	0.0
55-59	3	9.2	0	0.0	3	4.7	3	9.2	0	0.0	3	4.7
60-64	0	0.0	0	0.0	0	0.0	1	4.2	0	0.0	1	2.1
65-69	1	5.3	0	0.0	1	2.6	2	10.6	0	0.0	2	5.2
70–74	2	13.3	0	0.0	2	6.0	1	6.6	0	0.0	1	3.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	7		1		8		7		0		7	
Crude rate		0.9		0.1		0.5		0.9		0.0		0.5
95% CI		0.2 - 1.6		0.0 - 0.4		0.2 - 0.9		0.2 - 1.6		0.0 - 0.0		0.1 - 0.8
AS rate (Aust 1991)		1.1		0.1		0.6		1.2		0.0		0.6
95% CI		0.3 - 1.9		0.0 - 0.3		0.2 - 1.0		0.3 - 2.1		0.0 - 0.0		0.1 - 1.0
AS rate (World)		0.9		0.1		0.5		1.0		0.0		0.5
95% CI		0.2 - 1.6		0.0 - 0.3		0.1 - 0.8		0.3 - 1.7		0.0 - 0.0		0.1 - 0.9
Lifetime risk (0-74)		1 in 669		1 in 12,250		1 in 1,316		1 in 651		NA		1 in 1,331
PYLL (0–74) Per cent of all								82.5		0.0		82.5
cancers		0.3		0.0		0.2		0.6		0.0		0.3

Table B4-10: Malignant Neoplasm of Unspecified Parts of Pharynx: ICD-10 C14

			Inciden	ce					Mortali	ty		
_	Male	s	Female	es	Person	s	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	1	4.3	1	2.1	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	1	5.1	1	2.6
70–74	1	6.6	0	0.0	1	3.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	1	38.9	0	0.0	1	11.4	1	38.9	0	0.0	1	11.4
Total	2		1		3		1		1		2	
Crude rate		0.3		0.1		0.2		0.1		0.1		0.1
95% CI		0.0 - 0.6		0.0 - 0.4		0.0 - 0.4		0.0 - 0.4		0.0 - 0.4		0.0 - 0.3
AS rate (Aust 1991)		0.5		0.2		0.3		0.3		0.2		0.2
95% CI		0.0 - 1.3		0.0 - 0.5		0.0 - 0.6		0.0 - 1.0		0.0 - 0.6		0.0 - 0.5
AS rate (World)		0.3		0.2		0.2		0.2		0.2		0.1
95% CI		0.0 - 0.8		0.0 - 0.5		0.0 - 0.4		0.0 - 0.6		0.0 - 0.5		0.0 - 0.3
Lifetime risk (0-74)		1 in 3,015		1 in 4,671		1 in 3,890		NA		1 in 3,946		1 in 7,705
PYLL (0–74) Per cent of all								0.0		7.5		7.5
cancers		0.1		0.0		0.1		0.1		0.1		0.1

Table B4-11: Malignant Neoplasm of Oesophagus: ICD-10 C15

			Inciden	ce					Mortal	ity		
_	Males	S	Female	es	Person	ıs	Males		Female	es	Person	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	1	1.7	0	0.0	1	0.8	1	1.7	0	0.0	1	0.8
45-49	3	5.1	0	0.0	3	2.5	2	3.4	0	0.0	2	1.7
50-54	2	4.2	0	0.0	2	2.1	0	0.0	0	0.0	0	0.0
55-59	3	9.2	0	0.0	3	4.7	1	3.1	0	0.0	1	1.6
60-64	1	4.2	3	12.8	4	8.5	0	0.0	0	0.0	0	0.0
65-69	6	31.9	3	15.2	9	23.4	5	26.6	3	15.2	8	20.8
70-74	6	39.8	5	27.6	11	33.1	4	26.5	5	27.6	9	27.1
75–79	3	31.2	3	22.6	6	26.2	1	10.4	3	22.6	4	17.5
80-84	6	125.6	2	23.6	8	60.4	4	83.7	2	23.6	6	45.3
85 and over	1	38.9	4	64.3	5	56.9	1	38.9	1	16.1	2	22.7
Total	32		20		52		19		14		33	
Crude rate		4.2		2.6		3.4		2.5		1.8		2.1
95% CI		2.7 - 5.6		1.4 - 3.7		2.4 - 4.3		1.4 - 3.6		0.9 - 2.7		1.4 - 2.9
AS rate (Aust 1991)		6.3		3.3		4.7		4.0		2.4		3.0
95% CI		4.0 - 8.6		1.9 - 4.8		3.4 - 5.9		2.1 - 5.8		1.1 - 3.6		2.0 - 4.1
AS rate (World)		4.0		2.2		3.0		2.5		1.4		1.9
95% CI		2.6 - 5.5		1.2 - 3.2		2.2 - 3.9		1.3 - 3.6		0.6 - 2.2		1.2 - 2.6
Lifetime risk (0–74)		1 in 209		1 in 360		1 in 267		1 in 327		1 in 468		1 in 386
PYLL (0-74)								152.5		35.0		187.5
Per cent of all												
cancers		1.2		0.9		1.0		1.7		1.4		1.6

Table B4-12: Malignant Neoplasm of Stomach: ICD-10 C16

_	•		Inciden	ce					Mortal	ity		
_	Males	}	Female	es	Person	ıs	Males	3	Femal	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	1	1.5	1	0.8	0	0.0	1	1.5	1	0.8
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	4	6.4	1	1.5	5	3.9	3	4.8	1	1.5	4	3.1
40-44	1	1.7	1	1.6	2	1.6	1	1.7	0	0.0	1	0.8
45-49	4	6.7	0	0.0	4	3.3	4	6.7	2	3.3	6	5.0
50-54	6	12.5	4	8.5	10	10.6	3	6.3	0	0.0	3	3.2
55-59	8	24.7	3	9.5	11	17.2	7	21.6	3	9.5	10	15.7
60-64	9	38.2	5	21.4	14	29.8	6	25.5	2	8.6	8	17.0
65-69	11	58.5	6	30.4	17	44.1	6	31.9	4	20.3	10	26.0
70–74	12	79.6	6	33.1	18	54.2	10	66.3	4	22.1	14	42.2
75–79	5	52.0	5	37.7	10	43.7	5	52.0	5	37.7	10	43.7
80-84	6	125.6	5	59.0	11	83.0	3	62.8	6	70.8	9	67.9
85 and over	4	155.6	6	96.4	10	113.7	8	311.2	7	112.5	15	170.6
Total	70		43		113		56		35		91	
Crude rate		9.1		5.5		7.3		7.3		4.5		5.9
95% CI		7.0 - 11.3		3.9 - 7.2		6.0 - 8.6		5.4 - 9.2		3.0 - 6.0		4.7 - 7.1
AS rate (Aust 1991)		13.1		6.7		9.6		11.2		5.4		7.9
95% CI		9.9 - 16.4		4.7 - 8.8		7.8 - 11.4		8.0 - 14.3		3.6 - 7.2		6.2 - 9.5
AS rate (World)		9.3		4.7		6.8		7.7		3.5		5.3
95% CI		7.1 - 11.5		3.2 - 6.2		5.5 - 8.1		5.6 - 9.7		2.3 - 4.7		4.2 - 6.4
Lifetime risk (0–74)		1 in 88		1 in 186		1 in 121		1 in 122		1 in 300		1 in 176
PYLL (0–74) Per cent of all								590.0		257.5		847.5
cancers		2.6		1.9		2.3		5.0		3.5		4.3

Table B4-13: Malignant Neoplasm of Small Intestine: ICD-10 C17

			Inciden	ce					Mortali	ity		
_	Males	8	Female	es	Person	ıs	Males		Female	es	Perso	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	1	1.7	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	3	5.1	2	3.3	5	4.1	0	0.0	0	0.0	0	0.0
50-54	1	2.1	0	0.0	1	1.1	2	4.2	0	0.0	2	2.1
55–59	1	3.1	0	0.0	1	1.6	0	0.0	0	0.0	0	0.0
60-64	1	4.2	2	8.6	3	6.4	1	4.2	1	4.3	2	4.3
65-69	0	0.0	0	0.0	0	0.0	1	5.3	1	5.1	2	5.2
70–74	1	6.6	1	5.5	2	6.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	2	20.8	1	7.5	3	13.1
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	2	32.1	2	22.7	0	0.0	2	32.1	2	22.7
Total	7		8		15		6		5		11	
Crude rate		0.9		1.0		1.0		0.8		0.6		0.7
95% CI		0.2 - 1.6		0.3 - 1.7		0.5 - 1.5		0.2 - 1.4		0.1 - 1.2		0.3 - 1.1
AS rate (Aust 1991)		0.9		1.1		1.1		1.1		0.8		1.0
95% CI		0.2 - 1.6		0.3 - 2.0		0.5 - 1.7		0.2 - 1.9		0.1 - 1.6		0.4 - 1.6
AS rate (World)		0.8		1.0		0.9		0.7		0.6		0.7
95% CI		0.2 - 1.5		0.3 - 1.7		0.4 - 1.4		0.1 - 1.4		0.0 - 1.1		0.3 - 1.1
Lifetime risk (0-74)		1 in 948		1 in 1,053		1 in 1,001		1 in 1,456		1 in 2,139		1 in 1,730
PYLL (0–74) Per cent of all								65.0		20.0		85.0
cancers		0.3		0.3		0.3		0.5		0.5		0.5

Table B4-14: Malignant Neoplasm of Colon: ICD-10 C18

			Inciden	ce					Mortali	ty		
	Males	1	Female	s	Person	s	Males		Female	es	Perso	ons
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
35–39	2	3.2	3	4.6	5	3.9	0	0.0	1	1.5	1	0.8
40-44	8	13.6	3	4.8	11	9.0	4	6.8	2	3.2	6	4.9
45-49	11	18.5	10	16.3	21	17.4	3	5.1	5	8.2	8	6.6
50-54	26	54.3	19	40.5	45	47.5	3	6.3	6	12.8	9	9.5
55-59	35	107.9	25	79.5	60	93.9	6	18.5	8	25.5	14	21.9
60-64	35	148.5	19	81.4	54	115.1	21	89.1	6	25.7	27	57.5
65-69	28	149.0	22	111.5	50	129.8	16	85.1	12	60.8	28	72.7
70–74	37	245.5	24	132.4	61	183.7	23	152.6	14	77.2	37	111.4
75–79	26	270.2	17	128.2	43	187.9	13	135.1	14	105.6	27	118.0
80-84	20	418.7	19	224.1	39	294.2	4	83.7	11	129.7	15	113.2
85 and over	10	389.0	16	257.2	26	295.7	6	233.4	13	208.9	19	216.1
Total	238		178		416		99		92		191	
Crude rate		31.0		22.8		26.9		12.9		11.8		12.3
95% CI	2	27.1 - 35.0		19.5 - 26.2		24.3 – 29.5	1	0.4 - 15.4		9.4 - 14.2		10.6 - 14.1
AS rate (Aust 1991)		44.0		27.0		34.5		19.7		14.2		16.8
95% CI	3	38.1 – 49.9	:	22.9 – 31.0		31.1 – 37.9	1	5.7 - 23.7		11.3 – 17.2		14.4 – 19.3
AS rate (World)		31.2		19.8		25.0		13.9		9.6		11.6
95% CI	2	27.2 – 35.3		16.7 – 22.8		22.5 - 27.5	1	1.1 - 16.7		7.5 - 11.6		9.9 – 13.3
Lifetime risk (0–74)		1 in 28		1 in 43		1 in 34		1 in 56		1 in 94		1 in 71
PYLL (0–74) Per cent of all								825.0		715.0		1,540.0
cancers		8.8		7.7		8.3		8.9		9.2		9.0

Table B4-15: Malignant Neoplasm of Rectum: ICD-10 C19-20

			Inciden	ice					Mortali	ty		
	Males		Female	es	Person	ıs	Males		Female	S	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	2	2.8	0	0.0	2	1.4	1	1.4	0	0.0	1	0.7
25–29	1	1.5	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
30-34	1	1.6	1	1.6	2	1.6	0	0.0	1	1.6	1	0.8
35–39	1	1.6	2	3.1	3	2.4	0	0.0	1	1.5	1	0.8
40-44	5	8.5	4	6.3	9	7.4	3	5.1	1	1.6	4	3.3
45-49	12	20.2	7	11.4	19	15.8	1	1.7	4	6.5	5	4.1
50-54	14	29.3	4	8.5	18	19.0	3	6.3	2	4.3	5	5.3
55-59	16	49.3	10	31.8	26	40.7	8	24.7	3	9.5	11	17.2
60-64	15	63.6	4	17.1	19	40.5	5	21.2	1	4.3	6	12.8
65-69	18	95.8	11	55.8	29	75.3	8	42.6	1	5.1	9	23.4
70–74	17	112.8	6	33.1	23	69.3	10	66.3	8	44.1	18	54.2
75–79	15	155.9	11	83.0	26	113.6	8	83.1	11	83.0	19	83.0
80-84	1	20.9	9	106.2	10	75.4	3	62.8	3	35.4	6	45.3
85 and over	3	116.7	9	144.6	12	136.5	3	116.7	7	112.5	10	113.7
Total	121		78		199		53		43		96	
Crude rate		15.8		10.0		12.9		6.9		5.5		6.2
95% CI		13.0 – 18.6		7.8 - 12.2		11.1 - 14.6		5.0 - 8.8		3.9 - 7.2		5.0 - 7.4
AS rate (Aust 1991)		20.5		11.7		16.1		10.2		6.4		8.2
95% CI		16.7 – 24.3		9.0 - 14.3		13.8 - 18.4		7.3 - 13.1		4.4 - 8.3		6.5 - 9.8
AS rate (World)		15.6		8.1		11.8		7.0		4.0		5.5
95% CI		12.8 – 18.5		6.3 - 10.0		10.1 – 13.5		5.1 - 8.9		2.8 - 5.3		4.4 - 6.6
Lifetime risk (0-74)		1 in 52		1 in 119		1 in 73		1 in 119		1 in 255		1 in 164
PYLL (0–74) Per cent of all								532.5		360.0		892.5
cancers		4.5		3.4		4.0		4.8		4.3		4.5

Table B4-16: Malignant Neoplasm of Anus: ICD-10 C21

			Inciden	ce			Mortality						
_	Males	5	Female	es	Person	s	Males		Female	s	Person	ns	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
50-54	0	0.0	1	2.1	1	1.1	0	0.0	0	0.0	0	0.0	
55-59	0	0.0	1	3.2	1	1.6	0	0.0	1	3.2	1	1.6	
60-64	2	8.5	1	4.3	3	6.4	0	0.0	0	0.0	0	0.0	
65-69	1	5.3	0	0.0	1	2.6	2	10.6	0	0.0	2	5.2	
70–74	2	13.3	0	0.0	2	6.0	0	0.0	0	0.0	0	0.0	
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
85 and over	1	38.9	3	48.2	4	45.5	1	38.9	1	16.1	2	22.7	
Total	6		6		12		3		2		5		
Crude rate		0.8		0.8		0.8		0.4		0.3		0.3	
95% CI		0.2 - 1.4		0.2 - 1.4		0.3 - 1.2		0.0 - 0.8		0.0 - 0.6		0.0 - 0.6	
AS rate (Aust 1991)		1.3		0.9		1.1		0.8		0.3		0.5	
95% CI		0.2 - 2.4		0.2 - 1.5		0.5 - 1.7		0.0 - 1.6		0.0 - 0.7		0.1 - 0.9	
AS rate (World)		1.0		0.6		0.8		0.5		0.2		0.3	
95% CI		0.2 - 1.7		0.1 - 1.2		0.3 - 1.3		0.0 - 1.1		0.0 - 0.5		0.0 - 0.6	
Lifetime risk (0-74)		1 in 739		1 in 2,085		1 in 1,135		1 in 1,880		1 in 6,287		1 in 2,960	
PYLL (0–74) Per cent of all								15.0		17.5		32.5	
cancers		0.2		0.3		0.2		0.3		0.2		0.2	

Table B4-17: Malignant Neoplasm of Colon (Excluding anus): ICD-10 C18-20

			Incider	ıce			Mortality						
_	Males		Femal	es	Person	ıs	Males	3	Female	es	Perso	ons	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	2	2.8	0	0.0	2	1.4	1	1.4	0	0.0	1	0.7	
25–29	1	1.5	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0	
30-34	1	1.6	2	3.1	3	2.4	0	0.0	1	1.6	1	0.8	
35–39	3	4.8	5	7.7	8	6.3	0	0.0	2	3.1	2	1.6	
40-44	13	22.0	7	11.1	20	16.4	7	11.9	3	4.8	10	8.2	
45-49	23	38.7	17	27.8	40	33.2	4	6.7	9	14.7	13	10.8	
50-54	40	83.6	23	49.1	63	66.5	6	12.5	8	17.1	14	14.8	
55–59	51	157.2	35	111.4	86	134.7	14	43.2	11	35.0	25	39.1	
60-64	50	212.1	23	98.5	73	155.6	26	110.3	7	30.0	33	70.3	
65-69	46	244.8	33	167.3	79	205.1	24	127.7	13	65.9	37	96.1	
70–74	54	358.3	30	165.5	84	253.0	33	218.9	22	121.3	55	165.6	
75–79	41	426.0	28	211.2	69	301.5	21	218.2	25	188.5	46	201.0	
80-84	21	439.6	28	330.3	49	369.7	7	146.5	14	165.1	21	158.4	
85 and over	13	505.6	25	401.8	38	432.2	9	350.1	20	321.4	29	329.8	
Total	359		256		615		152		135		287		
Crude rate		46.8		32.8		39.7		19.8		17.3		18.5	
95% CI	2	42.0 – 51.6		28.8 - 36.8		36.6 – 42.9		16.7 - 23.0		14.4 - 20.2		16.4 - 20.7	
AS rate (Aust 1991)		64.5		38.7		50.5		29.9		20.6		25.0	
95% CI	:	57.5 – 71.5		33.8 - 43.5		46.4 - 54.6	2	24.9 – 34.8		17.1 - 24.1		22.1 - 28.0	
AS rate (World)		46.8		27.9		36.8		20.9		13.6		17.1	
95% CI	2	41.9 – 51.8		24.3 - 31.5		33.8 - 39.8		17.5 - 24.3		11.2 - 16.0		15.1 - 19.1	
Lifetime risk (0-74)		1 in 18		1 in 32		1 in 23		1 in 38		1 in 69		1 in 50	
PYLL (0–74) Per cent of all								1,357.5		1,075.0		2,432.5	
cancers		13.3		11.1		12.3		13.6		13.5		13.6	

Table B4-18: Malignant Neoplasm of Colon (Including anus): ICD-10 C18-21

			Incide	nce			Mortality						
_	Male	s	Femal	es	Person	ns	Males	5	Fema	les	Pers	ons	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	2	2.8	0	0.0	2	1.4	1	1.4	0	0.0	1	0.7	
25–29	1	1.5	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0	
30-34	1	1.6	2	3.1	3	2.4	0	0.0	1	1.6	1	0.8	
35–39	3	4.8	5	7.7	8	6.3	0	0.0	2	3.1	2	1.6	
40-44	13	22.0	7	11.1	20	16.4	7	11.9	3	4.8	10	8.2	
45-49	23	38.7	17	27.8	40	33.2	4	6.7	9	14.7	13	10.8	
50-54	40	83.6	24	51.2	64	67.6	6	12.5	8	17.1	14	14.8	
55-59	51	157.2	36	114.5	87	136.2	14	43.2	12	38.2	26	40.7	
60-64	52	220.6	24	102.8	76	162.0	26	110.3	7	30.0	33	70.3	
65-69	47	250.1	33	167.3	80	207.7	26	138.4	13	65.9	39	101.2	
70–74	56	371.5	30	165.5	86	259.0	33	218.9	22	121.3	55	165.6	
75–79	41	426.0	28	211.2	69	301.5	21	218.2	25	188.5	46	201.0	
80-84	21	439.6	28	330.3	49	369.7	7	146.5	14	165.1	21	158.4	
85 and over	14	544.5	28	450.0	42	477.7	10	389.0	21	337.5	31	352.6	
Total	365		262		627		155		137		292		
Crude rate		47.6		33.6		40.5		20.2		17.6		18.9	
95% CI		42.7 – 52.5		29.5 - 37.7		37.4 - 43.7		17.0 - 23.4		14.6 - 20.5		16.7 - 21.0	
AS rate (Aust 1991)		65.8		39.5		51.6		30.7		20.9		25.5	
95% CI		58.7 – 72.9		34.6 - 44.4		47.5 - 55.7	2	25.6 – 35.7		17.3 - 24.4		22.5 - 28.5	
AS rate (World)		47.8		28.6		37.6		21.4		13.8		17.4	
95% CI		42.8 - 52.8		25.0 - 32.2		34.6 - 40.7		17.9 – 24.8		11.4 - 16.2		15.4 – 19.5	
Lifetime risk (0–74)		1 in 18		1 in 31		1 in 23		1 in 37		1 in 68		1 in 49	
PYLL (0–74) Per cent of all								1,372.5		1,092.5		2,465.0	
cancers		13.5		11.4		12.5		13.9		13.7		13.8	

Table B4-19: Malignant Neoplasm of Liver: ICD-10 C22

			Inciden	ce			Mortality						
•	Males		Female	s	Person	s	Males		Female	es	Person	ıs	
•	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0–4	0	0.0	1	1.9	1	0.9	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
35-39	1	1.6	1	1.5	2	1.6	0	0.0	1	1.5	1	0.8	
40-44	0	0.0	0	0.0	0	0.0	1	1.7	0	0.0	1	0.8	
45-49	4	6.7	1	1.6	5	4.1	3	5.1	2	3.3	5	4.1	
50-54	0	0.0	1	2.1	1	1.1	0	0.0	0	0.0	0	0.0	
55-59	2	6.2	0	0.0	2	3.1	0	0.0	0	0.0	0	0.0	
60-64	5	21.2	0	0.0	5	10.7	4	17.0	0	0.0	4	8.5	
65-69	5	26.6	2	10.1	7	18.2	6	31.9	4	20.3	10	26.0	
70–74	4	26.5	1	5.5	5	15.1	2	13.3	1	5.5	3	9.0	
75–79	4	41.6	2	15.1	6	26.2	4	41.6	2	15.1	6	26.2	
80-84	1	20.9	0	0.0	1	7.5	2	41.9	0	0.0	2	15.1	
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	1	16.1	1	11.4	
Total	26		10		36		22		11		33		
Crude rate		3.4		1.3		2.3		2.9		1.4		2.1	
95% CI		2.1 - 4.7		0.5 - 2.1		1.6 - 3.1		1.7 - 4.1		0.6 - 2.2		1.4 - 2.9	
AS rate (Aust 1991)		4.7		1.5		3.0		4.3		1.7		2.9	
95% CI		2.8 - 6.6		0.5 - 2.4		2.0 - 4.0		2.4 - 6.1		0.7 - 2.8		1.9 - 3.9	
AS rate (World)		3.4		1.2		2.3		2.9		1.2		2.0	
95% CI		2.1 - 4.8		0.4 - 1.9		1.5 - 3.0		1.7 - 4.2		0.5 - 2.0		1.3 - 2.8	
Lifetime risk (0–74)		1 in 226		1 in 877		1 in 366		1 in 291		1 in 654		1 in 406	
PYLL (0-74)								215.0		125.0		340.0	
Per cent of all													
cancers		1.0		0.4		0.7		2.0		1.1		1.6	

Table B4-20: Malignant Neoplasm of Gall Bladder: ICD-10 C23-24

			Inciden	ce			Mortality						
	Males	3	Female	es	Person	ıs	Males		Female	es	Person	ns	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
40-44	1	1.7	1	1.6	2	1.6	1	1.7	0	0.0	1	0.8	
45-49	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0	
50-54	0	0.0	3	6.4	3	3.2	1	2.1	1	2.1	2	2.1	
55-59	2	6.2	0	0.0	2	3.1	3	9.2	0	0.0	3	4.7	
60-64	0	0.0	2	8.6	2	4.3	0	0.0	1	4.3	1	2.1	
65-69	2	10.6	1	5.1	3	7.8	0	0.0	2	10.1	2	5.2	
70-74	3	19.9	1	5.5	4	12.0	2	13.3	1	5.5	3	9.0	
75–79	1	10.4	4	30.2	5	21.8	1	10.4	2	15.1	3	13.1	
80-84	4	83.7	2	23.6	6	45.3	4	83.7	2	23.6	6	45.3	
85 and over	0	0.0	2	32.1	2	22.7	0	0.0	2	32.1	2	22.7	
Total	13		17		30		12		11		23		
Crude rate		1.7		2.2		1.9		1.6		1.4		1.5	
95% CI		0.8 - 2.6		1.1 - 3.2		1.2 - 2.6		0.7 - 2.4		0.6 - 2.2		0.9 - 2.1	
AS rate (Aust 1991)		2.7		2.5		2.6		2.4		1.8		2.0	
95% CI		1.2 - 4.3		1.3 - 3.8		1.6 - 3.5		0.9 - 3.8		0.7 - 2.8		1.2 - 2.9	
AS rate (World)		1.6		1.7		1.6		1.4		1.1		1.2	
95% CI		0.7 - 2.5		0.8 - 2.6		1.0 - 2.2		0.6 - 2.1		0.4 - 1.8		0.7 - 1.8	
Lifetime risk (0-74)		1 in 521		1 in 696		1 in 609		1 in 761		1 in 907		1 in 834	
PYLL (0–74) Per cent of all								112.5		52.5		165.0	
cancers		0.5		0.7		0.6		1.1		1.1		1.1	

Table B4-21: Malignant Neoplasm of Pancreas: ICD-10 C25

			Inciden	ce			Mortality						
	Males	S	Female	es	Person	ıs	Males		Female	es	Person	ıs	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
30-34	1	1.6	0	0.0	1	0.8	1	1.6	0	0.0	1	0.8	
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
40-44	1	1.7	2	3.2	3	2.5	1	1.7	0	0.0	1	0.8	
45-49	4	6.7	3	4.9	7	5.8	2	3.4	2	3.3	4	3.3	
50-54	3	6.3	3	6.4	6	6.3	1	2.1	1	2.1	2	2.1	
55-59	3	9.2	4	12.7	7	11.0	4	12.3	2	6.4	6	9.4	
60-64	7	29.7	2	8.6	9	19.2	5	21.2	4	17.1	9	19.2	
65-69	3	16.0	8	40.5	11	28.6	3	16.0	8	40.5	11	28.6	
70–74	8	53.1	10	55.2	18	54.2	14	92.9	10	55.2	24	72.3	
75–79	2	20.8	7	52.8	9	39.3	2	20.8	6	45.2	8	35.0	
80-84	4	83.7	8	94.4	12	90.5	4	83.7	8	94.4	12	90.5	
85 and over	6	233.4	6	96.4	12	136.5	6	233.4	7	112.5	13	147.8	
Total	42		53		95		43		48		91		
Crude rate		5.5		6.8		6.1		5.6		6.2		5.9	
95% CI		3.8 - 7.1		5.0 - 8.6		4.9 - 7.4		3.9 - 7.3		4.4 - 7.9		4.7 - 7.1	
AS rate (Aust 1991)		8.5		8.2		8.2		9.0		7.8		8.2	
95% CI		5.7 – 11.2		6.0 - 10.5		6.5 - 9.9		6.2 - 11.8		5.5 - 10.0		6.5 - 9.9	
AS rate (World)		5.8		5.5		5.5		6.0		5.0		5.4	
95% CI		4.0 - 7.6		3.9 - 7.0		4.4 - 6.7		4.1 - 7.8		3.5 - 6.6		4.2 - 6.5	
Lifetime risk (0-74)		1 in 161		1 in 153		1 in 156		1 in 133		1 in 161		1 in 147	
PYLL (0–74) Per cent of all								342.5		247.5		590.0	
cancers		1.6		2.3		1.9		3.9		4.8		4.3	

Table B4-22: Malignant Neoplasm of Nasal Cavity: ICD-10 C30-31

			Inciden	се			Mortality						
_	Males	3	Female	s	Persor	ıs	Males	5	Female	s	Persoi	ns	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20–24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
35–39	2	3.2	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0	
40-44	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0	
45–49	1	1.7	1	1.6	2	1.7	0	0.0	1	1.6	1	0.8	
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
55–59	0	0.0	0	0.0	0	0.0	1	3.1	0	0.0	1	1.6	
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
65–69	1	5.3	0	0.0	1	2.6	0	0.0	0	0.0	0	0.0	
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
75–79	0	0.0	1	7.5	1	4.4	0	0.0	0	0.0	0	0.0	
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	1	16.1	1	11.4	
Total	5		2		7		1		2		3		
Crude rate		0.7		0.3		0.5		0.1		0.3		0.2	
95% CI		0.1 - 1.2		0.0 - 0.6		0.1 - 0.8		0.0 - 0.4		0.0 - 0.6		0.0 - 0.4	
AS rate (Aust 1991)		0.7		0.3		0.5		0.1		0.2		0.2	
95% CI		0.1 - 1.3		0.0 - 0.6		0.1 - 0.8		0.0 - 0.4		0.0 - 0.6		0.0 - 0.5	
AS rate (World)		0.6		0.2		0.4		0.1		0.2		0.2	
95% CI		0.1 - 1.1		0.0 - 0.4		0.1 - 0.6		0.0 - 0.4		0.0 - 0.4		0.0 - 0.4	
Lifetime risk (0-74)		1 in 1,680	1	in 12,250		1 in 3,011		1 in 6,488		1 in 12,250		1 in 8,352	
PYLL (0-74)								17.5		27.5		45.0	
Per cent of all													
cancers		0.2		0.1		0.1		0.1		0.2		0.1	

Table B4-23: Malignant Neoplasm of Larynx: ICD-10 C32

			Inciden	ce			Mortality						
_	Males	s	Female	es	Person	ns	Males	3	Femal	es	Person	ns	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
40-44	0	0.0	0	0.0	0	0.0	1	1.7	0	0.0	1	0.8	
45-49	1	1.7	0	0.0	1	0.8	1	1.7	0	0.0	1	0.8	
50-54	5	10.4	0	0.0	5	5.3	1	2.1	0	0.0	1	1.1	
55-59	4	12.3	0	0.0	4	6.3	0	0.0	0	0.0	0	0.0	
60-64	2	8.5	0	0.0	2	4.3	1	4.2	0	0.0	1	2.1	
65-69	5	26.6	0	0.0	5	13.0	1	5.3	0	0.0	1	2.6	
70–74	4	26.5	0	0.0	4	12.0	4	26.5	0	0.0	4	12.0	
75–79	5	52.0	1	7.5	6	26.2	2	20.8	0	0.0	2	8.7	
80-84	3	62.8	1	11.8	4	30.2	1	20.9	1	11.8	2	15.1	
85 and over	1	38.9	0	0.0	1	11.4	2	77.8	0	0.0	2	22.7	
Total	30		2		32		14		1		15		
Crude rate		3.9		0.3		2.1		1.8		0.1		1.0	
95% CI		2.5 - 5.3		0.0 - 0.6		1.4 - 2.8		0.9 - 2.8		0.0 - 0.4		0.5 - 1.5	
AS rate (Aust 1991)		5.6		0.3		2.7		2.9		0.2		1.3	
95% CI		3.5 - 7.8		0.0 - 0.8		1.7 - 3.7		1.3 - 4.6		0.0 - 0.5		0.6 - 2.0	
AS rate (World)		3.8		0.1		1.8		1.9		0.1		0.8	
95% CI		2.4 - 5.2		0.0 - 0.3		1.2 - 2.5		0.9 - 2.9		0.0 - 0.2		0.4 - 1.3	
Lifetime risk (0–74)		1 in 233		NA		1 in 481		1 in 482		NA		1 in 1,027	
PYLL (0–74) Per cent of all								112.5		0.0		112.5	
cancers		1.1		0.1		0.6		1.3		0.1		0.7	

Table B4-24: Malignant Neoplasm of Trachea and Lung: ICD-10 C33-34

			Incide	ence			Mortality						
	Male	es	Fema	les	Person	ns	Males	5	Female	es	Perso	ons	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
30-34	1	1.6	1	1.6	2	1.6	0	0.0	0	0.0	0	0.0	
35–39	3	4.8	1	1.5	4	3.1	0	0.0	1	1.5	1	0.8	
40-44	4	6.8	4	6.3	8	6.6	3	5.1	3	4.8	6	4.9	
45-49	7	11.8	8	13.1	15	12.4	9	15.2	4	6.5	13	10.8	
50-54	10	20.9	11	23.5	21	22.2	5	10.4	8	17.1	13	13.7	
55–59	19	58.6	15	47.7	34	53.2	16	49.3	8	25.5	24	37.6	
60-64	27	114.5	17	72.8	44	93.8	19	80.6	11	47.1	30	63.9	
65-69	34	180.9	20	101.4	54	140.2	25	133.0	16	81.1	41	106.4	
70–74	40	265.4	26	143.4	66	198.8	37	245.5	23	126.8	60	180.7	
75–79	36	374.1	21	158.4	57	249.1	35	363.7	15	113.1	50	218.5	
80-84	16	334.9	10	118.0	26	196.2	25	523.3	15	176.9	40	301.8	
85 and over	7	272.3	13	208.9	20	227.5	8	311.2	11	176.8	19	216.1	
Total	204		147		351		182		115		297		
Crude rate		26.6		18.8		22.7		23.7		14.7		19.2	
95% CI		22.9 - 30.2		15.8 - 21.9		20.3 - 25.1		20.3 - 27.2		12.0 - 17.4		17.0 - 21.4	
AS rate (Aust 1991)		40.2		22.9		30.4		37.6		18.1		26.3	
95% CI		34.4 - 45.9		19.1 - 26.7		27.2 - 33.7		31.9 – 43.2		14.8 - 21.5		23.3 - 29.4	
AS rate (World)		27.0		16.5		21.2		23.6		12.4		17.3	
95% CI		23.2 - 30.8		13.7 – 19.3		18.9 - 23.5	2	20.1 - 27.2		10.0 - 14.8		15.3 – 19.4	
Lifetime risk (0-74)		1 in 31		1 in 49		1 in 38		1 in 38		1 in 65		1 in 48	
PYLL (0–74) Per cent of all								1,255.0		880.0		2,135.0	
cancers		7.5		6.4		7.0		16.3		11.5		14.0	

Table B4-25: Malignant Neoplasm of Other Thoracic Organs: ICD-10 C37-38

			Incidenc	e					Mortali	ty		
	Male	es	Female	s	Persons	3	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	1	1.6	1	0.8	0	0.0	1	1.6	1	0.8
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	1	5.1	1	2.6
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	1	20.9	0	0.0	1	7.5	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	1		1		2		0		2		2	
Crude rate		0.1		0.1		0.1		0.0		0.3		0.1
95% CI		0.0 - 0.4		0.0 - 0.4		0.0 - 0.3		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
AS rate (Aust 1991)		0.3		0.1		0.2		0.0		0.3		0.2
95% CI		0.0 - 0.8		0.0 - 0.4		0.0 - 0.4		0.0 - 0.0		0.0 - 0.8		0.0 - 0.4
AS rate (World)		0.1		0.1		0.1		0.0		0.2		0.1
95% CI		0.0 - 0.3		0.0 - 0.3		0.0 - 0.2		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
Lifetime risk (0–74)		NA		1 in 12,746		1 in 25,105		NA		1 in 3,013		1 in 5,896
PYLL (0–74) Per cent of all								0.0		50.0		50.0
cancers		0.0		0.0		0.0		0.0		0.2		0.1

Table B4-26: Malignant Neoplasm of Bone: ICD-10 C40-41

			Inciden	ce					Mortalit	y		
_	Males		Female	s	Person	ns	Males		Females	1	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	1	1.7	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
10-14	0	0.0	1	1.8	1	0.9	0	0.0	0	0.0	0	0.0
15–19	0	0.0	3	5.0	3	2.4	0	0.0	0	0.0	0	0.0
20-24	1	1.4	1	1.5	2	1.4	1	1.4	0	0.0	1	0.7
25-29	1	1.5	0	0.0	1	0.8	1	1.5	0	0.0	1	0.8
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	1	1.6	1	0.8
50-54	2	4.2	0	0.0	2	2.1	1	2.1	0	0.0	1	1.1
55–59	0	0.0	1	3.2	1	1.6	0	0.0	0	0.0	0	0.0
60-64	1	4.2	0	0.0	1	2.1	0	0.0	0	0.0	0	0.0
65-69	1	5.3	0	0.0	1	2.6	1	5.3	0	0.0	1	2.6
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	1	7.5	1	4.4	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	7		7		14		4		1		5	
Crude rate		0.9		0.9		0.9		0.5		0.1		0.3
95% CI		0.2 - 1.6		0.2 - 1.6		0.4 - 1.4		0.0 - 1.0		0.0 - 0.4		0.0 - 0.6
AS rate (Aust 1991)		1.0		0.9		1.0		0.5		0.1		0.3
95% CI		0.2 - 1.7		0.2 - 1.6		0.4 - 1.5		0.0 - 1.1		0.0 - 0.3		0.0 - 0.6
AS rate (World)		0.9		0.9		0.9		0.5		0.1		0.3
95% CI		0.2 - 1.7		0.2 - 1.6		0.4 - 1.4		0.0 - 1.0		0.0 - 0.3		0.0 - 0.6
Lifetime risk (0–74)		1 in 1,086		1 in 1,751		1 in 1,352		1 in 1,931		1 in 12,250		1 in 3,357
PYLL (0–74) Per cent of all								130.0		27.5		157.5
cancers		0.3		0.3		0.3		0.4		0.1		0.2

Table B4-27: Malignant Neoplasm of Skin/Melanoma: ICD-10 C43

			Incide	nce					Mortal	ity		
_	Male	s	Femal	les	Person	ns	Male	s	Femal	es	Perso	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	1	1.9	1	0.9	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	1	1.7	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
15-19	1	1.6	2	3.3	3	2.4	0	0.0	0	0.0	0	0.0
20-24	4	5.7	9	13.1	13	9.3	0	0.0	0	0.0	0	0.0
25–29	11	16.9	12	18.1	23	17.5	1	1.5	0	0.0	1	0.8
30-34	13	21.0	11	17.3	24	19.1	1	1.6	2	3.1	3	2.4
35–39	12	19.2	15	23.0	27	21.2	0	0.0	2	3.1	2	1.6
40-44	33	56.0	25	39.7	58	47.5	1	1.7	2	3.2	3	2.5
45-49	39	65.7	25	40.8	64	53.1	2	3.4	3	4.9	5	4.1
50-54	44	91.9	28	59.7	72	76.0	5	10.4	1	2.1	6	6.3
55-59	34	104.8	29	92.3	63	98.6	2	6.2	0	0.0	2	3.1
60-64	29	123.0	17	72.8	46	98.0	3	12.7	1	4.3	4	8.5
65-69	33	175.6	23	116.6	56	145.4	4	21.3	4	20.3	8	20.8
70–74	30	199.0	12	66.2	42	126.5	4	26.5	4	22.1	8	24.1
75–79	13	135.1	11	83.0	24	104.9	3	31.2	2	15.1	5	21.8
80-84	8	167.5	8	94.4	16	120.7	1	20.9	1	11.8	2	15.1
85 and over	3	116.7	8	128.6	11	125.1	4	155.6	0	0.0	4	45.5
Total	308		236		544		31		22		53	
Crude rate		40.1		30.3		35.2		4.0		2.8		3.4
95% CI		35.7 - 44.6		26.4 - 34.1		32.2 - 38.1		2.6 - 5.5		1.6 - 4.0		2.5 - 4.3
AS rate (Aust 1991)		46.5		32.2		38.9		5.9		3.2		4.2
95% CI		41.0 - 52.0		27.9 - 36.4		35.5 - 42.3		3.6 - 8.1		1.9 - 4.6		3.1 - 5.4
AS rate (World)		37.5		26.6		31.8		4.2		2.4		3.1
95% CI		33.3 – 41.8		23.1 - 30.1		29.1 - 34.6		2.7 - 5.7		1.4 - 3.4		2.2 - 4.0
Lifetime risk (0-74)		1 in 23		1 in 36		1 in 28		1 in 235		1 in 318		1 in 270
PYLL (0–74) Per cent of all								402.5		382.5		785.0
cancers		11.4		10.2		10.8		2.8		2.2		2.5

Table B4-28: Mesothelioma: ICD-10 C45

_			Inciden	ice					Mortali	ity		
	Males	s	Female	es	Person	ns	Males	S	Female	es	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30–34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	1	1.6	0	0.0	1	0.8	1	1.6	0	0.0	1	0.8
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	3	6.3	0	0.0	3	3.2	0	0.0	0	0.0	0	0.0
55–59	0	0.0	0	0.0	0	0.0	1	3.1	0	0.0	1	1.6
60-64	1	4.2	0	0.0	1	2.1	2	8.5	0	0.0	2	4.3
65-69	4	21.3	1	5.1	5	13.0	1	5.3	1	5.1	2	5.2
70–74	4	26.5	1	5.5	5	15.1	3	19.9	1	5.5	4	12.0
75–79	1	10.4	0	0.0	1	4.4	1	10.4	0	0.0	1	4.4
80-84	1	20.9	0	0.0	1	7.5	1	20.9	0	0.0	1	7.5
85 and over	1	38.9	1	16.1	2	22.7	1	38.9	1	16.1	2	22.7
Total	16		3		19		11		3		14	
Crude rate		2.1		0.4		1.2		1.4		0.4		0.9
95% CI		1.1 - 3.1		0.0 - 0.8		0.7 - 1.8		0.6 - 2.3		0.0 - 0.8		0.4 - 1.4
AS rate (Aust 1991)		3.1		0.5		1.7		2.3		0.5		1.3
95% CI		1.5 - 4.7		0.0 - 1.1		0.9 - 2.4		0.9 - 3.7		0.0 - 1.1		0.6 - 1.9
AS rate (World)		2.2		0.3		1.2		1.5		0.3		0.9
95% CI		1.1 - 3.2		0.0 - 0.7		0.6 - 1.7		0.6 - 2.4		0.0 - 0.7		0.4 - 1.3
Lifetime risk (0-74)		1 in 334		1 in 1,890		1 in 587		1 in 521		1 in 1,890		1 in 839
PYLL (0-74)								95.0		10.0		105.0
Per cent of all		0.6		0.1		0.4		1.0		0.2		0.7
cancers		0.6		0.1		0.4		1.0		0.3		0.7

Table B4-29 : Kaposi's Sarcoma: ICD-10 C46

			Inciden	ce					Mortali	ty		
	Males		Female	s	Person	s	Males		Female	s	Perso	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	1	1.6	0	0.0	1	0.8	1	1.6	0	0.0	1	0.8
35–39	2	3.2	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
40-44	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
45-49	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.1	1	1.1	0	0.0	0	0.0	0	0.0
55-59	0	0.0	1	3.2	1	1.6	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	5		2		7		1		0		1	
Crude rate		0.7		0.3		0.5		0.1		0.0		0.1
95% CI		0.1 - 1.2		0.0 - 0.6		0.1 - 0.8		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (Aust 1991)		0.6		0.2		0.4		0.1		0.0		0.1
95% CI		0.1 - 1.1		0.0 - 0.6		0.1 - 0.7		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (World)		0.5		0.2		0.4		0.1		0.0		0.0
95% CI		0.1 - 0.9		0.0 - 0.6		0.1 - 0.6		0.0 - 0.3		0.0 - 0.0		0.0 - 0.1
Lifetime risk (0–74)		1 in 2,438		1 in 3,764		1 in 3,014		1 in 12,360		NA		1 in 25,105
PYLL (0–74) Per cent of all								42.5		0.0		42.5
cancers		0.2		0.1		0.1		0.1		0.0		0.0

Table B4-30: Malignant Neoplasm of Connective and Soft Tissues: ICD-10 C47-49

			Inciden	ce					Mortali	ity		
_	Males	S	Femal	es	Person	ıs	Males		Female	es	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	2	3.6	0	0.0	2	1.8	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	1	1.6	1	1.7	2	1.6	0	0.0	0	0.0	0	0.0
20-24	2	2.8	0	0.0	2	1.4	3	4.2	0	0.0	3	2.2
25–29	0	0.0	1	1.5	1	0.8	0	0.0	1	1.5	1	0.8
30-34	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
35–39	0	0.0	1	1.5	1	0.8	0	0.0	0	0.0	0	0.0
40-44	0	0.0	1	1.6	1	0.8	0	0.0	1	1.6	1	0.8
45-49	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
50-54	2	4.2	2	4.3	4	4.2	1	2.1	1	2.1	2	2.1
55-59	2	6.2	0	0.0	2	3.1	0	0.0	0	0.0	0	0.0
60-64	2	8.5	0	0.0	2	4.3	0	0.0	0	0.0	0	0.0
65-69	1	5.3	2	10.1	3	7.8	0	0.0	3	15.2	3	7.8
70–74	0	0.0	3	16.5	3	9.0	1	6.6	2	11.0	3	9.0
75–79	1	10.4	3	22.6	4	17.5	0	0.0	1	7.5	1	4.4
80-84	1	20.9	1	11.8	2	15.1	1	20.9	0	0.0	1	7.5
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	0	0.0	0	0.0
Total	15		17		32		6		9		15	
Crude rate		2.0		2.2		2.1		0.8		1.2		1.0
95% CI		1.0 - 2.9		1.1 - 3.2		1.4 - 2.8		0.2 - 1.4		0.4 - 1.9		0.5 - 1.5
AS rate (Aust 1991)		2.3		2.5		2.5		0.9		1.4		1.2
95% CI		1.1 - 3.5		1.3 - 3.7		1.6 - 3.3		0.1 - 1.7		0.5 - 2.4		0.6 - 1.8
AS rate (World)		2.1		1.8		2.0		0.7		1.1		0.9
95% CI		1.0 - 3.1		0.9 - 2.6		1.3 - 2.7		0.1 - 1.2		0.4 - 1.8		0.4 - 1.3
Lifetime risk (0-74)		1 in 593		1 in 515		1 in 536		1 in 1,543		1 in 636		1 in 883
PYLL (0–74) Per cent of all								182.5		130.0		312.5
cancers		0.6		0.7		0.6		0.5		0.9		0.7

Table B4-31: Malignant Neoplasm of Breast: ICD-10 C50

			Incide	ence					Mortal	ity		
_	Male	es	Fema	ales	Perso	ons	Male	s	Femal	es	Perso	ons
-	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	4	6.0	4	3.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	16	25.1	16	12.7	0	0.0	3	4.7	3	2.4
35–39	0	0.0	39	59.9	39	30.6	0	0.0	6	9.2	6	4.7
40-44	0	0.0	78	123.8	78	63.9	0	0.0	8	12.7	8	6.6
45-49	2	3.4	105	171.4	107	88.7	0	0.0	24	39.2	24	19.9
50-54	0	0.0	125	266.6	125	131.9	0	0.0	21	44.8	21	22.2
55-59	0	0.0	94	299.1	94	147.2	0	0.0	25	79.5	25	39.1
60-64	2	8.5	73	312.6	75	159.8	1	4.2	23	98.5	24	51.1
65-69	1	5.3	68	344.7	69	179.1	0	0.0	20	101.4	20	51.9
70–74	0	0.0	61	336.4	61	183.7	0	0.0	15	82.7	15	45.2
75–79	2	20.8	36	271.5	38	166.1	2	20.8	17	128.2	19	83.0
80-84	0	0.0	25	294.9	25	188.6	0	0.0	25	294.9	25	188.6
85 and over	0	0.0	18	289.3	18	204.7	0	0.0	16	257.2	16	182.0
Total	7		742		749		3		203		206	
Crude rate		0.9		95.1		48.4		0.4		26.0		13.3
95% CI		0.2 - 1.6		88.3 - 102.0		44.9 - 51.9		0.0 - 0.8		22.4 - 29.6		11.5 - 15.1
AS rate (Aust 1991)		1.2		101.5		53.6		0.6		29.6		16.5
95% CI		0.3 - 2.2		93.9 - 109.0		49.6 - 57.6		0.0 - 1.4		25.4 - 33.7		14.2 - 18.8
AS rate (World)		0.9		83.8		43.6		0.4		22.0		11.9
95% CI		0.2 - 1.6		77.6 - 90.0		40.4 - 46.8		0.0 - 0.8		18.9 - 25.2		10.2 - 13.6
Lifetime risk (0-74))	1 in 1,165		1 in 11		1 in 20		1 in 4,715		1 in 43		1 in 83
PYLL (0–74) Per cent of all								12.5		2,657.5		2,670.0
cancers		0.3		32.1		14.9		0.3		20.3		9.7

Table B4-32: Malignant Neoplasm of Vulva: ICD-10 C51

			Inciden	ice					Mortali	ity		
_	Male	s	Femal	es	Person	ns	Males	}	Female	es	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	3	4.9	3	2.5	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.1	1	1.1	0	0.0	0	0.0	0	0.0
55-59	0	0.0	1	3.2	1	1.6	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	1	5.1	1	2.6	0	0.0	0	0.0	0	0.0
70–74	0	0.0	1	5.5	1	3.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	1	7.5	1	4.4	0	0.0	1	7.5	1	4.4
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	3	48.2	3	34.1	0	0.0	1	16.1	1	11.4
Total	0		11		11		0		2		2	
Crude rate		0.0		1.4		0.7		0.0		0.3		0.1
95% CI		0.0 - 0.0		0.6 - 2.2		0.3 - 1.1		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
AS rate (Aust 1991)		0.0		1.5		0.9		0.0		0.3		0.2
95% CI		0.0 - 0.0		0.6 - 2.4		0.3 - 1.4		0.0 - 0.0		0.0 - 0.7		0.0 - 0.5
AS rate (World)		0.0		1.1		0.6		0.0		0.2		0.1
95% CI		0.0 - 0.0		0.4 - 1.8		0.2 - 1.0		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2
Lifetime risk (0-74)		NA		1 in 962		1 in 1,867		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.0		0.5		0.2		0.0		0.2		0.1

Table B4-33: Malignant Neoplasm of Vagina: ICD-10 C52

			Inciden	ce					Mortalit	ty		
_	Males	}	Female	es	Person	s	Males		Female	s	Person	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70-74	0	0.0	1	5.5	1	3.0	0	0.0	1	5.5	1	3.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	0	0.0	0	0.0
Total	0		2		2		0		1		1	
Crude rate		0.0		0.3		0.1		0.0		0.1		0.1
95% CI		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2
AS rate (Aust 1991)		0.0		0.3		0.2		0.0		0.2		0.1
95% CI		0.0 - 0.0		0.0 - 0.7		0.0 - 0.5		0.0 - 0.0		0.0 - 0.5		0.0 - 0.3
AS rate (World)		0.0		0.2		0.1		0.0		0.1		0.1
95% CI		0.0 - 0.0		0.0 - 0.5		0.0 - 0.3		0.0 - 0.0		0.0 - 0.3		0.0 - 0.2
Lifetime risk (0–74)		NA		1 in 3,627		1 in 6,642		NA		1 in 3,627		1 in 6,642
PYLL (0-74) Per cent of all								0.0		2.5		2.5
cancers		0.0		0.1		0.0		0.0		0.1		0.0

Table B4-34: Malignant Neoplasm of Cervix Uteri: ICD-10 C53

			Inciden	ce					Mortali	ty		
_	Male	s	Female	es	Person	ns	Males	8	Female	es	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	7	10.6	7	5.3	0	0.0	1	1.5	1	0.8
30-34	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
35–39	0	0.0	12	18.4	12	9.4	0	0.0	0	0.0	0	0.0
40-44	0	0.0	10	15.9	10	8.2	0	0.0	5	7.9	5	4.1
45-49	0	0.0	5	8.2	5	4.1	0	0.0	2	3.3	2	1.7
50-54	0	0.0	5	10.7	5	5.3	0	0.0	3	6.4	3	3.2
55-59	0	0.0	5	15.9	5	7.8	0	0.0	3	9.5	3	4.7
60-64	0	0.0	2	8.6	2	4.3	0	0.0	1	4.3	1	2.1
65-69	0	0.0	5	25.3	5	13.0	0	0.0	3	15.2	3	7.8
70–74	0	0.0	3	16.5	3	9.0	0	0.0	4	22.1	4	12.0
75–79	0	0.0	1	7.5	1	4.4	0	0.0	1	7.5	1	4.4
80-84	0	0.0	3	35.4	3	22.6	0	0.0	2	23.6	2	15.1
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	1	16.1	1	11.4
Total	0		60		60		0		26		26	
Crude rate		0.0		7.7		3.9		0.0		3.3		1.7
95% CI		0.0 - 0.0		5.7 - 9.6		2.9 - 4.9		0.0 - 0.0		2.1 - 4.6		1.0 - 2.3
AS rate (Aust 1991)		0.0		7.9		4.1		0.0		3.7		2.0
95% CI		0.0 - 0.0		5.8 - 9.9		3.0 - 5.2		0.0 - 0.0		2.2 - 5.1		1.2 - 2.7
AS rate (World)		0.0		6.4		3.3		0.0		2.8		1.5
95% CI		0.0 - 0.0		4.8 - 8.1		2.5 - 4.2		0.0 - 0.0		1.7 - 4.0		0.9 - 2.1
Lifetime risk (0-74)		NA		1 in 152		1 in 298		NA		1 in 285		1 in 551
PYLL (0–74) Per cent of all								0.0		430.0		430.0
cancers		0.0		2.6		1.2		0.0		2.6		1.2

Table B4-35: Malignant Neoplasm of Corpus Uteri: ICD-10 C54

			Inciden	ce					Mortali	ty		
_	Males		Female	S	Person	ıs	Males		Female	es	Person	as
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	1	1.5	1	0.8	0	0.0	0	0.0	0	0.0
30-34	0	0.0	2	3.1	2	1.6	0	0.0	0	0.0	0	0.0
35–39	0	0.0	2	3.1	2	1.6	0	0.0	0	0.0	0	0.0
40-44	0	0.0	3	4.8	3	2.5	0	0.0	0	0.0	0	0.0
45-49	0	0.0	5	8.2	5	4.1	0	0.0	0	0.0	0	0.0
50-54	0	0.0	12	25.6	12	12.7	0	0.0	1	2.1	1	1.1
55–59	0	0.0	12	38.2	12	18.8	0	0.0	2	6.4	2	3.1
60-64	0	0.0	12	51.4	12	25.6	0	0.0	3	12.8	3	6.4
65-69	0	0.0	14	71.0	14	36.3	0	0.0	1	5.1	1	2.6
70–74	0	0.0	15	82.7	15	45.2	0	0.0	5	27.6	5	15.1
75–79	0	0.0	12	90.5	12	52.4	0	0.0	4	30.2	4	17.5
80-84	0	0.0	1	11.8	1	7.5	0	0.0	1	11.8	1	7.5
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	0		91		91		0		17		17	
Crude rate		0.0		11.7		5.9		0.0		2.2		1.1
95% CI		0.0 - 0.0		9.3 - 14.1		4.7 - 7.1		0.0 - 0.0		1.1 - 3.2		0.6 - 1.6
AS rate (Aust 1991)		0.0		13.9		7.3		0.0		2.8		1.5
95% CI		0.0 - 0.0		11.0 – 16.8		5.7 - 8.8		0.0 - 0.0		1.4 - 4.1		0.8 - 2.2
AS rate (World)		0.0		10.9		5.6		0.0		1.9		1.0
95% CI		0.0 - 0.0		8.6 - 13.2		4.4 - 6.8		0.0 - 0.0		1.0 - 2.9		0.5 - 1.5
Lifetime risk (0–74)		NA		1 in 70		1 in 135		NA		1 in 371		1 in 709
PYLL (0–74) Per cent of all								0.0		115.0		115.0
cancers		0.0		3.9		1.8		0.0		1.7		0.8

Table B4-36: Malignant Neoplasm of Uterus Unspecified: ICD-10 C55

			Inciden	ce					Mortali	ty		
_	Males		Female	es	Person	ıs	Males		Female	s	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	1	3.2	1	1.6	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70-74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	0	0.0	0	0.0
Total	0		2		2		0		0		0	
Crude rate		0.0		0.3		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (Aust 1991)		0.0		0.3		0.2		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.7		0.0 - 0.4		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (World)		0.0		0.2		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.5		0.0 - 0.3		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
Lifetime risk (0–74)		NA		1 in 6,287		1 in 12,774		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.0		0.1		0.0		0.0		0.0		0.0

Table B4-37: Malignant Neoplasm of Ovary: ICD-10 C56

			Inciden	ce					Mortali	ty		
_	Males	s	Female	es	Person	s	Males		Female	es	Persons	iS
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	2	3.0	2	1.5	0	0.0	1	1.5	1	0.8
30-34	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	1	1.5	1	0.8
40-44	0	0.0	4	6.3	4	3.3	0	0.0	1	1.6	1	0.8
45-49	0	0.0	11	18.0	11	9.1	0	0.0	6	9.8	6	5.0
50-54	0	0.0	9	19.2	9	9.5	0	0.0	11	23.5	11	11.6
55-59	0	0.0	12	38.2	12	18.8	0	0.0	7	22.3	7	11.0
60-64	0	0.0	4	17.1	4	8.5	0	0.0	4	17.1	4	8.5
65-69	0	0.0	6	30.4	6	15.6	0	0.0	5	25.3	5	13.0
70–74	0	0.0	8	44.1	8	24.1	0	0.0	7	38.6	7	21.1
75–79	0	0.0	3	22.6	3	13.1	0	0.0	5	37.7	5	21.8
80-84	0	0.0	3	35.4	3	22.6	0	0.0	4	47.2	4	30.2
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	0		63		63		0		52		52	
Crude rate		0.0		8.1		4.1		0.0		6.7		3.4
95% CI		0.0 - 0.0		6.1 - 10.1		3.1 - 5.1		0.0 - 0.0		4.9 - 8.5		2.4 - 4.3
AS rate (Aust 1991)		0.0		8.7		4.5		0.0		7.3		3.9
95% CI		0.0 - 0.0		6.5 - 10.8		3.4 - 5.7		0.0 - 0.0		5.3 - 9.4		2.8 - 5.0
AS rate (World)		0.0		7.2		3.7		0.0		5.8		3.0
95% CI		0.0 - 0.0		5.3 - 9.0		2.7 - 4.6		0.0 - 0.0		4.2 - 7.4		2.2 - 3.8
Lifetime risk (0–74)		NA		1 in 113		1 in 220		NA		1 in 142		1 in 276
PYLL (0–74) Per cent of all								0.0		757.5		757.5
cancers		0.0		2.7		1.3		0.0		5.2		2.5

Table B4-38: Malignant Neoplasm of Other Female Genital Organs: ICD-10 C57

			Inciden	ce					Mortali	ty		
_	Males	}	Female	es	Person	ıs	Males		Female	s	Person	ıs
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.1	1	1.1	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	1	5.1	1	2.6	0	0.0	1	5.1	1	2.6
70-74	0	0.0	3	16.5	3	9.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	0	0.0	0	0.0
Total	0		6		6		0		1		1	
Crude rate		0.0		0.8		0.4		0.0		0.1		0.1
95% CI		0.0 - 0.0		0.2 - 1.4		0.1 - 0.7		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2
AS rate (Aust 1991)		0.0		0.9		0.5		0.0		0.2		0.1
95% CI		0.0 - 0.0		0.2 - 1.7		0.1 - 0.9		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
AS rate (World)		0.0		0.7		0.4		0.0		0.2		0.1
95% CI		0.0 - 0.0		0.1 - 1.2		0.1 - 0.7		0.0 - 0.0		0.0 - 0.5		0.0 - 0.2
Lifetime risk (0–74)		NA		1 in 843		1 in 1,577		NA		1 in 3,946		1 in 7,705
PYLL (0-74) Per cent of all								0.0		7.5		7.5
cancers		0.0		0.3		0.1		0.0		0.1		0.0

Table B4-39: Malignant Neoplasm of Placenta: ICD-10 C58

			Inciden	ce					Mortali	ty		
_	Males	3	Female	es .	Persons	s	Males		Female	es	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	1	1.5	1	0.8	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70-74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	0		2		2		0		0		0	
Crude rate		0.0		0.3		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (Aust 1991)		0.0		0.2		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (World)		0.0		0.2		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.5		0.0 - 0.3		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
Lifetime risk (0–74)		NA		1 in 6,464		1 in 12,660		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.0		0.1		0.0		0.0		0.0		0.0

Table B4-40: Malignant Neoplasm of Penis: ICD-10 C60

			Inciden	ce					Mortali	ty		
_	Males		Female	s	Person	ıs	Males	5	Female	S	Person	S
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55–59	1	3.1	0	0.0	1	1.6	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	2	41.9	0	0.0	2	15.1	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	1	38.9	0	0.0	1	11.4
Total	4		0		4		1		0		1	
Crude rate		0.5		0.0		0.3		0.1		0.0		0.1
95% CI		0.0 - 1.0		0.0 - 0.0		0.0 - 0.5		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2
AS rate (Aust 1991)		0.8		0.0		0.3		0.3		0.0		0.1
95% CI		0.0 - 1.7		0.0 - 0.0		0.0 - 0.7		0.0 - 1.0		0.0 - 0.0		0.0 - 0.3
AS rate (World)		0.4		0.0		0.2		0.2		0.0		0.1
95% CI		0.0 - 0.9		0.0 - 0.0		0.0 - 0.4		0.0 - 0.6		0.0 - 0.0		0.0 - 0.2
Lifetime risk (0–74)		1 in 4,268		NA		1 in 8,510		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.1		0.0		0.1		0.1		0.0		0.0

Table B4-41: Malignant Neoplasm of Prostate: ICD-10 C61

			Inciden	ce					Mortali	ty		
	Male	es	Female	es	Person	ıs	Males		Female	es	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
45-49	11	18.5	0	0.0	11	9.1	1	1.7	0	0.0	1	0.8
50-54	41	85.7	0	0.0	41	43.3	0	0.0	0	0.0	0	0.0
55-59	82	252.8	0	0.0	82	128.4	5	15.4	0	0.0	5	7.8
60-64	117	496.3	0	0.0	117	249.3	6	25.5	0	0.0	6	12.8
65-69	169	899.3	0	0.0	169	438.7	15	79.8	0	0.0	15	38.9
70–74	175	1,161.0	0	0.0	175	527.0	29	192.4	0	0.0	29	87.3
75–79	129	1,340.4	0	0.0	129	563.7	18	187.0	0	0.0	18	78.7
80-84	60	1,256.0	0	0.0	60	452.7	32	669.9	0	0.0	32	241.4
85 and over	29	1,128.0	0	0.0	29	329.8	17	661.2	0	0.0	17	193.3
Total	814		0		814		123		0		123	
Crude rate		106.1		0.0		52.6		16.0		0.0		7.9
95% CI	ģ	98.8 – 113.4		0.0 - 0.0		49.0 – 56.2	1	3.2 - 18.9		0.0 - 0.0		6.5 - 9.4
AS rate (Aust 1991)		163.0		0.0		72.9		29.6		0.0		11.7
95% CI	15	51.5 – 174.6		0.0 - 0.0		67.8 – 77.9	2	24.2 - 35.0		0.0 - 0.0		9.6 – 13.8
AS rate (World)		111.0		0.0		51.1		16.5		0.0		6.7
95% CI	10	03.2 – 118.8		0.0 - 0.0		47.5 – 54.7	1	3.5 – 19.5		0.0 - 0.0		5.5 - 8.0
Lifetime risk (0–74)		1 in 7		NA		1 in 15		1 in 64		NA		1 in 136
PYLL (0–74) Per cent of all								375.0		0.0		375.0
cancers		30.0		0.0		16.2		11.0		0.0		5.8

Table B4-42: Malignant Neoplasm of Testis: ICD-10 C62

			Incider	ice					Mortali	ty		
	Males		Femal	es	Person	ıs	Males		Female	es	Perso	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	1	1.8	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	8	11.3	0	0.0	8	5.7	0	0.0	0	0.0	0	0.0
25-29	8	12.3	0	0.0	8	6.1	1	1.5	0	0.0	1	0.8
30-34	13	21.0	0	0.0	13	10.4	0	0.0	0	0.0	0	0.0
35–39	8	12.8	0	0.0	8	6.3	0	0.0	0	0.0	0	0.0
40-44	10	17.0	0	0.0	10	8.2	0	0.0	0	0.0	0	0.0
45-49	8	13.5	0	0.0	8	6.6	1	1.7	0	0.0	1	0.8
50-54	3	6.3	0	0.0	3	3.2	0	0.0	0	0.0	0	0.0
55-59	3	9.2	0	0.0	3	4.7	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	63		0		63		2		0		2	
Crude rate		8.2		0.0		4.1		0.3		0.0		0.1
95% CI		6.2 - 10.2		0.0 - 0.0		3.1 - 5.1		0.0 - 0.6		0.0 - 0.0		0.0 - 0.3
AS rate (Aust 1991)		7.7		0.0		3.8		0.2		0.0		0.1
95% CI		5.8 - 9.6		0.0 - 0.0		2.8 - 4.7		0.0 - 0.5		0.0 - 0.0		0.0 - 0.3
AS rate (World)		6.8		0.0		3.4		0.2		0.0		0.1
95% CI		5.1 - 8.5		0.0 - 0.0		2.5 - 4.2		0.0 - 0.5		0.0 - 0.0		0.0 - 0.3
Lifetime risk (0–74)		1 in 188		NA		1 in 379		1 in 6,216		NA		1 in 12,585
PYLL (0–74) Per cent of all								75.0		0.0		75.0
cancers		2.3		0.0		1.3		0.2		0.0		0.1

Table B4-43: Malignant Neoplasm of Other Male Genitals: ICD-10 C63

			Incidenc	e					Mortalit	ty		
_	Males		Female	s	Persons	5	Males		Female	s	Person	IS
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	1		0		1		0		0		0	
Crude rate		0.1		0.0		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (Aust 1991)		0.1		0.0		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.4		0.0 - 0.0		0.0 - 0.2		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (World)		0.1		0.0		0.0		0.0		0.0		0.0
95% CI		0.0 - 0.3		0.0 - 0.0		0.0 - 0.1		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
Lifetime risk (0-74)		1 in 11,796		NA		1 in 24,401		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.0		0.0		0.0		0.0		0.0		0.0
		0.0		0.0		0.0		0.0		0.0		0.0

Table B4-44: Malignant Neoplasm of Kidney: ICD-10 C64

			Inciden	ce					Mortali	ty		
_	Males	5	Female	es	Person	ıs	Males	8	Female	es	Person	as
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	1	1.9	1	0.9	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	1	1.7	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
15–19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
35–39	1	1.6	2	3.1	3	2.4	0	0.0	0	0.0	0	0.0
40-44	6	10.2	2	3.2	8	6.6	4	6.8	0	0.0	4	3.3
45-49	4	6.7	2	3.3	6	5.0	1	1.7	0	0.0	1	0.8
50-54	12	25.1	4	8.5	16	16.9	1	2.1	0	0.0	1	1.1
55-59	7	21.6	3	9.5	10	15.7	0	0.0	0	0.0	0	0.0
60-64	10	42.4	3	12.8	13	27.7	4	17.0	1	4.3	5	10.7
65-69	5	26.6	2	10.1	7	18.2	2	10.6	1	5.1	3	7.8
70–74	10	66.3	8	44.1	18	54.2	7	46.4	2	11.0	9	27.1
75–79	7	72.7	9	67.9	16	69.9	10	103.9	4	30.2	14	61.2
80-84	5	104.7	5	59.0	10	75.4	1	20.9	5	59.0	6	45.3
85 and over	1	38.9	3	48.2	4	45.5	4	155.6	1	16.1	5	56.9
Total	70		45		115		34		14		48	
Crude rate		9.1		5.8		7.4		4.4		1.8		3.1
95% CI		7.0 - 11.3		4.1 - 7.5		6.1 - 8.8		2.9 - 5.9		0.9 - 2.7		2.2 - 4.0
AS rate (Aust 1991)		11.8		6.7		9.2		7.2		2.3		4.4
95% CI		8.9 - 14.8		4.7 - 8.7		7.4 - 10.9		4.7 - 9.7		1.1 - 3.5		3.1 - 5.6
AS rate (World)		8.8		4.6		6.7		4.5		1.2		2.6
95% CI		6.7 - 10.9		3.2 - 6.0		5.4 - 7.9		2.9 - 6.0		0.5 - 1.9		1.9 - 3.4
Lifetime risk (0–74)		1 in 99		1 in 204		1 in 134		1 in 237		1 in 982		1 in 395
PYLL (0–74) Per cent of all								262.5		25.0		287.5
cancers		2.6		1.9		2.3		3.0		1.4		2.3

Table B4-45: Malignant Neoplasm of Renal Pelvis: ICD-10 C65

			Inciden	ce					Mortali	ty		
_	Males		Female	s	Person	s	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.1	1	1.1	0	0.0	2	4.3	2	2.1
55-59	1	3.1	0	0.0	1	1.6	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	1	4.3	1	2.1
65-69	1	5.3	1	5.1	2	5.2	0	0.0	0	0.0	0	0.0
70-74	1	6.6	0	0.0	1	3.0	0	0.0	2	11.0	2	6.0
75–79	0	0.0	1	7.5	1	4.4	1	10.4	0	0.0	1	4.4
80-84	0	0.0	2	23.6	2	15.1	0	0.0	2	23.6	2	15.1
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	1	16.1	1	11.4
Total	4		6		10		1		8		9	
Crude rate		0.5		0.8		0.6		0.1		1.0		0.6
95% CI		0.0 - 1.0		0.2 - 1.4		0.2 - 1.0		0.0 - 0.4		0.3 - 1.7		0.2 - 1.0
AS rate (Aust 1991)		0.7		0.9		0.9		0.2		1.2		0.8
95% CI		0.0 - 1.3		0.2 - 1.7		0.3 - 1.4		0.0 - 0.7		0.3 - 2.0		0.3 - 1.3
AS rate (World)		0.5		0.5		0.6		0.1		0.8		0.5
95% CI		0.0 - 1.0		0.1 - 1.0		0.2 - 0.9		0.0 - 0.3		0.2 - 1.4		0.2 - 0.8
Lifetime risk (0–74)		1 in 1,201		1 in 2,778		1 in 1,721		NA		1 in 1,022		1 in 1,949
PYLL (0–74) Per cent of all								0.0		62.5		62.5
cancers		0.1		0.3		0.2		0.1		0.8		0.4

Table B4-46: Malignant Neoplasm of Ureter: ICD-10 C66

			Inciden	ee					Mortali	ty		
_	Males		Female	s	Person	s	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.1	1	1.1	0	0.0	0	0.0	0	0.0
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	1	5.3	0	0.0	1	2.6	2	10.6	0	0.0	2	5.2
70–74	0	0.0	1	5.5	1	3.0	0	0.0	0	0.0	0	0.0
75–79	1	10.4	1	7.5	2	8.7	1	10.4	1	7.5	2	8.7
80-84	0	0.0	1	11.8	1	7.5	2	41.9	1	11.8	3	22.6
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	2		4		6		5		2		7	
Crude rate		0.3		0.5		0.4		0.7		0.3		0.5
95% CI		0.0 - 0.6		0.0 - 1.0		0.1 - 0.7		0.1 - 1.2		0.0 - 0.6		0.1 - 0.8
AS rate (Aust 1991)		0.4		0.6		0.5		1.2		0.3		0.7
95% CI		0.0 - 1.0		0.0 - 1.2		0.1 - 1.0		0.1 - 2.3		0.0 - 0.8		0.2 - 1.2
AS rate (World)		0.3		0.4		0.3		0.6		0.1		0.4
95% CI		0.0 - 0.6		0.0 - 0.7		0.1 - 0.6		0.1 - 1.2		0.0 - 0.3		0.1 - 0.6
Lifetime risk (0–74)		1 in 3,759		1 in 2,616		1 in 3,002		1 in 1,880		NA		1 in 3,853
PYLL (0-74) Per cent of all								15.0		0.0		15.0
cancers		0.1		0.2		0.1		0.4		0.2		0.3

Table B4-47: Malignant Neoplasm of Kidney, Ureter and Urethra: ICD-10 C64-66, C68

			Inciden	ce					Mortali	ty		
_	Males	S	Female	es	Person	ıs	Males		Female	es	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	1	1.9	1	0.9	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	1	1.7	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
15–19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	1	1.6	1	1.6	2	1.6	0	0.0	0	0.0	0	0.0
35–39	1	1.6	2	3.1	3	2.4	0	0.0	0	0.0	0	0.0
40-44	6	10.2	2	3.2	8	6.6	4	6.8	0	0.0	4	3.3
45-49	4	6.7	2	3.3	6	5.0	1	1.7	0	0.0	1	0.8
50-54	12	25.1	6	12.8	18	19.0	1	2.1	2	4.3	3	3.2
55-59	8	24.7	3	9.5	11	17.2	0	0.0	0	0.0	0	0.0
60-64	10	42.4	3	12.8	13	27.7	4	17.0	2	8.6	6	12.8
65-69	7	37.2	3	15.2	10	26.0	4	21.3	1	5.1	5	13.0
70–74	12	79.6	10	55.2	22	66.3	8	53.1	5	27.6	13	39.2
75–79	9	93.5	11	83.0	20	87.4	12	124.7	5	37.7	17	74.3
80-84	5	104.7	8	94.4	13	98.1	3	62.8	8	94.4	11	83.0
85 and over	1	38.9	4	64.3	5	56.9	4	155.6	2	32.1	6	68.2
Total	78		56		134		41		25		66	
Crude rate		10.2		7.2		8.7		5.3		3.2		4.3
95% CI		7.9 - 12.4		5.3 - 9.1		7.2 - 10.1		3.7 - 7.0		1.9 - 4.5		3.2 - 5.3
AS rate (Aust 1991)		13.4		8.4		10.9		8.8		4.0		6.0
95% CI		10.2 - 16.5		6.2 - 10.6		9.0 - 12.7		6.0 - 11.6		2.4 - 5.5		4.6 - 7.5
AS rate (World)		9.8		5.6		7.7		5.3		2.3		3.6
95% CI		7.6 - 12.0		4.1 - 7.2		6.3 - 9.0		3.7 - 7.0		1.3 - 3.2		2.7 - 4.5
Lifetime risk (0-74)		1 in 87		1 in 169		1 in 115		1 in 197		1 in 440		1 in 278
PYLL (0–74) Per cent of all								280.0		90.0		370.0
cancers		2.9		2.4		2.7		3.7		2.5		3.1

Table B4-48: Malignant Neoplasm of Bladder: ICD-10 C67

			Incider	nce					Mortali	ty		
_	Males	5	Femal	les	Person	ıs	Males	5	Female	es	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	1	1.5	1	0.8	0	0.0	0	0.0	0	0.0
40-44	1	1.7	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
45-49	3	5.1	0	0.0	3	2.5	1	1.7	0	0.0	1	0.8
50-54	5	10.4	1	2.1	6	6.3	2	4.2	0	0.0	2	2.1
55-59	2	6.2	3	9.5	5	7.8	1	3.1	0	0.0	1	1.6
60-64	7	29.7	3	12.8	10	21.3	0	0.0	1	4.3	1	2.1
65-69	18	95.8	4	20.3	22	57.1	14	74.5	5	25.3	19	49.3
70–74	18	119.4	2	11.0	20	60.2	8	53.1	2	11.0	10	30.1
75–79	14	145.5	1	7.5	15	65.5	7	72.7	2	15.1	9	39.3
80-84	15	314.0	3	35.4	18	135.8	12	251.2	1	11.8	13	98.1
85 and over	4	155.6	0	0.0	4	45.5	7	272.3	0	0.0	7	79.6
Total	87		18		105		52		11		63	
Crude rate		11.3		2.3		6.8		6.8		1.4		4.1
95% CI		9.0 - 13.7		1.2 - 3.4		5.5 - 8.1		4.9 - 8.6		0.6 - 2.2		3.1 - 5.1
AS rate (Aust 1991)		18.5		2.9		9.5		12.3		2.0		6.0
95% CI		14.5 – 22.5		1.6 - 4.3		7.6 - 11.3		8.8 - 15.7		0.8 - 3.2		4.5 - 7.5
AS rate (World)		11.4		2.2		6.2		7.1		1.4		3.7
95% CI		9.0 - 13.9		1.1 - 3.2		5.0 - 7.4		5.1 - 9.1		0.5 - 2.2		2.7 - 4.6
Lifetime risk (0-74)		1 in 75		1 in 349		1 in 128		1 in 147		1 in 492		1 in 233
PYLL (0–74) Per cent of all								215.0		55.0		270.0
cancers		3.2		0.8		2.1		4.7		1.1		3.0

Table B4-49: Malignant Neoplasm of Other Urinary Organs: ICD-10 C68

			Inciden	ce					Mortali	ty		
	Males	5	Female	s	Person	s	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	1	6.6	1	5.5	2	6.0	1	6.6	1	5.5	2	6.0
75–79	1	10.4	0	0.0	1	4.4	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	2		1		3		1		1		2	
Crude rate		0.3		0.1		0.2		0.1		0.1		0.1
95% CI		0.0 - 0.6		0.0 - 0.4		0.0 - 0.4		0.0 - 0.4		0.0 - 0.4		0.0 - 0.3
AS rate (Aust 1991)		0.4		0.2		0.3		0.2		0.2		0.2
95% CI		0.0 - 1.0		0.0 - 0.5		0.0 - 0.6		0.0 - 0.6		0.0 - 0.5		0.0 - 0.4
AS rate (World)		0.2		0.1		0.2		0.1		0.1		0.1
95% CI		0.0 - 0.6		0.0 - 0.3		0.0 - 0.4		0.0 - 0.4		0.0 - 0.3		0.0 - 0.3
Lifetime risk (0-74)		1 in 3,015		1 in 3,627		1 in 3,321		1 in 3,015		1 in 3,627		1 in 3,321
PYLL (0–74) Per cent of all								2.5		2.5		5.0
cancers		0.1		0.0		0.1		0.1		0.1		0.1

Table B4-50: Malignant Neoplasm of Eye: ICD-10 C69

			Inciden	ce					Mortalit	ty		
	Males		Female	es	Person	ns	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5-9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	1	1.5	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	2	3.4	2	3.2	4	3.3	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	1	1.7	0	0.0	1	0.8
50-54	0	0.0	1	2.1	1	1.1	0	0.0	1	2.1	1	1.1
55-59	1	3.1	1	3.2	2	3.1	0	0.0	0	0.0	0	0.0
60-64	0	0.0	1	4.3	1	2.1	0	0.0	0	0.0	0	0.0
65-69	1	5.3	0	0.0	1	2.6	0	0.0	0	0.0	0	0.0
70–74	2	13.3	0	0.0	2	6.0	1	6.6	2	11.0	3	9.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	1	20.9	1	11.8	2	15.1	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	0	0.0	0	0.0
Total	8		7		15		2		3		5	
Crude rate		1.0		0.9		1.0		0.3		0.4		0.3
95% CI		0.3 - 1.8		0.2 - 1.6		0.5 - 1.5		0.0 - 0.6		0.0 - 0.8		0.0 - 0.6
AS rate (Aust 1991)		1.4		1.0		1.2		0.3		0.4		0.4
95% CI		0.4 - 2.4		0.2 - 1.7		0.6 - 1.8		0.0 - 0.7		0.0 - 0.9		0.0 - 0.7
AS rate (World)		1.0		0.7		0.9		0.2		0.3		0.3
95% CI		0.3 - 1.7		0.2 - 1.3		0.4 - 1.3		0.0 - 0.6		0.0 - 0.7		0.0 - 0.5
Lifetime risk (0–74)		1 in 752		1 in 1,567		1 in 1,054		1 in 2,405		1 in 1,520		1 in 1,832
PYLL (0–74) Per cent of all								30.0		27.5		57.5
cancers		0.3		0.3		0.3		0.2		0.3		0.2

Table B4-51: Malignant Neoplasm of Brain: ICD-10 C71

			Inciden	ce					Mortali	ty		
_	Males	3	Female	es	Person	ns	Males		Female	es	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	1	1.8	2	3.7	3	2.7	0	0.0	0	0.0	0	0.0
5–9	1	1.7	3	5.4	4	3.5	1	1.7	1	1.8	2	1.8
10-14	1	1.7	1	1.8	2	1.8	1	1.7	0	0.0	1	0.9
15-19	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
20-24	3	4.2	1	1.5	4	2.9	1	1.4	0	0.0	1	0.7
25-29	2	3.1	1	1.5	3	2.3	3	4.6	0	0.0	3	2.3
30-34	2	3.2	1	1.6	3	2.4	1	1.6	1	1.6	2	1.6
35-39	6	9.6	2	3.1	8	6.3	2	3.2	3	4.6	5	3.9
40-44	5	8.5	1	1.6	6	4.9	2	3.4	2	3.2	4	3.3
45-49	4	6.7	3	4.9	7	5.8	1	1.7	2	3.3	3	2.5
50-54	3	6.3	3	6.4	6	6.3	2	4.2	4	8.5	6	6.3
55-59	4	12.3	7	22.3	11	17.2	7	21.6	7	22.3	14	21.9
60-64	3	12.7	1	4.3	4	8.5	5	21.2	1	4.3	6	12.8
65-69	7	37.2	2	10.1	9	23.4	7	37.2	2	10.1	9	23.4
70–74	4	26.5	3	16.5	7	21.1	3	19.9	3	16.5	6	18.1
75–79	4	41.6	2	15.1	6	26.2	3	31.2	3	22.6	6	26.2
80-84	4	83.7	1	11.8	5	37.7	4	83.7	1	11.8	5	37.7
85 and over	1	38.9	1	16.1	2	22.7	1	38.9	1	16.1	2	22.7
Total	56		35		91		44		31		75	
Crude rate		7.3		4.5		5.9		5.7		4.0		4.8
95% CI		5.4 - 9.2		3.0 - 6.0		4.7 - 7.1		4.0 - 7.4		2.6 - 5.4		3.8 - 5.9
AS rate (Aust 1991)		9.1		4.8		6.7		7.7		4.3		5.8
95% CI		6.6 - 11.7		3.2 - 6.4		5.3 - 8.1		5.3 - 10.1		2.7 - 5.8		4.4 - 7.1
AS rate (World)		6.9		4.4		5.5		5.8		3.4		4.5
95% CI		5.1 - 8.8		2.8 - 5.9		4.3 - 6.7		4.0 - 7.5		2.2 - 4.7		3.5 - 5.6
Lifetime risk (0-74)		1 in 146		1 in 237		1 in 182		1 in 162		1 in 263		1 in 202
PYLL (0–74) Per cent of all								825.0		590.0		1,415.0
cancers		2.1		1.5		1.8		3.9		3.1		3.5

Table B4-52: Malignant Neoplasm of Meninges CNS: ICD-10 C70, C72

			Inciden	ce					Mortalit	ty		
_	Males		Female	s	Person	s	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	1	1.8	1	0.9	0	0.0	0	0.0	0	0.0
15–19	0	0.0	1	1.7	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	1	1.6	1	0.8	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	1	5.5	1	3.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	1	11.8	1	7.5	0	0.0	1	11.8	1	7.5
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	1		4		5		0		2		2	
Crude rate		0.1		0.5		0.3		0.0		0.3		0.1
95% CI		0.0 - 0.4		0.0 - 1.0		0.0 - 0.6		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3
AS rate (Aust 1991)		0.1		0.5		0.3		0.0		0.3		0.2
95% CI		0.0 - 0.4		0.0 - 1.0		0.0 - 0.6		0.0 - 0.0		0.0 - 0.8		0.0 - 0.5
AS rate (World)		0.1		0.5		0.3		0.0		0.2		0.1
95% CI		0.0 - 0.3		0.0 - 1.0		0.0 - 0.5		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2
Lifetime risk (0-74)		1 in 12,474		1 in 3,928		1 in 6,049		NA		1 in 3,627		1 in 6,642
PYLL (0–74) Per cent of all								0.0		2.5		2.5
cancers		0.0		0.2		0.1		0.0		0.2		0.1

Table B4-53: Malignant Neoplasm of Brain and CNS: ICD-10 C70-72

			Incider	ice					Mortali	ty		
_	Males	s	Femal	es	Person	ns	Males	}	Female	es	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	1	1.8	2	3.7	3	2.7	0	0.0	0	0.0	0	0.0
5–9	1	1.7	3	5.4	4	3.5	1	1.7	1	1.8	2	1.8
10-14	1	1.7	2	3.6	3	2.6	1	1.7	0	0.0	1	0.9
15-19	1	1.6	1	1.7	2	1.6	0	0.0	0	0.0	0	0.0
20-24	3	4.2	1	1.5	4	2.9	1	1.4	0	0.0	1	0.7
25-29	2	3.1	1	1.5	3	2.3	3	4.6	0	0.0	3	2.3
30-34	2	3.2	1	1.6	3	2.4	1	1.6	1	1.6	2	1.6
35-39	7	11.2	2	3.1	9	7.1	2	3.2	3	4.6	5	3.9
40-44	5	8.5	1	1.6	6	4.9	2	3.4	2	3.2	4	3.3
45-49	4	6.7	4	6.5	8	6.6	1	1.7	2	3.3	3	2.5
50-54	3	6.3	3	6.4	6	6.3	2	4.2	4	8.5	6	6.3
55-59	4	12.3	7	22.3	11	17.2	7	21.6	7	22.3	14	21.9
60-64	3	12.7	1	4.3	4	8.5	5	21.2	1	4.3	6	12.8
65-69	7	37.2	2	10.1	9	23.4	7	37.2	2	10.1	9	23.4
70-74	4	26.5	3	16.5	7	21.1	3	19.9	4	22.1	7	21.1
75–79	4	41.6	2	15.1	6	26.2	3	31.2	3	22.6	6	26.2
80-84	4	83.7	2	23.6	6	45.3	4	83.7	2	23.6	6	45.3
85 and over	1	38.9	1	16.1	2	22.7	1	38.9	1	16.1	2	22.7
Total	57		39		96		44		33		77	
Crude rate		7.4		5.0		6.2		5.7		4.2		5.0
95% CI		5.5 - 9.4		3.4 - 6.6		5.0 - 7.4		4.0 - 7.4		2.8 - 5.7		3.9 - 6.1
AS rate (Aust 1991)		9.3		5.3		7.0		7.7		4.6		6.0
95% CI		6.7 - 11.8		3.6 - 7.0		5.6 - 8.5		5.3 - 10.1		3.0 - 6.2		4.6 - 7.3
AS rate (World)		7.0		4.8		5.8		5.8		3.6		4.6
95% CI		5.2 - 8.9		3.2 - 6.4		4.6 - 7.0		4.0 - 7.5		2.3 - 4.9		3.5 - 5.7
Lifetime risk (0-74)		1 in 144		1 in 223		1 in 177		1 in 162		1 in 245		1 in 196
PYLL (0–74) Per cent of all								825.0		592.5		1,417.5
cancers		2.1		1.7		1.9		3.9		3.3		3.6

Table B4-54: Malignant Neoplasm of Thyroid: ICD-10 C73

			Incide	ıce					Mortali	ity		
_	Male	es	Femal	es	Perso	ns	Males	}	Female	es	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												<u></u>
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	1	1.8	1	0.9	0	0.0	0	0.0	0	0.0
15–19	0	0.0	1	1.7	1	0.8	0	0.0	0	0.0	0	0.0
20-24	4	5.7	3	4.4	7	5.0	0	0.0	0	0.0	0	0.0
25–29	1	1.5	5	7.5	6	4.6	0	0.0	0	0.0	0	0.0
30-34	1	1.6	3	4.7	4	3.2	0	0.0	0	0.0	0	0.0
35–39	1	1.6	8	12.3	9	7.1	0	0.0	0	0.0	0	0.0
40-44	2	3.4	5	7.9	7	5.7	1	1.7	0	0.0	1	0.8
45-49	1	1.7	7	11.4	8	6.6	0	0.0	0	0.0	0	0.0
50-54	0	0.0	4	8.5	4	4.2	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	2	10.6	1	5.1	3	7.8	0	0.0	0	0.0	0	0.0
70–74	1	6.6	0	0.0	1	3.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	4	30.2	4	17.5	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	2	32.1	2	22.7
Total	13		43		56		1		2		3	
Crude rate		1.7		5.5		3.6		0.1		0.3		0.2
95% CI		0.8 - 2.6		3.9 - 7.2		2.7 - 4.6		0.0 - 0.4		0.0 - 0.6		0.0 - 0.4
AS rate (Aust 1991)		1.8		5.3		3.6		0.1		0.3		0.3
95% CI		0.8 - 2.8		3.7 - 6.9		2.6 - 4.6		0.0 - 0.4		0.0 - 0.7		0.0 - 0.6
AS rate (World)		1.5		4.4		3.0		0.1		0.2		0.2
95% CI		0.7 - 2.4		3.1 - 5.7		2.2 - 3.8		0.0 - 0.3		0.0 - 0.4		0.0 - 0.3
Lifetime risk (0-74)		1 in 611		1 in 307		1 in 409		1 in 11,796		NA		1 in 24,401
PYLL (0–74) Per cent of all								32.5		0.0		32.5
cancers		0.5		1.9		1.1		0.1		0.2		0.1

Table B4-55: Malignant Neoplasm of Adrenal Gland: ICD-10 C74

			Inciden	ce					Mortalit	y		
_	Male	s	Female	es	Person	s	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												_
0–4	2	3.6	0	0.0	2	1.8	1	1.8	1	1.9	2	1.8
5–9	0	0.0	0	0.0	0	0.0	1	1.7	0	0.0	1	0.9
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	1	1.5	1	0.8	0	0.0	1	1.5	1	0.8
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	1	1.6	1	0.8
50-54	0	0.0	0	0.0	0	0.0	1	2.1	0	0.0	1	1.1
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	2		1		3		3		3		6	
Crude rate		0.3		0.1		0.2		0.4		0.4		0.4
95% CI		0.0 - 0.6		0.0 - 0.4		0.0 - 0.4		0.0 - 0.8		0.0 - 0.8		0.1 - 0.7
AS rate (Aust 1991)		0.3		0.1		0.2		0.4		0.4		0.4
95% CI		0.0 - 0.6		0.0 - 0.4		0.0 - 0.4		0.0 - 0.8		0.0 - 0.8		0.1 - 0.7
AS rate (World)		0.4		0.1		0.3		0.5		0.4		0.5
95% CI		0.0 - 1.0		0.0 - 0.4		0.0 - 0.6		0.0 - 1.1		0.0 - 1.0		0.1 - 0.9
Lifetime risk (0-74)		1 in 5,558		1 in 13,267		1 in 7,716		1 in 3,556		1 in 3,996		1 in 3,730
PYLL (0–74) Per cent of all								162.5		147.5		310.0
cancers		0.1		0.0		0.1		0.3		0.3		0.3

Table B4-56: Malignant Neoplasm of Other Endocrine: ICD-10 C75

			Incidenc	ee					Mortali	ty		
_	Male	S	Female	s	Person	ıs	Males		Female	s	Person	ıs
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15-19	0	0.0	1	1.7	1	0.8	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25–29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	0		1		1		0		0		0	
Crude rate		0.0		0.1		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (Aust 1991)		0.0		0.1		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
AS rate (World)		0.0		0.1		0.1		0.0		0.0		0.0
95% CI		0.0 - 0.0		0.0 - 0.4		0.0 - 0.2		0.0 - 0.0		0.0 - 0.0		0.0 - 0.0
Lifetime risk (0–74)		NA		1 in 12,021		1 in 24,638		NA		NA		NA
PYLL (0–74) Per cent of all								0.0		0.0		0.0
cancers		0.0		0.0		0.0		0.0		0.0		0.0

Table B4-57: Hodgkin's Disease: ICD-10 C81

			Inciden	ice					Mortali	ty		
_	Males		Female	es	Person	ıs	Males		Female	S	Person	ns
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	2	3.5	0	0.0	2	1.8	0	0.0	0	0.0	0	0.0
15–19	0	0.0	3	5.0	3	2.4	0	0.0	0	0.0	0	0.0
20-24	1	1.4	3	4.4	4	2.9	1	1.4	0	0.0	1	0.7
25-29	2	3.1	3	4.5	5	3.8	0	0.0	2	3.0	2	1.5
30-34	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
35-39	3	4.8	2	3.1	5	3.9	1	1.6	0	0.0	1	0.8
40-44	2	3.4	0	0.0	2	1.6	0	0.0	0	0.0	0	0.0
45-49	0	0.0	2	3.3	2	1.7	0	0.0	0	0.0	0	0.0
50-54	0	0.0	1	2.1	1	1.1	1	2.1	0	0.0	1	1.1
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
65-69	0	0.0	2	10.1	2	5.2	0	0.0	0	0.0	0	0.0
70-74	0	0.0	1	5.5	1	3.0	0	0.0	0	0.0	0	0.0
75–79	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
80-84	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	1	16.1	1	11.4
Total	11		17		28		3		3		6	
Crude rate		1.4		2.2		1.8		0.4		0.4		0.4
95% CI		0.6 - 2.3		1.1 - 3.2		1.1 - 2.5		0.0 - 0.8		0.0 - 0.8		0.1 - 0.7
AS rate (Aust 1991)		1.4		2.2		1.8		0.3		0.4		0.4
95% CI		0.6 - 2.2		1.1 - 3.3		1.1 - 2.5		0.0 - 0.7		0.0 - 0.8		0.1 - 0.7
AS rate (World)		1.3		2.1		1.7		0.3		0.3		0.3
95% CI		0.5 - 2.0		1.1 - 3.1		1.0 - 2.3		0.0 - 0.7		0.0 - 0.7		0.1 - 0.6
Lifetime risk (0–74)		1 in 1,126		1 in 527		1 in 711		1 in 3,917		1 in 6,634		1 in 4,905
PYLL (0–74) Per cent of all								112.5		95.0		207.5
cancers		0.4		0.7		0.6		0.3		0.3		0.3

Table B4-58: Non-Hodgkin's Lymphoma: ICD-10 C82-85, C96

			Incide	nce					Mortali	ity		
_	Mal	es	Femal	les	Perso	ns	Males	s	Female	es	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	1	1.7	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
10-14	3	5.2	0	0.0	3	2.6	1	1.7	0	0.0	1	0.9
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	1	1.4	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0
25–29	0	0.0	1	1.5	1	0.8	0	0.0	1	1.5	1	0.8
30-34	2	3.2	3	4.7	5	4.0	0	0.0	0	0.0	0	0.0
35–39	4	6.4	4	6.1	8	6.3	4	6.4	0	0.0	4	3.1
40-44	5	8.5	3	4.8	8	6.6	1	1.7	1	1.6	2	1.6
45-49	12	20.2	6	9.8	18	14.9	1	1.7	4	6.5	5	4.1
50-54	10	20.9	11	23.5	21	22.2	5	10.4	1	2.1	6	6.3
55–59	3	9.2	14	44.5	17	26.6	2	6.2	3	9.5	5	7.8
60-64	16	67.9	7	30.0	23	49.0	5	21.2	1	4.3	6	12.8
65-69	10	53.2	11	55.8	21	54.5	7	37.2	10	50.7	17	44.1
70–74	19	126.1	14	77.2	33	99.4	9	59.7	10	55.2	19	57.2
75–79	11	114.3	10	75.4	21	91.8	11	114.3	10	75.4	21	91.8
80-84	12	251.2	9	106.2	21	158.4	10	209.3	10	118.0	20	150.9
85 and over	2	77.8	10	160.7	12	136.5	4	155.6	11	176.8	15	170.6
Total	111		103		214		60		62		122	
Crude rate		14.5		13.2		13.8		7.8		7.9		7.9
95% CI		11.8 - 17.2		10.7 - 15.8		12.0 - 15.7		5.8 - 9.8		6.0 - 9.9		6.5 - 9.3
AS rate (Aust 1991)		19.9		15.2		17.3		12.4		9.7		10.9
95% CI		16.0 - 23.8		12.2 - 18.2		14.9 - 19.7		9.1 - 15.7		7.3 - 12.2		8.9 - 12.9
AS rate (World)		14.1		11.1		12.5		7.6		6.1		6.8
95% CI		11.4 - 16.8		8.9 - 13.3		10.8 - 14.2		5.7 - 9.6		4.5 - 7.7		5.6 - 8.1
Lifetime risk (0-74)		1 in 62		1 in 78		1 in 70		1 in 137		1 in 153		1 in 145
PYLL (0–74) Per cent of all								557.5		377.5		935.0
cancers		4.1		4.5		4.3		5.4		6.2		5.8

Table B4-59: All Lymphoma's: ICD-10 C81-85, C96

_			Inciden	ice					Mortali	ity		
	Males	S	Femal	es	Person	ıs	Males	S	Female	es	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	1	1.7	0	0.0	1	0.9	0	0.0	0	0.0	0	0.0
10-14	5	8.7	0	0.0	5	4.4	1	1.7	0	0.0	1	0.9
15–19	0	0.0	3	5.0	3	2.4	0	0.0	0	0.0	0	0.0
20-24	2	2.8	3	4.4	5	3.6	1	1.4	0	0.0	1	0.7
25-29	2	3.1	4	6.0	6	4.6	0	0.0	3	4.5	3	2.3
30-34	3	4.9	3	4.7	6	4.8	0	0.0	0	0.0	0	0.0
35-39	7	11.2	6	9.2	13	10.2	5	8.0	0	0.0	5	3.9
40-44	7	11.9	3	4.8	10	8.2	1	1.7	1	1.6	2	1.6
45-49	12	20.2	8	13.1	20	16.6	1	1.7	4	6.5	5	4.1
50-54	10	20.9	12	25.6	22	23.2	6	12.5	1	2.1	7	7.4
55–59	3	9.2	14	44.5	17	26.6	2	6.2	3	9.5	5	7.8
60-64	16	67.9	7	30.0	23	49.0	5	21.2	1	4.3	6	12.8
65-69	10	53.2	13	65.9	23	59.7	7	37.2	10	50.7	17	44.1
70–74	19	126.1	15	82.7	34	102.4	9	59.7	10	55.2	19	57.2
75–79	11	114.3	10	75.4	21	91.8	11	114.3	10	75.4	21	91.8
80-84	12	251.2	9	106.2	21	158.4	10	209.3	10	118.0	20	150.9
85 and over	2	77.8	10	160.7	12	136.5	4	155.6	12	192.9	16	182.0
Total	122		120		242		63		65		128	
Crude rate		15.9		15.4		15.6		8.2		8.3		8.3
95% CI		13.1 - 18.7		12.6 - 18.1		13.7 - 17.6		6.2 - 10.2		6.3 - 10.4		6.8 - 9.7
AS rate (Aust 1991)		21.3		17.4		19.1		12.8		10.1		11.3
95% CI		17.3 - 25.2		14.2 - 20.6		16.6 - 21.5		9.5 - 16.1		7.6 - 12.6		9.3 - 13.3
AS rate (World)		15.3		13.2		14.2		8.0		6.4		7.1
95% CI		12.6 – 18.1		10.7 - 15.6		12.3 - 16.0		5.9 - 10.0		4.8 - 8.1		5.9 - 8.4
Lifetime risk (0–74)		1 in 59		1 in 68		1 in 64		1 in 133		1 in 149		1 in 140
PYLL (0-74)								670.0		472.5		1,142.5
Per cent of all						4.0						
cancers		4.5		5.2		4.8		5.7		6.5		6.1

Table B4-60 : Immunoproliferative Neoplasms: ICD-10 C88

			Inciden	ice					Mortali	ty		
_	Males		Femal	es	Person	ıs	Males	S	Female	s	Person	ns
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Age group												
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
55-59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
60-64	1	4.2	0	0.0	1	2.1	1	4.2	0	0.0	1	2.1
65-69	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
70–74	1	6.6	0	0.0	1	3.0	0	0.0	0	0.0	0	0.0
75–79	2	20.8	0	0.0	2	8.7	0	0.0	0	0.0	0	0.0
80-84	1	20.9	1	11.8	2	15.1	0	0.0	2	23.6	2	15.1
85 and over	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total	5		1		6		1		2		3	
Crude rate		0.7		0.1		0.4		0.1		0.3		0.2
95% CI		0.1 - 1.2		0.0 - 0.4		0.1 - 0.7		0.0 - 0.4		0.0 - 0.6		0.0 - 0.4
AS rate (Aust 1991)		1.1		0.2		0.6		0.2		0.3		0.3
95% CI		0.1 - 2.1		0.0 - 0.5		0.1 - 1.0		0.0 - 0.5		0.0 - 0.7		0.0 - 0.6
AS rate (World)		0.6		0.1		0.3		0.2		0.1		0.2
95% CI		0.1 - 1.2		0.0 - 0.2		0.0 - 0.6		0.0 - 0.5		0.0 - 0.3		0.0 - 0.4
Lifetime risk (0-74)		1 in 1,839		NA		1 in 3,890		1 in 4,715		NA		1 in 9,386
PYLL (0–74) Per cent of all								12.5		0.0		12.5
cancers		0.2		0.0		0.1		0.1		0.2		0.1

Table B4-61: Multiple Myeloma: ICD-10 C90

			Inciden	ce			Mortality						
_	Males	s	Female	es	Person	ns	Males	S	Female	es	Person	ns	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
35-39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
40-44	0	0.0	0	0.0	0	0.0	1	1.7	0	0.0	1	0.8	
45-49	2	3.4	1	1.6	3	2.5	1	1.7	0	0.0	1	0.8	
50-54	4	8.4	2	4.3	6	6.3	0	0.0	1	2.1	1	1.1	
55-59	1	3.1	1	3.2	2	3.1	2	6.2	0	0.0	2	3.1	
60-64	7	29.7	1	4.3	8	17.0	2	8.5	0	0.0	2	4.3	
65-69	6	31.9	3	15.2	9	23.4	1	5.3	3	15.2	4	10.4	
70–74	5	33.2	5	27.6	10	30.1	7	46.4	0	0.0	7	21.1	
75–79	4	41.6	5	37.7	9	39.3	3	31.2	2	15.1	5	21.8	
80-84	5	104.7	0	0.0	5	37.7	6	125.6	4	47.2	10	75.4	
85 and over	2	77.8	2	32.1	4	45.5	2	77.8	3	48.2	5	56.9	
Total	36		20		56		25		13		38		
Crude rate		4.7		2.6		3.6		3.3		1.7		2.5	
95% CI		3.2 - 6.2		1.4 - 3.7		2.7 - 4.6		2.0 - 4.5		0.8 - 2.6		1.7 - 3.2	
AS rate (Aust 1991)		7.2		3.2		4.9		5.5		2.1		3.5	
95% CI		4.8 - 9.7		1.7 - 4.6		3.6 - 6.2		3.2 - 7.7		0.9 - 3.2		2.4 - 4.6	
AS rate (World)		4.9		2.2		3.4		3.2		1.2		2.1	
95% CI		3.2 - 6.5		1.2 - 3.1		2.5 - 4.3		1.9 - 4.5		0.5 - 1.9		1.4 - 2.7	
Lifetime risk (0-74)	ı	1 in 183		1 in 357		1 in 243		1 in 287		1 in 1,154		1 in 482	
PYLL (0–74) Per cent of all								145.0		45.0		190.0	
cancers		1.3		0.9		1.1		2.2		1.3		1.8	

Table B4-62: Lymphoid Leukemia: ICD-10 C91

			Inciden	ce		Mortality							
_	Males	}	Female	es	Perso	ns	Males	S	Female	es	Person	ns	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0-4	4	7.2	3	5.6	7	6.4	1	1.8	1	1.9	2	1.8	
5–9	3	5.2	1	1.8	4	3.5	0	0.0	0	0.0	0	0.0	
10–14	0	0.0	2	3.6	2	1.8	0	0.0	0	0.0	0	0.0	
15–19	3	4.8	0	0.0	3	2.4	1	1.6	1	1.7	2	1.6	
20-24	1	1.4	0	0.0	1	0.7	0	0.0	0	0.0	0	0.0	
25–29	1	1.5	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0	
30-34	1	1.6	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0	
35–39	0	0.0	1	1.5	1	0.8	0	0.0	1	1.5	1	0.8	
40-44	1	1.7	2	3.2	3	2.5	0	0.0	0	0.0	0	0.0	
45-49	3	5.1	0	0.0	3	2.5	1	1.7	0	0.0	1	0.8	
50-54	0	0.0	5	10.7	5	5.3	0	0.0	2	4.3	2	2.1	
55–59	5	15.4	3	9.5	8	12.5	0	0.0	2	6.4	2	3.1	
60-64	4	17.0	1	4.3	5	10.7	1	4.2	1	4.3	2	4.3	
65-69	4	21.3	3	15.2	7	18.2	2	10.6	0	0.0	2	5.2	
70–74	3	19.9	2	11.0	5	15.1	0	0.0	0	0.0	0	0.0	
75–79	2	20.8	4	30.2	6	26.2	3	31.2	2	15.1	5	21.8	
80-84	1	20.9	2	23.6	3	22.6	4	83.7	1	11.8	5	37.7	
85 and over	0	0.0	1	16.1	1	11.4	1	38.9	3	48.2	4	45.5	
Total	36		30		66		14		14		28		
Crude rate		4.7		3.8		4.3		1.8		1.8		1.8	
95% CI		3.2 - 6.2		2.5 - 5.2		3.2 - 5.3		0.9 - 2.8		0.9 - 2.7		1.1 - 2.5	
AS rate (Aust 1991)		5.6		4.3		5.0		3.1		2.0		2.4	
95% CI		3.7 - 7.5		2.7 - 5.9		3.8 - 6.2		1.4 - 4.8		0.9 - 3.0		1.5 – 3.3	
AS rate (World)		5.2		3.7		4.5		1.9		1.6		1.7	
95% CI		3.4 - 6.9		2.3 - 5.1		3.4 - 5.6		0.9 - 2.9		0.7 - 2.4		1.0 - 2.3	
Lifetime risk (0-74)		1 in 196		1 in 302		1 in 239		1 in 1,003		1 in 1,002		1 in 1,012	
PYLL (0–74) Per cent of all								185.0		260.0		445.0	
cancers		1.3		1.3		1.3		1.3		1.4		1.3	

Table B4-63: Myeloid Leukemia: ICD-10 C92-94

			Inciden	ice			Mortality						
	Male	s	Femal	es	Person	ns	Males	3	Females		Perso	ns	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0-4	1	1.8	2	3.7	3	2.7	1	1.8	1	1.9	2	1.8	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10-14	0	0.0	1	1.8	1	0.9	0	0.0	1	1.8	1	0.9	
15-19	2	3.2	0	0.0	2	1.6	2	3.2	0	0.0	2	1.6	
20-24	0	0.0	1	1.5	1	0.7	1	1.4	0	0.0	1	0.7	
25-29	1	1.5	0	0.0	1	0.8	1	1.5	0	0.0	1	0.8	
30-34	1	1.6	0	0.0	1	0.8	1	1.6	0	0.0	1	0.8	
35-39	1	1.6	1	1.5	2	1.6	2	3.2	0	0.0	2	1.6	
40-44	3	5.1	0	0.0	3	2.5	2	3.4	0	0.0	2	1.6	
45-49	1	1.7	1	1.6	2	1.7	1	1.7	3	4.9	4	3.3	
50-54	2	4.2	3	6.4	5	5.3	2	4.2	1	2.1	3	3.2	
55-59	1	3.1	2	6.4	3	4.7	1	3.1	0	0.0	1	1.6	
60-64	2	8.5	1	4.3	3	6.4	2	8.5	1	4.3	3	6.4	
65-69	1	5.3	3	15.2	4	10.4	2	10.6	3	15.2	5	13.0	
70–74	4	26.5	7	38.6	11	33.1	10	66.3	8	44.1	18	54.2	
75–79	6	62.3	0	0.0	6	26.2	10	103.9	2	15.1	12	52.4	
80-84	4	83.7	1	11.8	5	37.7	7	146.5	1	11.8	8	60.4	
85 and over	4	155.6	2	32.1	6	68.2	5	194.5	1	16.1	6	68.2	
Total	34		25		59		50		22		72		
Crude rate		4.4		3.2		3.8		6.5		2.8		4.7	
95% CI		2.9 - 5.9		1.9 - 4.5		2.8 - 4.8		4.7 - 8.3		1.6 - 4.0		3.6 - 5.7	
AS rate (Aust 1991)		6.8		3.7		4.8		10.4		3.4		6.1	
95% CI		4.4 - 9.3		2.2 - 5.1		3.5 - 6.0		7.4 - 13.5		1.9 - 4.8		4.7 - 7.6	
AS rate (World)		4.4		3.1		3.5		6.4		2.6		4.1	
95% CI		2.9 - 5.9		1.8 - 4.4		2.6 - 4.5		4.6 - 8.2		1.5 - 3.7		3.1 - 5.1	
Lifetime risk (0-74)		1 in 313		1 in 247		1 in 274		1 in 181		1 in 270		1 in 219	
PYLL (0–74) Per cent of all								625.0		295.0		920.0	
cancers		1.3		1.1		1.2		4.5		2.2		3.4	

Table B4-64: Leukemia Unspecified: ICD-10 C95

			Inciden	ce			Mortality							
_	Males		Female	es	Person	ns	Males		Female	es	Person	ıs		
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate		
Age group														
0-4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
15-19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
25-29	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
30-34	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
40-44	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
45-49	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
50-54	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
55–59	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
60-64	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
65-69	1	5.3	0	0.0	1	2.6	0	0.0	0	0.0	0	0.0		
70–74	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
75–79	0	0.0	1	7.5	1	4.4	0	0.0	0	0.0	0	0.0		
80-84	0	0.0	0	0.0	0	0.0	0	0.0	1	11.8	1	7.5		
85 and over	0	0.0	1	16.1	1	11.4	0	0.0	1	16.1	1	11.4		
Total	1		2		3		0		2		2			
Crude rate		0.1		0.3		0.2		0.0		0.3		0.1		
95% CI		0.0 - 0.4		0.0 - 0.6		0.0 - 0.4		0.0 - 0.0		0.0 - 0.6		0.0 - 0.3		
AS rate (Aust 1991)		0.2		0.3		0.3		0.0		0.3		0.2		
95% CI		0.0 - 0.6		0.0 - 0.7		0.0 - 0.6		0.0 - 0.0		0.0 - 0.7		0.0 - 0.5		
AS rate (World)		0.2		0.2		0.2		0.0		0.1		0.1		
95% CI		0.0 - 0.5		0.0 - 0.4		0.0 - 0.4		0.0 - 0.0		0.0 - 0.3		0.0 - 0.2		
Lifetime risk (0–74)		1 in 3,759		NA		1 in 7,705		NA		NA		NA		
PYLL (0–74) Per cent of all								0.0		0.0		0.0		
cancers		0.0		0.1		0.1		0.0		0.2		0.1		

Table B4-65: Unknown Primary Site: ICD-10 C76-80, C26, C39

			Incide	nce			Mortality						
_	Males	3	Fema	les	Person	ns	Males	3	Femal	es	Perso	ons	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0–4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25–29	1	1.5	2	3.0	3	2.3	1	1.5	2	3.0	3	2.3	
30-34	1	1.6	0	0.0	1	0.8	1	1.6	0	0.0	1	0.8	
35–39	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
40-44	6	10.2	4	6.3	10	8.2	5	8.5	2	3.2	7	5.7	
45-49	3	5.1	3	4.9	6	5.0	3	5.1	5	8.2	8	6.6	
50-54	7	14.6	11	23.5	18	19.0	4	8.4	5	10.7	9	9.5	
55-59	10	30.8	8	25.5	18	28.2	13	40.1	6	19.1	19	29.7	
60-64	12	50.9	3	12.8	15	32.0	9	38.2	1	4.3	10	21.3	
65-69	18	95.8	9	45.6	27	70.1	21	111.7	2	10.1	23	59.7	
70-74	18	119.4	10	55.2	28	84.3	13	86.2	10	55.2	23	69.3	
75–79	18	187.0	11	83.0	29	126.7	14	145.5	8	60.3	22	96.1	
80-84	8	167.5	18	212.3	26	196.2	8	167.5	16	188.7	24	181.1	
85 and over	8	311.2	14	225.0	22	250.2	8	311.2	16	257.2	24	272.9	
Total	110		93		203		100		73		173		
Crude rate		14.3		11.9		13.1		13.0		9.4		11.2	
95% CI		11.7 – 17.0		9.5 - 14.3		11.3 – 14.9	1	10.5 - 15.6		7.2 - 11.5		9.5 - 12.8	
AS rate (Aust 1991)		21.9		13.9		17.5		20.0		10.6		15.0	
95% CI		17.6 – 26.2		11.0 - 16.7		15.1 - 20.0	1	15.9 – 24.2		8.2 - 13.1		12.8 - 17.3	
AS rate (World)		14.7		9.1		11.7		13.5		6.6		9.9	
95% CI		11.9 – 17.5		7.2 - 11.1		10.0 - 13.3	1	10.8 – 16.2		5.0 - 8.2		8.4 - 11.4	
Lifetime risk (0-74)		1 in 61		1 in 114		1 in 81		1 in 67		1 in 176		1 in 98	
PYLL (0–74) Per cent of all								955.0		567.5		1,522.5	
cancers		4.1		4.0		4.0		9.0		7.3		8.2	

Table B4-66: Cancers with alcohol use as an identified risk factor: ICD-10 C01-06, C09-10, C12-15, C22, C32, C50

			Incider	ıce			Mortality						
	Males		Femal	es	Perso	ns	Males		Female	es	Person	ns	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0-4	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	
5–9	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
10-14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
15–19	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
20-24	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
25-29	1	0.4	6	0.5	7	0.4	0	0.0	0	0.0	0	0.0	
30-34	0	0.0	16	0.5	16	0.3	0	0.0	3	0.1	3	0.0	
35-39	1	0.3	41	1.5	42	0.9	0	0.0	7	0.3	7	0.2	
40-44	4	1.4	78	3.7	82	2.6	4	1.3	8	0.4	12	0.8	
45-49	10	3.1	110	6.0	120	4.6	7	2.2	27	1.8	34	2.0	
50-54	15	7.1	128	8.6	143	7.9	1	0.5	21	1.3	22	0.9	
55-59	18	10.4	96	9.5	114	9.9	8	4.7	25	2.4	33	3.5	
60-64	12	9.7	78	10.7	90	10.2	8	6.4	23	3.0	31	4.7	
65-69	21	16.8	74	12.8	95	14.7	14	11.1	31	7.8	45	9.4	
70–74	20	15.3	72	14.8	92	15.0	14	10.7	25	6.7	39	8.6	
75–79	16	10.5	42	4.6	58	7.1	8	5.2	23	2.8	31	3.8	
80-84	11	7.7	29	4.2	40	5.5	7	4.6	28	4.0	35	4.2	
85 and over	3	4.3	25	5.5	28	5.1	4	5.8	19	3.9	23	4.4	
Total	132		796		928		75		240		315		
Crude rate		2.5		3.0		2.8		1.3		0.9		1.1	
95% CI		1.4 - 3.6		1.8 - 4.3		1.9 - 3.6		0.5 - 2.1		0.3 - 1.6		0.6 - 1.6	
AS rate (Aust 1991)		3.0		3.3		3.1		1.7		1.1		1.4	
95% CI		1.6 - 4.4		1.9 - 4.6		2.2 - 4.1		0.6 - 2.8		0.3 - 1.9		0.7 - 2.1	
AS rate (World)		2.5		2.8		2.6		1.3		0.9		1.1	
95% CI		1.3 - 3.6		1.6 - 3.9		1.8 - 3.4		0.5 - 2.2		0.2 - 1.5		0.6 - 1.6	
Lifetime risk (0–74)		1 in 311		1 in 292		1 in 301		1 in 542		1 in 840		1 in 663	
PYLL (0–74) Per cent of all								131.1		99.4		230.5	
cancers		0.7		1.0		0.9		0.9		0.7		0.8	

Table B4-67: Cancers with smoking as an identified risk factor: ICD-10 C00-06, C09-16, C21.0, C25, C32-34, C51.9, C53-55, C62, C64, C65, C67

			Incide	nce			Mortality						
_	Male	S	Fema	les	Perso	ns	Males	S	Femal	les	Pers	ons	
_	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	
Age group													
0–4	1	0.0	1	0.0	2	0.0	0	0.0	0	0.0	0	0.0	
5–9	1	0.0	0	0.0	1	0.0	1	0.0	0	0.0	1	0.0	
10–14	2	0.0	0	0.0	2	0.0	0	0.0	0	0.0	0	0.0	
15-19	2	0.6	0	0.0	2	0.3	0	0.0	0	0.0	0	0.0	
20-24	8	3.1	0	0.0	8	1.6	0	0.0	0	0.0	0	0.0	
25–29	11	6.4	11	4.3	22	5.3	1	0.4	2	0.5	3	0.5	
30-34	18	11.0	5	2.0	23	6.4	1	0.4	0	0.0	1	0.2	
35–39	16	9.5	20	7.1	36	8.3	4	1.7	2	1.4	6	1.5	
40-44	27	18.8	24	12.1	51	15.3	12	9.9	8	5.1	20	7.4	
45–49	38	29.1	30	18.2	68	23.5	22	20.6	11	7.5	33	13.9	
50-54	55	55.2	48	28.5	103	42.0	13	14.2	13	14.1	26	14.1	
55–59	64	109.4	49	43.5	113	77.0	37	65.8	18	21.6	55	44.0	
60-64	71	162.5	51	71.3	122	117.1	38	92.5	22	37.8	60	65.3	
65-69	91	274.9	67	98.7	158	184.7	58	178.6	44	86.3	102	131.4	
70–74	108	377.4	83	140.8	191	248.2	88	308.6	57	118.4	145	204.7	
75–79	76	454.8	64	133.6	140	268.7	64	390.6	38	92.7	102	218.0	
80-84	56	535.9	42	93.1	98	252.7	50	584.3	36	99.3	86	274.1	
85 and over	27	425.5	42	152.0	69	232.0	37	536.4	30	101.6	67	228.7	
Total	672		537		1,209		426		281		707		
Crude rate		43.9		19.4		31.5		29.8		12.4		21.1	
95% CI		39.2 - 48.6		16.3 - 22.5		28.7 - 34.3	:	26.0 - 33.7		9.9 – 14.9		18.8 - 23.3	
AS rate (Aust 1991)		62.7		22.9		40.5		46.9		15.3		28.6	
95% CI		55.7 – 69.7		19.1 - 26.6		36.8 - 44.2	4	40.5 - 53.2		12.2 - 18.4		25.4 - 31.7	
AS rate (World)		43.7		17.1		29.3		30.1		10.8		19.2	
95% CI		38.9 - 48.5		14.2 - 19.9		26.6 - 31.9	:	26.1 - 34.1		8.6 - 13.1		17.1 - 21.4	
Lifetime risk (0–74)		1 in 19		1 in 47		1 in 28		1 in 29		1 in 69		1 in 42	
PYLL (0–74) Per cent of all								1,757.2		840.4		2,597.5	
cancers		12.4		6.6		9.7		20.5		9.7		15.4	

GLOSSARY

Age-specific rate: A rate for a specified age group. The numerator and denominator refer to the same age group. Example:

Number of deaths among residents aged 25-34 years in an area in a year

Age-specific death rate = (aged 25-34 years)

Average (or midyear) population aged 25-34 years in the area in that year

The multiplier (usually 100,000 or 1,000,000) is chosen to produce a rate that can be expressed as a convenient number. ²²

Age-standardisation: A procedure for adjusting rates, e.g. Death rates, designed to minimize the effects of differences in age composition when comparing rates for different populations. ²²

Crude rate: Crude rates are usually calculated by dividing the number of vital events which occurred in a population in one calendar year by the size of the population at the middle of that year. The mid-year population is taken as an estimate of the average population during the whole calendar year.²³

Estimated resident population: The Estimated resident population (ERP) is the official estimate of the Australian population. The ERP is based on results of the Census of Population and Housing. The ERP comprises the count of persons usually resident in Australia adjusted for underenumeration and Australian residents temporarily overseas at the time of the Census. Births, deaths, and internal and overseas migration are then taken into account to bring forward the estimates from the census date.²⁴

Incidence: The number of instances of illness commencing, or of persons falling ill, during a given period in a specified population. More generally, the number of new events, such as the number of new cases of a disease in a defined population, within a specified period of time. The term incidence is sometimes used to denote INCIDENCE RATE. ²²

Incidence rate: The rate at which new events occur in a population. The numerator is the number of new events that occur in a defined period; the denominator is the population at-risk of experiencing the event during this period, sometimes expressed as person-time. The incidence rate most often used in public health practice is calculated by the formula:

Number of new events in specified period

* 10ⁿ

Number of persons exposed to risk during this period

In a dynamic population, the denominator is the average size of the population, often the estimated population at the mid-period. If the period is a year, this is the annual incidence rate. This rate is an estimate of the person-time incidence rate, ie, the rate per 10ⁿ person-years. If the rate is low, as with many chronic diseases, it is also a good estimate of the cumulative incidence rate. ²²

International Classification of Diseases: A classification of diseases can be defined as a system of categories to which morbid entities are assigned according to established criteria. The purpose of the ICD-10-AM is to permit the systematic recording, analysis, interpretation and comparison of morbidity data collected in different hospitals, states and countries. The ICD-10-AM system

enables the translation of diagnoses and procedures and other health problems from words into an alphanumeric code, which permits easy storage, retrieval and analysis of the data.²⁵

Life expectancy: The average number of years an individual of a given age is expected to live if current mortality rates continue to apply. ²²

Lifetime risk: The risk to an individual that a given health effect will occur at any time after exposure, without regard for the time at which that effect occurs. ²²

Malignant: Tending to become progressively worse and to result in death; having the properties of anaplasia, invasiveness, and metastasis; said of tumours. ²⁶

Mean: The mean is the most popular measure of central tendency, and it is the sum of all the scores divided by the number of scores. ²⁷

Median: The median is the "middle score" in the sense that 50 per cent of the cases lie below it. ²⁷

Mortality rate (death rate): An estimate of the proportion of a population that dies during a specified period. The numerator is the number of persons dying during the period; the denominator is the size of the population, usually estimated as the mid-year population. The death rate in a population is generally calculated by the formula

Number of deaths during a specified period

* 10ⁿ

Number of persons at risk of dying during the period

This rate is an estimate of the person-time death rate, ie. the death rate per 10ⁿ person-years. If the rate is low, it is also a good estimate of the cumulative death rate. This rate is also called the crude death rate. ²²

Moving averages: A moving average is a form of average which has been adjusted to allow for seasonal or cyclical components of a time series. Moving average smoothing is a smoothing technique used to make the long-term trends of a time series clearer.

When a variable, like the number of unemployed, or the cost of strawberries, is graphed against time, there are likely to be considerable seasonal or cyclical components in the variation. These may make it difficult to see the underlying trend. These components can be eliminated by taking suitable moving averages.

By reducing random fluctuations, moving average smoothing makes long-term trends clearer. ²⁸

Neoplasm (tumour): Any new and abnormal growth, specifically one in which cell multiplication is uncontrolled and progressive. Neoplasms may be benign or malignant.²⁶

Person-years of life lost: Person-years of life lost is a concept which attempts to measure the number of years of life lost per annum due to death as a result of a specific cause, eg. lung cancer, given life expectancies at specific ages. Age-groups 0-4 up to 70-74 were used for the calculations, as deaths before age 75 are regarded as premature for both men and women. The method used for the calculation of person-years of life lost is an aggregation of years between age at death and 75 for each person for each cancer, eg. a person dying at age 50 contributes 25 years to the measure of person-years of life lost.¹⁴

Primary cancers (primary site of cancer): The site of origin of the tumour, as opposed to the secondary or metastatic sites. It is described by reporting the anatomical position (topography) of the tumour. ²⁹

PSA (Prostate Specific Antigen) testing: A test used to screen for cancer of the prostate and to monitor treatment.

PSA is a protein produced by the prostate gland. Although most PSA is carried out of the body in semen, a very small amount escapes into the blood stream. The PSA test is done on blood. Since the amount of PSA in blood is normally minute, the PSA test requires a very sensitive method based on monoclonal antibody technology. PSA in blood can be by itself as free PSA or it can join with other substances in the blood as bound PSA. Total PSA is the sum of free and bound forms. This is what is measured as the standard PSA test.

The PSA value used most frequently as the highest normal level is 4 ng/mL (nanograms per millilitre). However, since the prostate gland generally increases in size and produces more PSA with increasing age, it is normal to have lower levels in young men and higher levels in older men. Age-specific PSA levels are as follows (age group, upper normal): (40 - 49, 2.5), (50 - 59, 3.5), (60 - 69, 4.5), (70 - 79, 6.5). The use of age-specific PSA ranges for the detection of prostate cancer is controversial. Not all studies have agreed that this is better than simply using a level of 4 ng/mL as the highest normal value.

The PSA test is used in two distinctly different ways with respect to detecting prostate cancer. It can be used in men who are not known to have the disease as a screening test and it can be used in men known to have the disease as a tumor marker or monitoring test:

- Screening test: An abnormal result usually requires additional testing. Levels above 4
 ng/mL but less than 10 ng/mL are suspicious. However, most men who have this level of
 abnormality will actually not have prostate cancer. As levels increase above 10 ng/mL, the
 probability of prostate cancer increases dramatically.
- Monitoring test: An abnormal result following therapy indicates recurrence of prostate cancer.

PSA is not specific to prostate cancer. Other diseases can cause an elevated PSA. The most frequent is benign prostatic hypertrophy (BPH), an increase in the size of the prostate that typically occurs with aging. Infection of the prostate gland (prostatitis) is another relatively common cause of an elevated PSA. Other confounding conditions that can increase PSA include ischemia or infarction, urethral instrumentation, and urinary retention, and prostate biopsy.

The PSA test has other limitations. A small proportion of prostate cancers do not produce a detectable increase in blood PSA, even with advanced disease. Many early cancers will also not produce enough PSA to cause a significantly abnormal blood level. It is therefore important not to rely only on blood PSA testing. The most useful additional test is a physical prostate exam known as the digital rectal exam (DRE). ³⁰

Risk factor: An aspect of personal behaviour or lifestyle, an environmental exposure, or an inborn or inherited characteristics, which on the basis of epidemiologic evidence is known to be associated with health-related condition(s) considered important to prevent.²²

Standardised rate: A standardised rate is a hypothetical crude rate that would apply if the age structure were that of the standard instead of what it happens to be. ²⁴

Topography: A special description of an anatomic region or a special part. ²⁶

Unemployment rate: For any group, the number of unemployed persons expressed as a percentage of the labour force in the same group. ³¹

REFERENCES

¹ Australian Bureau of Statistics. 2003. *Australian Demographic Statistics: December Quarter 2002*. Cat. No. 3101.0. Australian Bureau of Statistics. Canberra.

² Australian Bureau of Statistics. 2001. *2000 Population by Age and Sex: Australian Capital Territory*. Cat. No. 3235.8. Australian Bureau of Statistics. Canberra.

³ Australian Bureau of Statistics. 2001. *Australian Social Trends 2001*. Cat. No. 4102.0. Australian Bureau of Statistics. Canberra.

⁴ Australian Bureau of Statistics. 2002. 2001 Census Basic Community Profile and Snapshot: 8 Australian Capital Territory. www.abs.gov.au Viewed 17/06/03.

⁵ Australian Bureau of Statistics. 2002. *Australian Capital Territory in Focus 2002*. Cat. No. 1307.8. Australian Bureau of Statistics. Canberra.

⁶ Australian Bureau of Statistics. 2001. *Births, Australia – 2000.* Cat. No. 3301.0. Australian Bureau of Statistics. Canberra.

⁷ Australian Bureau of Statistics. 2001. *Demography, Australian Capital Territory - 2000. Cat.* No. 3311.8. Australian Bureau of Statistics. Canberra.

⁸ ACT Maternal Perinatal Data Collection, 2000.

⁹ Australian Bureau of Statistics. 2002. *Australian Social Trends 2002*. Cat. No. 4102.0. Australian Bureau of Statistics. Canberra.

¹⁰ Australian Bureau of Statistics. 2002. Causes of Death, Australia, 2000. Cat. No. 3303.0. Canberra, Australian Bureau of Statistics.

¹¹ Australian Bureau of Statistics. 2002. *2001 National Health Survey: Summary of Results*. Cat. No. 4364.0. Canberra, Australian Bureau of Statistics.

¹² ACT Health, Population Health Research Centre. 2002. *Physical Activity Patterns of Adults in the ACT*, 2000. Health Series No. 29. Canberra, ACT Health.

¹³ ACT Cancer Registry, 1996-2000.

¹⁴ Australian Institute of Health and Welfare. 2002. *Cancer in Australia, 1999.* Cat. No. CAN 15. Cancer Series No. 20. Canberra. Australian Institute of Health and Welfare.

¹⁵ Canadian Cancer Society website: www.cancer.ca. Viewed 23/06/03.

¹⁶ Litwin M, Hays R, Fink A, Ganz PA, Leake B & Brook RH. 1998. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. *Med Care.* 36(7):1002-1012.

¹⁷Braunwald E, Fauci A, Kasper D, Hauser S, Longo D & Jameson J. 2001. *Harrison's Principles of Internal Medicine*. 15th Edition. Vol 1. Sydney, McGraw-Hill.

¹⁸ American Cancer Society website: www.cancer.org Viewed 23/06/03.

¹⁹ Mathers C, Vos T, & Stevenson C. 1999. *The Burden of Disease and Injury in Australia*. Canberra, Australian Institute of Health and Welfare.

²⁰ Australian Institute of Health and Welfare. 2000. *Australia's Health 2000.* Cat. No. 19. Canberra, Australian Institute of Health and Welfare.

²¹ Australian Institute of Health and Welfare. 2000. *BreastScreen Australia Achievement Report* 1997 and 1998. Cat. No. CAN 8. Canberra, Australian Institute of Health and Welfare. Cancer Series No. 13.

²² Last JM. 1998. *A Dictionary of Epidemiology*. Second Edition. Sydney, Oxford University Press.

²³ Pollard AH, Yusuf F, Pollard GN. 1995. *Demographic Techniques*. Third Edition. Sydney, Pergamon Press.

²⁴ Australian Bureau of Statistics. 1986. *Household Estimates Australia*. Cat No. 3229.0. Canberra, Australian Bureau of Statistics.

²⁵ National Centre for Classification in Health. 2000. *ICD-10-AM Australian Coding Standards*. Volume 5. Sydney, University of Sydney.

²⁶ Miller BF, Keane CB. 1997. *Miller-Keane Encyclopedia & Dictionary of Medicine, Nursing & Allied Health*. Sixth Edition. London, Saunders Publications.

²⁷ Smithson M. 2000. Statistics with Confidence. London, Sage Publications.

²⁸ Easton VJ & McColl JH (online). *Statistics Glossary. V 1.1.* www.cas.lancs.ac.uk/glossaryv1.1/confinterval. Viewed 25/09/03.

²⁹ NSW Clinical Cancer Data Collection for Outcomes and Quality. 2001. *Data Dictionary Version 1*. Sydney, NSW Health.

³⁰ Webster's New World Medical Dictionary. Second Edition. (Online).

³¹ Australian Bureau of Statistics. 2003. *Labour Force Australia*. Cat. No. 6203.0. Canberra, Australian Bureau of Statistics.